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ABSTRACT
 
The active form of vitamin B6, pyridoxal 5’-phosphate (PLP), is a cofactor required for 
many essential functions such as the metabolism of amino acids and 
neurotransmitters, the one-carbon cycle, haem biosynthesis, glycogenolysis, and 
sphingolipid metabolism. Humans are not capable of de novo PLP synthesis but do 
have a pathway for the interconversion of B6 vitamers. Several inborn errors of 
metabolism (IEMs) can lead to an insufficient supply of available PLP (e.g. 
pyridox(am)ine 5’-phosphate oxidase [PNPO], aldehyde dehydrogenase 7 family 
member A1 [ALDH7A1] and pyridoxal 5’-phosphate homeostasis protein [PLPHP] 
deficiencies). These disorders are typically characterised by neonatal/infantile-onset 
seizures refractive to standard anti-epileptic drugs but responsive to vitamin B6 
supplementation. 
This thesis describes the investigation of B6 vitamer measurement from dried blood 
spots (DBS) as a diagnostic method for the B6-responsive epilepsies with a focus on 
PNPO deficiency. In addition, a diagnostic LC-MS/MS-based enzyme assay was 
developed for the measurement of PNPO activity from DBS. The biochemical effect 
of a novel IEM leading to pyridoxal kinase deficiency was also characterised using 
LC-MS/MS-based enzyme assays. 
Some PNPO deficient individuals receiving high-dose PLP for seizure treatment 
develop signs of liver damage leading eventually to cirrhosis. The photodegradation 
profile of PLP was characterised in order to help elucidate the mechanism causing 
liver damage in these patients; hypotheses as to the cause of this phenomenon are 
discussed. 
Vitamin B6 has been reported as an effective anticonvulsant in genetic epilepsies 
other than those known to directly affect vitamin B6 metabolism. Whole exome and 
whole genome sequencing data was used in order to investigate a genetic basis for 
vitamin B6-responsive seizures in 5 children. In two of these individuals, variants 
affecting the ion channel KCNQ2 were identified. A response to B6 supplementation 
in cases of KCNQ2-related epilepsy has also been documented in the literature.  The 
mechanism behind this was investigated using electrophysiological techniques. 
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IMPACT STATEMENT
 
This thesis has developed new strategies for the diagnosis of vitamin B6-responsive 
disorders and has further elucidated their biochemical mechanisms; this will aid 
clinical management and hence disease outcome. An emphasis was placed on the 
development of methods utilising mass spectrometry for the quantification of analytes 
of interest.  
Firstly, the measurement of B6 vitamers from dried blood spots (DBS) was assessed 
as an analytical method for the diagnosis of vitamin B6-dependent disorders, in 
particular pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency. An enzyme assay 
for measuring PNPO activity from DBS was also developed. This will give clinicians 
a tool in order to rapidly diagnose patients with PNPO deficiency; a disorder 
associated with an improved outcome upon prompt and appropriate treatment with 
vitamin B6 supplementation. Each of these methods were enabled by the availability 
of more sensitive modern LC-MS/MS instrumentation and this thesis is a good 
example of the application of this technology towards the diagnosis of inborn errors 
of metabolism. 
We were also able to confirm the pathogenicity of a variant in the PDXK gene 
encoding pyridoxal kinase (PK) found in three siblings with childhood-onset peripheral 
neuropathy. This aided in the development of a successful treatment regime for two 
of these individuals. More broadly, this has implications within the field of genetic 
neuropathies if variants affecting PK are found to be a more common cause of this 
disorder. 
As well as the diagnosis of patients with these disorders, the development of rapid 
LC-MS/MS-based enzyme assays for both pyridoxal kinase and PNPO activity from 
DBS will allow the screening of larger cohorts to detect treatable disorders at a pre-
symptomatic or very early symptomatic stage. These could include neuropathy 
caused by PDXK mutations or a less severe presentation of PNPO deficiency caused 
by, for example, homozygosity for the p.R116Q variant in PNPO.  
The photodegradation profiles and rates of photolysis were characterised from PLP 
preparations mimicking those given to B6-dependent epilepsy patients receiving high 
dose PLP for seizure treatment. This was important in order to investigate the 
mechanism causing hepatic cirrhosis in these patients and to work towards a 
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formulation of pyridoxal 5’-phosphate that treats the seizure disorder effectively but 
does not cause liver damage.  
Investigation was also carried out on the effect of B6 vitamers upon KCNQ2/3 
channels in a cell model. This work was valuable in order to investigate the 
anticonvulsant effect of vitamin B6 in epilepsy caused by KCNQ2 mutations and opens 
opportunities for further work in this field. 
Away from the direct clinical implications of this thesis, important insight can be 
gained into the homeostasis of the B6 vitamers. An example of this is the additional 
evidence that, in the blood, the phosphorylated B6 vitamers are sequestered in red 
blood cells. This leads to further questions as to the transport of B6 vitamers across 
the cell membrane. In addition, the discovery that a variant in PDXK leading to 
reduced PK activity causes neuropathy but not epilepsy raises several questions as 
to the mechanisms protecting the brain from PLP deficiency; for example, how the B6 
metabolic enzymes are regulated both pre and post-transcriptionally in a tissue-
specific manner. 
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 Vitamin B6  
Vitamin B6 was first described in 1934 by György as a ‘rat pellagra preventative 
factor’. Over the next few decades the structures of the B6 vitamers were determined 
as several closely related 2-methyl-3-hydroxypyridine analogues differing only at the 
4’ and 5’ positions (Figure 1.1).1 Substitution at the 4’ position leads to pyridoxine 
(PN - CH2OH), pyridoxal (PL - CHO) and pyridoxamine (PM - CH2NH2). At the 5’ 
position each of these vitamers can have either a hydroxymethyl (CH2OH), 
phosphomethyl (CH2PO4H2) or methoxyglucosyl (C7H13O6) moiety. The 
phosphorylated forms are known as pyridoxine 5’-phosphate (PNP), pyridoxal 5’-
phosphate (PLP) and pyridoxamine 5’-phosphate (PMP). In humans, excess vitamin 
B6 is excreted as 4-pyridoxic acid (PA – COOH at the 4’ position). PLP is the active 
coenzyme form of vitamin B6. In humans, PLP is a cofactor for more than 50 diverse 
enzymes required for many essential metabolic functions (Section 1.1.2).2-4  
 
 
Figure 1.1: The B6 vitamers and 4-Pyridoxic acid. The B6 vitamers: Pyridoxine (PN); Pyridoxal (PL); 
Pyridoxamine (PM); Pyridoxine 5’-phosphate (PNP); Pyridoxal 5’-phosphate (PLP); Pyridoxamine 5’-phosphate 
(PMP). Human urinary excretion product: 4-Pyridoxic acid (PA). 
1 
2 
3 
4 
5 
6 
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 Vitamin B6 metabolism and homeostasis 
The use of PLP as a cofactor is widespread across all domains of life. Indeed, PLP is 
thought to be a prebiotic compound (i.e. a compound that existed prior to the 
emergence of life).5 In lower organisms there are two major pathways for the 
biosynthesis of vitamin B6, the deoxyxylulose 5-phosphate (DXP)-dependent and 
DXP-independent pathways.6 However, in man the body’s needs must largely be met 
from dietary sources (despite a contribution from gut microbiota).7 The ubiquitous use 
of B6 as a cofactor means it is prevalent in most components of the human diet. In 
food derived from plant matter it is present mostly in the form of pyridoxine, pyridoxine 
5’-phosphate or pyridoxine 5’-glucoside.8 In meat it is more prevalent as pyridoxal and 
pyridoxal 5’-phosphate, this is also true for human breast milk.9 Vitamin B6 derived 
from meat is also present as pyridoxamine 5’-phosphate.10-11  
The prevalence of vitamin B6 in most foods as well as its synthesis by gut microbiota 
may be why dietary B6 deficiency is rare. A deficiency is however more likely to occur 
early in life when the gut microbiota is not fully established; in the 1950’s, infants fed 
a heat-treated milk formula developed seizures due to B6 deficiency, the vitamin B6 in 
this milk formula having been thermally degraded.12 Seizures due to B6 deficiency 
have also been reported in an autistic child with a severely self-restricted diet13 and 
in adults with impaired liver function.14 
Whilst humans are not capable of de novo synthesis of pyridoxal 5’-phosphate, they 
do have a pathway for the interconversion and regulation of the B6 vitamers (Figure 
1.2). The 5’-phosphorylated B6 vitamers present in the diet must first be hydrolysed 
by intestinal phosphatases before absorption across the gut barrier. The absorbed 
non-phosphorylated vitamers (PN, PL and PM) are then rapidly taken up into the liver 
before rephosphorylation to PNP, PLP and PMP by pyridoxal kinase (PK). Conversion  
of PNP and PMP to active PLP is carried out by pyridox(am)ine 5’-phosphate oxidase 
(PNPO).15 In addition, it has recently been shown that the B6 metabolic pathway is 
intact in a Caco-2 (enterocyte) cell model. It is possible that at least some dietary B6 
is metabolised to PL or PLP before basolateral excretion into the blood and thus 
transport around the body16, removing the requirement for hepatic conversion of PL 
to PLP. Excess B6 is excreted in the urine as PA after the hepatic conversion of PL 
to PA by aldehyde oxidase or aldehyde dehydrogenases.17-18  
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Figure 1.2: Enzymes and transporters responsible for human PLP synthesis and homeostasis. 
Pyridoxal 5′-phosphate (PLP); pyridoxal (PL); pyridoxamine 5′-phosphate (PMP); pyridoxamine (PM); pyridoxine 
5′-phosphate (PNP); pyridoxine (PN); pyridoxine-5′-β-D-glucoside (PNG); 4-pyridoxic acid (PA); intestinal 
phosphatases (IP); plasma membrane transporter (identity unknown; T1); mitochondrial membrane 
transporter (postulated to be encoded by the SLC25A39/40  genes; T2); pyridoxal kinase (PK); pyridox(am)ine 
5′-phosphate oxidase (PNPO); tissue non-specific alkaline phosphatase (TNSALP); pyridoxal-phosphatase 
(PLPase); aldehyde oxidase (Mo cofactor)/β-NAD dehydrogenase (AOX/DH); glycosylphosphatidylinositol (GPI) 
anchor; pyridoxal 5’-phosphate binding protein (PLPHP/PROSC or PLPBP); cerebrospinal fluid (CSF); choroid 
plexus (CP). This figure shows the homeostasis and supply of PLP to the brain, other cells such as hepatocytes 
derive their B6 from the plasma directly. 
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PLP is exported from the liver bound to lysine-190 of albumin.19 The removal of the 
5’ phosphate is then required in order for the vitamin to cross cell membranes and be 
delivered to the tissues that require it (e.g. across the blood-brain barrier). This is 
carried out by TNSALP, an ecto-enzyme encoded by the ALPL gene. TNSALP is 
bound to the cell surface by a glycosylphosphatidylinositol anchor.20 PL and PLP are 
the two major forms of B6 found in human plasma and CSF when subjects are not 
receiving high-dose B6 supplementation.21-22  
Whilst there is evidence from a Caco-2 cell model of a transporter for 
dephosphorylated B6 vitamers on the plasma membrane facilitating, in particular, 
intestinal absorption23, a B6  transporter has yet to be identified in mammals. However, 
one has been reported in Saccharomyces cerevisiae (Tpn1p)24, Arabidopsis thaliana 
(PUP1)25 and Saccharomyces pombe (bsu1+).26 Intracellular trafficking of PLP has 
been postulated to rely on the pyridoxal 5’-phosphate homeostasis protein 
(PLPHP/PLPBP/PROSC), perhaps between subcellular compartments.27 
Cytoplasmic rephosphorylation of PL to PLP by PK provides intracellular enzymes 
with active cofactor.  Typically, this is bound to a lysine residue at the active site of 
PLP-dependent enzymes. These enzymes are present in multiple intracellular 
compartments such as the mitochondrion (e.g. mitochondrial glutamic oxaloacetic 
transaminase [mGOT], mitochondrial serine hydroxymethyltransferase [mSHMT], 
and aminolevulinic acid synthase [ALAS]) and peroxisome (e.g. alanine-glyoxylate 
aminotransferase [AGXT]). This presents a biological challenge with regards to the 
intracellular trafficking of PLP to the compartments in which it is required. The B6 
metabolic enzymes are thought to be primarily localised to the cytoplasm28 with the 
exception of PLPHP, recently localised mostly to the mitochondria of human and 
yeast cell models.29 The trafficking and homeostasis of PLP is discussed further in 
Section 1.1.4. 
Recently the Mtm1p carrier has been identified as a mitochondrial PLP transporter in 
Saccharomyces cerevisiae.30 In humans the mechanism by which PLP is transported 
into the mitochondrion is currently unknown, the SLC25A39 and SLC25A40 proteins 
are good candidates due to their homology with Mtm1p but have yet to be 
characterised.30-31 Indeed, silencing of slc25a39 in murine erythroleukaemia cells 
impaired iron incorporation into protoporphyrin IX, potentially indicative of reduced 
PLP-dependent mitochondrial δ-aminolevulinate synthase activity.32  
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PLP-dependent half-transamination reactions can produce an apo-enzyme with 
bound PMP. This can then be recycled to PLP by PNPO. The pyridoxal 5’-phosphate 
phosphatase (PLPase) enzyme is thought to be responsible for subsequent 
intracellular hydrolysis of pyridoxal 5’-phosphate when it is surplus to requirements.33 
PLPase deficiency induced by knockout of the pdxp gene in a mouse model leads to 
raised PLP and GABA in the brain alongside neurological changes such as improved 
cognition, mild anxiety and decreased motor performance.34 
Unsurprisingly given the importance of PLP-dependent enzymes to human 
metabolism, PK, PNPO and PLPase are present in most human tissues.35 The 
regulation of human B6 metabolic enzymes has been partially characterised.  The 
enzymatic activities of PK and PNPO are subject to feedback inhibition by their 
product, PLP.36 In addition, recent work in an epithelial ovarian cancer cell line has 
indicated that PNPO expression is regulated by TGF-β. In this model, PNPO 
expression was suppressed by PLP administration and enhanced by PN 
administration.37  
There are population differences in the red blood cell activities of both PK38 and 
PNPO.39 In PK these differences have been ascribed to an erythroid specific 
promoter.40 PK is also known to be under the control of temporally regulated PAR 
bZip transcription factors. Knockout of these transcription factors in mice leads to 
seizures and low brain concentrations of dopamine, serotonin and PLP.41  In 
Salmonella typhimurium, the PtsJ protein has been identified as a MocR-like 
transcriptional repressor that binds PLP as an effector and regulates the expression 
of PK, providing feedback regulation.42  
In humans, a genome-wide association study indicated that the C allele of a common 
SNP (rs4654748; T>C) close to the ALPL gene (encoding TNSALP) is associated 
with lower plasma PLP concentrations.43 
 
  Reactions catalysed by PLP-dependent enzymes 
According to the Enzyme Commission, pyridoxal 5’-phosphate is a cofactor for 
approximately 140 enzymatic activities (greater than 50 in man). In total, this is 4% of 
all enzymatic activities (http://www.chem.qmul.ac.uk/iubmb/enzyme). These include 
many critical for amino acid and neurotransmitter metabolism, as well as those 
important for gluconeogenesis from amino acids, glycogenolysis and one-carbon 
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metabolism. Table 1.1 summarises all currently characterised PLP-dependent 
enzymes in humans, as described by Percudani and Peracchi3, as well as a summary 
of their main activities and any known inborn errors of metabolism caused by their 
aberrant function.  
In humans, the cofactor activity of PLP is facilitated by the formation of a covalent 
Schiff base linkage to the ε-amino group of an active site lysine residue. The vast 
majority of subsequently catalysed reactions include the formation of a new Schiff 
base with an amino group on an amino acid substrate. This allows for increased 
reactivity of α, β and γ-carbons of the amino acid and subsequent transamination, 
decarboxylation, racemisation, replacement or elimination activities. The specific 
reaction depends upon the enzyme.44 
One notable exception to this mode of catalytic action is that of the glycogen 
phosphorylase enzyme (EC 2.4.1.1). In this case, although a Schiff base is formed 
with the Lys680 residue of glycogen phosphorylase, the next step instead results in 
the cleavage of the terminal α1,4 glycosidic bond in a linear glycogen chain and 
transfer of a phosphate group onto a newly liberated glucose monosaccharide.45 
Pathway PLP-dependent enzyme Main catalytic activities 
Biological and 
biochemical function 
Known disorders 
related to enzyme 
deficiency  
Amino acid 
and neuro-
transmitter 
metabolism 
Histidine decarboxylase 
(HDC; EC 4.1.1.22) 
The decarboxylation of histidine 
to form histamine 
Histamine is important as 
a neurotransmitter and for 
inflammatory responses 
 
Aspartate transaminase 
(AST or GOT; EC 2.6.1.1) 
The reversible transfer of an α-
amino group from aspartate to 
glutamate 
Important for the recycling 
of amino acids, the 
malate-aspartate shuttle 
and gluconeogenesis 
Mutations in 
mitochondrial GOT2 cause 
serine and B6-responsive 
epileptic encephalopathy, 
developmental delay and 
spastic paraparesis46 
Table 1.1: Human PLP-dependent enzymes. Abbreviations: pyridoxal 5′-phosphate (PLP); nicotinamide adenine dinucleotide 
(NAD); γ-aminobutyric acid (GABA); L-3,4-dihydroxyphenylalanine (L-DOPA); 5-hydroxytryptophan (5-HTP); 5-hydroxytryptamine (5-
HT, serotonin); cerebrospinal fluid (CSF); homovanillic acid (HVA); 5-hydroxyindoleacetic acid (5-HIAA); 3-O-methyldopa (3-OMD, 3-
methoxytyrosine); coenzyme A (CoA). 
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Alanine transaminase  
(ALT or GPT1 + 2; EC 
2.6.1.2) 
Reversible conversion of L-
alanine + α-ketoglutarate to 
pyruvate + L-glutamate 
GPT2 (mitochondrial) 
deficiency leads to 
developmental delay and 
neurological disease 
(MIM: 616281). Severe 
PLP deficiency can cause 
hypoglycaemia. 
Kynureninase  
(KYNU; EC 3.7.1.3) 
Conversion of L-kynurenine to 
anthranilic acid and alanine Degradation of 
kynurenine, part of the 
tryptophan catabolic 
pathway 
KYNU deficiency leads to 
congenital abnormalities, 
increased xanthurenic acid 
excretion and NAD 
deficiency (MIM: 617661).  
High xanthurenic acid 
excretion is a marker of 
systemic B6 deficiency. 
Kynurenine 
aminotransferase  
(KYAT1 & 2; EC 2.6.1.7) 
Conversion of L-kynurenine + 2-
oxoglutarate to kynurenic acid + 
L-glutamate 
Cystathionine-β-synthase 
(CBS; 4.2.1.22) 
The formation of L-cystathionine 
from L-serine + L-homocysteine 
Regulation of 
homocysteine levels and 
the removal of excess 
sulphur-containing amino 
acids 
Homocystinuria due to CBS 
deficiency (MIM: 236200). 
May be pyridoxine-
responsive 
Cystathionine-γ-lyase  
(CTH; EC 4.4.1.1) 
The conversion of L-cystathionine 
to cysteine, α-ketobutyrate and 
ammonia 
Important for glutathione 
production and has an 
alternate activity that 
produces H2S, a 
neuromodulator 
Cystathioninuria; thought 
to be a benign biochemical 
abnormality (MIM: 
219500) 
Glutamate decarboxylase 
(GAD1 + 2; EC 4.1.1.15) 
The decarboxylation of 
glutamate to GABA 
The regulation of GABA-
glutamate interconversion. 
Low GABA has been found 
in ALDH7A1-/- zebrafish 
and in a mouse model of 
hypophosphatasia with 
epilepsy 
 
GABA-transaminase  
(GABA-T; EC 2.6.1.19) 
The conversion of GABA + 2-
oxoglutarate to succinate 
semialdehyde + L-glutamate 
Amongst other pathways, 
important for the neuronal 
recycling of GABA to 
glutamate 
GABA-transaminase 
deficiency causes 
developmental delay and 
neurological abnormalities 
(MIM: 613163) 
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Aromatic L-amino acid 
decarboxylase  
(AADC; EC 4.1.1.28) 
Among other activities, the 
conversion of L-DOPA to 
dopamine; 5-HTP to 5-HT; L-
phenylalanine to phenethylamine 
and L-tyrosine to p-tyramine. 
Synthesis of monoamine 
central and peripheral 
neurotransmitters 
including dopamine, 
adrenaline, noradrenaline 
and 5-HT 
AADC deficiency causes 
serotonin/catecholamine 
deficiencies leading to 
hypotonia and other 
features of neurological 
dysfunction (MIM: 
608643). Biochemically 
this is indicated by low CSF 
HVA & 5-HIAA and high 
CSF 3-OMD & 5-HTP, 
features of B6 metabolic 
disorders such as PNPO 
deficiency;  these cause a 
secondary lack of AADC 
activity due to PLP 
deficiency 
Branched-chain amino 
acid aminotransferase  
(BCAT1 + 2; EC 2.6.1.42) 
Conversion of branched-chain 
amino acids to branched chain α-
keto acids and glutamate 
Important for the 
regulation of glutamate 
production in the brain 
 
L-Serine racemase  
(SRR; EC 5.1.1.18 ) 
Racemisation of L-serine to D-
serine 
D-serine is important for 
neuronal migration and as 
a neurotransmitter 
 
Alanine-glyoxylate 
aminotransferase  
(AGXT; EC 2.6.1.44 ) 
Conversion of L-alanine + 
glyoxylate into pyruvate + glycine 
Prevents the 
overproduction of oxalate 
and consequent renal 
stones 
Deficiency causes primary 
hyperoxaluria, type 1 
(MIM: 259900). May be 
pyridoxine-responsive 
Ornithine δ-
aminotransferase  
(OAT; EC 2.6.1.13) 
Reversibly transaminates 
ornithine to L-glutamate 5-
semialdehyde 
Important for the 
formation of 
glutamate/GABA, arginine 
and proline. 
Deficiency causes gyrate 
atrophy of choroid and 
retina and 
hyperammonaemia in 
infancy (MIM: 258870). 
May be pyridoxine-
responsive 
Phosphoserine 
aminotransferase  
(PSAT1; EC 2.6.1.52) 
Reversible conversion of O-
phospho-L-serine + 2-
oxoglutarate to 3-
phosphonooxypyruvate + L-
glutamate. 
Important for the 
biosynthesis of serine and 
glycine 
Deficiency causes low 
plasma and CSF serine and 
glycine leading to 
intractable seizures, 
microcephaly, craniofacial 
dysmorphism, hypertonia 
and developmental delay 
(MIM: 610992;  616038) 
Tyrosine 
aminotransferase (TAT; 
EC 2.6.1.5) 
Reversible liver-specific 
conversion of L-tyrosine + 2-
oxoglutarate to 4-
hydroxyphenylpyruvate + L-
glutamate 
Important for tyrosine 
catabolism 
Deficiency causes 
tyrosinaemia type 2 (MIM: 
276600) characterised by 
lesions of the cornea/skin 
and developmental delay 
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Glycine C-
acetyltransferase (GCAT; 
EC 2.3.1.29) 
Responsible for the second step 
of L-threonine conversion to 
glycine, converting 2-amino-3-
ketobutyrate + CoA to glycine + 
acetyl-CoA 
Important for threonine 
catabolism 
 
2-Aminoadipate 
aminotransferase  
(EC 2.6.1.39) 
Reversibly converts L-2-
aminoadipate + 2-oxoglutarate to 
2-oxoadipate + L-glutamate 
Important for lysine 
catabolism 
 
Serine/threonine 
deaminase  
(SDS; EC 4.3.1.17) 
Deamination of L-serine or L-
threonine to form pyruvate or 2-
oxobutanoate + 
ammonia/ammonium 
Important for the 
formation of pyruvate and 
hence gluconeogenesis 
from amino acids 
 
Folate cycle 
and one-
carbon 
metabolism 
Serine hydroxyl 
methyltransferase  
(SHMT1 + 2; EC 2.1.2.1) 
Reversible conversion of L-serine 
+ tetrahydrofolate to glycine and 
5,10-methylenetetrahydrofolate 
Essential part of the folate 
cycle; neuronal cells 
deprived of B6 have low 5-
methyltetrahydrofolate47 
 
Glycine dehydrogenase 
(decarboxylating)  
(GLDC; EC 1.4.4.2) 
The cleavage of glycine into CO2 + 
a protein-bound methylamine 
group 
Essential part of the 
glycine cleavage system 
Deficiency of GLDC and 
other enzymes in the 
glycine cleavage system 
cause glycine 
encephalopathy (MIM: 
605899). High CSF glycine 
can be a feature of PLP 
deficiency 
Protein 
Synthesis 
O-phosphoseryl-
tRNA(Sec) selenium 
transferase (SEPSECS; EC 
2.9.1.21) 
Transfers selenium from a 
selenophosphate to O-phospho-
L-seryl-tRNA(Sec) forming L-
selenocysteinyl-tRNA(Sec) 
Selenocysteinyl-tRNA(Sec) 
is the tRNA required for 
synthesis of 
selenoproteins 
Deficiency causes 
pontocerebellar 
hypoplasia type 2D 
characterised by 
progressive microcephaly 
and developmental delay 
(MIM: 613811) 
Carbo-
hydrate 
metabolism 
Glycogen phosphorylase 
(PYG(M[uscle],L[iver], 
B[rain]); EC 2.4.1.1) 
Liberation of glucose-1-
phosphate from the terminal 1,4-
glycosidic bond of glycogen 
The rate-limiting step in 
glycogenolysis 
Deficiency of PYGM + PYGL 
cause glycogen storage 
disease types V + VI, 
respectively (MIM: 
232600 + 232700). Severe 
PLP deficiency can cause 
hypoglycaemia 
Various - see amino acid 
and neurotransmitter 
metabolism  
(AST, ALT, AGXT, KYAT, 
GABA-T, BCAT, TAT, SDS) 
Various – see amino acid and 
neurotransmitter metabolism 
Gluconeogenesis from 
amino acids 
Severe PLP deficiency can 
cause hypoglycaemia. 
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Lipid 
Metabolism 
Serine 
palmitoyltransferase 
(SPT; EC 2.3.1.50) 
Conversion of palmitoyl-CoA + L-
serine into CoA, 3-dehydro-D-
sphinganine and CO2 
A step in the synthesis of 
sphingosine and therefore 
many additional 
sphingolipids 
Mutations cause 
hereditary sensory 
neuropathy type IA (MIM: 
162400) 
Sphingosine-1-phosphate 
lyase  
(SGPL1; EC 4.1.2.27) 
Converts sphingosine 1-
phosphate to 
phosphoethanolamine + 
palmitaldehyde 
Important for the 
regulation of phospholipid 
signalling through S1P 
Deficiency causes a 
nephrotic syndrome with 
systemic manifestations 
(MIM: 617575) 
 
Mito-
chondrial 
Function and 
Erythro-
poiesis 
Δ-Aminolevulinic acid 
synthase  
(ALAS1 + 2; EC 2.3.1.37) 
Conversion of succinyl-CoA + 
glycine into CoA, Δ-
Aminolevulinic acid and CO2 
Required for haem 
biosynthesis 
ALAS2 (erythroid-specific) 
deficiency causes 
sideroblastic anaemia 
(MIM: 300751). Anaemia 
and lactic acidosis are 
common features of 
severe PLP-deficiency 
Cysteine desulfurase  
(NFS1; EC 2.8.1.7) 
The conversion of L-cysteine to L-
alanine by transferring the sulfur-
group of free cysteine onto a 
cysteine residue of the NFS 
enzyme 
Part of the Fe-S core 
complex, essential for Fe-S 
cluster formation 
Deficiency causes 
myopathy with lactic 
acidosis (MIM: 255125) 
Molyb-
denum 
cofactor 
synthesis 
Molybdenum cofactor 
sulfurase 
 (MOCOS; EC 2.8.1.9) 
Sulphuration of the molybdenum 
cofactor of xanthine 
dehydrogenase (XDH; 607633) 
and aldehyde oxidase (AOX1; 
602841) 
XDH activity is required for 
purine metabolism and 
AOX1 is an promiscuous 
oxidase with several 
important activities 
Deficiency causes 
xanthinuria type II (MIM: 
603592). Can lead to 
urinary tract calculi, renal 
failure and myositis due to 
xanthine deposition 
 
Synthesis of 
Polyamines 
Ornithine decarboxylase 
(ODC1; EC 4.1.1.17) 
Decarboxylation of ornithine to 
form putrescine 
Polyamines are involved in 
cell signalling, growth and 
programmed death 
 
 
 Non-enzymatic roles of the B6 vitamers 
Reports suggest that the B6 vitamers may have important activities unrelated to their 
action as a cofactor. PLP is known to interact with P2 purinoceptor 7 receptors 
(P2X7R), thought to be linked to neuronal ATP-mediated inflammation48 and recently 
identified as a potential target for the treatment of AED-resistant epilepsy.49-50 B6 
vitamers are also antioxidants and can quench singlet oxygen effectively.51 PLP has 
been shown to affect gene expression in mammals through modulation of the 
transcription and activity of steroid hormone receptors.52-53 
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 The reactivity of pyridoxal 5’-phosphate – a mixed blessing 
Pyridoxal 5’-phosphate contains a reactive aldehyde at the 4’ position. This reactivity 
is essential for its role as a cofactor and, as mentioned previously (Section 1.1.2), 
leads to the formation of covalent Schiff bases with ε-amino groups of active site 
lysines in PLP-dependent enzymes.54 However, PLP can also react non-specifically 
with compounds containing an amine group.28, 55 This provides the cell with a very 
specific problem; how to supply PLP to the apoenzymes that require it as a cofactor, 
while simultaneously keeping free PLP low enough to avoid unwanted side reactions 
with both small molecules and proteins.28 These side reactions can result in the 
inhibition of enzymatic activity through the alteration of protein structure.56-57 
Aldehydes can also directly damage DNA.58 
There are several known mechanisms by which the human body maintains free PLP 
concentrations. Firstly, as mentioned previously (Section 1.1.1), PNPO is subject to 
product inhibition by PLP.36, 59 Evidence in vitro also suggests that PNPO helps to 
protect newly synthesised PLP; it has been proposed that PNPO contains a 
secondary PLP binding site, enabling it to function as a chaperone, directly delivering 
PLP to the target apoenzymes.60 Additionally, PLP in blood is found mostly bound to 
albumin (εLys190) in plasma, or haemoglobin (εLys82 or αVal1) in red blood cells;19, 
61 this protects it from degradation by the phosphatases (such as TNSALP) present 
in blood and also from reacting with other nucleophilic compounds in plasma or red 
blood cells. Similarly, pyridoxal 5’-phosphate homeostasis protein (PLPHP; 
previously known as PROSC or PLPBP) has recently been proposed as an 
intracellular chaperone of PLP.27, 62 Homologues of PLPHP are highly conserved 
across species, in E. Coli as YggS and yeast as YBL036C, suggesting an important 
cellular function.  
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 Inborn errors affecting vitamin B6 metabolism 
Although vitamin B6 deficiency is uncommon due to the prevalence of dietary B6, there 
are several disorders which can lead to a specific deficiency of bioavailable PLP. 
These include inborn errors which affect the B6 metabolic pathway i.e. PNPO 
deficiency [MIM: 610090]63, those which result in the inactivation of free PLP (e.g. 
Pyridoxine Dependent Epilepsy [PDE] due to mutations in ALDH7A1) [MIM: 
266100])64 and a disorder which is thought to cause aberrant intracellular regulation 
and trafficking of PLP (i.e. PLPHP deficiency [MIM: 617290]).27 These disorders are 
typically characterised by neonatal/infantile-onset seizures refractive to standard 
AEDs but responsive to vitamin B6 supplementation2, 27.  
Although B6-responsive seizures dominate the clinical pictures of PNPO, PLPHP and 
ALDH7A1 deficiencies, in the neonate systemic features such as lactic acidosis and 
anaemia may also be present. In all three disorders developmental delay is common 
in patients that survive into infancy. However, when treated promptly and 
appropriately, some individuals can have a normal developmental outcome. This is 
particularly evident in cases of PLPHP and PNPO deficiency.65-66 A summary of the 
clinical and biochemical features of pyridoxine-dependent epilepsy due to mutations 
in ALDH7A1 and PNPO deficiency can be found in Figures 1.3 and 1.4, respectively. 
To date, 27 individuals have been reported with PLPHP deficiency.  The clinical 
spectrum of this disorder appears broad, ranging from severe seizures immediately 
after birth alongside profound microcephaly and intellectual disability to seizure onset 
after 9 days of life and a normal developmental outcome at 30 years of age.27, 29, 67-68 
Other inborn errors of metabolism which can result in B6-responsive epilepsy include 
hypophosphatasia (MIM: 241500), glycosylphosphatidylinositol (GPI) anchor defects 
(MIM: 239300; 614749) and hyperprolinaemia type 2 (HPII [MIM: 239510]). These 
can cause B6-responsive seizures but are either clinically distinct from PNPO/PLPHP 
deficiency and PDE (in the cases of hypophosphatasia and GPI anchor defects) or 
very rare and leading to seizures only infrequently, in the case of HPII (Table 1.2).69-
71 Recently, compound heterozygous variants were identified in the GOT2 gene 
encoding mitochondrial glutamate oxaloacetate transaminase (mGOT) in a child with 
acquired microcephaly, severe seizures and spasticity alongside low plasma and 
CSF serine. Treatment with pyridoxine and serine supplements was effective for 
seizure resolution.46 
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Figure 1.3: Overview of the symptoms reported in the literature for patients with ATQ deficiency. Red 
box: symptoms or biochemical features present in the majority of patients. All other boxes: symptoms present in the 
minority of patients. *Ultra-rare symptoms, reported in eight literature patients or fewer. 1Unidentified peak in the 
HPLC chromatogram for CSF monoamine neurotransmitter analysis in ATQ deficiency patients. 2Can normalise on 
pyridoxine therapy. 3See van Karnebeek et al. 2016. 6-oxo-PIP, 6-oxo-pipecolic acid; α-AASA, α-aminoadipic 
semialdehyde; ADHD, attention deficit hyperactivity disorder; ATQ, antiquitin; CC, corpus callosum; CSF, cerebrospinal 
fluid; GABA, gamma-aminobutyric acid; OCD, obsessive–compulsive disorder; P6C, L-Δ1-piperideine-6 carboxylate. 
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Figure 1.4: Overview of the symptoms reported in the literature for patients with PNPO deficiency. Red 
box: symptoms or biochemical features present in the majority of patients. All other boxes: symptoms present in the 
minority of patients. *Ultra-rare symptoms, reported in three literature patients or fewer. 1Can normalise on 
effective treatment with PLP/PN. 2Seizure onset after 1 year seen with patients homozygous for the p.R116Q variant 
in PNPO. α-AASA, α-aminoadipic semialdehyde; ADHD, attention deficit hyperactivity disorder; ATQ, antiquitin; CSF, 
cerebrospinal fluid; GABA, gamma-aminobutyric acid; OCD, obsessive–compulsive disorder; P6C, L-Δ1-piperideine-6 
carboxylate; DBS, dried blood spot; VLA, vanillactic acid; HVA, homovanillic acid; 5-HIAA, 5-hydroxyindoleacetic acid; 
PL, pyridoxal; PLP, pyridoxal 5’-phosphate; L-DOPA, L-3,4-dihydroxyphenylalanine;  EIEE, early infantile epileptic 
encephalopathy; LFT, liver function test; PN, pyridoxine. 
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Inborn Error 
ALDH7A1/ATQ 
deficiency  
PNPO deficiency PLPHP deficiency 
Hyperprolinaemia 
type II 
Hypophosphatasia GPI anchor defects 
Molybdenum 
cofactor deficiency 
Genetic locus ALDH7A1 PNPO PLPBP (PROSC) ALDH4A1 ALPL PIGO; PIGV (+ others) 
MOCS1; MOCS2; 
GPHN 
Neonatal/infanti
le B6-responsive 
seizures 
± 
A few patients have 
presented with onset 
after the 1st year of 
life72 and as late as 
adolescence73 
± 
A few patients have 
presented with onset 
after 1st year of life74 
+ 
± 
(~50% of cases; 
seizure onset usually 
in infancy or 
childhood)75 
± 
Only 7.5% of 
hypophosphatasia 
cases are infantile – 
not all of these 
present with 
seizures76 
± 
Variable presentation 
according to specific 
GPI defect77 
± 
Only isolated cases 
reported to respond 
to pyridoxine78 
Prevalence of 
Developmental 
delay 
± 
75% have 
developmental 
abnormalities79 
± 
Can be 
developmentally 
normal – linked to 
early treatment 
(13/41 Guerin et al.)80 
+ 
Broad spectrum27 
± 
Asymptomatic 
individuals described81 
but in the absence of 
developmental delay 
behavioural 
problems/psychosis/a
nxiety are usually 
present82 
± 
Not in milder cases83 
+ 
+ 
Survival rare beyond 
early childhood84 
 
Table 1.2: Clinical and biochemical features of inborn errors leading to B6-responsive seizures. α-AASA = α-aminoadipic semialdehyde; NEE = neonatal epileptic encephalopathy; P5C = Δ1-
pyrroline-5-carboxylate; GPI = glycosylphosphatidylinositol; DBS = dried blood spot. Presentation of B6-responsive seizure disorders is often dependent upon prompt and appropriate treatment e.g. MRI 
abnormalities can be a consequence of NEE and are usually present only in patients with a more severe form of the disorder or those with delayed treatment. + Usually present; ± Variably present; - 
Not present. 
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Some cases 
resistant to 
pyridoxine 
- 
Ambiguous initial 
response is seen in 
about 15%66  
± 
~60% of cases80 
- - ±85 
± 
Proportion unknown77 
± 
Only isolated cases 
reported to respond 
to pyridoxine78 
Skeletal 
abnormalities 
± 
Macrocephaly, facial 
dysmorphia in rare 
cases86 
 
± 
Microcephaly in 
severe, untreated 
cases 
± 
Microcephaly at birth 
4/14; acquired 
microcephaly in an 
additional 4/1427, 67-68 
- 
+ 
Similar to rickets;  less 
pronounced in mild 
cases – some only 
dental83 
+ 
Brachytelephalangy 
± 
Microcephaly 
common84 
Abnormal MRI 
(including white 
matter changes) 
±  
Including  narrow 
corpus callosum 
(especially posterior), 
dilated ventricles, 
small cerebellum72 
± 
May have changes 
(including white 
matter oedema) as a 
result of untreated 
NEE87 Normal in 37% 
(5/15)80 
± 
Global 
underdevelopment 
(Coarse gyri shallow 
sulci) + 
underdeveloped 
white matter27 
- - 
± 
In one case of PIGO: 
Hypomyelination; 
Lesions in the bilateral 
basal ganglia and 
brainstem71 
+ 
Delayed myelination, 
enlarged ventricles, 
cerebral atrophy in 
>40%; corpus 
callosum & cerebellar 
atrophy in >20%84 
Parental history of 
infertility, 
miscarriage or 
prematurity 
- 
± 
8/22 families87 
- - - - - 
Unique 
biochemical 
features (Among 
B6-responsive 
seizure disorders) 
Raised plasma + 
urinary  α-AASA72   but 
normal urinary S-
sulphocysteine 
Raised plasma 
pyridoxamine/pyridox
ic acid ratio88; low DBS 
PNPO enzyme activity 
(<40% below the 
normal range)89 
N/A 
Raised plasma proline 
and P5C; Raised 
urinary P5C and N-
(pyrrole-2-carboxyl) 
glycine2, 90 
Low plasma alkaline 
phosphatase; high 
plasma phosphate, 
urine phosphoserine 
&  
phosphoethanolamine 
Raised plasma alkaline 
phosphatase 
Raised plasma + 
urinary  α-AASA AND 
raised urinary S-
sulfocysteine/xanthin
e/ taurine91 
45 
 
The mechanism causing PLP deficiency in cases of PNPO deficiency is the inability 
to convert PNP and PMP to PLP; this is important in the synthesis of PLP from dietary 
precursors and also for the recycling (salvage) pathway.63 The mechanism behind the 
PLP deficiency seen in patients with mutations in ALDH7A1 is related to the reactive 
nature of PLP. Low ALDH7A1 activity leads to a block in the lysine catabolic pathway, 
resulting in high concentrations of alpha-aminoadipic semialdehyde (α-AASA) and its 
cyclic analogue, Δ1-piperideine-6-carboxylate, the latter of which reacts with and 
inactivates PLP.64 Very recently, 6-oxo-pipecolic acid has been tentatively identified 
as a novel biomarker for ALDH7A1 deficiency but further work is required in order to 
confirm this finding.92 Less clear is the mechanism behind PLPHP deficiency. This is 
not fully understood as the function of PLPHP has yet to be fully elucidated. However, 
it has been hypothesised that the absence of three postulated aspects of PLPHP 
function lead to pathogenesis: i) PLPHP protects PLP from intracellular 
phosphatases; ii) PLPHP directly supplies PLP to apoenzymes; iii) PLPHP acts as a 
carrier, preventing PLP from reacting with other molecules.27   
In HPII, the mechanism involved in decreased PLP bioavailability is similar to that 
which occurs in ALDH7A1 deficiency, namely inactivation of PLP by a metabolite (i.e. 
Δ1-pyrroline-5-carboxylate) which accumulates due to a metabolic block in the proline 
catabolic pathway.2 The B6-responsive epilepsy seen in hypophosphatasia and GPI 
anchor defects is caused by the inability to hydrolyse plasma PLP, sequestering it in 
the circulatory system.  
The mechanism behind the seizures and other features of neurological dysfunction 
that result from PLP deficiency in the brain are not entirely understood. There is 
however direct evidence of alterations in the activity of PLP-dependent enzymes 
involved in neurotransmitter metabolism. Imbalances in GABA, glutamate, serotonin 
and dopamine are postulated to lead to the epilepsy seen in PLP deficiency.93 High 
glutamate and/or low GABA in particular could provide potentially excitotoxic 
conditions leading to seizures94-96; this hypothesis has been explored on various 
occasions and in different models47, 97 but results have sometimes been inconclusive, 
in part due to the difficulties encountered equating CSF neurotransmitter metabolite 
concentrations with those in the brain itself. 
Several of the other features of severe PLP deficiency such as lactic acidosis and 
hypoglycaemia can be explained by deficient activity of PLP-dependent enzymes. 
These enzymes are summarised in Table 1.3, alongside the postulated biochemical 
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mechanisms leading to the clinical phenotypes caused by the deficiency of PLP-
dependent enzymes. 
Clinical or 
biochemical features 
identified in 
individuals with 
impaired vitamin B6 
metabolism 
Implicated PLP-dependent 
enzymes 
Mechanism 
Seizures 
Branched-chain amino acid 
aminotransferase  
(BCAT1 + 2; EC 2.6.1.42) 
Major source of glutamate in the brain 
Glutamate decarboxylase  
(GAD1 + 2; EC 4.1.1.15) 
GAD produces GABA from glutamate; GABA-T 
produces glutamate from GABA. Both are 
therefore important for the regulation of neuronal 
GABA/glutamate interconversion and therefore 
neuronal excitability. Imbalances of these 
neurotransmitters are thought to explain the 
seizures caused by PLP deficiency. Low GABA has 
been found in ALDH7A1-/- zebrafish and in a mouse 
model of hypophosphatasia with epilepsy. 
GABA-transaminase  
(GABA-T; EC 2.6.1.19) 
Dystonic movements 
Aromatic L-amino acid decarboxylase 
(AADC; EC 4.1.1.28) 
Deranged regulation of serotonin and 
catecholamine neurotransmitters leads to dystonia 
and a characteristic CSF neurotransmitter profile 
seen in both primary AADC deficiency and that 
which is secondary to severe PLP deficiency. 
Low CSF HVA & 5-
HIAA; raised VA & 3-
OMD 
Neuronal migration 
defects 
L-Serine racemase  
(SRR; EC 5.1.1.18 ) 
Deficiency leads to an inability to form D-serine, 
implicated in neuronal migration & 
neurotransmission through NMDA receptors. 
Although rare, neuronal migration defects and 
dysplasia have been identified in individuals with 
perturbed vitamin B6 metabolism 
Anaemia & lactic 
acidosis 
Δ-Aminolevulinic acid synthase  
(ALAS1 + 2; EC 2.3.1.37) 
Disordered haem and Fe-S cluster synthesis due to 
severe PLP deficiency leads to haematological 
abnormalities and lactic acidosis.  Cysteine desulfurase (NFS1; EC 2.8.1.7) 
Table 1.3: Clinical and biochemical presentations caused by perturbed function of PLP-dependent 
enzymes in a PLP deficient state. Abbreviations: pyridoxal 5′-phosphate (PLP); γ-aminobutyric acid (GABA); 5-
hydroxytryptophan (5-HTP); 5-hydroxytryptamine (5-HT, serotonin); cerebrospinal fluid (CSF); vanillic acid (VA); 
homovallinic acid (HVA); 5-hydroxyindoleacetic acid (5-HIAA); 3-O-methyldopa (3-OMD, 3-methoxytyrosine); N-
methyl-D-aspartate (NMDA). 
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Hypoglycaemia 
Aspartate transaminase  
(AST or GOT; EC 2.6.1.1) 
Important for the formation of pyruvate and 
therefore gluconeogenesis from amino acids. 
Mitochondrial GOT important for the malate-
aspartate shuttle. 
Alanine transaminase  
(ALT or GPT1 + 2; EC 2.6.1.2) 
Serine/threonine deaminase  
(SDS; EC 4.3.1.17) 
Glycogen phosphorylase 
(PYG(M[uscle],L[iver],B[rain]); EC 
2.4.1.1) 
The rate-limiting step in glycogenolysis. Severe PLP 
deficiency leads to the inability to liberate 
sufficient glucose from stored glycogen through 
the action of hepatic phosphorylase 
Disordered plasma & 
CSF serine, threonine 
and glycine 
Serine hydroxymethyltransferase  
(SHMT1 + 2; EC 2.1.2.1) 
These enzymes are important for the biosynthesis 
and catabolism of serine, threonine, glycine and 
for the folate cycle. Recently, an in vitro study of 
neuronal cells has reported reduced synthesis of 
serine and glycine cultured in B6-deficient medium; 
the homeostasis of these amino acids is complex 
and tissue-specific.  
 
This manifests in severely PLP deficient humans as 
high concentrations of threonine, serine and 
glycine in plasma and CSF.  Neuronal cells deprived 
of B6 have low 5-methyltetrahydrofolate due to 
SHMT deficiency. 
 
Glycine dehydrogenase 
(decarboxylating) (GLDC; EC 1.4.4.2; 
component of the glycine cleavage 
system) 
Serine/threonine deaminase  
(SDS; EC 4.3.1.17) 
Phosphoserine aminotransferase  
(PSAT1; EC 2.6.1.52) 
Glycine C-acetyltransferase  
(GCAT; EC 2.3.1.29) 
Elevated urinary 
xanthurenic acid 
Kynureninase (KYNU; EC 3.7.1.3) Impaired tryptophan catabolism leads to elevated 
urinary xanthurenic acid excretion in cases of PLP 
deficiency 
Kynurenine aminotransferase (KYAT1 & 
2; EC 2.6.1.7) 
 
 Diagnosis and treatment of vitamin B6-responsive seizure 
disorders 
In a neonate presenting with seizures, a challenge for the treating clinician is to 
diagnose a B6-responsive disorder alongside much commoner causes of neonatal 
seizures. Within these disorders, once a response to B6 supplementation is identified, 
the similarity seen in the clinical pictures of PNPO, PLPHP and ALDH7A1 deficiencies 
means they are often difficult to distinguish diagnostically. It was previously thought 
possible to differentiate between PNPO and ALDH7A1 deficiencies by identifying an 
anticonvulsant effect of PLP, but resistance to PN, in PNPO deficiency. However, 
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more recently it has been shown that approximately 40% of PNPO deficient 
individuals respond to PN supplementation.80, 87, 98 
After the identification of a specific anti-epileptic response to either PLP or PN, 
differential diagnosis of these three disorders is currently performed by sequencing 
of candidate genes or, in the case of PDE, detection of a raised urinary α-AASA 
concentration.64 Sequencing is performed either on a single gene basis or as part of 
a gene panel. This genetic analysis is often not requested until after α-AASA 
measurement. It can therefore take several months to achieve a diagnosis. Prompt 
and appropriate treatment of PNPO deficiency is extremely important for prognosis; 
reports suggest that this is a major factor in facilitating a normal developmental 
outcome.65, 99   
Several methods have been proposed for the diagnosis of PNPO deficiency but have 
proven unreliable. Indeed, no specific biomarker exists for its diagnosis. Low CSF 
PLP prior to treatment is characteristic of the disorder and was previously considered 
a consistent biomarker.100 However, recently a patient in whom CSF PLP levels were 
normal has been reported.101 Equally, deficiency of ALDH7A1102 and PLPHP27 can 
also lead to low CSF PLP. Initially, Darin et al.27 reported that, in PLPHP deficiency, 
plasma PLP concentrations were higher, on treatment, than that seen in PNPO and 
ALDH7A1 deficiencies. However, this finding was recently shown to be inconsistent.67 
The CSF neurotransmitter metabolite profiles of PNPO deficient children have also 
been used in the diagnostic workup of this disorder. Although some patterns 
characteristic of low PLP-dependent enzyme activity such as high 3-O-methyldopa 
(3-OMD) or threonine and low homovanillic acid (HVA) or 5-hydroxyindoleacetic acid 
(5-HIAA) have emerged, these are not present in all patients or may only be transient. 
They can also be found in the other B6-repsonsive seizure disorders and are likely 
suggestive of PLP deficiency rather than PNPO deficiency itself.27  
A raised plasma pyridoxamine/pyridoxic acid ratio has recently been suggested as a 
specific biomarker of PNPO deficiency, seemingly due to an accumulation of 
pyridoxamine caused by low PNPO activity.88 However, this study included only six 
PNPO deficient patients, four of whom were homozygous for the same p.R225H 
variant. Whether this finding is consistent in more patients with a wide range of 
mutations and in samples taken prior to high-dose B6 supplementation remains to be 
seen.  
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Typically, oral supplements of either PN or PLP are used for the long term treatment 
of B6-dependent seizure disorders. High dose PLP is unpalatable and can lead to 
emesis; compliance can be problematic, particularly in infants.(personal communication). 
Intravenous infusion preparations of both compounds exist but for PLP this is 
available only in Japan. 
Recently there have been reports of raised liver function tests (LFTs) and hepatic 
cirrhosis in patients receiving high-dose PLP supplementation (> 30 mg/kg/d).99, 103 
Hepatotoxicity has not been identified in individuals receiving PN for seizure control. 
In aqueous solution some B6 vitamers, particularly PLP, are photolabile.104-106 It is 
possible that photodegradation products of PLP are hepatotoxic. Another hypothesis 
is that supraphysiological concentrations of one or more of the B6 vitamers cause liver 
damage. The plasma concentrations of PLP and PL in those receiving PLP for seizure 
control can be 10-1000 times higher than the normal range.22 In the liver of a PNPO 
deficient patient receiving 50 mg/kg/d PLP, the pyridoxal concentration measured 
after hydrolysis of phosphate esters was approximately 40 times higher than that of 
a control. However, this patient had also presented with hepatic cirrhosis, the effect 
of this upon B6 vitamer concentrations is unknown.103 
Patients receiving high-dose long-term PN supplementation do not develop liver 
damage but a side effect of PN supplementation is peripheral neuropathy.107 This is 
thought to be due to inhibition of PLP-dependent enzymes in peripheral nerves and 
is similar to that seen upon PLP deficiency induced by high doses of isoniazid or 
theophylline.108-111 
 
 Vitamin B6 for the treatment of genetic epilepsies 
Although in Europe and the United States, PN and PLP are occasionally used as 
second-line treatment options for patients with drug-resistant epilepsy, in Japan B6 
supplementation is often used as a first-line treatment option.112 Indeed, there is an 
increasing body of evidence that epilepsies other than those that directly affect B6 
metabolism can benefit from PN/PLP supplementation. 
Wang et al. reported that 11/94 children with idiopathic intractable epilepsy showed a 
dramatic and sustained response to PLP supplementation. In these patients PLP was 
more effective than PN for seizure control.113 Ohtahara et al. found high-dose vitamin 
B6 supplementation was effective for seizure control in 13.9% of West syndrome 
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cases, including 11.5% of those with identifiable brain pathologies.114 Recent 
research in mice has shown that B6 is a modifier of seizure severity in a model of 
SCN1A (Dravet syndrome) epilepsy113,115, another indication that vitamin B6 
supplementation of affected individuals could be important in the management of a 
number of epilepsies with varying aetiologies. 
It has also been reported that epilepsy caused by dominant mutations in the KCNQ2 
gene are particularly amenable to treatment with PLP.116-117 The KCNQ2 protein is a 
major constituent of the KCNQ or ‘M’-channels, these modulate the M-current, 
responsible for maintaining the resting potential of neurons and thus regulating 
neuronal excitability.118 M-channel openers such as retigabine can be used to treat 
epilepsy.119 Preservation of the M-current is also linked to the antiepileptic effect of 
valproate.120 The mechanism behind a response to vitamin B6 supplementation in 
individuals with KCNQ2 mutations has yet to be characterised. 
The concentration of PLP in the CSF of children with epilepsy has recently been 
shown to be lower than controls.121 Although this finding has not been consistent102,  
it is possible that the low CSF PLP seen in these patients is due to a secondary B6 
deficiency caused by poor nutrition of these often severely ill children. Another 
hypothesis however is that the seizures are causing a depletion of PLP through the 
creation of reactive oxygen species (ROS) or increased neurotransmitter turnover due 
to neuronal excitotoxicity. ROS and oxidative stress are hypothesised to be 
epileptogenic factors122 and PLP is protective against oxidative stress.123  
Supplementation with vitamin B6 could result in improved seizure control either by 
attenuating oxidative stress or simply replacing the PLP lost to reaction with ROS, or 
increased neurotransmitter turnover, hence rescuing a relative PLP-deficient state.124 
Currently however, it is unknown whether this seizure control conveyed by vitamin B6 
is due to a rescuing of relative PLP deficiency or whether PLP itself is having a direct 
anti-convulsant effect.125 
The identification of existing and novel genetic epilepsies amenable to vitamin B6 
supplementation is a priority in order to aid the treatment of individuals with these 
disorders. In addition, there are several genes encoding proteins linked to vitamin B6 
metabolism in which pathogenic variants have not been identified, but disorders 
caused by mutations in these genes could be amenable to treatment. These include 
the PDXK and PDXP genes encoding PK and PLPase, respectively, and the 
SLC25A39/40 genes, predicted to encode mitochondrial B6 transporters. 
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 LC-MS/MS for the diagnosis of inborn errors of 
metabolism.  
In the last 20 years, the importance of tandem mass spectrometry (MS/MS) for the 
diagnosis of inborn errors of metabolism has been steadily growing, particularly when 
coupled with an additional liquid chromatography (LC) separation step prior to MS/MS 
analysis.126-128 Although traditionally more expensive and requiring greater technical 
expertise than other methods129, LC-MS/MS provides unrivalled specificity and 
sensitivity in the field of clinical biochemistry, particularly for the analysis of small to 
medium biomolecules.130-131 
Liquid chromatography separates molecules of interest according to their variable 
affinity for a stationary phase when dissolved in a mobile (liquid) phase. This affinity 
depends on the chemistry of each individual compound as well as the composition of 
the mobile and stationary phases. By varying these parameters, a wide range of 
biomolecules can be separated from one another by the time it takes for them to elute 
from the column and reach a detector (the retention time). Prior to recent years, the 
length of time taken for LC separation was a concern with regards to clinical utility. 
However, the introduction of instrumentation capable of maintaining a higher mobile 
phase pressure, usually up to 15,000 psi132, has enabled the use of smaller stationary 
phase particle sizes of 1.6 – 1.8 µm. This has reduced a typical LC method length 
from > 20 to < 5 minutes133 while maintaining chromatographic separation, thereby 
enhancing practicability in the clinical diagnostic arena. 
The commonest type of tandem mass spectrometry used clinically is electrospray 
ionisation (ESI)-MS/MS analysis. This utilises two mass analysis steps, separated by 
a fragmentation step, typically colliding the ions of interest with an inert gas such as 
argon. This type of fragmentation is termed collision-induced dissociation (CID) and 
the process as a whole can be called ‘triple quadrupole mass spectrometry’, referring 
to the two mass analyser quadrupoles separated by a radio frequency (RF)-only 
quadrupole acting as the collision cell.  
In brief, MS/MS analysis is performed as follows: firstly, ions pertaining to the 
molecule of interest are formed in an ion source and selected according to their mass-
to-charge (m/z) ratio at the first quadrupole (Q1). ‘Precursor ions’ selected for analysis 
are then fragmented in the collision cell (q2) via CID, before proceeding to the second 
mass analyser (Q3) where ‘product ions’ are analysed, again according to their m/z 
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ratio (Figure 1.5). The use of CID allows for an increased level of selectivity as 
isobaric ions can be separated according to their fragmentation into specific product 
ions. Modern tandem mass spectrometers are capable of the analysis of many 
precursor and product ions simultaneously, by rapidly switching between the 
monitoring of different m/z ratios. This is termed multiple reaction monitoring (MRM) 
and enables the quantification of many compounds from one LC injection.130 
 
 
 
LC-MS/MS analysis is rendered quantitative by the use of isotopically labelled internal 
standards. Typically, this internal standard is identical to the molecule of interest apart 
from being labelled with several 15N, 13C or 2H atoms. By using the ratio of the non-
labelled analyte against that of the isotope-labelled internal standard, more accurate 
quantification is enabled and the effect of sample matrix minimised and often 
eliminated. In addition, analytical error introduced during sample preparation is 
reduced.134 
With regards to clinical application, the use of LC coupled with MS/MS allows for 
improved specificity, as compounds are separated according to both affinity for the 
stationary phase, molecular weight (as an m/z ratio), and fragmentation via CID. 
MS/MS analysis is also enhanced by LC separation as this step reduces the number 
of co-eluting compounds, enhancing sensitivity.135 
Within the field of inborn errors of metabolism, applications of LC-MS/MS (or other 
MS-based techniques) include newborn screening for the detection of, amongst other 
disorders, phenylketonuria (PKU)136, maple syrup urine disease (MSUD)137, medium-
chain acyl-CoA dehydrogenase deficiency (MCADD)138 and isovaleric acidaemia.139 
Figure 1.5: Liquid chromatography-tandem mass spectrometry. a) Schematic of a typical LC-MS/MS 
system. b) Waters Acquity I-Class LC coupled to a Xevo TQ-Sµ mass spectrometer, a modern LC-MS/MS system 
used in clinical laboratories.  
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LC-MS/MS methods are also widely used for the diagnosis of a wide variety of 
lysosomal storage disorders such as the mucopolysaccharidoses140, Gaucher, 
Pompe, Krabbe and Fabry diseases141 and Niemann-Pick disease types A/B142 and 
C.143 Clinical diagnostic laboratories are also moving towards LC-MS/MS for more 
routine analyses such as the quantification of amino acids from plasma, useful for the 
diagnosis of a wide variety of metabolic disorders.144 Specific to disorders causing 
vitamin B6 dependent epilepsy, LC-MS/MS methods exist for the quantification of  
α-AASA and P6C, important for the diagnosis of pyridoxine-dependent epilepsy due 
to mutations in ALDH7A1.64 LC-MS/MS is also useful for the measurement of B6 
vitamers in plasma and CSF.22 
Many of the recently developed methods mentioned above utilise dried blood spots 
(DBS) as a sample matrix. The application of a small amount of venous or capillary 
blood to filter paper is a convenient way to collect samples, particularly from infants. 
Storage of blood samples as DBS improves the stability of many analytes, including 
proteins, and often removes the need for freezing of the sample on storage.145-148  
DBS were first developed by Dr. Robert Guthrie for the neonatal detection of PKU in 
the 1960s.149 Their use has since expanded to newborn screening programs around 
the world. The enhanced sensitivity of LC-MS/MS equipment allows the detection of 
less abundant analytes from the small sample volumes found in DBS. This often 
requires only an elution step and subsequent analysis of this eluent.145 In recent 
years, diagnostic DBS tests have also been developed using the protein contained in 
a DBS sample to quantify the activity of a specific enzyme within the blood. Currently 
these are mostly limited to the diagnosis of lysosomal storage disorders.150-154 
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 Aims and scope of this thesis 
The aims of this thesis are to: 
 Develop an LC-MS/MS-based method to profile the B6 vitamers in dried blood 
spots from individuals with vitamin B6-dependent seizure disorders and, using 
this method, identify metabolite patterns that could aid the diagnosis or 
treatment of these individuals. 
 Develop an LC-MS/MS-based method for the measurement of PNPO activity 
from dried blood spots and determine if this method is a useful tool for the 
diagnosis of PNPO deficiency. 
 Characterise the biochemical abnormalities in a family with peripheral 
neuropathy thought to be caused by a pathogenic variant in the PDXK gene 
encoding pyridoxal kinase. 
 Characterise the photodegradation profile of PLP in aqueous solution in order 
to advise the treatment of individuals receiving PLP supplementation. 
 Use next generation sequencing technology to identify novel candidate gene 
loci responsible for seizures in undiagnosed B6-dependent epilepsy patients. 
 Determine the mechanism behind a response to vitamin B6 supplementation 
identified in some individuals with seizures caused by mutations in KCNQ2. 
In summary, this thesis aims to identify new strategies for the diagnosis of vitamin B6-
dependent disorders and elucidate further their biochemical mechanisms in order to 
aid their clinical management and hence disease outcome. This will also provide 
insights into the homeostasis of the B6 vitamers as well as other metabolic pathways 
in which vitamin B6 is important. 
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 MATERIALS AND METHODS 
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 Materials 
The following were purchased from Sigma Aldrich (Poole, UK): 
Acetic Acid (LC-MS Grade), Adenosine 5’-Triphosphate disodium salt, 
Amidosulphobetanine-14 (ASB-14), Amphotericin B, Dimethyl sulfoxide (DMSO), 1,4-
Dithiothreitol (DTE), 100% Ethanol, Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA), Glucose, Glycerol, Hank’s Balanced Salt Solution 
(HBSS), 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), 
Heptafluorobutyric Acid (LC-MS grade) (HFBA), Iodoacetamide (IAA), Linopirdine, 
Magnesium Chloride (MgCl2), Magnesium-Adenosine 5’-Triphosphate (MgATP), 
Potassium Chloride, Potassium Gluconate, Potassium Phosphate, Pyridoxal (PL), d3-
Pyridoxal, Pyridoxal 5’-phosphate (PLP), Pyridoxamine (PM), d3-Pyridoxamine, 
Pyridoxamine 5’-phosphate (PMP), 4-Pyridoxic acid (PA), d2-4-Pyridoxic acid, 
Pyridoxine (PN), d2-pyridoxine, 13C415N2-Riboflavin, Sodium Acetate, Sodium 
Chloride, Sylgard 184, Thiourea, Trifluoroacetic Acid, Tris Base, Tris-EDTA buffer, 
Tris(2-carboxyethyl)phosphine (TCEP), Urea. 
 
The following were purchased from Thermo Fisher Scientific (Waltham, MA, US): 
0.3ml Screw Top Fixed Insert Vials & Lids, BigDye Terminator v1.1 Cycle Sequencing 
Kit, B6-depleted Ham’s F-12 Medium, Dialysed Fetal Bovine Serum (FBS), DNA 
oligonucleotides used as primers for PCR amplification, dNTP solutions set (100 
mmol/L), Exonuclease I, Fetal Bovine Serum (FBS), Formic Acid (LC-MS Grade), 
Ham's F-12  Medium, Methanol (LC-MS Grade), Nuclease-Free Water, Orange DNA 
Loading Dye, Pierce BCA Protein Assay Kit, Taq DNA Polymerase (including MgCl2 
and PCR reaction mix), Tris-acetate-EDTA (TEA), Trypsin-EDTA (0.25%), Shrimp 
Alkaline Phosphatase (SAP), UltraPure Agarose 
 
The following were purchased from Genscript (Piscataway, NJ, US): 
Custom synthesized peptides (desalted): DGKPSAR; FFTNFESR; FFTNFESQK; 
SSQIGAVVSHQSSVIPDR. 
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The following were purchased from VWR (Lutterworth, UK): 
Acetone, Acetonitrile (LC-MS Grade), Calcium Chloride, Sodium Hydroxide. 
 
The following were purchased from Instruchemie B.V. (Delfzijl, The Netherlands): 
Alkaline D-575 Reagent, Haemoglobin standard 
 
The following were purchased from Toronto Research Chemicals (North York, 
Canada): d5-Pyridoxal 5’-phosphate, Pyridoxine 5’-phosphate 
 
1 kb DNA Ladder was purchased from New England Biolabs (Ipswich, MA, US). 6.1 
N Trichloroacetic Acid (TCA) was purchased from MP Biomedicals (Santa Ana, CA, 
US), 8.5% Orthophosphoric Acid was purchased from BDH Chemicals (Poole, UK), 
Flavin mononucleotide (FMN) was purchased from Applichem (Darmstadt, 
Germany), GC150 TF-15 borosilicate capillary tubes were purchased from Warner 
Instruments (Hamden, CT, US), Isolute C18 Solid-Phase Extraction Columns were 
purchased from Biotage (Ystrad Mynach, UK), d3-Pyridoxal Phosphate was 
purchased from Buchem B.V. (Apeldoorn, Netherlands), 4-Pyridoxic Acid 5’-
Phosphate (PAP) was purchased from the Vrije Universiteit Medical Centre 
(Amsterdam, The Netherlands), QIAamp DNA Micro Kit was purchased from Qiagen 
(Hilden, Germany), d2-pyridoxal 5’-phosphate was kindly provided as a gift by Dr. 
Coburn (Indiana University, Fort Wayne), Whatman 903 Protein Saver Cards were 
purchased from GE Healthcare (Little Chalfont, UK), Yeast Enolase standard protein 
was purchased from Waters (Milford, MA, US). 
 
Unless specified, all H2O used was purified using a Millipore Milli-Q Direct 8 system 
with a 0.22 µm filter. 
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 Ethics statement 
Where appropriate, this study was approved by the National Research Ethics Service 
(NRES) Committee (London, Bloomsbury [RED ref. no. 3/LO/0168]). Written informed 
consent was obtained from all subjects before sample collection. 
 
 Collection and storage of dried blood spots 
DBS from PNPO deficient patients and subjects with other/undiagnosed vitamin B6-
responsive epilepsies were collected from centres across Europe. Child control DBS 
were collected from patients attending Great Ormond Street Hospital for Children, 
London, UK.  
Whatman 903 Protein Saver cards were used for the collection of samples from either 
venous or capillary blood. Sample collection from individuals that had received a 
blood transfusion in the preceding 100 days was avoided. Blood was spotted in the 
centre of the printed circle and allowed to dry for 16-24 hours prior to storage in a zip-
lock bag with silica desiccant, protecting from both humidity and light. Cards were 
kept at 22 °C for a maximum of 7 days prior to storage at either -20 °C or -80 °C until 
analysis. Those with poor quality sampling were rejected after visual inspection. 
 
 Quantification of B6 vitamers and 4-pyridoxic acid using 
LC-MS/MS 
 Identification of B6 vitamers and pyridoxic acid 
PLP, PNP, PMP, PL, PN, PM and PA were quantified using a protocol similar to that 
of Footitt et al.22 with some modifications. A flow-through needle H-Class UPLC 
system coupled to a Xevo TQ-S triple quadrupole mass spectrometer using 
electrospray ionisation (ESI) and multiple reaction monitoring (MRM) was used for 
UPLC-MS/MS analysis (Waters, MA, US). Positive ion mode was used for compound 
detection. Injection volume was 8 µL and the samples were flow-injected onto a 
Waters Acquity UPLC HSS T3 column (1.8 µm, 2.1 x 50 mm) protected by a 1.8 µm 
Acquity UPLC HSS T3 guard column. The mobile phase constituents and gradient 
used for reversed-phase separation can be found in Table 2.1. Mass spectrometry 
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settings were as follows: capillary 2.50 kV, source temperature 150°C, desolvation 
temperature 600°C, cone gas flow rate 150 L/h and desolvation gas flow rate 1200 
L/h. The wash solvents used were: Purge Solvent = 95% dH2O; 5% Methanol; Seal 
Wash and Sample Manager Wash = 5% dH2O; 95% Methanol. 
Time (min) 
% mobile phase 
Flow rate (mL/min) Gradient curve 
A B 
0.00 97.5 2.5 0.40 N/A 
0.40 97.5 2.5 0.40 6 
3.75 50.0 50.0 0.40 6 
4.25 0.1 99.9 0.40 11 
5.00 97.5 2.5 0.40 11 
6.50 97.5 2.5 0.40 6 
 
Table 2.1: Gradient profile for separation of B6 vitamers and pyridoxic acid by LC-MS/MS.  
(A) = 3.7% acetic acid, 0.02% HFBA; (B) = 100% Methanol. 
Figure 2.1: LC-MS/MS detection of the B6 vitamers and pyridoxic acid. X-axis = mins. 
Pyridoxine 5’-phosphate 
Pyridoxamine 5’-phosphate 
Pyridoxal 5’-phosphate 
Pyridoxic acid 
Pyridoxine 
Pyridoxamine 
Pyridoxal 
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The precursor and product ions used for B6 vitamer detection are as detailed in Table 
2.2, as well as the optimised cone voltage and collision energy for each compound. 
All vitamers could be specifically identified according to the m/z ratios of their 
precursor and product ions and retention times. All compounds were detected in ES+ 
mode. An example chromatogram can be found in Figure 2.1. 
Analyte 
Retention 
time 
(min) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Cone 
voltage 
(V) 
Collision 
energy 
(V) 
Loss upon 
Fragmentation 
Pyridoxamine 5’-
phosphate 
0.62 249.04 134.05 27 22 H3PO4 + NH3 
Pyridoxine  
5’-phosphate 
0.77 250.16 134.13 58 20 H3PO4 + H2O 
d5-Pyridoxal  
5’-phosphate 
0.78 253.16 155.18 30 18 H3PO4 
d3-Pyridoxal  
5’-phosphate 
0.78 251.16 153.18 30 18 H3PO4 
d2-Pyridoxal  
5’-phosphate 
0.78 250.10 152.10 30 18 H3PO4 
Pyridoxal  
5’- phosphate 
0.78 248.00 150.01 30 18 H3PO4 
d2-Pyridoxic acid 0.92 186.06 149.99 18 18 2H2O 
Pyridoxic acid 0.92 184.06 147.99 18 18 2H2O 
d3-Pyridoxal 1.17 171.10 153.05 21 12 H2O 
Pyridoxal 1.17 168.10 150.05 21 12 H2O 
d3-Pyridoxamine 1.32 172.12 137.04 22 20 H2O + NH3 
Pyridoxamine 1.32 169.12 134.04 22 20 H2O + NH3 
d2-Pyridoxine 1.60 172.09 136.04 27 19 2H2O 
Pyridoxine 1.60 170.09 134.04 27 19 2H2O 
Table 2.2: Parameters used for the MRM-based identification of the B6 vitamers and pyridoxic acid 
and their stable isotope internal standards. V = voltage; m/z = mass/charge ratio. Several internal 
standards were used for pyridoxal 5’-phosphate quantification during method developed. The MRM 
transitions for each of these are shown individually. 
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Stock solutions of the vitamers and internal standards were stored individually in H2O 
at -80 °C for long-term storage. During experimentation, vitamer solutions were kept 
in the dark and on ice when possible. Calibration curves were created using the ratios 
of vitamers against a known concentration of their deuterated internal standard with 
the exception of PMP and PNP as stable isotopes of these compounds were not 
available. These vitamers were ratioed against d3-PLP or d5-PLP for quantification.  
The LLOQ for B6 vitamer quantification was determined as the lowest point on the 
calibration curve. On each occasion the signal/noise (S/N) ratio was above 10. The 
S/N ratio is calculated by dividing the peak height of the analyte by the background 
signal before and after the peak of interest. 
In all cases, data was collected using the Waters MassLynx software package and 
quantification was carried out by interpolating the ratio of each vitamer/internal 
standard combination to its respective calibration curve. 
 
 Identification and quantification of FMN 
Flavin mononucleotide (FMN) was quantified using methodology similar to that 
described in Section 2.4.1. Apart from those detailed in Table 2.3, the liquid 
chromatography conditions and mass spectrometry parameters were identical. No 
deuterated standard of FMN was available so a B2 analogue (13C415N2-riboflavin) was 
used instead. MRM transitions for both compounds were determined by direct 
infusion into the Xevo TQ-S mass spectrometer and using the Waters Intellistart 
software package for optimisation. A calibration curve was established using differing 
concentrations of FMN and a fixed concentration of 13C415N2-riboflavin, FMN was 
quantified as described for the B6 vitamers in Section 2.4.1. 
Analyte 
Retention 
time 
(min) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Cone 
voltage 
(V) 
Collision 
energy (V) 
Flavin 
mononucleotide 
1.88 475.2 359.3 4 22 
13C415N2-Riboflavin 3.12 383.2 249.1 84 38 
 
Table 2.3: Parameters used for the MRM-based identification of FMN and 13C415N2-Riboflavin 
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 Sample preparation for measurement of B6 vitamers and 
pyridoxic acid 
2.4.3.1 Dried blood spots 
Two duplicate 3 mm punches were taken from each DBS sample and placed in 
separate 1.5 ml polypropylene tubes; one for low and one for high concentration 
quantification (see below). 120 µL H2O was then added to each tube prior to 
sonication in an XUBA3 Ultrasonic Bath (Grant Instruments Ltd., Royston, UK) for 10 
minutes at 22 °C. 120 µl of 0.3 N TCA containing deuterated internal standards (d5-
PLP, d3-PL, d2-PN, d3-PM and d2-PA) at 50 or 5 nmol/L was then added to each tube. 
This gave final concentrations of 0.15 N TCA and 25 or 2.5 nmol/L. Samples were 
incubated for 45 min on ice, prior to centrifugation at 16,000 x g for 10 minutes at 4 
°C. The supernatant was then taken and stored at -20 °C until analysis. On the day 
of LC-MS/MS analysis samples were again centrifuged at 16,000 x g for 10 minutes 
at 4 °C and the supernatant was transferred into a 300 µl insert vial. 
It was necessary to create two calibration curves, one for quantifying low 
concentrations of 0.0675 – 5 nmol/L and another for high concentrations of 5 – 200 
nmol/L. A final stable isotope internal standard concentration of 2.5 nmol/L was used 
for quantifying lower concentrations, whereas a concentration of 25 nmol/L was used 
for higher concentrations. This method using two calibration curves allowed linearity 
of all vitamers across both measurement ranges (R2 > 0.99) and therefore more 
accurate quantification of lower concentrations than would otherwise be possible. 
Due to the high doses of B6 supplements taken by B6-responsive epilepsy subjects, 
the vitamer concentrations found in these samples can be up to four orders of 
magnitude greater than controls – this made the creation of two calibration curves 
necessary. 
Calibration standards were created by spiking an aqueous 0.15 N TCA mix with 
known concentrations of the B6 vitamers to the final concentrations required (0.0675 
– 200 nmol/L). These concentrations upon analysis (0.0675 – 200 nmol/L) are 
equivalent to 5 – 15,000 nmol/L in whole blood, once a x 75 dilution factor is taken 
into account. This corresponds to a 3 mm DBS containing 3.2 µL blood155 being placed 
into a total volume of 240 µL for analysis. The amount of blood contained within a 3 
mm DBS punch is affected by factors such as the amount of blood spotted on the 
card on the card and the haematocrit of the subject. This is discussed further in 
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Sections 3.1.1 and 4.1.2.6. Quantification of the B6 vitamers and pyridoxic acid was 
carried out using the LC-MS/MS method described in Section 2.4.1. 
 
2.4.3.2 Cell Lysates 
Chinese Hamster Ovary (CHO) cell pellets were stored at -80°C after being harvested 
as described in Section 2.13.1. After removal from storage, they were resuspended 
in 50 µL dH2O and mixed by vortexing. Each pellet was then lysed by freeze-thawing 
five times. This was carried out by alternating the samples between methanol cooled 
to -79°C using dry ice, and a 37°C water bath. The sample was pelleted by 
centrifuging at 4,500 x g for 10 minutes; the cell lysate supernatant was then collected 
for analysis. This cell lysate was used for the determination of protein concentration 
using a Pierce BCA Protein Assay Kit (see Section 2.13.2). 
The cell lysate was prepared for quantification of B6 vitamers and pyridoxic acid by 
adding 10 µL cell lysate to 50 µL dH2O and 60 µL 0.3 N TCA containing deuterated 
internal standards (d5-PLP, d3-PL, d2-PN, d3-PM and d2-PA) at 50 nmol/L each (25 
nmol/L final concentration). Each sample was subsequently vortexed and incubated 
for 45 minutes on ice in order to ensure precipitation of protein in the sample. The 
sample was then centrifuged for 10 minutes at 16,000 x g (at 4°C) and the supernatant 
was transferred into a 300 µl insert vial. Calibration curves from 0.5 – 200 nmol/L 
were prepared in parallel for each B6 vitamer and pyridoxic acid. LC-MS/MS analysis 
for quantification of these analytes was carried out using the method described in 
Section 2.4.1. 
 
2.4.3.3 Cell culture medium 
The B6 vitamers and pyridoxic acid were quantified in Ham’s F-12 medium, B6-
depleted Ham’s F-12 medium, Fetal Bovine Serum (FBS) and dialysed FBS. 120 µL 
0.3 N TCA containing deuterated internal standards (d5-PLP, d3-PL, d2-PN, d3-PM 
and d2-PA) at 50 nmol/L (25 nmol/L final concentration) was added to 120 µL of 
media. Samples were vortexed and incubated for 45 minutes on ice in order 
precipitate protein prior to centrifugation for 10 minutes at 16,000 x g, 4°C. The 
supernatant was transferred to a 300 µL glass insert vial for analysis. A calibration 
curve from 0.5 – 200 nmol/L was prepared for each B6 vitamer and pyridoxic acid. 
Quantification was performed using the LC-MS/MS protocol detailed in Section 2.4.1. 
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 Enzyme assay for the quantification of PNPO activity 
from dried blood spots 
The protocol described below is the optimised method for a single step PNPO enzyme 
assay using PNP as substrate, the development of which is described in Section 3.1. 
Two 3 mm punches (T0 and T30) were taken for each patient sample from a spotted 
blood card and placed in a 1.5 ml polypropylene tube. Each punch was first 
rehydrated in 60 µL 40 mmol/L TrisPO4 and then sonicated in an XUBA3 Ultrasonic 
Bath (Grant Instruments Ltd., Royston, UK) at 22 °C for 2 min. 60 µL reaction buffer 
containing 800 nmol/L PNP substrate and 3 µmol/L FMN was then added to each 
tube. The final concentrations of PNP and FMN were 400 nmol/L and 1.5 µmol/L, 
respectively. A reaction stop solution of 120 µL 0.3 N TCA (containing 50 nmol/L 
internal standard d5-PLP) was then added immediately to the T0 punch. Final 
concentrations of TCA and d5-PLP for analysis were 0.15 N and 25 nmol/L, 
respectively.  
The TrisPO4 buffer was prepared by adjusting a 40 mmol/L Tris solution to pH 7.6 
using 8.5% orthophosphoric acid. Potassium phosphate and Tris-Cl buffers were 
prepared in a similar manner during method development, with the pH adjusted 
according to requirements using HCl or 85% orthosphosphoric acid. 
The T30 punch was incubated with rotary shaking at 300 rpm at 37 °C for 30 min in 
a Thermomixer C (Eppendorf, Hamburg, Germany) before addition of 120 µl reaction 
stop solution. Both the T0 and T30 punches were incubated for 45 mins on ice, in the 
dark, prior to sonicating for 5 minutes at 22 °C. The addition of TCA was required for 
protein precipitation as well as the release of protein-bound PLP into solution and 
cessation of enzyme activity. Subsequent centrifugation at 16,000 x g for 10 min at  
4°C resulted in pelleting of the punches and precipitated blood proteins. The 
supernatant containing B6 vitamers was then taken and stored at -20 °C until analysis. 
After thawing, each sample was re-centrifuged at 16,000 x g for 10 min at 4 °C and 
transferred to a 300 µL insert vial.  
Quantification of PLP formation was used to calculate PNPO activity. Endogenous 
PLP was measured at 0 min in the T0 DBS punch and subtracted from that measured 
after 30 min incubation with substrate in the T30 punch. Enzyme activity was 
expressed as pmol PLP/3 mm DBS/h. PNP concentrations were also monitored but 
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not used for quantification of PNPO activity. Calibration curves were used to quantify 
PLP and PNP from 1.25 to 200 nmol/L using the analyte/internal standard ratio 
(PLP/PNP to d5-PLP). Apart from where specified in Section 3.1, the other B6 
vitamers and pyridoxic acid were not monitored during this experimentation. All LC-
MS/MS data acquisition and analysis was performed using Masslynx software 
(Waters, Milford, USA) as described in Section 2.4.1.  
 
 Measurement of the haemoglobin concentration of whole 
blood stored in DBS 
Haemoglobin quantification was carried out using the Alkaline Haematin D-575 
Reagent according to the manufacturer’s specification, with minor modifications made 
in order to analyse the volumes of blood in a 3 mm DBS punch. 1 x 3 mm DBS was 
placed into a 1.5 mL microcentrifuge tube alongside 310 µL Alkaline Haematin D-575 
Reagent and 10 µL dH2O. Each sample was then either agitated for 30 minutes at  
22°C in a Thermomixer C (Eppendorf, Hamburg, Germany) or sonicated in a XUBA3 
Ultrasonic Bath (Grant Instruments Ltd., Royston, UK) for varying times according to 
the experimentation detailed in Section 3.1.2.6. After incubation, microcentrifuge 
tubes were centrifuged for 5 minutes at 16,000 x g before the supernatant was placed 
into a 96-well microplate. A calibration curve was created in parallel by the addition 
of appropriately diluted 0 – 0.25 g/dL haemoglobin standards to adjacent wells with 
310 µL Alkaline Haematin D-575 Reagent. This allowed the creation of a calibration 
curve and extrapolation of haemoglobin concentrations in the 3.2 µL blood contained 
in a 3 mm DBS155, diluted in 320 µL reagent to those in whole blood by using a 100 x 
dilution factor. Final concentrations of haemoglobin were expressed at gHb/dL in 
whole blood. Samples were analysed at 595 nm on a Tecan Infinite 200 Microplate 
Reader (Tecan, Mannedorf, Switzerland) and the absorbance of standards were 
plotted against their known concentrations. The haemoglobin concentration of the 
eluted DBS blood samples was calculated using this calibration curve. 
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 Enzyme assay for the study of recombinant PNPO 
enzyme 
Bacterially prepared recombinant human PNPO enzyme was a kind gift from Dr. 
Wyatt Yue (Structural Genomics Consortium, The University of Oxford). The PNPO 
enzyme was stored at -80 °C in 50 mmol/L HEPES, 500 mmol/L NaCl, 5% glycerol, 
0.5 mmol/L TCEP.  
For all experiments, 100 ng of recombinant protein was used per reaction. Protein 
was diluted to 20 ng/µl in dH2O and 5 µL was added to each well of a 96-well plate. 
115 µL reaction buffer containing 20 mmol/L pH 7.6 TrisPO4, substrates and cofactors 
was added to each well. TrisPO4 was prepared as described in Section 2.5. Substrate 
type, cofactor concentration and incubation time were varied according to 
experimentation (0 - 10 µmol/L PNP or PMP, 0 – 3 µmol/L FMN, 0 – 60 minutes). As 
described in Section 2.5, after gentle vortexing, a reaction stop mixture of 120 µl 0.3 
N TCA containing internal standard (d3-PLP – 50 nmol/L) was immediately added to 
the T0 wells. The other wells were incubated at 37 °C with agitation at 300 rpm for 
their allotted times before addition of the reaction stop mixture. After incubation on ice 
for 45 min, samples vortexed and analysed by LC-MS/MS using the method 
described in Section 2.4.1. PNPO activity was calculated by quantifying PLP formed 
during the incubation and expressed as nmol PLP/L/h. This can be converted to 
pmol/mg protein/h using a conversion factor of x 2.4 (e.g. 1 nmol/L/h = 2.4 
pmol/mg/h). Subtraction of PLP at T0 was required not as no endogenous PLP was 
measured from T0 time points. Kinetic parameters were calculated using the 
Graphpad Prism software package. 
 
 Quantification of FMN associated with the recombinant PNPO 
protein 
FMN was measured from the same reaction mix used for the T0 time point during 
experimentation with p.R116Q and wild-type PNPO enzymes, prepared as described 
above. FMN was quantified using the LC-MS/MS method detailed in Section 2.4.2. 
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 LC-MS/MS detection of PNPO-derived tryptic digest 
peptides 
 Selection of peptides 
Peptides predicted to be formed upon tryptic digest of the PNPO protein were 
identified using the Skyline software package (MacCoss Lab Software, University of 
Washington, US). The specificity of these peptides to the PNPO protein was 
determined using the BLASTp online tool (www.blast.ncbi.nlm.nih.gov). Peptides that 
were not specific to PNPO were discarded, 4 peptides were selected for analysis 
(Peptides 1-4, Table 2.4). Additional rationale for the selection of these peptides can 
be found in Section 3.2.3.1. 
 
 
 LC-MS/MS analysis of PNPO-derived peptides 
Custom synthesised peptides 1-4 were resuspended in 50:50 dH2O:acetonitrile 
(ACN) to a concentration of 10 µmol/L and stored at -20°C. For LC-MS/MS tuning, 
each peptide was diluted to a working stock at 10 nmol/L in 1 mL 97% dH2O,  
3% ACN, 0.1 % trifluoroacetic acid (TFA). Tuning was carried out using direct infusion 
(DI) of each working stock at 10 µL/min into a Xevo TQ-S mass spectrometer (Waters, 
MA, US) with a carrier stream of 50:50 dH2O:ACN, 0.1% FA at 0.4 mL/min. An MS1 
scan (Cone voltage ramp = 0 – 80V) was performed for each peptide in order to 
identify the most abundant ion produced from each peptide. All experimentation was 
carried out using positive ion mode. Instrument tuning parameters for this and 
subsequent analyses were as follows: capillary 2.70 kV, source temperature 150°C, 
Table 2.4:  Selected peptides for LC-MS/MS analysis of trypsin digested PNPO protein. AA = amino acid. 
Peptide 
AA position in 
PNPO protein 
Monoisotopic 
mass (daltons) 
Notes 
1: DGKPSAR 89 - 95 729.37 Upstream of p.R116Q 
2: FFTNFESR 109 - 116 1046.47 Only present in wild-type PNPO protein 
3: FFTNFESQK 109 - 117 1146.52 Only present in wild-type p.R116Q protein 
4: SSQIGAVVS 
HQSSVIPDR 
164 - 181 1865.95 Downstream of p.R116Q 
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desolvation temperature 600°C, cone gas flow rate 150 L/h and desolvation gas flow 
rate 1000 L/h. 
The most abundant precursor ions were selected from each peptide, optimal multiple 
reaction monitoring (MRM) transitions were determined by infusing each peptide, as 
above, using the Intellistart software package (Waters, MA, US) to automatically 
adjust the ionisation and collision energies in order to select the most abundant 
daughter ions. The resulting MRM transitions and ionisation conditions are shown in 
Table 2.5. These were used for all further analysis of peptides 1-4. 
 
Peptide 
Precursor ion 
(m/z) 
Product 
ion (m/z) 
Cone 
voltage 
(V) 
Collision 
Energy (V) 
1: DGKPSAR 365.94 430.42 2 10 
2: FFTNFESR 524.31 753.65 32 16 
3: FFTNFESQK 574.43 267.27 52 18 
4: SSQIGAVVS 
HQSSVIPDR 
623.22 726.81 2 18 
 
In order to optimise the liquid chromatography conditions, each of the peptide working 
stocks were pooled and diluted to a concentration of 100 pmol/L in 300 µL 97% dH2O, 
3% ACN, 0.1 % FA. 10 µL of this pooled peptide mix was injected using an flow-
through needle H-Class UPLC system (Waters, MA, US) coupled to a Xevo TQ-S 
triple quadrupole mass spectrometer. 
During initial experimentation, samples were injected onto a CORTECS UPLC C18+ 
column (1.6µm, 2.1 x 50 mm; Waters, MA, US) protected by a CORTECS UPLC C18 
VanGuard Pre-column (1.6 µm; Waters, MA, US). As detailed in Section 3.2.3.1, this 
column was later changed to an Acquity UPLC HSS T3 column (1.8 µm, 2.1 x 50 mm; 
Waters, MA, US) protected by an Acquity UPLC HSS T3 guard column; (1.8 µm; 
Waters, MA, US). The final mobile phase composition and gradient profile used for 
liquid chromatography analysis can be found in Table 2.6. The column and precolumn 
heaters were operated at 45°C. Wash solvents were as follows: Purge solvent = 97% 
dH2O, 3% ACN, 0.1 % FA; Seal wash: 3% dH2O, 97% ACN; Sample manager wash: 
3% dH2O, 97% ACN. The retention time (RT) of each peptide was monitored by 
Table 2.5:  MRM transitions for LC-MS/MS analysis of trypsin digested PNPO 
protein. V = voltage; m/z = mass/charge ratio   
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MS/MS analysis using the MRM transitions in Table 2.5. Each peptide could be 
identified according to their RT and the m/z ratio of their corresponding precursor and 
product ions. Where appropriate, alterations made to the protocol during method 
development are detailed in Section 3.2.3.1. 
 
Time (min) 
% mobile phase 
Flow rate (ml/min) Gradient curve 
A B 
0.00 97.0 3.0 0.80 N/A 
0.40 97.0 3.0 0.80 6 
7.00 60.0 40.0 0.80 6 
7.01 0.1 99.9 0.80 6 
8.50 0.1 99.9 0.80 6 
8.51 97.0 3.0 0.80 1 
10.00 97.0 3.0 0.80 1 
 
MRM transitions for the detection of two peptides derived from human albumin and 
yeast enolase were also monitored during method development (Table 2.7). These 
were analysed using the same LC-MS/MS conditions used for analysis of peptides 1-
4 and could be separated from the other peptides according to their retention time 
and respective m/z ratios of their precursor and product ions. For quantification, the 
relative abundance of all peptides was calculated by measuring the area of their 
respective peaks identified on LC-MS/MS analysis. 
A longer 45 minute gradient profile was also used in order to improve the sensitivity 
of LC-MS/MS detection of the target peptides. This can be found in Table 2.8. All 
other LC-MS/MS conditions were identical for this analysis. 
 
 
 
 
 
Table 2.6: Gradient profile for separation of tryptic digest peptides.  Conditions of Mobile phase A: 0.2% 
FA in H2O, 0.01% HFBA; Mobile Phase B: 0.2% FA in acetonitrile, 0.01% HFBA. N/A = not applicable. 
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Peptide 
Parent 
protein 
Precursor ion 
(m/z) 
Product 
ion 
(m/z) 
Cone 
voltage 
(V) 
Collision 
Energy (V) 
AVMDDFAAFVEK DGKPSAR Albumin 671.99 578.02 54 18 
SIVPSGASTGVHEALEMR Yeast enolase 614.60 547.90 46 12 
 
 
 Sample preparation 
Trypsin digestion of proteins from dried blood spots (DBS) following disruption of 
disulphide bonds and blocking of sulphydryl groups with iodoacetamide was 
performed as follows: 1, 2 or 4 x 3 mm punches from healthy control DBS were first 
placed into a 1.5 mL microcentrifuge tube and sonicated for 5 minutes in a XUBA3 
Ultrasonic Bath (Grant Instruments Ltd., Royston, UK) at 22°C after the addition of  
60 µL digestion buffer containing 100 mmol/L Tris-HCl, 6 mol/L urea, 2 mol/L thiourea 
and 2% amidosulphobetaine-14 (pH 7.8). Subsequently, 4.5 µL of 200 mmol/L 
dithiothreitol (DTE) in 100 mmol/L Tris-HCl (pH 7.8) was added before shaking at 
1500 rpm, 22°C for one hour. 9 µL iodoacetamide (IAA) was added thereafter, 
samples were then protected from light, shaken for 5 minutes at 1500 rpm and then 
incubated at 22°C for 45 minutes. 497 µL dH2O was added to each sample prior to 
vortexing and the 3 mm DBS was then removed. 30 µL of 0.1 µg/µL mass 
Table 2.7:  MRM transitions for LC-MS/MS detection of peptides derived from trypsin digested human 
albumin and yeast enolase proteins. V = voltage; m/z = mass/charge ratio  
Time (min) 
% mobile phase 
Flow rate (mL/min) Gradient curve 
A B 
0.00 97.0 3.0 0.80 N/A 
0.20 97.0 3.0 0.80 6 
40.00 60.0 40.0 0.80 6 
41.00 0.1 99.9 0.80 6 
42.00 0.1 99.9 0.80 6 
44.00 97.0 3.0 0.80 1 
45.00 97.0 3.0 0.80 1 
Table 2.8: Extended gradient profile for separation of tryptic digest peptides.  Mobile phase A: 0.1% FA 
in H2O; Mobile Phase B: 0.1% FA in acetonitrile.  
71 
 
spectrometry grade trypsin gold was added and each sample was incubated at 37°C 
for 16 hours in a Thermomixer C (Eppendorf, Hamburg, Germany). 
After digestion, samples were ‘cleaned’ using C18 solid phase extraction (SPE) in 
order to remove the salts, detergents and reagents used. Digested samples were 
diluted 1:1 in 0.2% TFA in order to facilitate interaction with the SPE column. The C18 
columns were first primed with 2 x 1 mL washes of 30:70% H2O:ACN, 0.1% TFA and 
then 2 x 1 mL H2O, 0.1% TFA. The prepared sample was then applied to the C18 
SPE column. The eluent was collected in a 1.5 mL microcentrifuge tube and reapplied 
to ensure binding to the column. After this second application 1 mL H2O, 0.1% TFA 
was applied to the column in order to wash away residual salts. The column-bound 
peptides were then eluted using 1 mL 30:70 H2O:ACN, 0.1% TFA. The eluent was 
collected in a clean 1.5 mL microcentrifuge tube and lyophilised overnight. The 
resulting pellets were resuspended in 100 µL 97%:3% H2O:ACN, 0.1% TFA, vortexed 
for 10 seconds and centrifuged at 16,000 x g for 10 minutes. The supernatant was 
transferred to 300 µL insert vials for LC-MS/MS analysis. 
TCA acetone precipitation was added to the protocol in order to further clean samples 
by removing proteins of extremely high abundance such as albumin. Samples were 
prepared for this by first adding 300 µL dH2O containing 500 ng yeast enolase protein 
to DBS in a 1.5 mL microcentrifuge tube. This was sonicated in a XUBA3 Ultrasonic 
Bath (Grant Instruments Ltd., Royston, UK) at 22°C for 5 minutes. TCA acetone 
precipitation was then performed by adding the supernatant to 1.2 mL -20°C 10% 
TCA in acetone. Samples were vortexed then incubated for 16 hours at -20°C. 
Thereafter, each tube was centrifuged for 10 minutes at 16,000 x g, 4°C and the 
supernatant discarded. 1 mL 100% acetone was added to the remaining pellet, 
samples were vortexed and centrifuged again for 10 minutes at 16,000 x g, 4°C. The 
supernatant was discarded and the pellet dried in a fume hood at 22°C for two hours 
before digestion.  
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 Enzyme assay for the study of recombinant pyridoxal 
kinase enzyme 
Bacterially prepared recombinant pyridoxal kinase enzyme was a gift from 
collaborators (Dr. Viorica Chelban, UCL Institute of Neurology). The purified 
recombinant protein was stored in 25 mmol/L HEPES (pH 7.4), 100 mmol/L KCl and 
1mmol/L DTT. 
100 ng protein was used for each reaction after diluting the protein in dH2O to 20 
ng/µL. A round-bottomed 96-well plate was heated to 37°C in a Thermomixer C 
(Eppendorf, Hamburg, Germany). 5 µL of diluted protein at 20 ng/µL was added to 
each well before the subsequent addition of 115 µL reaction buffer containing 20 
mmol/L potassium phosphate adjusted to pH 6.1 with 8.5% orthophosphoric acid. 
This reaction buffer also contained substrate (pyridoxal; 0 – 100 µmol/L) and cofactors 
(MgCl2; 0 – 3 mmol/L, Na2ATP; 0 – 500 µmol/L, MgATP; 0 – 500 µmol/L) at 
concentrations as described in Section 5.1. Plates were covered and the reaction in 
each well proceeded at 37°C with agitation at 300 rpm before being stopped with the 
addition of 120 µL 0.3 N TCA containing 50 nmol/L d5-PLP internal standard after 10 
minutes. The 96-well plate was subsequently covered and briefly vortexed before 
being placed on ice for 45 minutes. The plate was again vortexed before the reaction 
mixture from each well was transferred to 300 µL insert vials for LC-MS/MS analysis.  
Pyridoxal kinase activity was measured by calculating the PLP formed from PL 
substrate after the 10 minute incubation period at 37°C. Activity was expressed as 
µmol PLP/L/h. Activity can be converted to nmol/mg protein/h using a conversion 
factor of x 2.4 (e.g. 1 µmol/L/h = 2.4 nmol/mg/h). Subtraction of PLP at T0 was not 
required as no endogenous PLP was detectable. PLP quantification was carried out 
using the LC-MS/MS protocol detailed in Section 2.4.1 and elsewhere. Kinetic 
parameters were calculated using the GraphPad Prism software package. 
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 Enzyme assay for quantification of pyridoxal kinase 
activity from dried blood spots 
Two 3 mm punches (T0 and T10) from each sample source were placed into separate 
1.5 mL microcentrifuge tubes. 60µL 40 mmol/L potassium phosphate pH 6.1 was 
added to each tube. Potassium phosphate buffer was prepared by adjusting the pH 
of a 40 mmol/L potassium phosphate buffer with 8.5% orthophosphoric acid. Each 
DBS was then sonicated in an XUBA3 Ultrasonic Bath (Grant Instruments Ltd., 
Royston, UK) for 2 minutes at 22°C. Subsequently, 60 µL of a reaction buffer 
containing 20 µmol/L pyridoxal and 600 µmol/L MgATP in dH2O was added. The final 
concentrations of substrate (pyridoxal) and cofactor (MgATP) were therefore 10 
µmol/L and 300 µmol/L, respectively. Next, the reaction in the T0 DBS punch was 
stopped by the addition of 120 µL 0.3 N TCA containing 50 nmol/L of d5-PLP as 
internal standard. The T10 DBS punch was incubated in a Thermomixer C 
(Eppendorf, Hamburg, Germany) at 37°C for 10 minutes with agitation at 300 rpm. 
Each of the T0 and T10 DBS punches were, after the addition of the TCA reaction 
stop solution, incubated for 45 minutes on ice in order to precipitate blood protein. 
Each sample was then sonicated again for 5 minutes at 22°C before centrifugation at 
16,000 x g to pellet precipitated protein. The supernatant was transferred to a 300 µL 
insert vial and taken for analysis. 
LC-MS/MS-based quantification of pyridoxal kinase activity was carried out by 
measuring PLP formed over the 10 minute incubation period. PLP was measured in 
each of the T0 and T10 with the PLP measured at T0 subtracted from that in the T10 
punch. Quantification of PLP was carried out using a PLP:d5-PLP calibration curve 
from 0.5 – 200 nmol/L, this was prepared as discussed in Section 2.4.1. Pyridoxal 
kinase activity was expressed as pmol PLP 3 mm DBS/h. All LC-MS/MS data 
acquisition and analysis was performed using Masslynx software (Waters, Milford, 
USA) as described in Section 2.4.1.  
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 Characterisation of the photodegradation profile of PLP 
 Photodegradation protocol & sample preparation 
For the initial investigation of PLP degradation, 1 mmol/L solutions of > 99.8% PLP 
were, after mixing to solubilise PLP, prepared in 2 mL dH2O and left at 22 °C in sealed 
transparent glass vials on a sunny window ledge for 1 h, 5 h, 72 h and 144 h before 
freezing at -20 °C until analysis. Another 0 h sample was frozen at -20°C immediately 
after preparation. 
For the further characterisation of PLP degradation and PAP formation, samples were 
prepared by incubation in a custom-made enclosed wooden box containing 2 Philips 
TL 8W/35 fluorescent lamps and a 240 V AC cooling fan running at a speed of 50 - 
60 Hz at 23 W; this was necessary to maintain a consistent temperature of 22 °C. 2 
mL 20.24 mmol/L solutions of PLP in dH2O were, after stirring for 45 min in order to 
solubilise the high concentrations of PLP, incubated for 0 h, 1 h, 4 h and 24 h before 
being frozen at -20 °C until analysis. 
Commercially available PLP nutraceutical products were also assessed by the 
dissolution of samples in 10 mL dH2O at 5 mg/mL (20.24 mmol/L). In order to facilitate 
dissolution, tablets were crushed using a mortar and pestle prior to preparation. 
Capsules were emptied directly into dH2O, ensuring they were fully dispensed. After 
preparation, each sample was agitated in the dark for 1 hour to ensure the dissolution 
of all PLP. After this, samples were split into equal volumes at 0 h and 24 h time points 
and incubated under the same conditions used for pure PLP. Samples were frozen 
at -20°C until analysis. 
The postulated diketone dimer of PLP was investigated using a Uvikon XL 
spectrophotometer (NorthStar Scientific, Leeds, UK). A sample believed to 
correspond to this dimer was collected by collaborators (Dr. A Mohamed-Ahmed, 
School of Pharmacy, UCL) from the eluent of a single peak seen using HPLC-UV/VIS. 
The absorbance of each this sample was measured over the range of 226 – 400 nm. 
A sample containing 90% dH2O, 10% methanol, 0.2% formic acid was also measured 
(blank sample). This is the mobile phase that was used for separation of the PLP 
degradation products by HPLC. The absorbance measured at each wavelength in 
this blank was subtracted from that calculated over the same range upon analysis of 
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the peak seen by HPLC-UV/VIS analysis postulated to correspond to a diketone 
dimer of PLP. 
 LC-MS/MS for the assessment of photodegradants 
2.10.2.1 Investigation of PLP photodegradation products 
Initial investigation of the potential degradation products of PLP was performed by 
flow injection analysis-mass spectrometry. The carrier stream was 97.5% A (3.7% 
acetic acid, 0.01% HFBA) and 2.5% B (100% methanol). Before infusion, all samples 
were diluted in dH2O to a concentration of 10 µmol/L. All compounds were detected 
in ES+ mode. Analyses were performed with full MS scans using either the MS1 or 
MS2 quadrupoles. Product scans were performed according to a loss of H3PO4 (-98) 
upon fragmentation in order to investigate phosphorylated compounds. Exact 
parameters used for analysis (i.e. cone voltages, collision energies) are described in 
Section 6. The mass spectrometry tuning parameters used for analysis can be found 
in Section 2.4.1. 
After the identification of several unidentified compounds of interest, MRM transitions 
for these potential photodegradants were created as described in Section 6. The 
area under the curve (AUC) was used to semi-quantitatively calculate the relative 
abundancy of these compounds at each specified time point. The levels of PLP, PL 
and PA were assessed similarly. For LC-MS/MS analysis, samples were first diluted 
to 200 nmol/L in dH2O and then acidified with an equal amount of 0.3 N TCA (final 
concentration 0.15 N TCA; nominal 100 nmol/L PLP), the injection volume was 8 µl. 
The gradient profile in Table 2.1 was used for chromatographic separation. 
 
2.10.2.2 Quantification of pyridoxic acid 5’-phosphate 
PAP formation and PLP degradation were quantified from the solutions described 
above by the creation of a calibration curve from 1.25 – 200 nmol/L in a solution of 
H2O with 0.15 N TCA and 25 nmol/L d3-PLP as internal standard. 4-Pyridoxic acid 5’-
phosphate (PAP) was purchased from the VU Medical Centre, Amsterdam, The 
Netherlands. PLP and PAP to d3-PLP calibration curves were linear (R2 > 0.99) 
between 1.25 – 200 nmol/L. PLP and PAP were distinguishable according to both 
their retention time and m/z ratio. The MRM transition used for quantification of PAP 
was 264.07 > 166.07 with a cone voltage and collision energy of 27 and 16, 
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respectively. This corresponded to the loss of H3PO4 (-98) upon fragmentation. PAP 
eluted at 0.82 minutes from the HSS T3 column used for analysis. Experimentation 
was performed using the LC-MS/MS method described in Section 2.4.1. 
 
 Whole exome and whole genome sequencing 
Whole exome sequencing (WES) and whole genome sequencing (WGS) was 
performed by GOSgene, UCL GOS Institute of Child Health, London, UK or the 
Universitair Medisch Centrum Groningen (UMCG), Groningen, The Netherlands. The 
processing of raw data and creation of VCF files was performed by Dr. Hywel Williams 
of GOSgene or Drs. Erica Gerkes and Roan Kanninga of the UMCG.  
VCF files were uploaded to the Ingenuity Variant Analysis software package (IVA; 
Ingenuity, Redwood City, CA, US). Filtering of variants was carried out using 
parameters that differed according to each patient analysed and were adjusted as 
appropriate during analysis. The default parameters can be found in Table 2.9. 
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 Interpretation of variants using bioinformatics tools 
Variants that were considered potentially pathogenic were assessed using a variety 
of tools. These included those for assessment of amino acid substitutions in affected 
proteins such as SIFT (www.sift.bii.a-star.edu.sg) and PolyPhen-2 (www. 
genetics.bwh.harvard.edu/pph2). These online tools assign pathogenicity scores to 
identified variants according to the impact on protein structure and evolutionary 
conservation. The biological function of proteins encoded by the genes in which 
variants were identified were assessed using the UniProt (www.uniprot.org), OMIM 
(www.omim.org) and proteinatlas (www.proteinatlas.org) databases. This was used 
in order to assess whether the proteins identified could be implicated in the 
phenotypes of each patient. 
Filter Parameter 
Confidence (keep only variants which 
satisfy these criteria) 
Call Quality is at least 20 in any case and at least 20 
in each control 
Read depth is at least 10 in any case and 10 in any 
control 
Variant is outside the top 1% of most exonically 
variable genes (defined by the 1000 genomes 
project) 
Common variants (Exclude variants that 
have an allele frequency greater than)* 
1% prevalence in the 1000 genomes project 
1% prevalence in the ExAC database 
1% prevalence in the gnomAD database 
1% prevalence in the NHLBI ESP exomes 
Predicted Deleterious (Keep only variants 
no more than 20 bases into an intron that 
satisfy these criteria) 
Experimentally observed to be associated with a 
pathogenic or likely pathogenic phenotype according 
to computed AMCG guidelines classification 
Listed in HGMD or ClinVar 
Associated with a Frameshift, in-frame indel or 
start/stop codon change 
Associated with a missense change 
Associated with a splice site loss up to 7 bases into 
an intron 
Table 2.9: Ingenuity Variant Analysis parameters for filtering variants identified in VCF files derived 
from whole exome or genome data.  *Unless the variant is established as a pathogenic common variant. 
ExAC = Exome Aggregation Consortium (www.exac.broadinstitute.org); gnomAD = genome Aggregation Database 
(www.gnomad.broadinstitute.org); NHLBI ESP = National Heart, Lung, and Blood Institute Exome Sequencing 
Project); AMCG = American College of Medical Genetics and Genomics; HGMD = Human Gene Mutation Database 
(www.hgmd.cf.ac.uk); ClinVar = Clinical Variance (www.ncbi.nlm.nih.gov/clinvar).  
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 DNA Extraction and Sanger sequencing 
 DNA extraction from DBS 
Genomic DNA was extracted from dried blood spots using the QIAamp DNA Micro 
Kit as specified by the manufacturer. Three 3 mm DBS punches were placed into a 
1.5 mL microcentrifuge tube. 180 µL Buffer ATL was then mixed with 20 µL proteinase 
K by vortexing. The microcentrifuge tube was incubated for 1 hour with 900 rpm 
shaking at 56°C. After this incubation, 200 µL of Buffer AL was added and the solution 
was mixed again by pulse vortexing. The mixture was then incubated again at 70°C 
for 10 minutes, with shaking at 900 rpm. This lysate was placed into a MinElute 
column inside a 2 mL collection tube and centrifuged at 6,000 x g for 1 minute. The 
flow-through was discarded and the MinElute column was placed inside another 2 mL 
collection tube before the addition of 500 µL Buffer AW1. The tube was again 
centrifuged for 1 minute at 6,000 x g before this process was repeated, this time with 
the addition of 500 µL Buffer AW2. The MinElute column was then placed into a fresh 
1.5 mL microcentrifuge tube before the addition of 50 µL Buffer AE (elution buffer). 
This was incubated for 5 minutes at room temperature before centrifugation at 20,000 
x g for 1 minute to elute the genomic DNA. The resulting DNA samples were stored 
at -20°C until analysis. The concentration and purity of extracted DNA was 
determined using a NanoDrop 100 (Thermo Scientific). 
 
 Primer design 
In order to design primers for the amplification of target areas of genomic DNA using 
the Polymerase Chain Reaction (PCR), the gene sequence was downloaded from the 
Ensembl database (www.ensembl.org). The sequence was then imported into the 
Thermo Fisher Primer Designer tool (Thermo Fisher, Loughborough, UK) and primers 
were selected according to the parameters detailed in Section 5.3.1, Table 5.2. The 
Primer-BLAST tool (www.ncbi.nlm.nih.gov/tools/primer-blast) was used to ensure 
specificity of the primers chosen to the region of interest. 
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 Amplification of target genes from genomic DNA using the 
Polymerase Chain Reaction (PCR) 
2.12.3.1 PCR conditions 
Standard PCR reactions were carried out using the conditions detailed in Table 2.10. 
For each reaction, negative controls were prepared simultaneously using nuclease-
free water in order to ensure the PCR reaction mix had not been contaminated. A 
Veriti 96-well Thermal Cycler (Thermo Fisher, Loughborough, UK) was used for PCR 
amplification. The cycling parameters can be found in Table 2.11. 
 
 
 
 
Table 2.10: Standard conditions for targeted PCR amplification of genomic DNA. Tm = melting 
temperature; bp = base pairs 
Parameter/Reagent Condition 
MgCl2 concentration 1.5 mmol/L 
Primer concentration 0.5 µmol/L 
Taq Polymerase per reaction 1 U 
Template genomic dsDNA ~50 ng 
dNTP concentrations 200 µmol/L 
Annealing temperature Variable (50°C – 65°C) but approx. 2°C lower than Tm of primer pair 
Extension time 30 s  for ~500 bp amplicons (1 min per 1000 bases) 
Table 2.11: Standard thermal cycling parameters for PCR amplification of genomic DNA. * varies according 
to primer pair. **Extension time can vary according to amplicon length. *** Number of cycles can be extended, this 
will increase the final yield of PCR product DNA but can induce errors. 
Step Conditions 
1 96°C; 5 minutes 
2 96°C; 30 seconds 
3 Specified annealing temperature*; 30 seconds 
4 72°C; 30 seconds** 
5 Repeat steps 2-4 34 times for 35 cycles*** 
6 72°C; 10 minutes 
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2.12.3.2 Visualisation of PCR products by agarose gel electrophoresis 
In order to assess whether PCR amplification had been effective and specific to the 
target region, products were visualized using agarose gel electrophoresis. A 1% (w/v) 
agarose gel was prepared using 1 g of UltraPure Agarose in 100 mL 1X Tris-acetate-
EDTA (TAE) buffer. After heating to allow dissolution of the agarose into the TAE 
buffer, the gel was decanted into a sealed tray containing a comb; this was allowed 
to set at room temperature. This gel was then placed into a tank containing 1X TAE 
buffer and the comb removed. 
Before loading the DNA of interest into each well, 5 µL of PCR product was combined 
with 3 µL Orange DNA Loading Dye. 5 µL of 1 kb DNA Ladder was also placed into 
the first well to allow size quantification of the PCR products. Conditions of 
electrophoresis varied according to the size of the PCR products visualised, but was 
usually carried out at 100 V for 30 – 60 minutes. Visualisation of bands was achieved 
using a ChemiDoc MP System (Bio-Rad, Hemel-Hempstead, UK) and the Image Lab 
software package. 
 
 Sanger sequencing 
2.12.4.1 Purification of PCR products  
Purification of PCR products was carried out using the ExoSAP protocol; 10 µL PCR 
product was added to 1 µL of shrimp alkaline phosphatase (SAP), 0.75 µL dH2O,  
0.5 µL of exonuclease I and 0.25 µL of a SAP dilution buffer. Using the Veriti 96-well 
Thermal Cycler (Thermo Fisher), the sample was mixed and incubated at 37°C for  
15 minutes, then 80°C for 15 minutes. 
 
2.12.4.2 Sanger sequencing preparation 
Cleaned PCR products were prepared for Sanger sequencing using the Big Dye 
Terminator v1.1 Cycle Sequencing Kit. 1.5 µL of sequencing buffer, 0.5 µL of Big Dye 
Terminator v1.1, 4 µL dH2O and 1 µL of forward or reverse primer was added to 3 µL 
cleaned PCR product. The parameters in Table 2.12 were then used for amplification. 
 
81 
 
 
2.12.4.3 DNA precipitation 
Sequencing products prepared using the protocol in Section 2.12.4.2 were incubated 
at room temperature for 20 minutes with 50 µL pure ethanol and 2 µL 3 M sodium 
acetate. Centrifugation at 20,000 x g was carried out for 40 minutes before discarding 
the supernatant. The resulting DNA pellet was washed using 50 µL 70% ethanol and 
centrifuged again for 10 minutes at 20,000 x g. The supernatant was discarded and 
plates were inverted before pulse centrifugation for 10 – 20 seconds. The sequencing 
products were then suspended in 10 µL 0.1X Tris-EDTA buffer before sequencing at 
the North East Thames Regional Genetics Service Laboratories, Great Ormond 
Street Hospital, London on an ABI DNA Sequencer (Applied Biosystems, Foster City, 
CA, US). Resulting electropherograms were visualised using the Sequencher 
software package (v4.10.1; Gene Codes, Ann Arbor, MI, US). 
 
 Cell culture of CHO cells 
 Cell culture conditions 
Chinese Hamster Ovary (CHO) cells, were cultured in Ham’s F-12 medium 
supplemented with 10% fetal bovine serum (FBS). Cultures were grown in 75 cm2 
sterile flasks, at 37°C in 5% CO2. When cells were approximately 75% confluent the 
media was removed and cells were washed with 8 mL Hank’s Balanced Salt Solution 
(HBSS) prior to the addition of 3 mL 0.25% trypsin-EDTA at 37°C for 2 minutes to 
help detach the cells. Detachment was performed by gently banging the flasks. 13 
mL Ham’s F-12 medium was then added and the resulting mixture split between two 
new flasks. Cells were transfected by collaborators with KCNQ2/3 cDNA as per the 
Step Conditions 
1 95°C; 2 minutes 
2 95°C; 20 seconds 
3 50°C; 10 seconds 
4 60°C; 3 minutes 
5 Repeat steps 2-4 34 times for 35 cycles 
Table 2.12: Thermal cycling parameters for Sanger Sequencing of PCR products.  
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protocol detailed by Selyanko et al.156 and split into several 35 x 10 mm culture dishes. 
M-current recording was performed 2 days after transfection. 
When cells were harvested for measurement of B6 vitamers (Section 2.4.3.3) or total 
protein quantification (Section 2.13.2), confluence was first achieved and the media 
was removed. Cells were then subjected to trypsin digestion as described above 
before addition of 10 mL medium and were then decanted into a 15 mL falcon tube. 
The resulting cell suspension was centrifuged at 4,500 x g for 5 minutes before 
removal of the supernatant and storage of the pellet at -80°C until analysis. 
The B6 depletion protocol referenced in Section 7.2 was carried out by transitioning 
cells from Ham’s F-12 with 10% normal FBS, as described above, to B6-depleted 
Ham’s F-12 with 10% dialysed FBS (DFBS). Initially, cells were placed in B6-depleted 
Ham’s F-12 with 10% normal FBS and grown for three weeks, with regular splitting 
as above. The 10% FBS fraction of this culture medium was then changed on a 
weekly basis as follows: Week 1: (20:80 DFBS:FBS); Week 2: (50:50 DFBS:FBS); 
Week 3 (80:20 DFBS:FBS); Week 4 (100:0 DFBS:FBS). This resulting B6 depleted 
CHO cell culture was used for experimentation. 
 
 Protein assay 
The concentration of protein in CHO cell lysates was measured according to 
manufacturer’s instructions for the Pierce BCA Protein Assay Kit; analysis was 
performed in a 96-well plate. The working reagent mix was prepared by mixing 
reagents A and B at a 50:1 ratio. 10 µL of the Pierce BCA Protein Assay Kit calibration 
standards were added to consecutive wells of a 96-well plate, alongside 10 µL of each 
cell lysate. Cell lysates were prepared using the protocol detailed in Section 2.4.3.3. 
200 µL BCA reagent was added to each cell lysate before mixing and incubation for 
30 minutes at 37°C. Absorbance was measured at 555 nm for each sample using a 
Tecan Infinite 200 Microplate Reader (Tecan, Mannedorf, Switzerland). For 
standards, the absorbances were plotted against their known concentrations in order 
to create a calibration curve (0 – 2000 µg/mL) from which the protein concentration 
of the cell lysate samples was calculated. 
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 Patch recording of the M-current from CHO cells 
Formed of a KCNQ2/3 tetramer, the M-channels mediate the M-current; this carries 
K+ ions and is of importance for the regulation of neuronal excitability. 
Electrophysiology experimentation using CHO cells for the measurement of the M-
current was carried out with the kind assistance of collaborators at the UCL 
department of Neuroscience, Physiology & Pharmacology.  
 
 Preparation of solutions 
The extracellular bath solution (Table 2.13) was prepared on the day of analysis. 
Additional solutions containing PLP, PL and Linopirdine (an M-channel blocker) were 
prepared identically with the addition of these components at a final concentration of 
10 µmol/L, as required. 
 
Component Concentration (mmol/L) 
NaCl 144 
KCl 2.5 
CaCl2 2 
MgCl2 0.5 
HEPES 5 
Glucose 10 
Tris base Adjusted to pH 7.4 
 
The internal pipette solution (Table 2.14) was also prepared on the day of analysis. 
The pipette solution was filtered using a 0.22 µm filter prior to filling pipettes. When 
performing perforated patches, the pipette solution also contained 100 µg/mL 
Amphotericin B.  
 
 
 
Table 2.13: Composition of extracellular patching solution.  
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Component Concentration (mmol/L) 
K Gluconate 90 
KCl 20 
CaCl2 1 
MgCl2 3 
HEPES 40 
EGTA 3 
NaOH Adjusted to pH 7.4 
 
 
 Data acquisition and analysis 
Chinese Hamster Ovary (CHO) cells transfected with KCNQ2/3 were prepared as 
described in Section 2.13.1. 35 x 10 mm cell culture dishes containing the cells were 
placed onto a custom-adapted Eclipse TE200 Microscope (Nikon, Tokyo, Japan). 
This allowed visualisation of CHO cells and manual micromanipulation of the pipette 
containing the electrode used to determine the M-current parameters. The cells were 
allowed to stand for 10 minutes to allow equilibration to 22°C and for the cell culture 
medium to be replaced by the extracellular bath solution (Table 2.13). This was 
continuously replenished throughout experimentation using a Reciprocating Piston 
Air Pump (Medcalf Bros., Potters Bar, UK).  
Pipettes were pulled from 150 mm borosilicate capillaries (GC150 TF-15) to a 
resistance of 3.0 – 5.0 MΩ. The tip of each pipette was coated in Sylgard and heated 
in order to reduce capacitance. For perforated patching, each pipette was filled with 
pipette solution (Table 2.14) containing 100 µg/mL Amphotericin B before the tip was 
held for 30 seconds in pipette solution containing no Amphotericin B; this was in order 
to avoid contaminating the extracellular bath solution with Amphotericin B.  
Subsequently, the pipette was fitted over the ‘internal’ electrode and lowered rapidly 
to the CHO cell of interest. Each electrode was coated in silver chloride on the day of 
analysis. The resistance of each pipette was monitored using a test pulse of +10 mV 
for 10 ms at 100 ms intervals, this was to check for damaged pipettes. Once close to 
the target cell (identified both visually and by a raised resistance), negative pressure 
Table 2.14: Composition of pipette solution.  
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was applied manually in order to facilitate a seal on the cell membrane. When a 
‘gigaseal’ (resistance > 1 GΩ) was achieved, the test pulse was terminated and a 
holding potential of -60mV was initiated. 10 minutes was taken in order for the cell 
membrane to permeabilise – this was required to achieve a perforated patch. A further 
summary of this technique is described in Section 7.2.1. 
The M-current was activated according to a step protocol from -60 to +20 mV, in 10mV 
steps, at 5 second intervals for 500 ms. M-currents were quantified by measuring the 
current amplitude, in picoamperes (pA), when the membrane potential was 0 mV. In 
order to determine the effect of exogenous compound addition to the extracellular 
bath solution, recordings were initiated in 1 minute intervals around bath solution 
exchange. The mean of 3-5 recordings prior to and 3-5 recordings after were taken 
and compared to one another in order to determine the effect of the exogenous 
compound. 
Data was acquired using a HEKA EPC 9 and analysed using the PULSE Software 
package v8.8 (HEKA Electronik, Lambrecht, Germany). Currents were filtered at >0.5 
kHz and sampled at 5–10 kHz.  
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 DRIED BLOOD SPOTS AS A TOOL TO PROFILE 
THE B6 VITAMERS; USEFULNESS FOR THE 
DIAGNOSIS OF PNPO DEFICIENCY 
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Pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency is a genetic disorder of 
vitamin B6 metabolism that results in seizures caused by a deficiency of the active 
form of B6, pyridoxal 5’-phosphate (PLP). Treatment includes supplementation with 
high doses of vitamin B6 in the form of PLP or pyridoxine (PN). Since most cases 
present in the newborn period, the challenge is to distinguish this rare cause of 
seizures from common causes of neonatal seizures such as hypoxic ischaemic 
encephalopathy. Sometimes the neonataologist will get a strong indication of a B6 
responsive disorder from the cessation of fits in response to administration of PN or 
PLP (if this is carried out), however, this does not distinguish between deficiencies of 
ALDH7A1, PLPHP and PNPO.157 Currently, diagnosis of PNPO deficiency is carried 
out by sequencing of the PNPO gene. This is, however, often delayed until after 
ALDH7A1 deficiency is excluded by urinary α-AASA analysis. Prompt diagnosis and 
appropriate treatment of PNPO deficiency is associated with a good 
neurodevelopmental outcome. There is therefore a need for a rapid and reliable 
diagnostic test for PNPO deficiency.  
Using LC-MS/MS techniques, concentrations of the B6 vitamers and pyridoxic acid 
have been characterised in plasma and CSF from controls and patients with B6-
responsive epilepsies. However, these cohorts have been relatively small and have 
included a limited number of PNPO-deficient patients.21-22, 88 It was hoped that, by 
measuring the B6 vitamers in dried blood spots (DBS), diagnostic information could 
be obtained from each individual. If patterns diagnostically specific to PNPO 
deficiency (or another B6-dependent seizure disorder) could be identified, this would 
be useful as an adjunct to other assays (i.e. urinary α-AASA) or in its own right as a 
diagnostic test. This could include studying ratios of B6 vitamer concentrations 
between CSF and the blood.4 In addition, it would be an advantage to quantify the B6 
vitamers from an easily obtained sample source such as DBS, particularly as many 
analytes are more stable when stored in a DBS card, compared to other sample 
sources (i.e. plasma). This could be particularly important for the labile B6 vitamers 
(Section 1.1.4). 
This chapter describes the assessment of LC-MS/MS as a method to measure the B6 
vitamer concentrations in dried blood spots (DBS) from individuals with PNPO 
deficiency and other B6-dependent seizure disorders. This method also allowed an 
assessment of the pharmacokinetics of the PLP supplementation of two PNPO-
deficient individuals. This could have implications for the treatment of these 
individuals who require lifelong supplementation with supraphysiological PLP doses, 
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particularly as some patients with PNPO deficiency develop liver damage, potentially 
caused by high levels of some B6 vitamers (Section 6).  
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 Method validation 
The LC-MS/MS-based method for the quantification of the B6 vitamers and pyridoxic 
acid is based on that previously published by Footitt et al.22 Parameters for detection 
and quantification can be found in Section 2.4. 
Due to the supraphysiological B6 doses received by individuals with B6-dependent 
epilepsy, it was expected that concentrations would vary by several orders of 
magnitude compared to controls. Two calibration curves where therefore created and 
the duplicate analysis of DBS from each individual was performed, one at each 
concentration range. One calibration curve ranged from 5 nmol/L to 750 nmol/L and 
used an internal standard (IS) concentration of 187.5 nmol/L, the other from 750 to 
15,000 nmol/L with an IS concentration of 1,875 nmol/L.  
The dynamic range of the Xevo TQ-S MS/MS instrumentation used was not linear for 
all B6 vitamers above 15,000 nmol/L. Measurement of concentrations higher than 
15,000 nmol/L required reanalysis after dilution of the DBS extract prior to the addition 
of the TCA internal standard mix.  
 
 Assessment of recovery of the B6 vitamers and pyridoxic acid 
from DBS 
The recovery of B6 vitamers from DBS was assessed by spiking whole blood from a 
control individual with 0.75, 3.75 and 7.5 µmol/L (final concentrations) of each of the 
B6 vitamers and pyridoxic acid. 50 µL of whole blood was spotted onto Whatman 903 
protein saver cards and dried overnight before analysis. Endogenous concentrations 
(i.e. from samples that had not been spiked) were also measured and subtracted from 
the calculated final concentrations. In each case, measurement was carried out in 
triplicate from three 3 mm DBS punches. Recovery was calculated as a percentage 
of the nominal (spiked) concentrations. Whilst haematocrit can affect the amount of 
blood in a 3 mm punch158, as discussed in Section 4.1.1.2, this had not been 
measured prior to spotting  for our subjects or controls. The assumption was therefore 
made that each 3 mm DBS contained 3.2 µl blood.155  Recoveries of the B6 vitamers 
and pyridoxic acid are presented in Table 3.1.  
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Recovery greater than 100% was observed for PLP and PL at each concentration. At 
0.75 µmol/ extremely high recoveries of >150% were identified for these vitamers. 
For PNP, PMP, PN and PM, with one exception (PN; 7.5 µmol/L), recoveries were 
lower than 100%. In blood, PN and PM can be phosphorylated to PNP and PMP by 
PK and subsequently converted to PLP by PNPO. PLP can also be hydrolysed to PL 
by several phosphatase enzymes. These results indicate that PN, PM, PNP and PMP 
are converted to PLP and PL when spiked into whole blood and spotted onto a DBS 
card. This hypothesis is further supported by the accurate (<11% deviation from 
nominal) recovery of PA at all concentrations; as a urinary excretion product, PA is 
not subject to enzymatic degradation. The accurate recovery of PA also indicates that 
the enzymes responsible for conversion of PL to PA (aldehyde oxidase and aldehyde 
dehydrogenases) in humans are not active in the blood. This correlates with the 
current understanding of vitamin B6 metabolism.4 
During these experiments, the whole blood was stored on ice prior to the addition of 
exogenous B6 vitamers and PA. After this, the blood was immediately spotted onto 
DBS cards. Enzymatic interconversion of the B6 vitamers was therefore likely 
occurring while the whole blood was briefly on ice or during the drying step. This step 
is required for the accurate assessment of recovery from DBS. 
To address this, the B6 vitamers were prepared in a 0.3 N TCA solution (instead of 
H2O) prior to their addition to whole blood. It was hypothesised that this would halt 
interconversion of the spiked B6 vitamers by denaturing the enzymes responsible (PK 
and PNPO). However, the addition of TCA dramatically increased the viscosity of the 
blood, which did not then spread in a manner representative of normal whole blood. 
When calculating the recovery of analytes from DBS the spreading of blood across 
the card is important as it is necessary to know the exact quantity of blood contained 
within the 3 mm punch retrieved from a DBS card.  
Table 3.1: Recovery of the B6 vitamers and pyridoxic acid from DBS. Combined = Mean % recovery of 
all vitamers at that concentration. 
Spiked 
conc. 
(µmol/L) 
Recovery (%) 
PLP PNP PMP PL PN PM PA Combined  
0.75 249.6 50.3 58.6 177.1 31.2 17.0 103.5 98.2 
3.75 113.6 77.6 64.6 138.0 79.5 45.0 89.8 86.8 
7.5 103.6 76.9 48.8 143.5 106.3 65.9 97.2 91.7 
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Despite being unable to further validate the recovery of B6 vitamers from DBS, the 
accurate recovery of PA (90 – 104%) was encouraging. This meant that the correction 
factor applied in order to extrapolate to whole blood concentrations was accurate and 
that PA, at least, was fully liberated from the DBS.  
If enzymatic interconversion was the reason behind the inaccurate recoveries of 
individual B6 vitamers, an average recovery of all vitamers combined of close to 100% 
would still be expected. Indeed this was the case, with mean recoveries of 98.2, 86.8 
and 91.7% at 0.75, 3.75 and 7.5 µmol/L, respectively.  This indicated that the recovery 
of each of the individual vitamers was close to complete. 
 
 Assessment of the measurement precision of B6 vitamers and 
pyridoxic acid from dried blood spots 
In order to validate the intra assay precision of measurement for all six B6 vitamers 
and pyridoxic acid from DBS of patients receiving high doses of vitamin B6, eight 3 
mm punches were analysed from a single DBS card derived from a patient receiving 
42 mg/kg/d PLP for the management of their seizures. A summary of these results 
and statistical analyses performed can be found in Table 3.2. An acceptable % 
coefficient of variation (CV) is defined as <10% by the European Medicines Agency. 
The calculated %CV was < 10% for all vitamers except for PMP for which the %CV 
was 10.80%. 
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According to European Medicines Agency (EMA) guidelines, quality control (QC) 
standards were created by spiking blank vials with four concentration levels (Lower 
limit of quantification-QC (LLOQ-QC): 0.005 µmol/L, Low-QC: 0.075 µmol/L, Medium-
QC: 7.5 µmol/L and High-QC: 15 µmol/L) of each of the B6 vitamers. Each sample 
was injected three times, at the beginning, middle and end of an analytical run and 
the mean concentration calculated. EMA guidelines state that the mean calculated 
concentrations of these QC standards should deviate by less than 20% of their 
nominal values at the LLOQ and less than 15% at values higher than this. The 
majority of samples were found to have acceptable deviation with four exceptions. 
These were LLOQ-QC for the measurement of PMP; LLOQ-QC and L-QC for PM and 
LLOQ-QC for PL. Full details of this analysis can be found in Table 3.3.  
 
 
 
 B6 vitamer concentration (µmol/L) 
DBS punch no. PLP PNP PMP PL PN PM PA 
1 9.06 6.19 2.71 157.00 4.59 1.11 8.06 
2 8.47 6.33 2.07 156.86 4.85 1.23 8.19 
3 10.60 7.26 2.94 186.33 5.25 1.39 9.30 
4 9.16 6.74 2.50 163.12 4.72 1.13 7.72 
5 8.91 6.42 2.50 156.41 4.92 1.06 7.96 
6 9.25 6.54 2.48 164.59 5.08 1.24 8.73 
7 9.49 7.24 2.91 178.84 4.49 1.15 8.31 
8 9.33 7.11 2.64 165.60 4.45 1.05 8.02 
        
Mean 9.28 6.73 2.59 166.09 4.79 1.17 8.29 
Coefficient of variation 6.63% 6.33% 10.80% 6.61% 5.93% 9.60% 6.09% 
Table 3.2: Precision validation of B6 vitamer and pyridoxic acid measurement from DBS. All 
concentrations µmol/L. 
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Table 3.3: Precision validation of LC-MS/MS measurement of B6 vitamers and pyridoxic acid. % 
deviation calculated by comparing mean calculated concentrations to nominal spiked concentrations. All values 
µmol/L. Nominal values are 0.005, 0.75, 7.5 and 15 µmol/L for LLOQ-QC, L-QC, M-QC and H-QC respectively. 
Acceptable values: < 20% deviation at LLOQ-QC; < 15% above this. nd = not detected. 
 Calculated B6 vitamer concentration (µmol/L) 
LLOQ-QC  
(0.005 µmol/L) 
PLP PNP PMP PL PN PM PA 
Injection 1 0.0039 0.0053 0.0070 nd 0.0043 0.0062 0.0055 
Injection 2 0.0042 0.0049 0.0070 nd 0.0057 0.0071 0.0051 
Injection 3 0.0047 0.0048 0.0053 nd 0.0043 0.0062 0.0048 
Mean 0.0043 0.0050 0.0064 nd 0.0048 0.0065 0.0051 
% deviation -15.822 +1.593 +25.829  -5.88 +28.645 +1.287 
L-QC  
(0.075 µmol/L) 
PLP PNP PMP PL PN PM PA 
Injection 1 0.070 0.076 0.068 0.063 0.073 0.059 0.074 
Injection 2 0.070 0.075 0.071 0.049 0.071 0.050 0.075 
Injection 3 0.077 0.075 0.076 0.083 0.080 0.076 0.076 
Mean 0.072 0.075 0.072 0.065 0.075 0.062 0.075 
% deviation -3.516 +0.031 -4.078 -13.315 -0.139 -17.664 +0.136 
M-QC 
(7.5 µmol/L) 
PLP PNP PMP PL PN PM PA 
Injection 1 7.87 8.09 7.16 8.66 7.87 8.09 7.76 
Injection 2 7.96 7.64 7.10 7.82 7.96 7.64 7.48 
Injection 3 8.02 8.08 7.24 7.31 8.02 8.08 7.50 
Mean 7.95 7.94 7.17 7.93 7.95 7.94 7.58 
% deviation +5.96 +5.85 -4.452 +5.776 +5.96 +5.85 +1.078 
H-QC 
(15 µmol/L) 
PLP PNP PMP PL PN PM PA 
Injection 1 16.20 16.55 14.83 16.50 16.20 16.55 15.25 
Injection 2 16.36 15.65 14.91 16.40 16.36 15.65 15.14 
Injection 3 15.96 16.40 14.75 15.31 15.96 16.40 14.99 
Mean 16.17 16.20 14.83 16.07 16.17 16.20 15.12 
% deviation +7.816 +8.006 -1.124 +7.147 +7.816 +8.006 +0.832 
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 Analysis of B6 vitamer profiles of patient samples 
The B6 vitamer profiles of 19 patients with mutations identified in PNPO and 11 
subjects receiving vitamin B6 for their seizure control in whom PNPO deficiency had 
been excluded genetically or diagnostically are shown in Table 3.4. Preliminary 
control ranges were established using six healthy adult controls not receiving vitamin 
B6 supplementation (also shown in Table 3.4). 
Whilst control ranges of B6 vitamers in DBS have not been published previously, 
values have been reported for plasma. Midtunn et al.159  have reported that the only 
detectable B6 vitamers in plasma were PLP, PL and PA (n = 94 healthy adult controls); 
reference ranges: 17 - 102 (PLP), 6 – 28 (PL) and 11 - 88 (PA) nmol/L. Other studies 
using plasma from both children and adults show similar ranges.22, 88  In this study of 
B6 vitamers from DBS, comparable ranges of 41 - 110 (PLP), 7 – 24 (PL) and 7-13 
(PA) nmol/L were found.  
Similarly to plasma, no PM, PN or PNP were detectable in our adult DBS controls, 
however PMP was present at concentrations similar to that of PLP (range: 30 – 71 
nmol/L). In humans, PMP is thought to be found mostly inside the cell and protein-
bound, resulting from intracellular half-transamination enzymatic reactions. This, 
coupled with the fact that the phosphorylated B6 vitamers are not thought to effectively 
cross the plasma membrane, could account for intracellular PMP 
compartmentalisation and hence its presence in DBS but not plasma. 
Comparison of the patient samples (PNPO deficient and those with other epilepsies) 
with the control range revealed that concentrations of PLP, PL and PA are raised in 
all individuals known to be receiving vitamin B6 supplementation. In those individuals 
receiving high doses of PLP, concentrations of this vitamer were 10 – 100 times the 
control range. PL and PA were raised still further, with concentrations of up to 4,000 
times the upper limit of the control range established. PLP concentrations from 137 – 
17,307 nmol/L, PL concentrations from 266 - 102,524 nmol/L and PA concentrations 
from 83 – 22,931 nmol/L were measured. This wide range of concentrations is likely 
indicative of the range of doses (shown in Table 3.4); type of supplementation (PLP 
or PN) and also the timing of dosage relative to sample collection. Data with regards 
to timing of the most recent dose received was not collected.  
The DBS concentrations of PA are comparable to plasma concentrations identified 
by Mathis et al. (PA = 245 – 13,200) and Footitt et al. (PA = 144 – 7,926) in patients 
receiving B6 supplementation, the cohorts of patients reported in those papers are 
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comparable to that used in this study, with a mixture of children with diagnosed and 
undiagnosed B6-dependent epilepsies, including PNPO deficiency and ALDH7A1 
deficiency. 
In this study, PL and PLP concentrations of individuals on B6 supplementation are 
increased compared to the previous studies (For example, maximum plasma PL and 
PLP concentration in individuals receiving supplementation measured by Mathis et 
al. were 16,300 and 2,930, respectively, compared to 102,524 and 17,307 nmol/L in 
this study). However, when comparing to the plasma results of Mathis et al., it should 
also be noted that in their study almost all individuals for whom the type of 
supplementation was known were receiving PN monotherapy (35/37). In this study of 
DBS, however, only 4/26 were receiving PN monotherapy, with 22/26 receiving PLP 
supplementation for the treatment of their seizures. Hence, higher PLP or PL 
concentrations would be expected in our cohort. In addition, as was discussed with 
regard to PMP above, PLP may be compartmentalised within red blood cells, leading 
to higher concentrations in DBS samples compared to plasma. This will be discussed 
further below, particularly with regard to the B6 vitamer concentrations found in PNPO-
deficient individuals. 
 
 
 
 
 
 
 
 
 
 
 
96 
 
Subject 
Diag-
nosis 
B6 Therapy; Dose PNPO variant* PLP PNP PMP PL PN PM PA 
PM/PA 
ratio 
PNP/PLP 
ratio 
Control 
range 
(nmol/L) 
- - - 
41.2 – 
110.0 
<5.0 
29.6 – 
70.7 
6.7 – 
24.3 
<5.0 <5.0 6.5 -12.7 <0.01 <0.01 
1 PNPO PLP; 53 mg kg-1 d-1 p.R95H (het) + p.E50K; c.[364-1G>A] (het) 16812.3 10303.4 3532.4 94653.3 6550.7 1751.2 3952.8 0.44 0.61 
2 PNPO PLP; 50 mg kg-1 d-1 c.[364-1G>C] 17307.4 9301.0 5134.3 84784.3 2775.2 765.0 5932.7 0.13 0.54 
3 PNPO PLP; 50 mg kg-1 d-1 p.P213S 8538.9 6692.4 4405.3 64565.4 3893.6 2250.2 3062.8 0.74 0.78 
4 PNPO PLP; 50 mg kg-1 d-1 p.P213S 11758.8 10107.4 5157.1 48979.7 2313.2 1349.1 1929.2 0.70 0.86 
5 PNPO PLP; 40 mg kg-1 d-1 c.[263+2T>C] 2845.6 731.2 2377.7 34351.6 1264.9 1284.3 9942.7 0.13 0.26 
6 PNPO PLP; 38 mg kg-1 d-1 p.R229Q (het) + p.L136P (het) 557.5 42.5 705.4 1377.7 45.1 193.6 429.0 0.45 0.08 
7 PNPO PLP; 30 mg kg-1 d-1 c.[363+5G>A] 11777.3 937.7 187.3 102524 940.6 208.1 22930.6 0.01 0.08 
8 PNPO PLP; 30 mg kg-1 d-1 c.[363+5G>A] 296.4 6.3 103.4 266.6 <5.0 <5.0 82.8 0.00 0.02 
9 PNPO PLP; 30 mg kg-1 d-1 p.R225C 3596.8 2732.4 6795.1 8487.7 1078.4 1327.8 5411.5 0.24 0.76 
10 PNPO PLP; 10 mg kg-1 d-1 p.R116Q 1854.6 <5.0 495.2 2294.1 <5.0 <5.0 447.3 0.00 0.00 
11 PNPO PLP; 75 mg x 6 doses p.E50K; c.[364-1G>A] 5927.9 2239.6 8169.8 12956.7 722.7 1551.4 3957.2 0.39 0.38 
12 PNPO PLP; Unknown c.264-21_ 264-1delinsC (het) + p.D33V (het) 3600.1 8952.5 2304.4 38538.4 3752.7 377.5 3596.0 0.10 2.49 
13 PNPO PLP; Unknown p.Q214fs(het) + ? *** 10385.7 5374.2 2634.3 94787.3 6290.8 1408.5 8876.4 0.16 0.52 
14 PNPO PLP; unknown p.D33V (het) + p.Y157X (het) 2681.4 700.4 4962.1 3882.6 245.8 643.5 1443.2 0.45 0.26 
15 PNPO PLP; Unknown p.W65L 4540.5 7485.6 1159.1 50589.3 8922.3 585.0 5332.4 0.11 1.64 
16 PNPO PN; 123 mg kg-1 d-1 p.R116Q;p.R225H 865.6 6715.6 1589.5 4926.3 4171.0 474.0 868.0 0.55 7.76 
17 PNPO PN; 30 mg kg-1 d-1 p.D33V 136.9 8763.8 1322.7 680.6 3031.2 428.8 450.8 0.95 63.87 
18 PNPO PN; 100 mg x 2 doses p.R116Q 4059.4 8307.1 495.2 16477.8 5705.8 160.9 2860.5 0.02 2.04 
19 PNPO None; N/A p.R116Q** 146.9 <5.0 86.1 29.5 <5.0 <5.0 25.0 0.00 0.00 
Table 3.4:  Concentrations of B6 vitamers and pyridoxic acid measured in DBS from PNPO deficient patients, p.R116Q heterozygotes and other patients with epilepsy responding to B6 
supplementation. *homozygous unless denoted as heterozygous (het). **Sibling of Subject 10, has not presented with seizures or received B6 supplementation. ***no second variant identified. All 
concentrations shown as nmol/L. Control ranges are derived from 6 healthy adult controls not receiving B6 supplementation. Values shown are means of the duplicate analysis of 2 x 3 mm DBS from each 
subject. Time of supplementation unknown except for Subject 2 and Subject 11; Subject 2 = 4 h after initial PLP dose; Subject 11 = 30 min before dose, 3h 30 min after last dose.  PNPO deficient subject numbers 
also correspond to those in Table 4.5. Diagnosis = gene in which a disease causing mutation was identified. PNPO activity measured using the DBS assay developed in Section 3.1 N/A = not available.  
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Subject Diagnosis B6 Therapy; Dose PLP PNP PMP PL PN PM PA 
PM/PA 
ratio 
PNP/PLP 
ratio 
Control 
range 
(nmol/L) 
- - 
41.2 – 
110.0 
<5.0 
29.6 – 
70.7 
6.7 – 24.3 <5.0 <5.0 
6.5 -
12.7 
<0.01 <0.01 
C1 ? PLP; 30 mg kg-1 d-1 9109.3 <5.0 501.5 83314.2 79.5 225.7 2774.9 0.08 0.00 
C2 TRMT11 PLP; 30 mg kg-1 d-1 9633.8 41.6 172.1 20733.3 <5.0 <5.0 5994.7 0.00 0.00 
C3 ? PLP; 10 mg kg-1 d-1 3930.6 <5.0 17.6 7732.3 <5.0 18.9 4668.6 0.00 0.00 
C4 KCNQ2 PLP; Unknown 794.4 23.4 123.5 1357.8 81.40 108.0 298.10 0.36 0.03 
C5 ? PLP; Unknown 542.8 <5.0 244.1 861.8 <5.0 26.8 356.4 0.08 0.01 
C6 ? PLP; Unknown 1974.5 9.7 85.6 1702.6 <5.0 <5.0 235.5 0.00 0.00 
C7 ? PLP; Unknown 2997.4 13.1 <5.0 2993.6 <5.0 <5.0 481.4 0.00 0.00 
C8 PROSC PN; 250 mg d-1 973.1 <5.0 <5.0 918.1 <5.0 <5.0 165.9 0.00 0.00 
C9 ? Unknown 127.8 <5.0 38.4 100.9 <5.0 14.4 18.3 0.75 0.06 
C10 ALDH7A1 Unknown 7683.8 <5.0 <5.0 17854.9 <5.0 <5.0 2085.1 0.00 0.00 
C11 STX1B Unknown 1338.0 <5.0 <5.0 4341.2 <5.0 <5.0 750.5 0.00 0.00 
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The most striking observation upon examination of the DBS vitamer profiles is that, 
with a few exceptions, the concentrations of PNP, PMP, PN and PM are higher in 
DBS from PNPO deficient patients compared to the ‘other epilepsy’ cohort (Figure 
3.1). Although not exclusive to PNPO deficiency, this shows that raised 
concentrations of these vitamers can be indicative of PNPO deficiency. This is due to 
substrate accumulation caused by a deficiency of PNPO which catalyses PNP and 
PMP conversion to PLP.  
 
 
 
Figure 3.1:  B6 vitamer and pyridoxic acid concentrations in DBS. Data points shown 
are the mean from duplicate analysis of each DBS punch. 
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There are however three cases (Subjects 10, 19 and 8) within the PNPO cohort for 
whom PNP, PN and PM were not raised. Subject 10, who is homozygous for the 
p.R116Q PNPO variant, had a B6 vitamer profile similar to that seen in patients with 
normal PNPO activity receiving B6 supplementation (except for raised PMP). 
However, residual or tissue-specific p.R116Q activity cannot explain the dissimilarity 
of Subject 10’s vitamer profile to that of other PNPO-deficient subjects: Subject 18, 
also homozygous for p.R116Q, has raised levels of PNP, PMP, PN and PM. Subject 
19, the p.R116Q homozygous sibling of Subject 10, who has never been 
supplemented with B6 and has not presented with seizures, has a vitamer profile 
similar to controls. Subject 8 also appears to have only mildly raised vitamer 
concentrations compared to controls despite apparently receiving 30 mg/kg/d PLP; 
this raises questions with regards to the treatment compliance of this patient. 
In the remaining PNPO deficient patients, PNP concentrations were higher than those 
of individuals with other epilepsies receiving B6 supplementation. Previously it has not 
been possible to accurately quantify the concentration of PNP. However, a PNP 
standard has recently become commercially available and this allowed accurate 
quantification of PNP for the first time. In previous studies PNP concentrations were 
either expressed as ‘concentration units’ (CU)22 or excluded completely.21, 88 The 
assumption that Footitt et al. made with regard to their PNP ‘concentration units’ relied 
on the signals of PLP and PNP upon LC-MS/MS analysis being similar. We found this 
to be the case, with the raw signals of each vitamer being within 10% at the same 
concentration; this means an approximate comparison to the data of Footitt et al. can 
be made. If the PNP concentrations measured from DBS are compared with the 
‘concentration units’ (assumed to approximate to nmol/L) measured by Footitt et al. 
in plasma (43 and 77 CU in PNPO deficient patients; (n = 2)) those reported here in 
DBS are usually far higher (42.5 – 10,303 nmol/L; mean = 4,705 nmol/L).  
This is possibly due to PNP being compartmentalised in erythrocytes (as discussed 
above with regards to PLP and PMP), a hypothesis supported by results for the two 
subjects for whom we have PNP concentration measurements for paired DBS and 
plasma samples; Subject 17 (DBS: 8,764 nmol/L, plasma: 30 nmol/L) and Subject 
11 (DBS: 2,240 nmol/L, plasma 17 nmol/L). Similarly, a comparison of PMP 
concentrations measured from DBS of PNPO deficient patients (187.3 – 8170 nmol/L; 
mean = 2717 nmol/L; (n = 19)) to those measured in plasma by Footitt et al. (18 and 
101 nmol/L; (n = 2)) shower higher concentrations in DBS. 
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A previous study (Mathis et al.)88 has suggested that a raised PM/PA ratio in plasma 
is diagnostic for PNPO deficiency. However, the cohort of PNPO deficient patients 
included in that study was small (n = 6) and one subject homozygous for the p.R116Q 
mutation was excluded (not referred to as PNPO deficient). 4/6 of these patients had 
the same pathogenic homozygous PNPO variant (p.R225H). We did not see the 
same clear distinction when PM/PA ratios were measured in DBS in a larger cohort 
of PNPO deficient patients. Although a significant difference was identified between 
groups using a Mann-Whitney U test (P < 0.01), no diagnostic cut-off could be created 
using this data. 4/19 PNPO deficient individuals had a PM/PA ratio (≤ 0.01) similar to 
that seen in the adult control range (n = 6). 4/11 subjects receiving B6 supplementation 
who were not PNPO deficient (no mutations found in PNPO) had a raised PM/PA 
ratio (> 0.01) (Figure 3.2). It was not possible to obtain paired plasma samples from 
these individuals in order to make a direct comparison between DBS and plasma 
PM/PA ratios. However, it is unlikely that the sample type will affect the discrepancy 
between our results and those of Mathis et al. as the four PNPO deficient patients 
with PM/PA ratios less than 0.01 had PM concentrations of less than 5 nmol/L. 
Concentrations would not conceivably be high enough in matched plasma samples 
from each of these to provide PM/PA values raised enough to delineate these patients 
from the subjects receiving B6 supplementation who were not PNPO deficient. 
We hypothesise that the lack of diagnostic utility of PM/PA ratios, in our cohort, 
contrary to the findings of Mathis et al., is due to the expanded variety of genotypes 
or different types of supplementation. In total, our cohort included 19 subjects with 15 
different genotypes. The PNPO deficient cohort published by Mathis et al. included 6 
subjects with only 3 different homozygous mutations (4 x c.674G > A; 1 x 263+2T>C; 
1 x c.416A>C). Mathis et al. also excluded one individual homozygous for p.R116Q 
as being PNPO deficient; this patient had a normal PM/PA ratio.  
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There has been some discussion as to the potential pathogenicity of the p.R116Q 
variant in PNPO.87 Of the PNPO deficient patients in our cohort for whom the PM/PA 
ration was <0.01, 2/3 were homozygous for p.R116Q. This data agrees with the 
findings of Mathis et al. and would suggest that p.R116Q is not pathogenic. However, 
the response of p.R116Q patients to PLP and the lack of other mutations found in 
these patients indicate that this variant can be pathogenic. Equally, studies have 
recently shown that p.R116Q affects the structure of PNPO.74 The effect of the 
p.R116Q variant will be discussed further in Section 4.2. 
Of the 7 PNPO deficient patients Mathis et al. measured PM/PA ratios for, only one 
PNPO deficient individual was receiving vitamin B6 exclusively in the form of PLP, 
with 6 receiving either a mixture of PN and PLP or PN monotherapy. 15/19 patients 
in our cohort received PLP supplementation for their seizures, with 3 of the remaining 
Figure 3.2:  PM/PA and PNP/PLP ratios in DBS. Note split Y axis. Data points shown 
are the mean of the ratios calculated (n=2).  
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4 receiving PN (one individual was not receiving supplementation). It is possible that 
PM/PA ratios are dependent upon type of B6 supplementation as well as genotype; it 
may be that, for some genotypes, PLP supplementation is less likely to lead to a 
raised PM/PA ratio than PN supplementation. For example, in our cohort, Subject 18 
is the only p.R116Q homozygote with a PM/PA ratio > 0.01, and also the only 
p.R116Q homozygote receiving PN monotherapy. This warrants further investigation. 
The raised PNP concentrations identified in DBS samples from PNPO deficient 
patients gave rise to the hypothesis that a raised PNP/PLP ratio could be a better 
indicator of PNPO deficiency than a raised PM/PA ratio (Figure 3.2). A Mann-Whitney 
U test was performed and a significant difference was identified between cohorts (P 
< 0.0001). Although some overlap is seen between controls and Subjects 10, 19 & 
8 when using PNP/PLP ratios, there appears to be a greater distinction of the PNPO-
deficient patients from controls than when PM/PA is used. Given the wide variety of 
supplementation type (PN or PLP), dosage and the variation in vitamer 
concentrations prior to and after supplementation (see Section 3.3.2), it is likely a 
PNP/PLP ratio will prove more indicative of PNPO deficiency. 
The p.R116Q homozygous Patients 10 & 19 did not have raised PNP/PLP ratios. As 
mentioned above, Patient 19 is not receiving B6 supplementation. Patient 10 
receives 10 mg/kg/d PLP. The other p.R116Q homozygote in this study (Patient 18) 
had a raised PNP/PLP ratio of 2.04; this patient was receiving 200 mg/d PN. This 
disparity within the same genotype could be due to difference in supplementation 
type. Indeed, this data allows a broader comparison of B6 vitamer profiles between 
PNPO deficient individuals receiving PLP (n = 15) and PN (n = 3) for seizure control. 
As has previously been reported in studies from plasma22, 88, little distinction could be 
made based solely on supplementation type. As mentioned above, in these prior 
studies PNP had not been quantified. It was predicted that PNP concentrations would 
be higher in patients receiving PN supplementation due to the metabolic block at the 
PNPO enzyme. The mean PNP concentration of PNPO deficient patients receiving 
PN supplementation was approximately twice that of those receiving PLP (PN sup. = 
7928 nmol/L PLP sup. = 4373 nmol/L). A similar pattern was seen when comparing 
the PNP/PLP ratios of patients receiving PN with those receiving PLP: (PN; range = 
2.04 – 63.87, n=3); (PLP; range = 0.00 – 2.49; n=15). However, in both cases the 
groups were not clearly delineated, with some overlap seen. When PN is used for 
treatment, there must be some residual PNPO activity, unless gut flora bacteria or 
another process is capable of converting PL or PLP to PN or PNP. 
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Subject 17, who receives 30 mg/kg/d PN supplementation for treatment of their 
PNPO deficiency, is particularly interesting. Their PLP concentration (137 nmol/L), 
unlike most other patients on B6 supplementation, is only slightly above the adult 
control range but the concentrations of other vitamers are raised dramatically (all at 
least ten times the upper limit of the control ranges established). Plasma and CSF 
PLP concentrations from this patient were within the normal range (data not shown). 
That this concentration of PLP is enough to provide seizure control in Subject 17 
raises the question of whether other PNPO deficient patients are receiving doses 
higher than required, an important factor when high doses of PLP have been 
suggested to be the cause of hepatic dysfunction in some of these patients (see 
Section 6).  
Although samples were collected from 11 individuals with B6-dependent seizures that 
were not due to PNPO deficiency, no more than one was collected from each of these 
disorders as defined genetically. This made it impossible to comment conclusively on 
whether a profile specific to each of these disorders could be identified.  
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 Kinetics of oral pyridoxal 5’-phosphate supplementation 
When developing a method for the measurement of B6 vitamers from DBS, one 
potential variable that should be taken into account is the variation of vitamer 
concentrations before and after a dose of vitamin B6. Patients usually receive PLP 
and PN orally. Mathis et al. have recently reported the plasma profile of PLP, PL, PA, 
PN and PM over a 24 hour period after a single 200 mg dose of PN in a healthy adult 
control.88 This confirmed the findings in mice160 that orally supplemented PN rapidly 
converts to pyridoxal; Mathis et al. showed that after 2 hours PN peaks at a 
concentration of ~2,000 nmol/L but returns to baseline concentrations after 4 hours. 
PLP concentrations increase steadily to ~800 nmol/L 12 hours after supplementation, 
before remaining steady at 24 hours. PL and PA concentrations increased to 4,000 – 
5,000 nmol/L 2 hours after supplementation. At this point they were the most 
abundant B6 metabolites, before declining to concentrations lower than that of PLP 
(<800 nmol/L) after 12 hours and continuing their gradual decline almost to baseline 
values after 24 hours. 
In rats, the plasma concentrations of PLP and PL after oral and intravenous doses of 
PLP have been studied.161 This showed much higher plasma PLP upon intravenous 
dosing and helped confirm the hypothesis that most oral PLP is dephosphorylated 
before gut absorption. However, to date, a human profile of the B6 vitamers 
immediately after oral PLP supplementation has not been measured. We report the 
DBS concentrations of B6 vitamers and pyridoxic acid prior to and after a single PLP 
dose in two PNPO deficient patients; a 15 year old child receiving long-term PLP 
supplementation (Subject 11) and a neonate receiving their first dose of PLP shortly 
after birth (Subject 2). 
 
 Long-term PLP treatment of an adolescent 
B6 vitamer and pyridoxic acid concentrations, before and after supplementation with 
PLP, were measured in a DBS from one of the original PNPO-deficient patients 
described by Mills et al. in 2005 (Patient J2). Their first PLP dose was 50 mg, 3 weeks 
after birth. Thereafter, they have received PLP for the treatment of their seizures for 
their entire life. This patient is now 15 years old and requires 75 mg PLP (orally) 6 
times a day to control their seizures. Compound heterozygous pathogenic PNPO 
variants are present in this individual (c.[148G> A]; c.[364-1G>A]). 
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Blood was taken from Subject 11 and spotted onto filter cards 30 minutes prior to PLP 
supplementation (T-30) and 10, 20, 30, 45, 60, 90 and 120 min (T10, T20, T30, T45, 
T60, T90 and T120) after oral supplementation with one 75 mg dose of PLP. 
Concentrations of the B6 vitamers and pyridoxic acid over this time course were 
quantified (Figure 3.3) using the method described in Section 3.2. 
  
 
Upon supplementation, concentrations of PL and PA show the most dramatic rise 
before returning to baseline after 120 min. This is similar to that seen in the plasma 
of healthy adult controls after PN supplementation (Mathis et al). Unlike the studies 
of Mathis et al., however, where PA was more abundant than PL after PN 
supplementation, PL concentrations were higher than PA in our patient. This is 
perhaps indicative of the differences between DBS and plasma samples, PLP and 
PN supplementation or the fact that our patient is receiving long-term 
supplementation. The increase in PA concentration suggests that PL is rapidly 
converted to PA by aldehyde oxidase and aldehyde dehydrogenases.  
In the study by Mathis et al., a steady and constant rise in PLP concentration was 
observed up to 12 h after PN supplementation of a healthy adult control, before 
Figure 3.3: Subject 11 - Concentrations of B6 vitamers and pyridoxic acid prior to and after oral 
supplementation with 75 mg PLP. Each point is the mean of 2 x 3 mm DBS punches and error bars indicate 
SEM.  
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plateauing. However, no increase in PM concentration was seen. In our subject PLP 
rose initially, peaking at about 150% of baseline at T30, but values then decreased 
quickly (T60) to those seen before supplementation. Concentrations of the other 
vitamers (PNP, PMP, PN, PM) stayed relatively constant over the time course but 
were much higher than those seen in healthy controls (reference ranges in Table 
3.4). These high concentrations were expected given the long term supplementation 
of this PNPO deficient patient; B6 vitamer profiles typical of these patients were 
discussed in Section 3.2. 
 
 
The ratios of PM/PA and PNP/PLP in the DBS of Subject 11 prior to and after oral 
PLP supplementation are raised at each time point relative to those of healthy adult 
controls (n = 6; ref range <0.01 for both PM/PA and PNP/PLP) (Figure 3.4; reference 
ranges in Table 3.4). This suggests that when using PM/PA or PNP/PLP ratios to 
inform the diagnosis of PNPO deficiency (see Section 3.2) in a patient receiving long-
term supraphysiological doses of PLP, the time of sampling around supplementation 
is not important. Although still raised, a reduction in both ratios is identified at each 
time point after supplementation when comparing to the dose 30 minutes before 
supplementation. This is unsurprising as PLP and PA concentrations appear to 
Figure 3.4: Subject 11 – PM/PA and PNP/PLP ratios prior to and after oral supplementation with 
75 mg PLP. Each point is the mean of 2 x 3 mm DBS punches and error bars indicate SEM. 
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increase after PLP supplementation whereas PNP and PM concentrations are 
relatively stable. 
 Neonatal prophylactic PLP treatment 
Subject 2 was prenatally diagnosed with PNPO deficiency (homozygous c.364-
1G>C) and a sibling was already receiving PLP for seizure control. Parents decided 
to continue with the pregnancy and steps were taken to avoid intrauterine seizures 
and neurological damage to the foetus. This included the mother taking daily dietary 
supplements containing 10 mg PN and prophylactically treating the child with PLP 
immediately after birth. 
The child was born at term (3.6 kg) and treated with oral PLP. Samples were collected 
10 mins prior to, and at three times points after a 36 mg dose of PLP given 15 mins 
after birth. The B6 vitamer concentrations for these DBS samples are shown in Figure 
3.5.  
 
Interestingly, at T-10, prior to supplementation, concentrations of PLP, PL and PA are 
already raised above those identified in the adult control range described in Section 
3.2. This could be due to the mother receiving B6 supplementation while pregnant and 
passing these vitamers to the foetus or simply reflective of differences between the 
blood B6 vitamer concentrations of a neonate and adults. PMP and PM are also both 
Figure 3.5: Subject 2 – Concentration of B6 vitamers and pyridoxic acid prior to and after oral 
supplementation with 35 mg PLP. Note split Y axis. Error bars indicate SEM. (n=2) 
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raised prior to supplementation, indicating that the metabolic block caused by PNPO 
deficiency has impaired the recycling of PMP after formation by half-transamination 
reactions in utero (see Section 1.1.1). PMP concentrations are relatively constant but 
those of PM increase over the time course. PN and PNP are not detectable at T-10, 
unlike most PNPO deficient individuals receiving long term supraphysiological PLP 
supplementation who often have concentrations orders of magnitude higher than 
those in controls. 
The most dramatic increase in concentration after supplementation was seen for PL, 
reaching 29,087 nmol/L one hour after supplementation. This was expected given 
that PLP must be hydrolysed to PL before intestinal absorption. PLP concentrations 
also increased over the first 60 minutes, before falling again between T60 and T180, 
though not to original concentrations seen prior to supplementation. PA 
concentrations increased, although at a slower rate initially to those of PL. 
The profile of the B6 vitamer concentrations seen in Subject 2 prior to 
supplementation is different to that described above for Subject 11. Although, as 
discussed, PLP, PL and PA concentrations are raised above the healthy adult control 
ranges described in Section 3.2, concentrations of most vitamers are approximately 
ten times lower in Subject 2 than those in Subject 11. This is indicative of an 
accumulation of the B6 vitamers and pyridoxic acid after long-term supplementation 
in Subject 11, a direct comparison is therefore impossible. 
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The PM/PA ratios in the DBS prior to and after PLP supplementation in Subject 2 
show a reduction over the time course, from 0.7 before supplementation (at birth) to 
0.1 three hours after the first 35 mg PLP dose (Figure 3.6). Hence an elevated PM/PA 
ratio was evident prior to the neonate presenting with seizures/receiving B6 
supplementation. However, the mother received oral supplementation with PN (10 
mg daily). It is possible the PM/PA ratio would not be raised in a neonate whose 
mother was not in receipt of supplements during pregnancy. 
PNP/PLP ratios are low before supplementation (within the adult control range of 
<0.01), and gradually increase over the time course studied. This is due to relatively 
low PNP concentrations present initially, unlike other PNPO deficient patients 
investigated previously. PL/PLP are the main B6 vitamers present in the blood of a 
healthy adult and only PL would have crossed the placenta.162 For this reason the 
patient had likely not been exposed to significant amounts of PN or PNP in utero. By 
this reasoning, it seems likely that PNP/PLP ratios will only be raised after feeding 
and exposure to pyridoxine via the diet. The main B6 vitamers in breast milk are PLP 
and PL.163 This may provide complications for the use of PNP/PLP ratios for the 
diagnosis of PNPO deficiency in children that are exclusively breastfed, and means 
that DBS taken from these babies may be unsuitable for PNP/PLP analysis.  
Figure 3.6: Subject 2 – PM/PA and PNP/PLP ratios prior to and after oral supplementation 
with 35 mg PLP. Error bars indicate SEM. (n=2) 
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Since the patient received only PLP supplementation the gradual rise seen in 
concentrations of PN and PNP was at first puzzling. There are no known processes 
in the human body capable of the reduction of PL or PLP to PN or PNP, respectively. 
However, it is known that Subject 2 received formula in place of breast milk 
immediately after birth. As mentioned, breast milk contains mostly PLP and PL, 
whereas baby formula usually contains PN. Ingestion of the PN present in formula 
could be another explanation for these gradually increasing concentrations of PN and 
PNP. It is also possible that the microbes constituting the neonatal gut microbiome164 
are capable of the conversion of PL or PLP to PN or PNP. However, an enzyme 
catalysing this reaction has not yet been characterised in bacteria or archaea. 
An NADPH-dependent pyridoxal reductase (PLR) has however been characterised 
in Saccharomyces cerevisiae165 and Arabidopsis thaliana166; it was postulated that an 
enzyme capable of catalysing this reaction is also present in humans. In order to 
investigate whether human red blood cells are capable of the reduction of PLP or PL 
to PNP or PN, 3 mm healthy adult control DBS punches and 3 mm empty DBS card 
punches were incubated for 30 minutes with 1 µmol/L PLP and 1 mmol/L NADPH. 
Experimentation was carried out using a potassium phosphate buffer adjusted to pH 
7.0. This pH is within the optimal range for yeast pyridoxal reductase and other 
conditions are similar to those previously used for the assay of pyridoxal reductase 
activity.165, 167 No decrease of PLP concentration or corresponding increase in PNP 
was identified (Data not shown).  
Using a pBLAST search, the human protein most homologous to A. Thaliana PLR is 
KCNAB2 (E-value: 1.4e-24; 27.1% identity), homology is strong across the entire 
protein sequence. This is a beta subunit of a cytoplasmic potassium channel and is 
known to modulate activity of these channels.168 KCNAB2 is an NADPH-dependent 
aldoketoreductase of broad substrate specificity169, it is possible that it accepts PLP 
or PL as a substrate but is not expressed highly enough in the blood to provide 
detectable reductase activity by the methodology used in this study. This would also 
be important if the mechanism behind the anti-epileptic action of PLP 
supplementation (See Section 7) is related to a change in the conformation of the 
KCNAB2 subunit upon the binding and reduction of PLP to PNP. Important future 
work would be to fully investigate the presence of an enzyme in humans capable of 
the conversion of PL or PLP to PN or PNP. Depending on the function of this enzyme, 
this could be important for the treatment of epilepsy and, in particular, PNPO deficient 
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individuals treated with PLP (if accumulation of PNP was having an effect upon their 
seizure susceptibility or treatment). 
Subject 2 is now 3 years of age, neurodevelopmentally normal and has not 
experienced any seizures. However, the subject has early stages of hepatic 
dysfunction on 40 mg/kg/d PLP. Specifically, the patient’s liver is mildly enlarged with 
mild cytolysis and elasticity of 10.6 kPa (personal communication: Dr. Manuel Schiff). 
This shows the importance of identifying the mechanism behind liver damage in 
PNPO deficient patients on PLP supplementation (see Section 6).  
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 Discussion and future work 
This work demonstrates that measurement of B6 vitamers from dried blood spots is a 
useful tool for the diagnosis of PNPO deficiency. Indeed, it appears that DBS are a 
more useful sample type than plasma due to the presence of higher PNP 
concentrations in DBS relative to plasma. This enables the use of a raised PNP/PLP 
ratio as a diagnostic indicator of PNPO deficiency.  
Despite the collection of 11 samples from individuals with B6-dependent seizures that 
were not due to PNPO deficiency, it was not possible to achieve numbers large 
enough to comment conclusively on whether a characteristic B6 vitamer profile in DBS 
can be identified that assists in the diagnosis of these other B6 dependent seizure 
disorders (e.g. PLPHP deficiency). The analysis of samples from a greater number of 
individuals with other disorders affecting B6 metabolism would be important future 
work. 
One potential limitation of the clinical and diagnostic utility of measuring B6 vitamer 
concentrations from subjects on high-dose supplementation is the variation in 
concentrations prior to and after oral doses of B6, which could be difficult to control 
for. This is described in more detail in Section 3.3 where B6 vitamer concentrations 
from two patients over a time course before and after doses of PLP are discussed. 
Similarly, it seems that the patterns identified (e.g. raised PNP/PLP and PM/PA ratios) 
are less pronounced or absent in patients receiving lower doses of PLP or PN (e.g. 
Subject 8), and in some patients homozygous for p.R116Q.  
A useful addition to the pharmacokinetic studies in Section 3.3 would be 
characterisation of the B6 vitamer profile in the blood of normal control subjects with 
intact vitamin B6 metabolism after receiving PLP supplementation.  
The work carried out so far has been performed using a limited control range of 6 
healthy adults. Since this method will be used mostly for the analysis of samples 
derived from children, age-matched control ranges should be established; these 
should include both children receiving B6 supplementation and others without 
exposure to supraphysiological B6 doses. Although control ranges have been 
published for plasma, we have shown that major differences are apparent when 
plasma profiles are compared to those of DBS (higher levels of PLP, PNP and PMP 
in DBS), thought to be due to the presence of erythrocytes.  
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In addition, it would be useful to look at whether there is any correlation between CSF 
and DBS B6 vitamer concentrations – this could help titrate dosage to the minimum 
required for seizure control. Towards a similar end, future work on the kinetics of 
PLP/PN supplementation should also involve the supplementation of a healthy control 
with high dose PLP in order to characterise the differences between PNPO deficient 
individuals and controls.  
With regards to the suitability of this method for clinical use, whilst the analysis of 
most B6 vitamers was acceptable, PM, PL and PMP had unacceptably high variability 
at their LLOQs (>15%). Future work should involve the optimisation of either the LC-
MS/MS method or sample preparation to enable the accurate quantitation of lower 
concentrations of these analytes. 
In addition, validation of the recovery of B6 vitamers and pyridoxic acid from DBS was 
unsuccessful due to enzymatic interconversion occurring when whole blood was 
spiked (Section 3.1.1). In the future, this experimentation should be repeated using, 
for example, inhibitors of the B6 metabolic enzymes in order to minimise this effect 
and ensure that recoveries are accurate. 
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 DEVELOPMENT OF LC-MS/MS-BASED ENZYME 
ASSAYS FOR THE MEASUREMENT OF PNPO 
ACTIVITY 
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A B6-dependent seizure disorder, pyridox(am)ine 5’-phosphate oxidase (PNPO) 
deficiency results in the inability to interconvert the inactive forms of vitamin B6 into 
the active cofactor, pyridoxal 5’-phosphate (PLP) (Section 1.2.1). PNPO deficiency 
is treatable with high doses of either PLP or pyridoxine (PN) and diagnosis is currently 
performed using genetic testing. 
Section 3 describes the assessment of whether the measurement of B6 vitamers and 
pyridoxic acid in dried blood spots (DBS) is a useful tool for the diagnosis of PNPO 
deficiency. It was discovered that raised PM/PA and PNP/PLP ratios may be 
important biomarkers for this disorder, with PNP/PLP proving the most useful. 
However, this still did not provide a conclusive diagnosis of PNPO deficiency; some 
PNPO deficient individuals had normal (≤0.01) PNP/PLP ratios. In particular, 
treatment naïve PNPO deficient individuals and/or those homozygous for the 
p.R116Q variant in PNPO may not have raised PNP/PLP ratios (Section 3.2) In 
addition, some individuals that had PNPO deficiency excluded genetically but were 
receiving B6 supplementation had PNP/PLP ratios >0.01.  
There is therefore still a requirement for a conclusive and rapid diagnostic test for 
PNPO deficiency.  It was hypothesised that the development of an LC-MS/MS-based 
enzyme assay for the measurement of PNPO activity using DBS could meet this 
need. Several enzymatic assays for measuring PNPO activity have been described 
in the literature. However, these are not suitable for routine clinical diagnostic use, 
they require large sample volumes, radiolabelled substrates or are simply too 
laborious.39, 59, 170-174 This chapter describes the development of an LC-MS/MS-based 
PNPO enzyme assay using DBS. 
The use of DBS from a heel or finger-prick is an established method for sample 
collection which was developed initially for the measurement of phenylalanine levels 
in the diagnosis of phenylketonuria in the 1960s.149 Subsequently the use of DBS to 
assay enzymes present in the circulating blood has been reported for various 
metabolic disorders.175 The non-invasive collection and simple transport/storage are 
a major advantage of DBS.  
In addition to measuring PNPO activity from patient DBS, the assay was also adapted 
for analysis of the kinetics of recombinant PNPO enzyme. This is useful for the in vitro 
assessment of potentially pathogenic variants in the PNPO protein. This form of 
PNPO assay was used to determine the effect of the p.R116Q substitution. 
Individuals homozygous for the p.R116Q variant have a variable phenotype, some 
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presenting with the B6-responsive seizures typical of PNPO deficiency and others 
seemingly healthy.87 It was hoped that by studying the kinetics of recombinant 
p.R116Q protein, the reason behind this variable phenotype could be elucidated. 
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 Investigation and development of an LC-MS/MS-based 
Enzyme assay using dried blood spots for the diagnosis of 
PNPO deficiency 
Several protocols for the measurement of PNPO activity from dried blood spots were 
investigated. This included the comparison of single-step and coupled enzyme 
assays (Figure 4.1; Section 4.1.1.1); the coupled assay was optimised and validated 
for clinical use (Sections 4.1.1.2 – 4.1.1.3). In contrast to a single-step enzyme assay 
this type of assay requires an additional enzymatic conversion step prior to that which 
is of interest. Measurement of the rate of this second step is used to quantify enzyme 
activity. In this case, the first step of the coupled assay relied on pyridoxal kinase 
(PK), which phosphorylates the B6 vitamer (in this case, PN) added as substrate prior 
to incubation. This results in PNP formation as an intermediate, the consumption and 
formation of which could be measured. The second step was conversion of PNP to 
PLP by the PNPO enzyme. The single-step assay investigated consisted of the 
conversion of PMP to PLP. Formation of PLP and the other B6 vitamers, as required, 
were quantified using the LC-MS/MS method described in Section 2.4. Whilst 
conditions were varied throughout experimentation a summary of the protocol used 
throughout this section for measurement of PNPO activity can be found in Figure 4.2.  
Figure 4.1: Coupled and single-step PNPO assays using d2-PN and PMP as substrates. a) coupled 
PNPO assay; b) single-step PNPO assay; IS = internal standard used for quantification of each analyte; PA = 4-
pyridoxic acid; PN = pyridoxine; PNP = pyridoxine 5’-phosphate; PLP = pyridoxal 5’-phosphate; PMP = 
Pyridoxamine 5’-phosphate; PNPO = pyridox(am)ine 5’-phosphate oxidase. 
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 Investigation and development of a coupled enzyme assay 
 
4.1.1.1 Comparison of single-step and coupled assays - Preliminary 
investigation of substrates and stable isotope internal 
standards 
Initial method development included comparison of d2-pyridoxine (d2-PN) and 
pyridoxamine 5’-phosphate (PMP) as substrates, the former as part of a coupled 
enzyme assay and the latter as a single-step assay (Figure 4.1). d2-PN was chosen 
Figure 4.2: Summary of the protocol used for the development of a PNPO activity assay from DBS. 
Compositions of the elution buffer, reaction mixture and reaction stop solution were varied according to 
experimentation, as detailed in the text. FMN = Flavin mononucleotide; ATP = adenosine 5’-triphosphate; T0 = 
DBS to which the reaction stop mixture was added immediately after the reaction mixture; TX = DBS incubated 
at 37°C for time X. 
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as substrate for the coupled assay as, ideally, a deuterated substrate is used; this 
makes it possible to differentiate formation from the exogenous substrate from that 
already present in the sample. It was not possible to carry out a single-step assay 
with deuterated PNP or PMP as dx-PNP was unavailable and dx-PMP prohibitively 
expensive. PMP was used as PNP was not commercially available. 
Conditions differed slightly between the coupled and single-step assays, as the 
requirements of PK in the coupled assay made necessary the addition of Mg2+ and 
ATP to the reaction mixture. Flavin Mononucleotide (FMN), the cofactor for PNPO, 
was required for both the single-step and coupled assays. The concentrations of 
these compounds in the final reaction mixture were 3 mmol/L MgCl2, 0.3 mmol/L ATP 
and 1.5 μmol/L FMN. These cofactor concentrations had been used in prior studies 
for the in vitro analysis of PNPO activity (in the case of FMN)87 or had been shown to 
saturate PK (in the cases of MgCl2 and ATP).176 d2-PLP (for the coupled assay) or 
PLP (for the single-step assay) formation was measured over a four hour incubation 
period. Unless otherwise stated, all initial method development was carried out using 
3 mm dried blood spots from healthy adult controls.  
As shown in Figure 4.1, deuterated pyridoxic acid (d2-PA) was used as an internal 
standard (IS) for the quantification of all analytes. Labelled internal standards are 
commonly used in LC-MS/MS methods. The addition of known concentrations to all 
calibration standards and samples of unknown concentration allows accurate 
quantification through the calculation of analyte/IS ratio in each sample. It is assumed 
that if there is any variation in recovery or MS performance the signal obtained from 
the IS will vary identically to the analyte of interest from sample to sample. This 
enables compensation for the variation in signal acquired between injections and 
samples upon LC-MS/MS analysis. Ideally, during LC-MS/MS analysis a labelled form 
of each individual analyte is used for quantification of that analyte; using an 
isotopically labelled analogue of the analyte itself is the best compensation for 
parameters that can affect quantification such as the matrix of the sample. These 
parameters include the recovery of the analyte upon sample preparation, or 
chromatography during analysis. The analyte/IS ratio provides an accurate measure 
of analyte concentration.  
Whilst not an isotopically-labelled form of the analytes of interest, the use of d2-PA as 
IS allowed its addition prior to incubation as activity of PK or PNPO should not be 
affected by its presence in the reaction buffer. The addition of other vitamers could 
affect measured PLP formation, for example, d2-PLP could cause feedback inhibition 
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of PNPO activity.36 It is preferable to add an IS at the earliest possible stage in a 
protocol as it then compensates for more steps of sample preparation. 
 
Preliminary experiments were carried out in order to determine the range of 
measurement for PLP using the LC-MS/MS equipment available. Linearity was 
achieved up to a concentration of 200 nmol/L when using d2-PA as internal standard 
(Figure 4.3a). Above this concentration the calibration curve created for PLP 
quantification was non-linear. A lower injection volume was attempted but this led to 
poor retention and peak shape of PLP. This is due to an effect of the sample matrix 
pH on the interaction of PLP with the stationary phase. 
The calibration curves for d2-PN and PMP were non-linear over the same range 
investigated for PLP (i.e. 0 – 200 nmol/L) (Figure 4.3b & c). d2-PLP linearity (product 
of the coupled d2-PN > d2-PNP > d2-PLP assay) was identical to that of PLP (data not 
shown). Since the calibration curve created for the quantification of PLP was only 
linear to approximately 200 nmol/L, this was designated as the upper detection limit 
for this vitamer.  
Figure 4.3: Linearity of calibration curves using 500 nmol/L d2-PA as internal standard. 
Concentrations of a) PLP, b) d2-PN and c) PMP from 0 – 200 nmol/L n=1 at each point. R2 = PLP: 0.998 
d2-PN: 0.978 PMP: 0.977. 
a) b) 
c) 
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Concentrations of the substrates d2PN and PMP were therefore adjusted so their 
concentrations would result in a maximum of 200 nmol/L on analysis (400 nmol/L 
before addition of the TCA stop mix). This meant their concentrations, and the 
formation of product (d2PLP or PLP) could be accurately monitored over the 
incubation period of the enzyme assay. Concentrations of the d2-PA internal standard 
were reduced to 50 nmol/L from 500 nmol/L to ensure that the IS concentration was 
not at a saturating concentration and was within the range of the calibration curves 
used. 
 
 
 
 
 
 
 
When d2-PA was used as the IS for quantification of d2-PLP concentrations in the 
coupled enzyme assay, product formation was approximately linear over a four hour 
period. In the single-step enzyme assay using PMP as substrate, conversion to PLP 
was also linear over the incubation period (Figure 4.4 (b)). However, PMP > PLP 
conversion was only 29% of d2-PLP formed in the coupled assay over the five hour 
incubation period. Approximate d2-PN and PMP concentrations were quantified using 
the non-linear calibration curves shown in Figure 4.3. d2-PNP concentrations were 
calculated semi-quantitatively by using the calibration curve for d2-PLP and assuming 
the ratios were the same as for d2-PN quantification. Comparison of the coupled and 
single-step assays indicated that PLP was produced at a much faster rate by the 
coupled assay based on  i) greater PLP than d2PLP formation and ii) rapid reduction 
of d2-PN substrate concentrations relative to PMP. A small amount of PLP at T = 0 
can be seen in Figure 4.4 (b), indicative of PLP contained in the PMP standard used 
a) b) 
Product formation Substrate reduction 
Figure 4.4: Initial comparison of coupled and single-step enzyme assays. Incubation conditions as 
follows: 20 mmol/L potassium phosphate buffer pH 7.6; 400nmol/L d2-PN or PMP; 0.3 mmol/L ATP; 3 mmol/L 
MgCl2; FMN 1.5 µmol/L; 37 °C; 300 rpm agitation; 0 – 5 h incubation; 1 x 3 mm DBS. AU = Arbitrary Units; calculated 
using the assumption that the d2PNP:d2PA ratio was identical to that of the d2PLP:d2PA calibration curve. Error 
bars = SEM. (n=2 at each data point). 
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as substrate, or endogenous PLP found in the DBS analysed; these factors are 
discussed in Sections 4.1.2.3 and 4.3.2.2.  
The use of d2-PLP as an IS was also investigated for the quantification of PLP 
formation and PMP consumption in the single-step assay. Comparable PLP 
concentrations were calculated when using either d2PA or d2PLP as the internal 
standard. However, PMP concentrations varied from those calculated when using d2-
PA as the IS. The same pattern was seen for d2-PN quantification (data not shown). 
This variability in the quantification when using different internal standards indicated 
that the difference in matrix (buffer composition and presence of DBS) between 
different samples could affect quantification of the B6 vitamers. It was hypothesised 
that PLP (or d2PLP) and d2PA were suppressed by a similar amount according to the 
sample matrix, but PMP to a different extent. This would explain the discrepancy in 
PMP measurements when swapping d2PA for d2PLP as internal standard, but 
similarity for PLP measurement between the two internal standards. 
 
Experiments were carried out in order to investigate which internal standards were 
suitable for the quantification of each B6 vitamer. It was hypothesised that the 
exogenous MgCl2 (3 mmol/L) added to samples undergoing incubation, but not to the 
calibration curve, could be introducing a matrix effect. In order to investigate this PLP, 
d2-PLP, PN, d2-PN, PL, d3-PL, PA, d2-PA, PM, d3-PM and PMP were individually 
Figure 4.5: Assessment of the matrix effect on LC-MS/MS signal intensity of the B6 vitamers and 
their isotopically-labelled analogues. Each sample contained a 100 nmol/L concentration of each vitamer 
in 0.15 N TCA with the matrix adjusted as specified in the figure legend. 100% = signal in H2O + 0.15 N TCA. Error 
bars = SEM.  n = 3. AUC = Area under curve. 
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spiked into 0.15 N TCA in the presence or absence of 3 mmol/L MgCl2. In addition, 
another set of samples were incubated with a 3 mm dried blood spot, as well as 0.15 
N TCA and 3 mmol/L MgCl2. The peak area of each analyte upon LC-MS/MS analysis 
was evaluated (Figure 4.5). Substantial differences were identified in the level of ion 
suppression/enhancement for several vitamers. The signals obtained for some 
vitamers (PLP ~80% reduction and PA ~50% reduction) were predominantly affected 
by the presence of MgCl2 where others were more dependent upon the matrix change 
found upon incubation with a 3 mm dried blood spot or showed little change 
irrespective of the sample matrix (e.g. PN; <10%).  
This highlights the importance of using the deuterated form of each analyte as an IS, 
to minimise any analytical error due to matrix effect. Interestingly, PLP has the 
shortest retention time of the B6 vitamers studied (0.9 minutes). The signal derived 
from this vitamer was most affected by sample matrix. It is possible that at the time of 
PLP elution, highly polar compounds and salts are co-eluting, forming adducts and 
reducing the detection of the protonated [PLP + H]+ ion. In all subsequent 
experiments, an equal concentration of MgCl2 to that added to the samples was 
added to calibration standards for those enzyme assays utilising MgCl2 in the reaction 
buffer in order to minimise matrix effect. 
The development of a coupled enzyme assay (PN > PNP > PLP) was initially pursued 
further, rather than monitoring PMP to PLP conversion in a single step assay. Several 
factors influenced this decision: i) A deuterated form of PMP for accurate 
quantification was unavailable ii) The chromatography and signal upon LC-MS/MS 
quantification of PMP was substantially worse than that of the other B6 vitamers iii) 
PMP to PLP conversion appeared to be considerably slower than that measured 
when a coupled assay was employed (Figure 4.4). iv) The PMP standard used was 
found to contain approximately 1−2% PLP as evident in Figure 4.4 (b); 9 nmol/L PLP 
is present at T0 in the single step assay, despite the fact that this DBS was not 
incubated with substrate before the TCA stop mix was added.  This would interfere 
with measurement of endogenous PLP in the DBS and may also lead to feedback 
inhibition.  
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A coupled assay using PN (final concentration of 400 nmol/L on incubation) as the 
exogenous substrate rather than the deuterated d2-PN was performed (Figure 4.6) 
thus allowing d2PN to be used as the internal standard; the importance of using an 
isotopically labelled form of the analyte of interest is described above. All other 
conditions were kept the same. PLP formation was monitored over 5 hours, as were 
the concentrations of PNP and PN. d2-PLP was used as the IS for PLP quantification 
and d2-PN for PN quantification. The response of PNP was assumed to be the same 
as that for PLP and the ratio of PNP to d2-PLP was used to quantitate PNP. This 
allowed relative and approximate quantification of PNP. Linear (R2 > 0.99) formation 
of PLP was seen over a five hour incubation period (Figure 4.7).  
Figure 4.7: Coupled pyridoxal kinase and pyridox(am)ine 5’-phosphate oxidase activity in a 
3 mm punch from a healthy adult control. Incubation conditions as follows: 20 mmol/L potassium 
phosphate buffer pH 7.6; 400nmol/L PN; 0.3 mmol/L ATP; 3 mmol/L MgCl2; FMN 1.5 µmol/L; 37 °C; 300 
rpm agitation; 0 – 5 h incubation; 1 x 3 mm DBS. Error bars = SEM. (n=9 at 2 h; n=3 at all other time 
points).   
Figure 4.6: Coupled pyridoxal kinase and pyridox(am)ine 5’-phosphate oxidase assay using PN as 
substrate. IS = internal standard used for quantification of each analyte; PNP = pyridoxine 5’-phosphate; PLP 
= pyridoxal 5’-phosphate; PN = pyridoxine; PK = pyridoxal kinase; PNPO = pyridox(am)ine 5’-phosphate 
oxidase. 
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4.1.1.2 Optimisation of coupled PK and PNPO enzyme assay 
conditions 
Proof of concept experiments described above showed that it was possible to 
measure PLP formation and therefore PNPO activity from DBS using a combined PK 
and PNPO enzyme assay. Subsequently, it was ensured that conditions for enzymatic 
PLP formation were optimal, providing suitable conditions for accurate quantification 
of PNPO activity.  
 
Optimisation of Flavin mononucleotide concentration 
Flavin mononucleotide (FMN; the active form of vitamin B2) is the cofactor for PNPO. 
Figure 4.8 shows the effect of increasing FMN concentration on PLP formation over 
a four hour incubation period, all other conditions were kept identical.  
 
 
Figure 4.8: Effect of FMN concentration on PNPO activity in a 3 mm DBS punch from a healthy 
adult control. Incubation conditions as follows: 20 mmol/L potassium phosphate buffer pH 7.6; 
400nmol/L PN; 0.3 mmol/L ATP; 3 mmol/L MgCl2; FMN 0 - 1.5 µmol/L; 37 °C; 300 rpm agitation; 0 – 4 h 
incubation; 1 x 3 mm DBS. (n=1 at each data point).   
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An FMN concentration of 1.5 µmol/L has been used previously in other published 
assays to study PNPO activity in mammalian tissues such as rabbit liver 177 and an in 
vitro over-expression system.87 In the coupled assay described here, PLP formation 
was linear over the four hour incubation period in the presence of 1.5 µmol/L FMN 
and 25% and 13% higher than at FMN concentrations of 0 and 0.75 µmol/L, 
respectively. The Kd for FMN binding to PNPO is in the low nanomolar range (13.1 
nmol/L)74 Concentrations in the µmol/L range were expected to saturate the PNPO 
enzyme with FMN cofactor and higher concentrations would be unnecessary; they 
were therefore not investigated. The presence of exogenous FMN in the reaction 
mixture would ensure that any patients with a vitamin B2 deficiency would not appear 
to have lower DBS PNPO activity.  
 
Optimisation of reaction mixture pH 
It has been reported that the red cell PNPO enzyme has optimal activity at pH 8.0.170 
Optimal pyridoxal kinase activity in erythrocytes occurs at pH 6 - 8.178 A balance in 
pH must be found to provide adequate conditions for the activity of both enzymes. 
Little difference was seen in PLP formation between pH 7.2 and 8.0 when 20 mmol/L 
potassium phosphate was used as the incubation buffer (Table 4.1). This buffer had 
been used previously for the assessment of in vitro PNPO activity.87 The buffering 
capacity of potassium phosphate is diminished above pH 8.0 hence higher pH ranges 
were not investigated. Additionally, above pH 7.8, peak splitting was observed during 
LC-MS/MS analysis (Figure 4.9). 
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pH 
PNPO Activity  
(pmol/DBS/h) 
7.0 4.01 
7.2 4.78 
7.4 5.47 
7.6 4.94 
7.8 5.29 
8.0 5.13 
 
This experiment was repeated and PNPO activity in a Tris-HCl buffer system was 
compared to that in a potassium phosphate buffer so that the activity of PNPO at a 
pH greater than 8 could be studied. Tris-HCl has an effective buffering capacity 
between pH 7 – 9. Figures 4.10 (a), (b) and (c) show the effect of potassium 
phosphate pH on PN depletion and the formation of PNP or PLP, respectively, at pH 
6.6, 7.0 and 7.6. PNPO activity increases as the pH becomes more alkaline, this is 
consistent with a red blood cell optimal pH of 8.0, as reported previously.170  
b) 
a) 
Figure 4.9: Pyridoxal 5’-phosphate chromatography on LC-MS/MS analysis. (a) Chromatography 
of PLP after samples incubated in a pH 7.6 potassium phosphate buffer. (b) Chromatography of PLP after 
samples incubated in a pH 8.0 potassium phosphate buffer. 
Table 4.1: Effect of pH on PNPO activity using a coupled assay. Incubation conditions: 20 
mmol/L potassium phosphate buffer (pH adjusted appropriately from 7.0 – 8.0); 1.5 µmol/L FMN; 
0.3 mmol/L ATP; 3mmol/L MgCl2; 400 nmol/L PN; 37 °C; 300 rpm agitation; 1 x 3 mm DBS; 0-4 h 
incubation. DBS from a healthy adult control. Activity was quantified by PLP formation and was 
calculated from the slope of a linear regression performed upon PLP concentrations at time points 
of 0, 1, 2, 3 and 4 h at each pH. ANCOVA analysis was performed and no significant difference was 
identified between groups. (n=1)  
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Figure 4.10 (f) shows PLP formation on incubation of a DBS in a reaction mixture 
buffered to pH 7.6, 8.0 and 8.6 with Tris-HCl. PLP formed was approximately 30 – 
50% that observed when using potassium phosphate at pH 7.6. Previous studies 
have shown that PK requires a monovalent cation such as K+ for effective 
phosphorylation. Without the addition of exogenous K+ in the reaction buffer, PK 
activity (measured as PNP formation), is reduced by at least 80% (Figure 4.10 (e)). 
A reaction buffer based solely on Tris-HCl is therefore unsuitable for a coupled PK 
and PNPO assay. Similar to the experiments using potassium phosphate as a buffer, 
peak splitting was evident at pH > 8.0. Subsequent experiments were therefore 
carried out at pH 7.6. 
 
a) 
c) 
b) 
d) 
f) 
e) 
Figure 4.10: PNPO activity between pH 6.6 - 8.6. Incubation conditions: 20 mmol/L potassium 
phosphate buffer or Tris Cl (pH adjusted appropriately); 1.5 µmol/L FMN; 0.3 mmol/L ATP; 3mmol/L 
MgCl2; 400 nmol/L PN; 37 °C; 300 rpm agitation; 1 x 3 mm DBS; 0-4 h incubation. DBS from a healthy adult 
control. n=1 at each data point. 
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4.1.1.3 Validation of coupled enzyme assay and stability of PK and 
PNPO in DBS upon storage 
In order to translate a research method into the clinical diagnostic arena, repeatability 
of analysis must be determined. Using the optimal conditions for PLP formation 
(Sections 4.1.1.1 and 4.1.1.2), the enzyme assay was repeated ten times, on four 
separate days, using 3 mm dried blood spots taken from a single healthy adult control. 
PLP formation was measured over a 2 h incubation period; PNPO activity had already 
been shown to be linear over this period (Section 4.1.1.1). Intra and inter-assay 
%CVs were 8.44% and 4.09%, respectively (Figure 4.11). Typically, %CVs of less 
than 15% are considered suitable for clinical diagnostic use.179  
 
The short-term stability of PNPO (and by extension PK) was determined by drying 
blood spots from a healthy adult control overnight on Whatman 903 DBS collection 
cards before storage at room temperature and at 37°C for 1, 3, 5, 7 and 14 days prior 
to analysis. A duplicate set of DBS were also stored inside foil bags with silica 
desiccant at room temperature, in order to determine the effect of ambient humidity 
Figure 4.11: Repeatability of PLP formation after a 2 hour incubation with a 3 mm DBS from a 
healthy adult. Incubation conditions: 20 mmol/L potassium phosphate buffer pH 7.6; 1.5 µmol/L FMN; 0.3 
mmol/L ATP; 3mmol/L MgCl2; 400 nmol/L PN; 37 °C; 300 rpm agitation; 10 x 3 mm DBS on each day; 2 h 
incubation. Mean intra-assay %CV = 8.44%. Inter-assay %CV = 4.09%. 
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upon PNPO stability. DBS stored under conditions of ambient humidity at RT and at 
37°C showed a reduction in activity of ~55% after 14 days (Figure 4.12 (a)). DBS 
protected from ambient humidity better retained PNPO activity however, with a 
reduction in activity of only 21% after 14 days storage. 
The effect of DBS storage at 4°C, -20°C and -80°C on PNPO activity was determined 
over a 24 week period (Figure 4.12 (b)). Under these conditions, PNPO was found 
to be more stable than when stored at room temperature. After 24 weeks at 4°C, 
PNPO activity was approximately 70% of initial levels, at -20°C, 85% of initial levels 
and at -80°C unaffected by storage. Some variation can be seen in Figure 4.12 (b) 
resulting in a seeming increase in PNPO activity at some time points. This is due to 
inter-assay variation. For all subsequent experiments, DBS were stored at -80°C prior 
to analysis.  
 
During this phase of method development, a potential source of error was identified 
in the quantification of the B6 vitamers by LC-MS/MS. Considerable crosstalk was 
identified between the MRM channels for d2-PLP (IS used to quantify PLP) and PNP 
(substrate of PNPO), which had become available commercially subsequent to the 
start of this project. Whilst both compounds have the same molecular mass some 
differentiation of the two was possible due to the different MRM transitions used i.e. 
loss of phosphate (-98) for d2-PLP quantification and loss of phosphate and water  
(-116) for PNP quantification. However, because PNP also contains phosphate 
crosstalk of approximately 10% of the signal of PNP was present. As the compounds 
co-elute, this could lead to inaccuracy in the measurement of compounds quantified 
using d2-PLP as an internal standard. Another internal standard was sought and d3-
Figure 4.12: Effect of (a) short and (b) long-term storage on PNPO activity measured in a 3 mm 
DBS from a healthy adult. Incubation conditions: 20 mmol/L potassium phosphate buffer pH 7.6; 1.5 
µmol/L FMN; 0.3 mmol/L ATP; 3mmol/L MgCl2; 400 nmol/L PN; 37 °C; 300 rpm agitation; 1 x 3 mm DBS; 2 h 
incubation. DBS stored for up to 14 days at 22°C or 37°C with or without desiccant. 
a) b) 
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PLP identified as a potential replacement. On investigation, it was confirmed that the 
PNP to d3-PLP crosstalk was greatly reduced. Although still approximately 1% of the 
PNP signal was evident in the d3-PLP channel due to the proportion of the 13C 
isotope present in PNP, this was deemed a considerable improvement. Hence, all 
further experimentation was carried out with d3-PLP used as the IS for PLP 
quantification. 
 
4.1.1.4 Effects of high dose PLP supplementation on the accuracy of 
analysis of dried blood spot PNPO activity. 
Preliminary results for the optimisation of the coupled PK and PNPO assay system 
described above were promising. The stability of PK and PNPO on storage in DBS 
was acceptable and the repeatability of the method was suitable for clinical use. All 
optimisation had been performed using DBS from healthy volunteers that were not 
receiving B6 supplementation. However, problems were identified during further 
assay optimisation when using DBS from PNPO deficient patients that could 
potentially to lead to false positive or negative results. 
The levels of (a) PN, (b) PNP, (c) PLP and (d) PL were measured upon incubation 
of a control DBS and a DBS from a PNPO-deficient subject over a 4 hour incubation 
period (Figure 4.13). PLP formation in the healthy adult control was linear over the  
4 hour incubation period and, as expected, higher than that identified in the PNPO 
deficient subject. However, higher initial concentrations of PLP, PNP and PL were 
seen in the DBS from the PNPO deficient child at 0 h relative to the control sample. 
This is indicative of the high endogenous concentrations of B6 vitamers in the blood 
of subjects receiving high dose vitamin B6 supplementation.  
An unexpected increase in PLP concentration was seen in the PNPO deficient 
individual over the 4 h time course studied. A concurrent decrease in PL (d) provides 
an explanation for this increasing PLP concentration. It is likely that PK was able to 
catalyse the phosphorylation of PL to PLP, hence accurate quantification of PNPO 
activity by measuring PLP formation using the coupled assay was not possible in this 
patient. 
In a healthy control not receiving supraphysiological B6 doses, PL concentrations are 
below the lower limit of quantification (i.e. < 1.25 nmol/L). These concentrations would 
not affect quantification of PNPO activity. However, in a patient receiving high dose 
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vitamin B6 supplementation, concentrations of B6 vitamers are high enough to 
obfuscate PNPO activity when measured as the second step in a coupled PN > PNP 
> PLP enzyme assay. 
 
In order to further characterise the effect of high PL and PLP concentrations on the 
analysis of PNPO activity, the assay was repeated using a DBS from a control and 
with the addition of 100 nmol/L PLP or PL to the reaction buffer. This concentration is 
similar to the concentrations found in patients receiving supraphysiological vitamin B6 
doses for seizure treatment. Figure 4.14 shows a) PLP, b) PNP and c) PN 
concentrations over a four hour incubation period of a control DBS with a reaction 
buffer containing additional exogenous PLP and PL.  
The presence of 100 nmol/L PLP in the reaction buffer resulted in a reduction in the 
activity of PNPO by approximately 55%. The increase in PLP concentration after 4 
hours of incubation when no exogenous PLP is added was 82.5 nmol/L, versus only 
37.8 nmol/L with 100 nmol/L PLP added to the reaction buffer. This reduction was 
Figure 4.13: Comparison of the B6 vitamer concentrations upon incubation of a 3 mm DBS from 
a healthy adult control and a PNPO deficient subject. Incubation conditions as follows: 20 mmol/L 
potassium phosphate buffer pH 7.6; 400nmol/L PN; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 rpm 
agitation; 0 – 4 h incubation; 1 x 3 mm DBS. (n=1 at each data point).  AUC = area under curve. CU = 
concentration units.) 
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likely due to the effect of product inhibition by PLP on PNPO. 36, 60 Equally, when 100 
nmol/L PL was included in the reaction buffer, 17.5% more PLP was formed after 4 
hours of incubation (97.0 vs 82.5 nmol/L). It is likely that this is due to the action of 
pyridoxal kinase, which is able to phosphorylate both pyridoxal and pyridoxine into 
their respective 5’-phosphates.  
This experiment was repeated with the following modification: i)   DBS from a control 
were incubated with a range of PLP concentrations from 0 – 100 nmol/L added to the 
reaction buffer ii) The incubation time of all DBS was kept to 2 h; this was to allow an 
easy comparison between conditions. In the control DBS in Figure 4.14, PLP 
formation and PN consumption were linear to 2 hours in all cases. 
The effect of PLP on PNPO activity as measured by the change in PLP concentration 
is shown in Figure 4.15. There was a dramatic reduction in PLP formation as added 
PLP concentrations were increased. In patients receiving vitamin B6 supplementation, 
DBS PLP concentrations of up to 17,000 nmol/L can be found (Section 3.2). Given 
that ~3.2 µL of blood is found in a 3 mm DBS punch and that this will be diluted in a 
final solution totalling 240 µL, if whole blood concentrations were 17,000 nmol/L you 
a) b) 
c) 
Figure 4.14: Comparison of the B6 vitamer concentrations upon incubation of a 3 mm DBS from a 
healthy adult with exogenous B6 vitamers. Incubation conditions as follows: 20 mmol/L potassium 
phosphate buffer pH 7.6; 400nmol/L PN + 100 nmol/L PL or PLP; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 
rpm agitation; 0 – 4 h incubation; 1 x 3 mm DBS. PNP concentrations expressed in arbitrary units assuming that 
the ratios are identical to those found in calibration curve created for PLP/d3-PLP.  (n=2 at each data point).   
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would expect PLP concentrations of approximately 226 nmol/L. Indeed, the PLP 
concentration in the T0 3 mm DBS from the PNPO deficient patient in Figure 4.14 
was 42 nmol/L. A reduction in activity of approximately 57% would be expected with 
this concentration of endogenous PLP (calculated from Figure 4.15). The effect of 
endogenous PLP on PLP synthesis may be due to product inhibition on PNPO. This 
effect would make the assay unsuitable for the analysis of samples from patients 
receiving supraphysiological doses of vitamin B6.  
 
It was postulated that this problem could be addressed by the addition of Tris to the 
reaction buffer. Tris is known to bind PLP and PL in solution, forming a Schiff base.180 
It is possible that with high (mmol/L) concentrations of Tris in the reaction buffer, free 
PLP/PL would be bound, reducing the availability of PL for phosphorylation to PLP as 
well as preventing feedback inhibition by PLP on the PNPO enzyme. However, when 
optimising the coupled PK and PNPO enzyme assay from DBS using Tris-HCl as the 
buffer, low PNPO activity was identified. It is likely that this was due to the lack of K+, 
required for PK activity (Section 4.1.1.3).  In order to address this, incubations were 
performed with the addition of varying KCl concentrations (0, 20 and 40 mmol/L) 
alongside 20 mmol/L Tris (pH 7.6) to the reaction buffer, each adjusted to pH 7.6 after 
KCl addition to ensure this did not affect the final buffer pH. Also included was the 
assay in its prior form; incubation with 20 mmol/L potassium phosphate buffer, pH 
7.6. Published studies suggest that at a tris concentration of 20 mmol/L, 
approximately 85% of free PLP/PL should be bound.180 
Figure 4.15: PLP formation after the 2 hour incubation of a 3 mm DBS with exogenous B6 
vitamers. Incubation conditions as follows: 20 mmol/L potassium phosphate buffer pH 7.6; 400nmol/L 
PN (substrate) + 0, 5, 10, 25, 50, 75 or 100 nmol/L PLP; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 rpm 
agitation; 1 x 3 mm DBS. (n=2 at each data point).   
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Figure 4.16 shows the concentrations of PL, PN, PLP and PNP over a four hour 
incubation period under these conditions. As previously (Section 4.1.1.3), when KCl 
was not added to the reaction buffer, PN conversion to PNP was reduced (Figure 
4.16 (a) and (c)). This ultimately resulted in lower PLP formation (Figure 4.16 (d)); 
41 nmol/L after 4 hours; 48% that achieved when using the potassium phosphate 
buffer system.  
The amount of PLP formed was similar when 20mmol/L Tris-HCl, pH 7.6 containing 
20 mmol/L KCl or 40 mmol/L KCl and  20 mmol/L potassium phosphate (74, 75 and 
85 nmol/L, respectively) were used as the incubation buffer. This confirmed previous 
reports that pyridoxal kinase activity requires the presence of a monovalent cation, in 
this case K+.176 Interestingly, PL formation was observed in all assays in which 
a) b) 
c) d) 
Figure 4.16: Concentrations of B6 vitamers after incubation of a 3 mm DBS with varying buffer 
compositions. Incubation conditions as follows: 20 mmol/L potassium phosphate buffer or 0/20/40 mmol/L KCl 
with 20 mmol/L Tris pH 7.6; 400nmol/L PN; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 rpm agitation; 0 – 4 h 
incubation; 1 x 3 mm DBS. No stable isotope standards were used for PL and PNP therefore concentrations are  
expressed in arbitrary units assuming that the ratios of these vitamers to d2PN and d3PLP are identical to those 
found in calibration curves created for PN:d2-PN and PLP:d3-PLP, respectively (n=1 at each data point).   
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potassium phosphate was not present (Figure 4.16 (b)). Inorganic (free) phosphate 
inhibits the various phosphatases present in the blood.181 In the reaction buffers not 
containing free phosphate it was therefore hypothesised that phosphatases present 
within the DBS were dephosphorylating PLP to PL. This would introduce variability in 
measured PNPO activities between DBS from individuals with differing blood 
phosphatase activities. 
 
Hence, it was postulated that a custom Tris-phosphate buffer containing KCl may 
enable PNPO activity to be measured more accurately. This would provide i) mmol/L 
concentrations of Tris to complex with free PL/PLP; ii) free phosphate, required to 
inhibit endogenous phosphatases and iii) K+ required for PK activity. 
Figure 4.17 shows PN, PLP (nmol/L), PNP and PL (AU) concentrations upon 
incubation with KCl/Tris-HCl, KCl/Tris-phosphate and potassium phosphate reaction 
a) b) 
c) d) 
Figure 4.17: Concentrations of B6 vitamers during incubation of a 3 mm DBS with varying buffer 
compositions. Incubation conditions as follows: 20 mmol/L potassium phosphate buffer or 40 mmol/L KCl with 
20 mmol/L Tris-HCl or Tris PO4 pH 7.6; 400nmol/L PN; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 rpm agitation; 
0 – 4 h incubation; 1 x 3 mm DBS. PL and PNP concentrations expressed in arbitrary units assuming that the ratios 
are identical to those found in calibration curves created for PN/d2-PN and PLP/d2-PLP, respectively (n=1 at each 
data point).   
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buffers, all adjusted to pH 7.6. Although PLP formation was similar (78 – 91 nmol/L 
after 4 hours incubation) in all three forms of the assay, a distinct difference is seen 
in both the rate of PNP formation and PL formation in the KCl/Tris-HCl buffered assay. 
The assays using Tris-phosphate/KCl and potassium phosphate showed almost 
identical results, indicating that a Tris-phosphate/KCl buffer is viable for use for the 
coupled enzyme assay of PNPO. The inclusion of Tris in the buffer means any 
potential feedback inhibition of PNPO by PLP would be reduced as described above. 
Experiments similar to those performed above to study the effect of high initial PL and 
PLP concentrations were repeated in this new Tris-phosphate/KCl (pH 7.6) buffer. 
Figure 4.18 (a) shows PLP formation upon the incubation of a 3 mm DBS from a 
healthy adult control in the presence of exogenous PLP at concentrations of 0, 25, 
50, 100, 150 and 200 nmol/L. In comparison with the data in Figure 4.15, where a 
potassium phosphate buffer was used to study the effect of exogenous PLP on PNPO 
activity, PLP formation after 2 hours incubation was increased. However, product 
inhibition seen in the presence of exogenous PLP caused a reduction in PLP 
formation of 3%, 20%, 18% and 41%, respectively (after 2 h), as compared to 
incubations where no PLP had been added.  
 
Figure 4.18 (b) shows PLP formation in the presence of PL (0 - 200 nmol/L). Relative 
to DBS incubated without exogenous PL an increase in PLP concentration of 18 - 
26% was seen. 
a) b) 
Figure 4.18: Formation of pyridoxal 5’-phosphate after incubation of a 3 mm DBS with varying 
PL and PLP concentrations. Conditions as follows: 20 mmol/L Tris + 40 mmol/L KCl, adjusted to pH 7.6 
with phosphoric acid; 400nmol/L PN + 0 – 200 nmol/L PL/PLP; 0.3 mmol/L ATP; 3 mmol/L MgCl2; 37 °C; 300 
rpm agitation; 0 – 4 h incubation; 1 x 3 mm DBS. (n=1 at each data point). In Figure 18 (a), exogenous PLP 
at T0 has been subtracted at each time point for clarity. 4 h time point with 50 nmol/L added PL was 
anomalous (~0 nmol/L PLP) and hence removed. 
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It was concluded that there were several limitations that made the use of a coupled 
PK and PNPO assay unsuitable for clinical diagnostic use. Firstly, although the 
addition of Tris to the reaction buffer limits the effect of high endogenous PL and PLP 
on PNPO activity, there was still potential for an unacceptable influence upon results 
for patients with high levels of B6 vitamers in the blood due to supplementation for 
seizure treatment. This was due to product inhibition in the case of PLP and due to 
PL conversion to PLP in the case of PL. 
Therefore, under these assay conditions, PNPO activity analysis could only be 
undertaken prior to B6 supplementation, when B6 vitamer concentrations in these 
individuals were not elevated. However, this would limit the clinical utility of a test that 
would usually only be requested after a response to vitamin B6 supplementation had 
been identified in a patient with epilepsy. 
Another inherent problem with using a coupled assay for the quantification of PNPO 
activity was potential variation in PK activity between subjects. As can be seen in 
Figure 4.13 (a), phosphorylation of PN (substrate of PK) to PNP was faster in a DBS 
from the PNPO deficient patient, compared to a healthy adult control. PK activity is 
also known to vary in the general population; activity in the erythrocytes of African 
Americans is approximately 50% lower than that of White Americans38, 182. If PK 
activity was the limiting factor in a coupled assay of PK and PNPO, this could produce 
PLP formation indicative of variation in PK activity rather than PNPO.  
Fortuitously, at this time, PNP became available from a commercial supplier, raising 
the potential for a single-step PNP > PLP enzyme assay. A PNPO assay using PNP 
could solve the problems identified when using the coupled assay. Section 4.1.2 
details the investigation and development of a single step PNP > PLP enzyme assay 
for the quantification of PNPO activity.           
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 Investigation and optimisation of a single-step PNPO enzyme 
assay from DBS 
The commercial availability of two compounds enabled the transition towards a 
single-step PNPO enzyme assay; i) PNP and ii) d3-PLP. PNP availability meant a 
substrate of PNPO was available that provided adequate throughput for accurate and 
rapid quantification (as opposed to the use of PMP as substrate, which was far 
slower). The availability of d3-PLP meant that this PNP could be accurately quantified. 
Studies in Section 4.1 showed that d2-PLP showed a large amount of crosstalk from 
the PNP MRM channel and was thus unsuitable for use in a PNPO assay, as 
described in Section 4.1.1.3. This section details the development of a single-step 
LC-MS/MS-based enzyme assay for the measurement of PNPO activity from DBS by 
quantifying PNP conversion to PLP (Figure 4.19). 
 
 
4.1.2.1 Development of PNPO assay using pyridoxine 5’-phosphate as 
substrate 
Initially, a direct comparison was made between the previously optimised coupled 
(PN > PNP > PLP) PNPO assay and a single-step (PNP > PLP) assay. Figure 4.20 
shows vitamer concentrations on incubation for 0, 1, 2, 3 and 4 hours with a 3 mm 
control DBS. Reaction mixtures were varied with regards to substrate, cofactor and 
buffer composition; these conditions are found in Table 4.2.  
 
Figure 4.19: Single-step PNPO assay using PNP as substrate. IS = internal standard used for 
quantification of each analyte; PNP = pyridoxine 5’-phosphate; PLP = pyridoxal 5’-phosphate; PNPO = 
Pyridox(am)ine 5’-phosphate oxidase. 
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Type of 
assay 
B6 Vitamers added Cofactors added Buffer used 
Reaction 
mixture A 
Coupled 400 nmol/L PN 
3 mmol MgCl2; 
0.3 mmol/L ATP; 
1.5 μmol/L FMN 
40 mmol/L KCl + 20 
mmol/L Tris- PO4  
pH 7.6 
Reaction 
mixture  B 
Coupled 400 nmol/L PN 1.5 μmol/L FMN 
20 mmol/L Tris-PO4 pH 
7.6 
Reaction 
mixture  C 
Single-
step 
400 nmol/L PNP 1.5 μmol/L FMN 
20 mmol/L Tris- PO4 pH 
7.6 
Reaction 
mixture  D 
Single-
step 
400 nmol/L PNP; 
200 nmol/L PL; 
200 nmol/L PMP 
1.5 μmol/L FMN 
20 mmol/L Tris- PO4 pH 
7.6 
 
 
a) b) 
c) d) 
Figure 4.20: Concentrations of B6 vitamers after incubation of a 3 mm DBS with varying initial B6 
concentrations and different buffers. Compositions of buffers A – D can be found in Table 3.2. Other 
conditions: 37 °C; 300 rpm agitation; 0 – 4 h incubation; 1 x 3 mm DBS. (n=1 at each data point). 
Table 4.2: Composition of reaction buffers for the measurement of PNPO activity from DBS.  
PNP = pyridoxine 5’-phosphate; PN = pyridoxine; PMP = pyridoxamine 5’-phosphate; PL = pyridoxal;  
ATP = adenosine-5’-triphosphate; FMN = flavin mononucleotide. 
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Data showed that: i) As previously (Section 4.1.1.3), without the addition of K+, Mg2+ 
and ATP to the reaction buffer, pyridoxal kinase activity in the DBS is negligible as 
measured by PN > PNP conversion in Reaction Mixture B and PL > PLP conversion 
in Reaction Mixture D ii) Upon incubation of the DBS with PNP in Tris-phosphate, 
pH 7.6 with 1.5 µmol/L FMN as cofactor (Reaction Mixture C), linear PLP formation 
was observed, comparable with that formed in the coupled PN > PNP > PLP assay 
(Reaction Mixture A) iii) the addition of exogenous PMP and PL to the reaction buffer 
at a final concentration of half that of the PNP substrate had no effect upon PNPO 
activity as measured by PLP formation (Reaction Mixture D). 
It was concluded that a single-step PNPO enzyme assay using unlabelled PNP as 
the substrate and monitoring the formation of PLP formed would be a viable method 
for the measurement of PNPO activity from dried blood spots. 
One of the limitations of the coupled PNPO assay was its inability to distinguish 
between conversion of PNP > PLP by the PNPO enzyme and conversion of PL > PLP 
by PK in individuals receiving high doses of B6 supplementation (Section 4.1.1.4). In 
order to confirm that a single-step PNPO assay would not suffer from the same 
limitations another comparison was made between the coupled and single-step 
assays. DBS from a control and a PNPO-deficient patient were incubated in Reaction 
Mixtures A & C (Table 4.2; Figure 4.21) for 4 hours and the concentrations of PN, 
PNP and PLP were determined at time 0, 1, 2, 3 and 4 hours. 
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In the control DBS, greater PLP formation was seen in the single-step assay than in 
the coupled PNPO assay. When using the coupled assay, PLP formation was still 
seen in the DBS from a PNPO deficient patient, hypothesised to consist of PL to PLP 
conversion through PK. However, when using the single-step PNP to PLP assay 
minimal PLP formation was apparent across the 4 hour incubation period in a PNPO 
DBS from a PNPO-deficient patient (Figure 4.21 (c)). Figure 4.21 (b) confirms that 
PNP was not converted to PLP in DBS from the PNPO deficient child, but was 
depleted linearly across the 4 hour period in DBS from an adult control.  
 
It was hypothesised that the high endogenous PLP found in patients receiving 
supplementation could still have an effect upon accuracy of the assay. Because 
PNPO activity is quantified by measurement of PLP formation, it is important in cases 
of high endogenous PLP that baseline concentrations are calculated accurately. In 
Figure 4.21, a small increase in PLP concentration occurs in DBS from the PNPO 
deficient patient, particularly between 0 – 2 hours, before plateauing. When measured 
between 0 – 2 hours, this equates to 26% of that seen in a DBS from an adult control. 
a) b) 
c) 
Figure 4.21: Comparison of coupled and single-step PNPO enzyme assay in DBS from a PNPO 
deficient patient and an adult control. Buffers for the coupled and single-step assays were made 
according to Table 4.2 Other conditions: 37 °C; 300 rpm agitation; 0 – 4 h incubation; 1 x 3 mm DBS. (n = 
1 at each data point). Control coupled or single-step = control DBS/coupled PK and PNPO assay or single-
step PNPO assay; PNPO coupled or single-step = PNPO-deficient individual/coupled PK and PNPO assay.  
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It was thought that, rather than this PLP formation being indicative of residual PNPO 
activity, it was due to some PLP being retained in the 3 mm DBS during the early 
stages of incubation before release after a longer incubation at 37°C with agitation at 
300 rpm.  
In order to test this hypothesis, two samples were run in parallel; one with a 40 second 
sonication step prior to the addition of reaction buffer, and one without. Sonication 
had been used for extraction of the B6 vitamers and pyridoxic acid in Section 3. PLP 
concentrations were compared after 0, 15, 30 and 60 minutes incubation of a control 
DBS and the same PNPO deficient child analysed previously. In case of sonication, 
the DBS was first placed in 60 μL 40 mmol/L Tris-phosphate buffer, pH 7.6. After 
sonication, an additional 60 μL of reaction buffer containing 3 μmol/L FMN and  
800 nmol/L PNP was added before incubation at 37°C. It was proposed that the 
sonication of DBS prior to incubation would ensure that the release of PLP from the 
T0 DBS was complete and independent of incubation at 37°C and/or agitation. This 
would mean that the release of PLP would be the same from the T0 and T30 DBS. 
 
Figure 4.22 shows the effect of this 40 second sonication step upon measured PLP 
concentrations after 0, 15, 30 and 60 minutes. Two important conclusions can be 
drawn from this data: i) A 40 second sonication step increased the PLP measured in 
the T0 DBS of a PNPO deficient individual with high endogenous PLP concentrations 
(receiving high dose PLP supplementation), in this case from 42 nmol/L to 61 nmol/L. 
ii) PLP formation and hence PNPO activity in a DBS from an adult control was 
a) b) 
Figure 4.22: Effect of sonication on PNP and PLP concentrations measured prior to incubation 
with a 3 mm DBS from a PNPO deficient child or adult control. Incubation conditions: 20 mmol/L 
TrisPO4 pH 7.6; 1.5 µmol/L FMN; 400 nmol/L PNP; 37 °C; 300 rpm agitation; 1 x 3 mm DBS. (n=1 at each data 
point). 
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unaffected by this sonication step, indicating that sonication did not lead to 
degradation of the PNPO protein. 
Anecdotally, it was noted that a red colour pertaining to haem release from the DBS 
was more prevalent in the buffer containing a T0 DBS that had undergone sonication. 
It is possible that without sonication some proteins remain bound to the filter paper. 
In the blood, most PLP is covalently bound to lysine residues of proteins such as 
haemoglobin and albumin.183 Although the TCA precipitation step breaks the Schiff 
Base forming this covalent bond, sonication solubilises these proteins, facilitating PLP 
release into solution and measurement by LC-MS/MS. This allows more complete 
PLP recovery from the T0 bloodspot and therefore more accurate quantification of 
PNPO activity in individuals with high blood PLP concentrations.  
In order to better characterise the effect of sonication on the assay, the sonication 
step prior to addition of the reaction buffer was varied (0, 30, 60, 120 and 300 
seconds). Figure 4.23 shows the PLP formation from a control DBS after each of 
these sonication periods. Sonication did not affect PNPO activity. All further 
experimentation was carried out using a 120 second sonication step prior to 
incubation. 
 
It was also hypothesised that greater PLP recovery from the DBS may be achieved 
by an additional sonication step after incubation with the TCA reaction stop mixture. 
TCA addition causes denaturation and precipitation of proteins in solution, the Schiff 
base binding PLP to these proteins is also broken; PLP is therefore free in solution. 
Figure 4.23: Effect of sonication on DBS PNPO activity. A 3 mm DBS from an adult control was sonicated for 
variable time periods prior to incubation for 30 minutes. Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 
µmol/L FMN; 400 nmol/L PNP; 37 °C; 300 rpm agitation; 1 x 3 mm DBS. (n=1 at each data point). 
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Prior to the implementation of this additional step it was however necessary to ensure 
that sonication did not cause degradation of PLP when in solution. PLP concentration 
was measured in a 0.15 N TCA solution spiked with 25 nmol/L d3-PLP and 100 nmol/L 
PLP after sonication for 0, 60, 120, 300 and 600 seconds. The recovery of PLP was 
unaffected by the length of sonication period (data not shown). A sonication period of 
300 seconds after the addition of the TCA stop mixture was therefore chosen for all 
future experimentation.  
Subsequent experiments were performed to ensure that the modified protocol 
including sonication steps released all PLP into solution from the T0 punch, as 
intended. DBS from a control and PNPO deficient individual were incubated for 0, 5, 
10, 15 and 30 minutes. Figure 4.24 shows the linear formation of PLP from PNP in 
the control DBS and the PLP concentrations measured over the same time period in 
a PNPO deficiency DBS. The DBS of a PNPO deficient child did not show an increase 
in PLP over 30 minutes. However, some fluctuation of PLP concentration is seen, this 
likely pertains to the variability of either the PLP extraction (optimised as fully as 
possible with sonication) or the LC-MS/MS method of PLP quantification itself. Further 
investigation of this is discussed alongside validation of assay precision in Section 
4.1.2.2. The effects of high endogenous PLP levels on this single-step assay from 
DBS are discussed further in Section 4.1.2.3. 
 
 
Figure 4.24: Conversion of PNP to PLP by control and PNPO deficient DBS when 
using optimised sonication protocol. Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 
µmol/L FMN; 400 nmol/L PNP; 37 °C; 300 rpm agitation; 1 x 3 mm DBS. (n=1 at each data point). 
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4.1.2.2 Further optimisation of single-step assay conditions 
This section details several steps that were taken in order to ensure the accuracy and 
clinical utility of a single-step PNPO assay when using PNP as a substrate. 
 
Incubation time and linearity of PLP formation 
Experiments were performed to investigate whether PNPO activity was linear as a 
function of the amount of enzyme by incubating substrate with increasing DBS weight, 
this was achieved by cutting a 6 mm DBS into sections. It was shown in earlier 
experimentation (Sections 4.1.1 & 4.1.2) that PNPO activity could be quantified from 
a 3 mm DBS (26 mg). When PLP production was measured with 0 – 80 mg of DBS 
from a healthy adult volunteer an approximately linear correlation was observed to  
30 mg. When a blank punch containing no blood was incubated with PNP, no PLP 
formation was seen (Figure 4.25). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: PNPO activity as a function of DBS weight. Data point at 0 mg corresponds 
to a 3mm punch containing no blood. Unbroken line is a second order polynomial best-fit of 
the data shown. Dashed line corresponds to the approximate weight of a 3mm punch filled 
with blood (26 mg). Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 µmol/L FMN;  
400 nmol/L PNP; 37 °C; 300 rpm agitation; 30 min incubation. Error bars = SEM (n=2). 
147 
 
In order to optimise the duration of incubation time, PLP formation was monitored 
over 120 min using DBS from two adult controls and one child control (age 7 months). 
Formation was linear to 60 min in all subjects (Figure 4.26). Subsequently, an 
incubation time of 30 min was used for all future sample analysis; this was to ensure 
adequate PLP production for accurate quantification, while simultaneously ensuring 
assay linearity in subjects with high PNPO activity. This also enabled us to keep 
incubation time as short as possible to increase throughput and thereby render the 
assay suitable for clinical diagnostic use. 
 
Selection of substrate 
The single-step assay had until now been developed using PNP as substrate. It is 
also possible that PMP would be a viable substrate. Indeed, PMP was considered as 
a potential substrate early in method development and discarded in favour of the 
coupled assay (Section 4.1.1.1). When a control DBS was incubated in the newly 
optimised single-step conditions for 30 minutes with 400 nmol/L PMP as substrate, 
PLP formation was only 14.1% of that seen when of 400 nmol/L PNP was used 
(Figure 4.27). This confirms earlier findings shown in Figure 4.3.  
Figure 4.26: PNPO activity as a function of PLP formation from 0-120 min. Control 1; Child 
hospital control (7 months old); Control 2; Healthy male adult control (33 years old); Control 3; Healthy 
female adult control (45 years old). Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 µmol/L FMN; 
400 nmol/L PNP; 37 °C; 300 rpm agitation; 1 x 3 mm DBS. Each data point represents n=1.  
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Michaelis-Menten kinetics were determined for each of these substrates. Figure 4.28 
displays a Lineweaver-Burk plot showing the effect of PNP and PMP substrate 
concentration on PLP formation. The Vmax of PNP conversion to PLP on the incubation 
of a 3 mm adult control DBS was found to be approximately twice that of PMP to PLP 
(39.5 vs 19.8 pmol DBS−1 h−1). The Km for PNP was 0.32 μmol/L as compared to 
0.53 μmol/L for PMP. These Km values were close to those previously reported  
(1-2 µmol/L for both PNP and PMP).60, 170 In contrast to the results reported here, 
human PNPO has been reported to prefer PMP as substrate. However, this prior work 
was carried out in different buffers and with either recombinant protein or whole 
blood.60, 170 In addition PMP > PLP conversion by E. Coli PNPO is extremely pH 
dependent, with a rapid increase between pH 7 - 8 whereas PNP > PLP conversion 
is less sensitive to pH.184 This comparison has not been fully characterised for human 
PNPO but could explain the relatively sluggish PMP > PLP conversion using this 
assay system.  
Figure 4.27: Effect of substrate on PNPO activity. Incubation conditions as follows: 20 
mmol/L TrisPO4 pH 7.6; 400nmol/L PNP/PMP; 37 °C; 300 rpm agitation; 30 min incubation;  
1 x 3 mm DBS. Error bars = SEM. Statistical analysis was performed using an unpaired t-test: 
**** = P<0.0001. (n=2).   
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Finally, a concentration of 400 nmol/L PNP was used for the assay for several 
reasons: i) this concentration of PNP permitted analysis of the resulting supernatant 
by LC−MS/MS without further dilution steps. ii) As previously noted (Section 4.1.1.4), 
there was a small amount of cross talk between the MRM channels for PNP and d3-
PLP (<1%). Although at a concentration of 0.4 µmol/L (as in the assay in its current 
form) the effect was negligible, at higher PNP concentrations interference increased 
proportionally; this could potentially affect results through incorrect PLP 
quantification. iii) Saturation of the enzyme with substrate would not facilitate 
detection of PNPO deficiency in patients with mutations that cause an alteration in 
the Km of PNPO where the enzyme has residual activity and the Vmax and Kcat are 
relatively unaffected. By mildly limiting the substrate concentration but still achieving 
easily measurable conversion in controls, it is likely that the diagnosis of PNPO 
deficiency in patients with ‘milder’ mutations is enabled.  
Figure 4.28: Lineweaver-Burk plot showing the effect of substrate concentration on PLP formation. 
Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 µmol/L FMN; 0 - 1 µmol/L PNP or 0 – 5 µmol/L PMP; 37 °C; 
300 rpm agitation; 1 x 3 mm DBS from a healthy adult control. Calculated Vmax: PNP 39.55 ±3.55 pmol/DBS/h; PMP 
19.76 ±1.42 pmol/DBS/h. Calculated Km: PNP 0.319 ±0.081 µmol/L; PMP 0.530 ±0.143 µmol/L. Michaelis-Menten 
kinetics calculated using GraphPad Prism 6.05.  
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Optimisation of FMN Concentration 
Since PNPO is an FMN-dependent enzyme, there was concern that the vitamin B2 
status of subjects could affect results. When an adult control DBS was incubated in 
the presence of endogenous FMN only, 61% of the activity seen upon the addition of 
1.5 µmol/L FMN was measured (Figure 4.29). To ensure that the concentration of 
FMN was not limiting PNPO activity, an adult control DBS was incubated with varying 
concentrations (0.75 – 3.0 µmol/L) of FMN. As previously seen for the coupled assay 
(Section 4.1.1.2), no significant difference was observed in PNPO activity hence 1.5 
µmol/L was used for all subsequent experimentation.  
 
 
 
 
 
 
 
 
Figure 4.29: Effect of FMN concentration on PLP formation. Incubation conditions: 20 
mmol/L TrisPO4 pH 7.6; 400nmol/L PNP; 37 °C; 300 rpm agitation; 30 min incubation; 1 x 3 mm DBS. 
Error bars = SEM. Statistical analysis was performed using one-way ANOVA followed by Tukey’s 
multiple comparisons test: ns = no significance; ** = P<0.01. (n=2).   
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Optimisation of Buffer pH 
As described in Section 4.1.1.2, the optimal pH for PNPO enzyme activity in 
erythrocytes is pH 8.0. The pH dependence of PNPO was determined between pH 
7.0 – 8.0 and little difference in activity was identified (Table 4.3). As previously seen, 
(Section 4.1.1.1) peak splitting was evident at a pH > 7.8. Therefore, pH 7.6 was 
used for all further experimentation. 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.3 Effect of supraphysiological B6 vitamer concentrations found 
in patients on supplementation 
Previously, in Section 4.1.1.4, the effect of supraphysiological vitamer concentrations 
on the coupled PK and PNPO assay were characterised. A single-step assay meant 
that high PL concentrations in patient blood did not interfere with assay results. In 
order to ensure that the use of a Tris-based buffer in the single-step assay 
ameliorated the potential feedback inhibition that may occur in the presence of high 
levels of endogenous PLP, a DBS from a healthy adult control not receiving B6 
supplementation was incubated with varying concentrations (0 – 200 nmol/L) of PLP 
(Table 4.4). These concentrations were chosen as representative of those measured 
in the DBS of patients receiving high dose B6 supplementation (Section 3). 
Table 4.3: Effect of pH on PNPO Activity using a single step assay. PNPO 
activity measured in a healthy adult control DBS at pH 7 - 8. Incubation conditions: 
20 mmol/L TrisPO4 (pH adjusted appropriately); 1.5 µmol/L FMN; 400 nmol/L PNP; 
37 °C; 300 rpm agitation; 1 x 3 mm DBS; 30 min incubation; n = 3. Error = SEM.  
pH 
PNPO Activity  
(pmol/DBS/h) 
7.0 16.72 ±0.80 
7.2 20.37 ±0.36 
7.4 18.43 ±0.98 
7.6 19.88 ±1.06 
7.8 24.90 ±1.32 
8.0 22.72 ±1.78 
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Concentrations of PLP were measured in the T0 DBS from 21 PNPO deficient 
individuals and 27 children with other epilepsies (i.e. other patients) receiving B6 
supplementation. Concentrations of PLP ranged from 0 - 199 nmol/L. The majority of 
patients receiving B6 supplementation (16/21 PNPO; 24/27 others) had PLP 
concentrations lower than 100 nmol/L; 3/21 PNPO and 3/27 other patients on B6 had 
PLP concentrations between 100 - 150 nmol/L; 2/21 PNPO deficient patients had 
concentrations between 150 – 200 nmol/L. No product inhibition of PNPO activity was 
observed in the presence of concentrations ≤ 50 nmol/L PLP (final concentration after 
TCA precipitation). However, in the presence of 100 – 150 nmol/l PLP and 200 
nmol/L, a decrease in PNPO activity of 15 - 20% and 41% was observed, respectively 
(Table 4.4).  
Concentrations of PMP and PNP were measured in DBS from the same cohorts. 
These vitamers have been reported to be present in the blood of PNPO deficient 
patients receiving high doses of B6.22 In patients that were not PNPO deficient, 
concentrations of PNP and PMP were below the LLOQ (< 1.25 nmol/L). In PNPO 
deficient patients PNP and PMP concentrations were 0 – 137 nmol/L and 0 – 121 
nmol/L, respectively.  
Therefore the total substrate concentration (i.e. endogenous PNP or PMP and 
exogenous PNP) in some PNPO deficient patients will be higher than that found in 
control samples. In order to determine what effect this may have on the assay a 
comparison was made between DBS incubated in the presence of high 
Table 4.4: Effect of exogenous PLP on PNPO activity.  PNPO activity 
measured in a healthy adult control with varying amounts of PLP added to the 
reaction buffer, simulating high endogenous levels seen in individuals on B6 
supplementation. 100 % = Activity with no exogenous PLP. Incubation 
conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 µmol/L FMN; 400 nmol/L PNP; 37 °C; 
300 rpm agitation; 1 x 3 mm DBS; 30 min incubation. (n=1 in each condition). 
PLP added to 
reaction buffer 
(nmol/L) 
% activity* 
0 100.0 
25 101.5 
50 95.8 
100 76.5 
150 79.1 
200 58.7 
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concentrations of PMP (400 nmol/L) in addition to the normal PNP added as substrate 
(400 nmol/L) and those incubated under the standard assay conditions (i.e. only 400 
nmol/L PNP (Figure 4.30). Whilst previous studies using the rabbit liver enzyme have 
shown that PMP does not inhibit PNPO at any concentration,185 a 22% decrease in 
PLP formation was observed. Although this difference was not significant with only 
two repeats, it is possible that this decrease is indicative of competition between the 
two substrates, given the lower rate of PMP to PLP conversion using these assay 
conditions (see Figure 3.27). It would be useful to perform the assay with one of the 
two substrates isotopically labelled, however these were unavailable. 
 
 
 
 
 
 
 
 
Figure 4.30: Effect of exogenous PMP on PNPO activity measured as PLP formation. 
Incubation conditions as follows: 20 mmol/L TrisPO4 pH 7.6; 400 nmol/L PNP or 400 nmol/L PNP + 
400 nmol/L PMP ; 1.5 µmol/L FMN; 37 °C; 300 rpm agitation; 30 min incubation; 1 x 3 mm DBS. Error 
bars = SEM. Statistical analysis was performed using an unpaired t-test: ns = no significance (P = 
0.0944); (n=2).   
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4.1.2.4 Validation of single-step assay 
The intra and inter-assay precisions of the assay were determined by measuring 
PNPO activity from ten different 3 mm DBS punches from an individual on one day. 
This was repeated, in total, five times over a four week period. %CVs for intra and 
inter-assay precision were 7.93 and 10.31%, respectively (Figure 4.31). 
 
 
 
 
The accuracy of PLP measurement using the LC-MS/MS method described in 
Section 2.4 and Section 3 was characterised with the changes described in this 
chapter. The LLOQ and ULOQ for both PLP and PNP were set at the upper and lower 
bounds of the calibration curve created at 1.25 nmol/L and 200 nmol/L, respectively. 
The Signal/Noise (S/N) ratio at the LLOQ was greater than 10 and therefore the limit 
of detection (S/N greater than 3) was lower than 1.25 nmol/L. The back-calculated 
values at LLOQ and ULOQ were monitored to ensure they did not deviate from their 
Figure 4.31: Intra and inter-assay validation of a single-step DBS PNPO assay.  
Dried blood spots from 5 different cards simultaneously collected from one adult control 
were run on 5 separate days within a 2 week period, 10 times on each day. Intra and inter-
assay %CVs were 7.93 and 10.31%, respectively. 
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nominal values by more than 20 and 15%, respectively, as suggested by the 
European Medicines Agency (https://www.ema.europa.eu/documents/scientific-
guideline/guideline-bioanalytical-method-validation_en.pdf). QC standards were 
analysed alongside each run to ensure precision, the %CVs of PLP measurement on 
five repeated injections of QC standards at 5,10,100 and 175 nmol/L were 2.28, 0.90, 
2.30 and 3.45%, respectively. 
Accuracy of PLP quantification after extraction from a DBS collected from a PNPO 
deficient patient receiving a dose of 42 mg/kg/d PLP was evaluated. PNPO deficient 
patients on PLP typically receive 30 – 50 mg/kg/d for the control of their seizures and 
doses can range between 10 - 72 mg/kg/d87 hence 42 mg/kg/d was deemed 
representative of this cohort. The intra and inter-assay %CVs were acceptable at 5.92 
and 7.76%. 
 
4.1.2.5 Stability of dried blood spot PNPO activity 
In order to characterise the stability of PNPO activity when stored in a DBS format, 
cards were stored at different temperatures. Since ambient humidity is known to affect 
the stability of enzymes when stored in DBS186, duplicate cards were stored; one with 
desiccant in a sealed foiled bag, the other under ambient conditions. All cards were 
first dried for 16 – 24 h at room temperature without desiccant prior to storage. PNPO 
activity measured after this storage period was compared to baseline values 
measured after 16 - 24 h drying at room temperature. 
Short-term stability studies were carried out by storing cards in the dark for 1, 3, 5, 7, 
14 and 28 days at 22ºC with and without desiccant (Figure 4.32). Cards were 
subsequently stored at -80°C until day 28 when they were analysed. The day 28 
replicates were frozen and thawed once on the day of analysis to ensure an identical 
number of freeze-thaw cycles for every sample. When stored without desiccant at  
22 °C a 17% reduction in activity was seen after 3 days, which increased to a 48% 
reduction after 28 days. This compares to 8 and 26% reductions in the DBS stored 
with desiccant in sealed foil bags, indicating a protective advantage of storage under 
these conditions. 
 
156 
 
 
 
Long-term PNPO enzyme stability was studied by storage of DBS for 1, 4, 8 and 12 
weeks at 4 °C, -20°C and -80°C after the same initial 16-24 h drying period at 22 °C 
as described above (Figure 4.33). 73% PNPO activity was retained after storage for 
12 weeks at 4°C. DBS stored at -20°C and -80°C retained 93 and 87% activity, 
respectively. Under these conditions no difference in PNPO activity was identified 
between DBS cards stored with or without desiccant.  
 
Figure 4.32: Effect of humidity on the short-term stability of the PNPO enzyme in dried blood 
spots. DBS were stored in sealed foil bags with desiccant (▲) or under ambient conditions (■) at room 
temperature (22 °C). Error bars indicate SEM. Data points represent the mean percentage of activity compared 
to that found after 1 day (n=2). 
Figure 4.33: Effect of storage temperature on the long-term stability of the PNPO enzyme in 
dried blood spots. Data points represent the mean percentage of PNPO activity relative to 
measurement at time zero. Error bars indicate SEM.  (n=4). No significant difference was seen between 
activities of samples with/without desiccant. (4°C = ●; -20°C = ■ and -80°C = ▲) 
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After stability studies were performed, it was decided that for future analysis: i) DBS 
should be dried at room temperature (22°C for 16 - 24 h). ii) After this initial period, 
samples should be placed in sealed zip-lock bags with desiccant and stored at room 
temperature for no more than 7 days after the sample was taken iii) Thereafter, DBS 
should be stored at -20°C or below prior to analysis.  
 
4.1.2.6 Investigation of blood haemoglobin measurement from dried 
blood spots 
PNPO enzyme activity in dried blood spots is reliant on the amount of blood contained 
within the punch taken from the filter paper used for blood collection. Several 
estimates have been made as to the quantity of blood within a 3 mm DBS punch 
(such as used in this study), with a consensus of approximately 3.2 µL whole blood,155 
although estimates can be as low as 1.6 µL187 and as high as 5 µL.188 The precise 
amount of whole blood contained within a DBS punch of a given diameter is 
particularly dependent on the haematocrit of the patient providing the sample and 
hence the viscosity of blood and its spreading across the filter paper.158, 189 Ideally, 
the results reported utilising an assay from dried blood spots would include a 
correction factor to compensate for this effect as the amount of PNPO enzyme in the 
DBS punch will depend on the haematocrit of the sample.  
One potential solution to this problem would be the simultaneous analysis of another 
enzyme within the blood, with a consistent activity according to the haematocrit of the 
sample. However, this option was discarded due to concerns that the variability of 
another enzyme in the blood would be too high and not provide a good estimate of 
haematocrit. PNPO itself is almost ubiquitously expressed and can itself be regarded 
as a housekeeping enzyme.35 Despite this, PNPO activity can vary widely in the 
general population39, 170 and other enzymes can see this same variation.190 
Correlation of erythrocyte enzyme activities with a variety of factors such as gender, 
age, circadian rhythm and ethnicity have been identified.  These include enzymes 
involved in antioxidative activity191 and purine metabolism192.  
An alternative approach would be to quantify haemoglobin from the same dried blood 
spots used for PNPO assay, thus enabling the estimation of haematocrit. A safe and 
fast method widely used for the determination of the haemoglobin concentration 
(gHb/dL) in whole blood is the Haemoglobin Reagent Cyanide Free Method 
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(Instruchemie, NL).193 This method uses a buffer that reacts with haemoglobin in the 
blood, forming alkaline haematin D-575. This compound can be quantified using 
absorption spectroscopy.  
This method was adapted for use on the DBS samples used for PNPO enzyme 
activity measurement. Parameters to consider if the accurate quantification of gHb/dL 
from DBS was to be successful were: i) Ensuring that the method had sufficient 
sensitivity to achieve accurate measurement from the small volumes of blood present 
in a DBS ii) Ensuring that the elution of haemoglobin from the DBS was consistent 
between samples, and that the DBS matrix did not interfere with measurement.   
A calibration curve was constructed using a haemoglobin standard mixture at the 
concentrations expected upon elution of whole blood from a 3 mm punch taken from 
a DBS. This calibration curve showed good linearity (R2 > 0.99) (Figure 4.34). The 
method is designed for monitoring at 575 nm, with the absorption spectrum of alkaline 
haematin D-575 plateauing between 575 and 605 nm.193Absorption was measured at 
595 nm as a 575 nm filter was unavailable for the spectrophotometer used. 
Measurement was linear across the range evaluated therefore quantification would 
not be affected. 
 
 
Measurement of haemoglobin (gHb/dL) was carried out from seven healthy adult 
controls. This was performed by the addition of the alkaline D-575 reagent to a 3 mm 
DBS and incubation for 30 minutes at room temperature, with agitation at 1000 RPM. 
Figure 4.34: Haemoglobin calibration curve.  Concentrations shown are those after 
a correction factor has been applied to compensate for the dilution of a 3 mm DBS in a 
resuspension solution. R2 > 0.99. 
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After incubation and centrifugation at 13,000 g for 10 minutes, the absorbance of the 
supernatant was measured at 595 nm alongside a calibration curve spiked with a 
haemoglobin standard of known concentration. 3 x 3 mm punches were analysed for 
each individual. Mean gHb/L values ranged from 12.2 – 15.1 gHb/dL. In healthy 
adults, the haemoglobin concentration in whole blood typically ranges from 12 – 17 
gHb/dL. However, the accuracy and repeatability of measurement was extremely 
variable between repeated measurements from 3 mm punches taken from the same 
DBS card (Figure 4.35). 
 
In order to verify that the calculated gHb/dL values were similar to those measured 
from whole blood, the gHb/dL value was measured from the same whole blood 
samples from which the DBS were originally spotted onto newborn screening cards. 
This was performed in the accredited diagnostic laboratory at Great Ormond Street 
Hospital, also using the Haemoglobin Reagent Cyanide Free Method. A correlation 
between the values measured from DBS and those from whole blood was poor with 
an R2 value of 0.375 (Figure 4.36). The slope of linear regression was 1.49, indicating 
a 49% positive bias when measuring from DBS.  
 
 
Figure 4.35: Haemoglobin concentration (gHb/dL) measured in 3 mm DBS.  
Concentrations shown are those after a correction factor has been applied to 
compensate for the dilution of a 3 mm DBS in a resuspension solution. Each point is an 
individual measurement from a single 3 mm DBS punch. Line shown is the mean for 
each control. 
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It was hypothesised that this variation was due to incomplete liberation of blood from 
the 3 mm punches as, anecdotally, a small amount of Hb could be seen to remain in 
the punches after incubation. In order to ensure all Hb was removed from the protein 
saver cards punches were sonicated for 10 minutes after addition of the alkaline D-
575 reagent mixture (Figure 4.37). 
Figure 4.36: Correlation of haemoglobin concentration (gHb/dL) measured 
from whole blood and DBS.  Concentrations shown from DBS are those after a 
correction factor has been applied to compensate for the dilution of a 3 mm DBS in a 
resuspension solution. n = 3 at each point. Line indicates linear regression.  
 
Figure 4.37: Haemoglobin concentration (gHb/dL) measured from 3 mm DBS 
after a 10 minute sonication step. Concentrations shown are those after a 
correction factor has been applied to compensate for the dilution of a 3 mm DBS in a 
resuspension solution. Each point is an individual measurement from a single 3 mm DBS 
punch. Line shown is the mean for each control. 
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Unfortunately sonication of the DBS resulted in disintegration of the cellulose matrix 
of the DBS punch. Despite centrifugation some of the cellulose matrix would remain 
in suspension. This interfered with subsequent spectroscopic measurements, 
increasing the absorbance of the solution thereby providing aberrantly high gHb/dL 
values. This can be seen in, for example, some samples from subjects 6 and 7 
(Figure 4.37). 
The measurement of haemoglobin from DBS was therefore not pursued further due 
to the inaccuracies inherent in the current protocol. In subsequent experiments PNPO 
activity was expressed as: pmol PLP (3 mm DBS)-1 hour-1, denoted as pmol/DBS/h. 
In the future protocols enabling normalisation of PNPO activity to haematocrit could 
be investigated further. Upon the assessment of individuals in a clinical setting, the 
haematocrit would usually be measured as part of their care. 
 
4.1.2.7 Analysis of patient samples 
Samples were collected from 21 patients with mutations in PNPO (age range; 1 day 
– 25 years), 27 patients with other epilepsies receiving B6 supplementation (age 
range; 1 month – 16 years), 38 child hospital controls (age range; 5 days – 15 years) 
and 7 healthy adult controls. None of the child hospital controls had presented with 
seizures. In the cohort of patients with other epilepsies receiving B6 supplementation, 
PNPO deficiency had been excluded by genetic analysis or another cause of epilepsy 
had been identified. Identified causes included two individuals with mutations in 
ALDH7A1, one with PROSC deficiency and one with hyperprolinaemia type II. More 
details of the PNPO deficient cohort can be found in Table 4.5.  
Upon measurement of PNPO enzyme activity, hospital controls were found to have 
activities ranging from 10.0 – 95.0 pmol/DBS/h with a mean of 42.0 pmol/DBS/h. This 
was significantly (P < 0.0001) higher than the activity seen in patients with mutations 
in PNPO, who had a mean activity of 1.1 pmol/DBS/h (range: 0.0 – 4.6 pmol/DBS/h). 
Other epilepsy patients receiving vitamin B6 supplementation had activities ranging 
from 23.0 – 85.9 pmol/DBS/h (mean: 55.3 pmol/DBS/h), also significantly higher than 
activities identified in the PNPO cohort (P < 0.0001). Activities from healthy adult 
controls showed a similar significant difference (P < 0.01) (range: 13.8 – 44.0 
pmol/DBS/h; mean: 28.3 pmol/DBS/h) (Figure 4.38). 
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Subject 
Age at 
sampling 
Seizure 
Onset 
Mutation/sequence variant Presumed effect 
PNPO Activity 
(pmol/DBS/h) 
References 
1 2y n/a c.[98A>T] (M) + c.[576C>A] (P) p.D33V (M) + Y157X (P) 0.0 - 
2 1d None c.[364-1G>C] + [364-1G>C] Splice errors 0.7 - 
3 9y 5m c.[347G>A] + c.[347G>A] p.R116Q + p.R116Q 0.0 Mills et al. 2014 
4 5y No Seizures* c.[347G>A] + c.[347G>A] p.R116Q + p.R116Q 0.1 - 
5 25y 3h 
c.264-21_ 264-1delinsC (M) + 
c.[98A>T] (P) 
Splice errors (M)  
+ p.D33V (P) 
2.0 Mills et al. 2014 
6 7y 5h c.[641dupA] + ? ** p.Q214fs + ? ** 0.0 
Mills et al. 2014; 
Raimondi et al 2015 
7 6y 30 min 
c.[284G>A] (M) + c.[148G> A]; 
c.[364-1G>A] (P) 
p.R95H (M) + p.E50K; 
Splice errors (P) 
0.5 Mills et al. 2014 
8 16y n/a c.[363+5G>A] +  c.[363+5G>A] Splice errors + Splice errors 1.8 - 
9 17y n/a c.[363+5G>A] +  c.[363+5G>A] Splice errors + Splice errors 1.8 - 
10 12y 10h 
c.[347G>A];c.[674G>A] + c.[347G 
>A];c.[674G>A] 
p.R116Q;p.R225H + 
p.R116Q;p.R225H 
0.0 Mills et al. 2014 
Table 4.5: Summary of subjects with mutations identified in PNPO. Control ranges; Children receiving B6 supplementation: 23.0 – 83.9 pmol/DBS/h (n=16); Children not 
receiving B6 supplementation: 10.0 – 95.0 pmol/DBS/h (n=37); Healthy adults: 13.8 - 44.0 pmol/DBS/h (n=7). n/a = not available; d = day; m = month; y = year; w = week; M = maternal, 
P = paternal. Subject numbers also correspond to those in Table 3.4.  * Mother recipient of multivitamin containing pyridoxine during pregnancy **No second mutation found. ***Two 
seizures in childhood due to delayed doses of PLP 
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11 13y <12h 
c.[148G> A]; c.[364-1G>A] + 
c.[148G> A]; c.[364-1G>A] 
p.E50K;Splice errors + 
p.E50K;Splice errors 
3.1 Mills et al. 2005 
12 5m n/a c.[673C>T] + c.[673C>T] p.R225C + p.R225C 0.0 - 
13 3y n/a c.[347G>A] + c.[347G>A] p.R116Q + p.R116Q 0.0 - 
14 5y 90 min c.[637C>T] + c.[637C>T] p.P213S + p.P213S 2.3 
Mills et al. 2014; Hatch 
et al. 2015 
15 3y 
No neonatal 
seizures *** 
c.[637C>T] + c.[637C>T] p.P213S + p.P213S 4.7 
Mills et al. 2014; Hatch 
et al. 2015 
16 11m 3w c.[194G>T] +  c.[194G>T] p.W65L + p.W65L 0.0 - 
17 6y 6h c.[98A>T] + c.[98A>T] p.D33V + p.D33V 0.0 Mills et al. 2014 
18 4y unknown c.[263+2T>C] + c.[263+2T>C] Splice errors + Splice Errors 3.6 - 
19 8y unknown c.[686G>A] + c.[407T>C] p.R229Q + p.L136P 0.0 - 
20 9y 3w c.[98A>T] + c.[98A>T] p.D33V + p.D33V 2.9 Mills et al. 2014 
21 1y 10 months c.[98A>T] + c.[421C>T] p.D33V + p.R151C 0.5 - 
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Patients from the PNPO cohort could be clearly delineated from all control cohorts 
and no false-positives or negatives were identified. In agreement with previous 
studies170 there was large variation in the PNPO enzyme activity measured for 
controls.  
It has been shown previously that foetal expression of PNPO is low relative to that in 
adults.35 It was therefore investigated whether it was possible to differentiate ‘control’ 
neonates from PNPO deficient individuals particularly given that PNPO deficiency is 
a neonatal-onset seizure disorder. Five control neonates (less than one month of age) 
were included in the 37 child hospital controls analysed. The mean PNPO enzyme 
activity measured in these neonates was 52.7 pmol/DBS/h (range: 41.3 – 66.3 
pmol/DBS/h). This was not significantly different to the activity measured in the overall 
child hospital control cohort. The youngest neonate (5 days of age) had an activity of 
Figure 4.38: DBS PNPO activities of patients with PNPO deficiency relative to control individuals. 
Box plots indicate range, interquartile range and median. Statistical analysis was performed using one-way 
ANOVA followed by Tukey’s multiple comparisons test; ** = P<0.01; **** = P<0.0001. 
165 
 
 
64.3 pmol/DBS/h. No overall correlation of age with PNPO activity was identified 
when all controls (not receiving B6 supplementation) were analysed. 
Whilst the DBS PNPO enzyme assay is able to accurately identify patients with low 
PNPO activity and provide a diagnosis of PNPO deficiency, due to the limitations in 
accurately measuring small amounts of PLP formed, it is difficult to accurately 
determine the amount of residual activity in PNPO deficient patients, if any is present. 
It is possible that small differences in the residual PNPO activity of these individuals 
could be measured if longer incubation periods or very high concentrations of 
substrate were used. In the future two tiers of PNPO assay could be performed, the 
first a rapid screen using the assay in its current form to reliably detect PNPO deficient 
individuals and the second a more lengthy assay to precisely determine whether there 
is some residual PNP > PLP conversion.  
This will provide valuable extra information with regards to the genotype-phenotype 
correlation in PNPO deficiency. It is presumably more likely that a PNPO deficient 
individual with residual activity will respond to treatment with PN. This is clinically 
important as PN is shown to be a safer form of vitamin B6 supplementation than PLP 
and should be used preferentially where it provides adequate seizure control. The 
potential toxicity of high PLP doses is discussed in Section 6. 
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 The effect of the p.R116Q variant on PNPO activity and 
expression 
The PNPO deficient cohort analysed for DBS PNPO activity in Section 4.1.2.7 
included 21 subjects with 17 different genotypes. These included three individuals 
homozygous for p.R116Q (Subjects 3, 4 and 13; Table 4.5). The p.R116Q 
(c.347G>A) variant is reported in gnomAD with an allele frequency of 0.0547 (512 
homozygotes in 138,592 individuals). It has previously been hypothesised that the 
p.R116Q variant is a susceptibility factor for epilepsy. This variant is predicted to 
affect FMN binding and/or formation of active PNPO dimers but residual activity of 
this variant was found to be high (83% of wild-type) in vitro when assayed using 2.5 
µmol/L PMP as substrate in a potassium phosphate buffer. Indeed, it is known that 
not all individuals homozygous for p.R116Q present with the seizures typical of PNPO 
deficiency.87 This is also the case in our cohort; two of the patients receive B6 for the 
management of seizures but one (Subject 4, sister of Subject 3) has never presented 
with seizures and does not require B6 supplementation. Subject 3 had been 
investigated previously using an epilepsy gene panel containing approximately 140 
genes and no variants predicted pathogenic were identified.  
The PNPO activity in DBS of these individuals (including the asymptomatic sister) 
was extremely low (< 0.2 pmol/DBS/h). The ability of this method to identify patients 
homozygous for the p.R116Q variant is particularly important diagnostically since 
patients with this genotype do not seem to have a raised plasma PM/PA ratio, 
previously identified as the most consistent biomarker for PNPO deficiency.88 The 
presence of a raised PNP/PLP ratio was also shown in Section 3 to be inconsistent 
in these patients. The parents of Subjects 3 and 4, both of whom are heterozygous 
for the p.R116Q mutation, had intermediate PNPO activities of 7.1 and 10.8 
pmol/DBS/h. 
It is possible that the p.R116Q substitution causes a dramatic reduction in activity 
under the conditions used in the dried blood spot assay, but still retains some residual 
activity in vivo. This would correlate with the lack of seizures in Subject 4.  The reason 
that Subject 4 has not presented with seizures yet their sibling requires high-dose 
vitamin B6 treatment for their epilepsy is unknown. One potential explanation could 
be that although p.R116Q induces susceptibility to seizures, a ‘second hit’ is required 
for clinically apparent epilepsy. This could be either genetic (e.g. variant at another 
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epilepsy susceptibility locus) or environmental. This second environmental 
hypothesis is particularly interesting as it could involve differential dietary intake of 
the B6 vitamers. For example, since breast milk contains almost entirely PLP and PL, 
whereas baby formula generally contains PN, if a PNPO deficient child receives 
breast milk exclusively, this could convey some protection as PNPO activity would 
not be required for conversion of dietary B6 to PLP. In addition, as flavin 
mononucleotide (FMN; a vitamin B2 derivative) is the cofactor of PNPO, the B2 status 
of patients could also affect presentation. 
In order to study the effect of p.R116Q on PNPO enzyme activity further we were 
provided with bacterially expressed recombinant human wild-type and p.R116Q 
PNPO enzyme by collaborators from the University of Oxford. 
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 Preliminary development of a method to measure activity from 
bacterially-prepared recombinant PNPO enzyme 
Experiments were carried out as described in Section 2.6 and the activities of wild-
type and mutant p.R116Q PNPO enzymes were compared to one another. Incubation 
conditions (buffer, pH, temperature, substrate/cofactor concentrations) were identical 
to those used in the DBS assay, no significant difference in PLP formation could be 
identified between wild-type and mutant forms of protein (Figure 4.39). A negative 
control without the addition of PNPO protein was also analysed; no activity was 
observed. Product formation (PLP) was linear to 45 minutes and then plateaued.  
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The enzyme was stored in 1% glycerol at -80ºC. After one freeze thaw cycle, PNPO 
activity was reduced by ~50% (data not shown). For this reason all subsequent 
experiments comparing wild-type and mutant p.R116Q PNPO were carried out using 
protein that had undergone an identical number of freeze/thaw cycles. 
 
 Effect of flavin mononucleotide concentration on the kinetics of 
recombinant wild-type and p.R116Q PNPO activity  
PNPO is an FMN-dependent enzyme59 and p.R116Q has been predicted to have an 
effect upon FMN binding as it is close to the FMN binding pocket.87  PNPO activity 
Figure 4.39: Effect of the p.R116Q variant on the activity of recombinant PNPO. 
Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 1.5 µmol/L FMN; 400 nmol/L PNP; 37 °C; 
300 rpm agitation; 100ng PNPO enzyme; 0 – 60 min incubation. (n = 2). Error bars = SEM. 
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was therefore measured in both the wild-type and p.R116Q proteins in the presence 
of varying (0, 0.75, 1.5 and 3.0 µmol/L) concentrations of FMN (Figure 4.40). When 
no exogenous FMN was added (Figure 4.40 (a)) wild-type PNPO activity was 
significantly higher (P < 0.0001) than that of the p.R116Q variant protein. When 
exogenous FMN was added (0.75, 1.5 and 3 µmol/L), no significant difference in 
activity was identified between wild-type and p.R116Q recombinant PNPO.  
When comparing activity of the enzyme when incubated with 1.5 µmol/L FMN to that 
seen in preliminary experimentation (Figure 4.39) under the same conditions (1.5 
µmol/L FMN) a considerable reduction in activity was seen suggesting some 
denaturation of the enzyme had occurred when stored at -80 °C as well as after 
freeze/thaw cycles as mentioned above.  
 
 
Figure 4.40: Effect of FMN concentration on activity of recombinant wild-type and p.R116Q PNPO 
enzymes. Incubation conditions: 20 mmol/L TrisPO4 pH 7.6; 0.0 – 3.0 µmol/L FMN; 400 nmol/L PNP; 37 °C; 300 
rpm agitation; 100ng PNPO enzyme. ANCOVA analysis was performed on the slopes at each respective FMN 
concentration. No significant difference was identified when 0.75, 1.5 or 3.0 µmol/L FMN was added. A 
significant difference was identified in the absence of exogenous FMN (P = <0.0001) Error = SEM.  (n = 2 for each 
data point). 
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There was concern that the significant difference between wild-type and p.R116Q 
PNPO activity without the addition of exogenous FMN could be due to the 
concentration of residual FMN bound to the recombinant PNPO protein after 
purification. Although our collaborators attempted the removal of this FMN using 
hydrophobic interaction chromatography, residual PNPO activity indicates that some 
FMN remained either in solution or bound to the PNPO protein. A method was 
developed for the measurement of FMN (Section 2.6.1). When FMN was quantified 
in the T0 time point solutions of wild-type and p.R116Q proteins, similar FMN 
concentrations of 1.6 and 1.8 nmol/L were detected, respectively (Figure 4.41) 
suggesting that differing FMN concentrations were not responsible for the difference 
in enzyme activity identified between p.R116Q and wild-type PNPO when incubated 
without the addition of exogenous FMN. 
 
 
This experiment was repeated in order to verify the finding. A difference in activity 
was again apparent with no exogenous FMN but no firm conclusions could be drawn 
because activity of the PNPO enzyme was reduced yet further (another ~50%) due 
to the longer period of storage (data not shown). Subsequent experiments were 
performed on a newly synthesised batch of recombinant protein. This protein was 
immediately divided into many single-use aliquots to ensure additional freeze-thaw 
cycles were unnecessary. 
Figure 4.41: FMN concentration in T0 time points of the recombinant PNPO enzyme 
assay. Error bars indicate SEM. (n = 2). 
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Kinetics of WT and p.R116Q protein when using PNP and PMP as substrate were 
studied (Figure 4.42 (a) and (b)). 100 ng protein was incubated for 10 minutes with 
varying substrate concentrations (0 – 10 µmol/L PNP or PMP) and a fixed FMN 
concentration of 1.5 µmol/L in order to ensure that cofactor availability was not 
affecting catalytic efficiency. At higher concentrations of PNP some crosstalk with 
d3-PLP, which is used for quantification of PLP, was evident. Hence accurate PLP 
quantification in samples with higher PNP concentrations was not possible. PLP 
levels were therefore expressed as the area under the peak. This still allowed 
measurement and comparison of Km for each PNPO protein type.  
 
A similar issue was detected upon the addition of high PMP concentrations to the 
reaction mixture. As mentioned previously (Section 4.1.1.1), the commercially 
sourced PMP was found to contain a small, but significant (1.3%) amount of PLP. 
When adding large PMP concentrations and measuring relatively small quantities of 
Figure 4.42: Kinetics of PNPO protein when varying concentrations of substrates PNP and PMP.  
Km towards PNP: WT = 1.2 µmol/L; p.R116Q = 1.7 µmol/L. Km towards PMP: WT = 1.1 µmol/L; p.R116Q = 1.1 
µmol/L. Error bars indicate SEM. (n = 3 at each point). 
b) 
a) 
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PLP formation, this interfered with the calculation of PNPO kinetics. However, as the 
proportion of PLP in the PMP standard was known, the PLP inadvertently added to 
each sample could be calculated and subtracted from total PLP to calculate PLP 
formed. As these concentrations were small in relation to those of PMP, it is unlikely 
they would have influenced results through product inhibition of PNPO; the Ki for PLP 
has been reported as 3.2 µmol/L60 and the maximal PLP concentration as a proportion 
of the PMP standard was 130 nmol/L (1.3% of 10 µmol/L PMP).  
The Km values for wild-type and p.R116Q protein when using PNP as substrate were 
1.2 and 1.7 µmol/L, respectively. The Km values for PMP were calculated as 1.1 
µmol/L for both forms of PNPO. These values are almost identical to those calculated 
by Musayev et al. from recombinant PNPO60 (Wild-type Km: PNP = 1.8 µmol/L; PMP 
= 1.0 µmol/L). It was not possible to measure the Vmax due to the problems with 
accurately quantifying PLP formation alongside high PNP concentrations. Since 100 
ng of PNPO protein was added per sample, the reaction velocity measured as 
nmol/L/h can be expressed pmol/mg protein/h using a conversion factor of x 2.4 (e.g. 
1 nmol/L/h = 2.4 pmol/mg/h). 
The FMN-dependency of WT and p.R116Q PNPO protein was characterised by 
varying FMN concentration upon incubation with 1 µmol/L PNP (Figure 4.43). This 
experimentation was a repetition of the earlier kinetic studies using FMN (Figure 
4.40) but with a new batch of recombinant PNPO protein and lower FMN 
concentrations. Maximal PNPO activity was evident in the presence of a relatively low 
FMN concentration of 25 nmol/L indicating saturation of the enzyme with cofactor. No 
difference in Vmax was identified between wild-type and p.R116Q protein.  The FMN 
Km values for wild-type and p.R116Q proteins were 0.5 and 3.3 nmol/L, respectively. 
This indicated that there is a small difference in catalytic efficiency between the two 
forms of protein, although the uncertainty of this measurement was large with an R2 
value of 0.33 for both. 
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Earlier measurements of FMN (Figure 4.41) had been performed without the addition 
of a stable-isotope-labelled internal standard. In order to accurately quantify 
measurements of FMN associated with this new batch of recombinant PNPO enzyme 
a stable isotope of riboflavin was obtained (13C415N2-Riboflavin; labelled FMN was not 
commercially available).  
Figure 4.43: Kinetics of the PNPO protein when varying concentrations of FMN. Wild-type: Vmax = 
25.9 nmol/L/h; Km = 0.46. p.R116Q: Vmax = 26.2 nmol/L/h; Km = 3.3.  Error bars indicate SEM. (n = 3 at each 
point). 
Figure 4.44: Measurement of FMN bound to recombinant PNPO protein using a 13C415N2-
riboflavin internal standard. Means ±SEM: WT = 1.26 ±0.08; p.R116Q = 2.08 ±0.07.  Error bars indicate 
SEM. (n = 15 repeats). 
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Results showed (Figure 4.44) that significantly more FMN was found in p.R116Q 
than wild-type PNPO (2.1 vs 1.1 nmol/L) (P < 0.0001). This suggests that the 
difference in activity between WT and p.R116Q PNPO protein without the addition of 
exogenous FMN was not due to protein-bound FMN or FMN contained within the 
protein lysate. 
This section has shown that under the conditions used, little difference in PNPO 
activity could be identified between p.R116Q and wild-type recombinant PNPO 
protein. The only effect of this amino acid substitution appears to be a small reduction 
in enzymatic activity when exogenous FMN is not added to the reaction mixture. This 
correlates with the location of R116 close to the FMN binding site of PNPO (Figure 
4.45) but does not necessarily explain the large difference seen in vivo between the 
DBS of subjects homozygous for p.R116Q and wild-type controls, or the seizures 
experienced by some of these individuals.  
Figure 4.45:  Predicted structure of the PNPO active site. The positions of bound (a) pyridoxal 5’-
phosphate and (b) Flavin mononucleotide are shown as well as the (c) R116 residue. Adapted from the crystal 
structure of PNPO determined by Musayev et al. 2003 and stored in the swissmodel.expasy.org repository. 
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A recently published manuscript has shown that the thermal stability of PNPO is 
reduced in the presence of p.R116Q – FMN binding is a critical modulator of this 
effect.74 This suggests that the formation of the PNPO-FMN holoenzyme is critical for 
protein stability. The same study showed that the presence of p.R116Q can disrupt 
FMN binding (Kd (FMN) WT: 13.1 nmol/L; Kd (FMN) p.R116Q: 251 nmol/L) and therefore 
protein expression/function. In addition, the calculated Km values reported for PNP 
were 2.0 µmol/L and 3.1 µmol/L. Although these were higher than those in this study 
calculated from Figure 4.42 (a), the ratio of p.R116Q to wild-type Km was similar (1.55 
di Salvo et al., 1.42 in our study). The differences in Km can be explained by the 
different buffers used. 
In summary, the p.R116Q variant does not significantly impair the enzymatic function 
of PNPO unless its cofactor, FMN, is restricted. This is likely due to the proximity of 
R116 to the FMN binding site. However, di Salvo et al. have reported that p.R116Q 
reduces the stability of PNPO, particularly when concentrations of FMN are limited. 
The effect of the variant on thermal stability of the protein may be relevant to the 
pathophysiology of some patients homozygous for p.R116Q as these have, in at least 
one case, been preceded by a febrile illness. Perhaps a higher body temperature 
during fever precipitates these seizures through the thermal degradation of PNPO 
protein and subsequent lowering of available PLP.  
 
 Development of an LC-MS/MS method for the quantification of 
PNPO protein in DBS 
The findings discussed in Section 4.2.2 indicate that the thermal stability of p.R116Q 
PNPO is reduced compared to that of the wild-type protein. In addition, in-silico 
analysis using the Human Splicing Finder194 tool shows that the DNA base 
substitution present in these individuals (c.347G>A) is predicted to interfere with a 
splicing enhancer in exon 3 of the PNPO gene (Figures 4.46 and 4.47). Loss of this 
splice enhancer could lead to aberrant splicing and therefore nonsense-mediated 
decay, resulting in lower expression of PNPO. It is feasible that this effect could vary 
according to tissue type as splicing can be tissue specific.195 In order to further 
investigate whether decreased expression of p.R116Q PNPO protein might explain 
low DBS PNPO activity in individuals carrying the p.R116Q variant, an LC-MS/MS 
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method was developed for measurement of PNPO protein in the same DBS analysed 
for PNPO activity in Section 4.1.2.7.  
 
 
 
4.2.3.1 Selection of PNPO-derived tryptic peptides and LC-MS/MS 
method development 
A targeted MRM-based LC-MS/MS method was developed for the quantification of 
peptides produced upon the tryptic digestion of intact PNPO protein in dried blood 
spots. Other sample types such as fibroblasts and whole blood were unavailable. 
Trypsin digestion enzymatically breaks the dipeptide bond on the C-terminus sides of 
lysines and arginines in a protein/peptide. The peptides formed upon digestion can 
be accurately predicted and analysed quantitatively using LC-MS/MS. 
Peptides were identified using the Skyline software package (MacCoss Lab 
Software)196 and were submitted to BLAST to ensure they were specific to human 
PNPO. Suitable peptides were custom-synthesised (Figure 4.48) and MRM 
transitions for these were optimised using the Intellistart software package (Waters, 
Figure 4.46: Predicted exonic splicing enhancers in exon 3 of the PNPO gene. Predicted binding motifs 
for the splicing factors SF2/ASF, SRp40, SC35 and SRp55 are shown in red. Predicted exonic splicing enhancer 
hexamers/octamers are shown in pink. The location of c.347G (p.R116) is indicated by the blue vertical line. The 
variable yellow line indicates the relative strength of exonic splicing enhancer octamers across exon 3 of PNPO. 
Analysis performed using the Human Splicing Finder online tool.194 
Figure 4.47: Predicted disruption of exonic splicing enhancer sites by the c.347G>A (p.R116Q) variant 
in PNPO. Analysis performed using the Human Splicing Finder194 online tool, results indicate possible disruption of 
an exonic splicing enhancer.  
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MA, US). The optimised ionisation and fragmentation conditions for each of these 
peptides are as detailed in Table 4.6. 
 
  
Peptides both up and downstream of p.R116Q were chosen to allow the detection of 
an aberrant protein produced if the c.347 G>A substitution did affect splicing between 
exons 3 and 4 of PNPO (Figure 4.48). If this were the case and a truncated PNPO 
protein was created but not degraded, peptide 1 would be present but peptide 4 
absent. Equally, two peptides (peptides 3 & 4) were chosen that lie at the site of the 
p.R116Q missense change. Since the amino acid to the C-terminal side of R116 is a 
lysine, in the presence of the p.R116Q variant, R116 is replaced by Q116 + K117 
upon tryptic digestion. Theoretically, this would allow calculation of relative 
abundancies of wild-type and p.R116Q PNPO protein monomers (for example, in 
heterozygote carriers). 
The liquid chromatography gradients and mobile phase compositions used within this 
section are described in Section 2.7.2. Where adjustments were made to these 
conditions, these are detailed below. Initially, a 10 minute reversed-phase liquid 
chromatography gradient using H2O/acetonitrile with 0.1% formic acid as mobile 
Peptide 
AA 
position 
in protein 
Monoisotopic 
mass 
(daltons) 
MRM Transition 
Cone 
voltage 
(V) 
Collision 
Energy 
(V) 
1: DGKPSAR 89 - 95 729.37 365.94 > 430.42 2 10 
2: FFTNFESR 109 - 116 1046.47 524.31 > 753.65 32 16 
3: FFTNFESQK 109 - 117 1146.52 574.43 > 267.27 52 18 
4: SSQIGAVVS 
HQSSVIPDR 
164 - 181 1865.95 623.22 > 726.81 2 18 
Table 4.6:  Peptides selected for LC-MS/MS detection of trypsin digested PNPO protein.  Optimised 
MRM transitions, cone voltages and collision energies obtained using Waters Intellistart software. 
Figure 4.48: Amino acid sequence of the PNPO protein. Predicted peptides produced upon tryptic digest 
and chosen for analysis shown in red. / = relevant tryptic digest sites. * =altered tryptic digest site in the presence 
of the p.R116Q variant. 
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phases was used for analysis of the peptides. The column chosen was a Waters 
CORTECS UPLC C18+ column (1.6µm, 2.1 x 50 mm). Peptides 2, 3 and 4 were 
retained well on this column, eluting between 2.75 and 2.95 minutes. However, 
peptide 1 was not retained at all and eluted just <0.25 minutes after injection (Figure 
4.49 (a)). This is not unexpected as the amino acid residues present in peptide 1 are 
more polar than those found in those of peptides 2, 3 and 4. Equally, peptide 1 has a 
particularly basic isoelectric point (pI) of 9.37 as predicted by the online Peptide 
Calculator tool (http://www.pep-calc.com).197  
Several steps were then taken to attempt to improve the retention of peptide 1. Firstly, 
the column was changed to the Waters Acquity UPLC HSS T3 column (1.8 µm, 2.1 x 
50 mm). This column is specifically designed for the retention of polar compounds. 
The chromatography of each of the later eluting peptides was improved, leading to 
sharper peaks with improved signal intensity. However, effective retention of peptide 
1 was not enabled (Figure 4.49 (b)). With compounds of an approximately neutral pI 
(such as peptides 2, 3 and 4 with pI’s of 6.21, 6.20 and 7.12, respectively) further 
acidification of the mobile phase is a viable strategy to enable efficient retention. 
However, as a peptide with a basic pKa, this would act only to further charge peptide 
1; no retention was seen upon an increased formic acid concentration of 0.2% (Figure 
4.49 (c)). 
Addition of 0.01% HFBA to the mobile phase however did enable retention of peptide 
1 (Figure 4.49 (d)). As a strong acid, HFBA anions in solution interact with the 
positively charged peptides, neutralising them. This decreases their hydrophilicity and 
enables interaction with the hydrophobic C18 stationary phase. This technique is 
known as ion-pairing.  
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Figure 4.49: Chromatographic separation of peptides selected for UPLC-MS/MS detection from trypsin 
digested PNPO protein.  Numbers 1-4 correspond to the peptides in Table 4.6. Conditions: a) Cortecs C18+ column, 
MPA: 0.1% FA in H2O MPB: 0.1% FA in acetonitrile. b) HSS T3 column, MPA: 0.1% FA in H2O MPB: 0.1% FA in 
acetonitrile.  c) HSS T3 column, MPA: 0.2% FA in H2O MPB: 0.2% FA in acetonitrile.  d) HSS T3 column, MPA: 0.2% FA 
+ 0.01% HFBA in H2O MPB: 0.2% FA in acetonitrile. Liquid chromatography gradient used can be found in Table 2.6. 
FA = formic acid; HFBA = heptafluorobutyric acid. 
a) b) 
c) d) 
1) 
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4.2.3.2 Analysis of PNPO peptides in dried blood spots 
The linearity of LC-MS/MS detection of the peptides was measured from 0.1 pmol/L 
– 150 pmol/L). With an injection volume of 10 µL, the response was linear over this 
range (R2 > 0.99).  
The elution and tryptic digestion of peptides 1, 2, 3 and 4 derived from control DBS 
was performed using a previously optimised protocol (Section 2.7.3). A transition for 
the detection of a peptide pertaining to human serum albumin was also monitored 
(AVMDDFAAFVEK; MRM: 671.99 > 587.02) in addition to the optimised MRM 
transitions for peptides 1, 2, 3 and 4. Serum albumin is the most abundant plasma 
protein198 and therefore should be easily identified, indicating successful digestion. 
The area of the peak identified upon LC-MS/MS analysis was used for quantification.  
Peaks pertaining to peptides 1, 2, 3 or 4 could not be identified even though it had 
already been shown that PNPO protein was present in the DBS as PNPO activity had 
already been measured successfully (Section 4.1.2). Whilst it was possible to identify 
albumin, indicating that digestion was successful, sensitivity was poor; the signal from 
such an abundant protein should have been higher. Albumin had an area under peak 
value of 408 in the 2 punch digest and 1597 in the 4 punch digest. It was hypothesised 
that this was caused by ion suppression due to the sample matrix. To address this, 
desalting and removal of small compounds was performed by binding the peptides to 
a C18 solid-phase extraction column. By adjusting the organic/aqueous composition, 
salts and polar compounds are first eluted as a separate fraction, the compounds of 
interest are then analysed after elution in a fraction of interest.  
After this procedure (see Section 2.7.3) analysis was repeated. Unfortunately, 
detection of PNPO specific peptides was still unsuccessful. When peptides 1, 2, 3 
and 4 were spiked into the digest eluent from 2 DBS punches at 100 pmol/L, peaks 
were identified at the expected retention times, indicating that the inability to detect 
the peptides of interest was not due to dramatic changes in chromatography (e.g. 
retention time shift). 
However, the areas under peaks from peptides 2, 3 and 4 when spiked at 100 pmol/L 
into the digest eluent of 2 DBS punches were only 7.6, 30.2 and 15.9% that of a pure 
100 pmol/L standard with a sample matrix of 97% H2O 3% ACN. This is an example 
of the effect of sample matrix on detection by LC-MS/MS. Conversely, the signal from 
peptide 1 was 43.4% higher than that in the H2O:ACN standard. This could be an 
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example of ion enhancement but, since peptide 1 was also not detected in DBS, it did 
suggest that a factor other than ion suppression was the reason for non-detection of 
the PNPO-derived peptides. 
A TCA acetone precipitation step was added prior to digestion. This was used to 
remove contaminants and highly abundant proteins such as albumin, theoretically 
aiding the detection of peptides derived from lower-abundancy proteins. In addition, 
500 ng of recombinant p.R116Q and wild-type PNPO proteins (described in Section 
4.2.2) were digested alongside DBS samples and 500 ng of the protein yeast enolase 
was added to all samples. Tryptic digestion of yeast enolase produces a well 
characterised peptide (SIVPSGASTGVHEALEMR; MRM: 614.6 > 547.9) and would 
act as a positive digestion control. 
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 Several digestions were performed with varying combinations of recombinant 
protein, yeast enolase and 3 mm punches from dried blood spots (as shown in Table 
4.7). Target peptides from yeast enolase and albumin were successfully detected in 
all samples, indicating that tryptic digestion was successful. In samples containing 
recombinant wild-type and p.R116Q PNPO protein, the expected peptides were 
identified (Peptide 1, 2 and 4 in wild-type; Peptide 1, 3 and 4 in p.R116Q PNPO). 
Composition 
Human 
Serum 
Albumin 
Yeast 
Enolase (YE) 
PNPO 
Peptide 1 
PNPO 
Peptide 2 
PNPO 
Peptide 3 
PNPO 
Peptide 4 
Exp. Ident Exp. Ident Exp. Ident Exp. Ident Exp. Ident Exp. Ident 
0.5 µg YE + 
recombinant 
WT PNPO 
            
0.5 µg YE + 
recombinant 
p.R116Q PNPO 
            
4 x 3 mm DBS 
punches + 0.5 
µg YE 
            
4 x 3 mm DBS 
punches + 0.5 
µg YE + 0.5 µg 
recombinant 
WT PNPO 
            
4 x 3 mm DBS 
punches + 0.5 
µg YE + 0.5 µg 
recombinant 
p.R116Q PNPO 
            
Table 4.7: Peptides detected from tryptic digests of DBS and spiked standards. Exp. = expected due to spiked protein or 
endogenous presence in DBS; Ident. = detection of the peptide at the correct retention time. YE = yeast enolase. 
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However, it is important to note that the LC-MS/MS signal and therefore abundance 
of these peptides was very low (Figure 4.50). Poorly resolved and uneven peaks 
suggest a signal close to the lower detection limit of the LC-MS/MS instrumentation. 
 
Despite the addition of a TCA acetone precipitation step, peptides 1-4 were not 
detected in 4 x 3 mm DBS punches from a healthy adult control. This was not 
improved by an increase in injection volume from 10 to 20 µL (data not shown). Two 
additional steps were taken in order to improve the LC-MS/MS signal: i) HFBA was 
removed from the mobile phase. ii) The liquid chromatography gradient was extended 
to a 45 minute method from the 10 minute method used previously. The removal of 
HFBA from the mobile phase meant that peptide 1 would no longer be quantifiable 
but, since HFBA can cause ion suppression199, it was possible that detection of 
peptides 2, 3 and 4 would be enabled. The extension of a reversed-phase LC-MS/MS 
method can improve sensitivity as fewer compounds will co-elute with analytes of 
interest, reducing ion suppression.  
These steps were successful in increasing the signal derived for the peptides of 
interest. For example, the area under curve (AUC) of peptide 2 detected from the 
digest containing 4 x 3 mm DBS punches with 500 ng yeast enolase and recombinant 
a) b) 
1) 
2) 
3) 
4) 
5) 
6) 
Figure 4.50: Examples of chromatograms obtained upon LC-MS/MS analysis of DBS digests 
spiked with a) wild-type and b) p.R116Q recombinant PNPO protein. Chromatograms: 1) Albumin 
- AVMDDFAAFVEK; MRM: 671.99 > 587.02; RT 5.2 min 2) Yeast enolase - SIVPSGASTGVHEALEMR; MRM: 
614.6 > 547.9; RT 4.75 min 3) PNPO Peptide 1 – DGKPSAR; MRM: 365.94 > 430.42; RT 1.9 min 4) PNPO 
Peptide 2 – FFTNFESR; MRM: 524.31 > 753.65; RT 4.6 min 5) PNPO Peptide 3 – FFTNFESQK; MRM: 574.43 > 
267.27; RT 4.5 min 6) PNPO Peptide 4 – SSQIGAVVSHQSSVIPDR; MRM: 623.22 > 726.81; RT 4.4 min. 
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wild-type PNPO increased from 263 > 881 > 4525 with the removal of HFBA and the 
45 minute method extension, respectively.  
Despite these further optimisations, no signal specific for the endogenous peptides of 
interest was detected in DBS that had not been spiked with recombinant PNPO. It is 
possible that with larger volumes of concentrated blood this would be a viable assay. 
However, these were not available from the patients of interest.  
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 Discussion & future work 
The formulation of a PNPO assay using dried blood spots, as described here, 
exemplifies the importance of careful consideration of a multitude of factors such as 
substrate type, reaction buffer composition and incubation time when developing a 
diagnostic enzyme assay. A complicating factor in this case was the effect of 
supraphysiological vitamin B6 concentrations in patients receiving B6 for seizure 
treatment. Despite this, success was achieved and the development of an enzyme 
assay for the detection of PNPO deficiency from dried blood spots will prove a 
valuable tool for the rapid diagnosis of this disorder in infants and young children. 
This assay is the first specific and reliable biochemical test for PNPO deficiency viable 
for use in the modern clinical environment and has since been published in Analytical 
Chemistry.89 It is likely that the test can be used in conjunction with the measurement 
of B6 vitamers from DBS (Section 3) for the biochemical diagnosis of PNPO 
deficiency. For example, vitamer concentrations (specifically PNP/PLP ratio) could be 
useful in cases in which borderline PNPO activity is measured using the DBS enzyme 
assay. This analysis may be particularly valuable as both tests can be carried out 
from the same DBS sample.  
It is becoming increasingly apparent that even in the genomic era the pathogenicity 
of genetic variants identified must be assessed in order to provide a definitive 
diagnosis. Within the field of metabolic disorders the most effective and conclusive 
technique with which to do this is biochemical testing. Despite this, complications and 
paradoxes may be identified – this is apparent in the case of the p.R116Q variant in 
PNPO.  
Although it was found that the enzymatic characteristics of recombinant p.R116Q 
protein appear to differ little from those of the wild-type protein, it is known that some 
individuals present with the B6-dependent seizures characteristic of PNPO deficiency. 
Equally, no PNPO activity was detected in dried blood spots from these patients. The 
identification of differences in activity when the FMN cofactor was limited suggested 
that conformational changes upon cofactor binding or the cofactor binding itself could 
be pathological in these patients.Since this work was performed, other groups have 
also identified substantial differences in the thermal stability of wild-type and p.R116Q 
protein. If the levels of p.R116Q PNPO protein are held in a delicate balance in these 
patients they could be particularly susceptible to deficiencies of vitamins B6 or B2. 
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PNPO activity could also vary on a tissue-specific basis. Indeed, this would provide 
an explanation for the undetectable activity identified in the dried blood spots of 
asymptomatic p.R116Q homozygous individuals. 
Although the activity of recombinant p.R116Q protein towards different substrates 
(i.e. PNP and PMP) was characterised, a direct comparison was not made using DBS 
from p.R116Q homozygotes. Ideally in the future this should be investigated as it is 
possible that activity towards PMP is retained in DBS despite no measurable 
conversion of PNP to PLP. 
Unfortunately, it was not possible to detect PNPO protein in dried blood spots by LC-
MS/MS analysis of peptides derived from this tryptic digestion. The detection of 
peptides derived from trypsin digestion of proteins is affected by factors such as 
digestion efficiency200 and matrix effects specific to each protein/peptide.201 Future 
studies would prioritise the use of larger sample volumes to facilitate the detection of 
PNPO-derived peptides. In addition, a wider range of peptides could be chosen for 
analysis as it is possible that those chosen were not present in high enough 
concentrations to allow detection due to, for example, poor digestion efficiency.  It is 
possible that additional work such as further sample clean-up steps or other 
techniques such as high resolution mass spectrometry would allow quantification of 
PNPO expression in blood, or other tissues. A technique such as 2D-gel 
electrophoresis prior to digestion could provide a ‘clean fraction’ of PNPO protein for 
LC-MS/MS analysis, but this would require a sample type with more volume than 
DBS.202 It would be important as part of future work to better characterise the tissue-
specific expression of PNPO protein and whether the presence of the p.R116Q is a 
modifier in this process.  
As a relatively common variant with an allele frequency of 0.0547, it is possible that 
p.R116Q is an important modifier of epilepsy. If PLP or PN, relatively inexpensive and 
safe medications, could be used as an adjunct to the treatment of seizures it would 
be an important development in epileptology. Furthermore, if PLP or PN were known 
to be more effective in individuals hetero/homozygous for p.R116Q, this would be an 
example of a potential use of NGS data for the specific and personalised treatment 
of individuals on a case-by-case basis. In the near future, with the continuing 
decrease in price and widespread adoption of NGS, this will become increasingly 
feasible – the difficulty comes with interpreting the data collected.  
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 BIOCHEMICAL CHARACTERISATION OF A NOVEL 
NEUROPATHY CAUSED BY DEFICIENCY OF 
PYRIDOXAL KINASE 
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Inherited peripheral neuropathies (Charcot-Marie-Tooth [CMT] disease) are relatively 
common neuromuscular disorders, affecting 0.04% of the population.203 However, 
treatment is currently symptomatic204-205 and the genetic basis of CMT is identified in 
only a quarter of cases.206 The mechanisms behind CMT are unclear but defects are 
often found in genes encoding proteins involved in axonal transport and the 
cytoskeleton.207 Peripheral neuropathy may also occur with other pathologies in 
inborn errors of metabolism presenting in childhood. 
In collaboration with the UCL Institute of Neurology, we have recently identified three 
siblings with early-onset sensorimotor, axonal, peripheral neuropathy as well as adult-
onset optic atrophy (Subjects PK1, 2 and 3). All three siblings reported disabling 
peripheral neuropathy from early childhood followed by optic atrophy later in life. 
Subject PK1 (79 years old) was wheelchair bound and Subject PK2 (74 years old) 
also had limited mobility, requiring assistance in order to walk. Subject PK3 was 
deceased at the time of this study. 
Historically, considerable genetic and biochemical investigations were carried out on 
these individuals but failed to identify any known specific cause for their disorder, this 
is described by Chalmers et al.208   
More recently, collaborators performed whole genome sequencing on these patients. 
When filtered according to variants that segregated with the disease, a homozygous 
p.A228T variant in the PDXK gene, encoding pyridoxal kinase (PK), was identified. 
PK is the enzyme responsible for phosphorylation of the B6 vitamers pyridoxine, 
pyridoxamine and pyridoxal, making it integral for maintaining an adequate supply of 
pyridoxal 5’-phosphate (PLP), the active cofactor form of vitamin B6.209 
Typically, disorders of vitamin B6 metabolism lead to early-onset epileptic 
encephalopathy responsive to high doses of vitamin B6.2, 4 The individuals identified 
with the p.A228T variant in PK had not reported seizures as a feature of their disorder, 
an unexpected finding. It was deemed important to characterise the effect of p.A228T 
on the function of PK biochemically. 
Although other inborn errors of vitamin B6 metabolism haven’t been linked to 
peripheral neuropathies, there are known situations in which perturbation of normal 
B6 homeostasis can lead to this disorder. For example, extremely high doses of 
pyridoxine are known to cause neuropathy.110 In addition, the tuberculosis medication 
isoniazid109, 210, 4’-O-methyl pyridoxine (ginkgotoxin)211 and respiratory medication 
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theophylline108 are each known to cause peripheral neuropathy. The proposed 
mechanism for this effect is thought to be PLP deficiency through either inactivation 
of PLP or inhibition of PK.212-214 
Studies by collaborators showed that the levels of PK protein in fibroblasts 
homozygous for the p.A228T variant were similar to those in wild-type fibroblasts. 
This indicated that any conformational change induced by the p.A228T variant did not 
cause instability or degradation of the protein; alteration of PK enzymatic activity was 
therefore the more likely pathogenic mechanism, if it was indeed pathogenic. 
This chapter describes the development and utilisation of an LC-MS/MS-based 
enzyme assay from bacterially-prepared recombinant PK protein to assess the effect 
of p.A228T on the enzymatic activity of PK. In addition, the development of an assay 
for measurement of PK activity in dried blood spots is described. These DBS were 
collected from individuals homozygous for A228T-PK in order to assess the in vivo 
effect of the variant identified.  
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 Investigation of the in vitro effect of p.A228T on the 
enzyme kinetics of recombinant pyridoxal kinase 
In the diagnosis of inborn errors of metabolism there is an ever-present need to 
assess the pathogenicity of genetic variants identified, particularly as novel variants 
are identified by next generation sequencing (NGS). In-silico assessment of p.A228T 
indicated that the variant was not expected to be pathogenic; it was predicted 
tolerated/benign by SIFT/Polyphen, respectively. Although alanine (A) and threonine 
(T) belong to different amino acid classes (A = aliphatic; T = polar neutral), their 
structures are relatively similar. (Figure 5.1 (a)).  
 
Despite this in silico prediction, evidence such as an autosomal recessive inheritance 
pattern and the aforementioned link between disrupted vitamin B6 metabolism and 
peripheral neuropathy meant that biochemical characterisation of p.A228T was 
warranted. In addition, the structure of pyridoxal kinase, as predicted by X-ray 
crystallography214, shows the A228 residue is present at the active site, close to the 
ATP binding pocket but not interacting directly with ATP itself (Figure 5.1 (b)). One 
could, therefore, hypothesise that p.A228T may effect ATP binding and the catalytic 
Figure 5.1: (a) Structures of the amino acids alanine and threonine (b) Predicted structure of the PK 
active site. Positions of the (i) A228 residue (ii) ATP binding site and (iii) PL/PLP binding site are indicated (PLP & 
ATP shown bound). Positions of divalent cations (Mg2+) shown as green circles. Monovalent cation (K+) shown as 
a purple circle. Adapted from the crystal structure determined by Gandhi et al. 2012 and stored in the 
swissmodel.expasy.org repository. 
Alanine 
Threonine 
(a) (b) 
(i
(ii) (iii) 
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activity of PK. Furthermore, plasma PLP concentrations below the normal range were 
identified in the two siblings studied (7.5 and 9 nmol/L; normal range: 15 - 73 nmol/L) 
Similar methodology to that used in Section 3.2 was used to study the kinetics of 
pyridoxal kinase and specifically the effect of the p.A228T substitution. This 
experimentation was carried out using bacterially-expressed human recombinant 
protein, prepared by collaborators. 
 
   The effect of pyridoxal concentration on enzyme activity 
Experiments were performed by incubating 100 ng recombinant wild-type and 
p.A228T PK protein for 10 minutes in a 20 mmol/L potassium phosphate buffer, pH 
6.1 containing 300 µmol/L MgCl2, 300 µmol/L ATP. These conditions had been 
previously used by di Salvo et al. for the assay of recombinant pyridoxal kinase.215 As 
discussed in Section 3.1, PK requires both a monovalent and divalent cation for 
optimal activity (in this case K+ and Mg2+) and has an optimal pH from 6 – 7.176  
Di Salvo et al. suggested that pH 6.1 was the optimal pH and the Km of pyridoxal 
approximately 30 µmol/L.215 The pyridoxal concentration was therefore varied 
between 0 – 100 µmol/L.  
 
Figure 5.2: Effect of pyridoxal concentration on pyridoxal kinase activity.  Km for PL: WT = 14.5 µmol/L; 
p.A228T = 31.9 µmol/L as calculated from the nonlinear fit of PLP formation. Conditions: 20 mmol/L potassium 
phosphate pH 6.1; 0 - 100 µmol /L PL; 300 µmol/L MgCl2; 300 µmol/L ATP; 37°C; 10 minute incubation. Error 
bars indicate SEM. (n = 3 at each point). (a) is a nonlinear fit of PLP formation between 0 – 100 µmol/L PL; (b) 
is a nonlinear fit of PLP formation between 0 – 15 µmol/L PL.  
(a) (b) 
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Figure 5.2 (a) shows the dependence of PK activity on pyridoxal concentration as 
measured by pyridoxal phosphate formation after a 10 minute incubation period, 
represented by plotting reaction velocity (µmol/L/h) against the substrate 
concentration. As 100 ng PK protein was added to each solution, the reaction velocity 
can also be expressed as nmol/mg protein/h using a conversion factor of x 2.4 (e.g. 
1 µmol/L/h = 2.4 nmol/mg/h). Km values were calculated as the substrate 
concentration at half the maximum velocity of reaction (i.e. at saturating substrate 
concentrations). A Km of 14.5 µmol/L was determined for wild-type protein and a Km 
of 31.9 µmol/L for the p.A228T PK protein. This indicates a two-fold lower catalytic 
efficiency in the presence of p.A228T. At low pyridoxal concentrations (0 – 15 µmol/L) 
the difference in PLP formation was particularly pronounced (Figure 5.2 (b)). This is 
important as physiological concentrations of free pyridoxal are likely to be in the 
nanomolar range.159  
                                                                                                                
   Effect of adenosine 5’-triphosphate on enzyme activity 
Given the proximity of the A228 amino acid residue to the ATP binding site of PK, it 
was hypothesised that p.A228T would have a greater impact on ATP kinetics than 
pyridoxal kinetics. Recombinant PK was incubated with ATP (0 – 500 µmol/L) and 10 
µmol/L pyridoxal in initial experiments. Unless mentioned, other conditions were the 
same as those described in Section 5.1.1. 
Figure 5.3 (a) shows the dependence of PK activity on ATP concentration. The Km of 
wild-type PK was approximately ten times lower than that of p.A228T protein (4.4 
µmol/L vs 41.5 µmol/L). The p.A228T variant therefore has a greater effect on ATP 
binding than on PL binding, where only a two-fold difference in Km could be identified. 
Similarly to experiments investigating PL, the effect at low ATP concentrations was 
particularly pronounced (Figure 5.3 (b)).  
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In order to expand upon the data shown in Figure 5.3, two alterations were made in 
subsequent experimentation. Firstly, the pyridoxal concentration was increased to 50 
µmol/L as 10 µmol/L was lower than the Km identified. This concentration of PL 
saturates the protein whilst concentrations higher than this introduced inhibition 
(approximately 15% lower activity at 100 µmol/L compared to 50 µmol/L PL). The 
second modification was to increase the MgCl2 concentration to 3 mmol/L in order to 
ensure that all ATP was in its Mg-bound form. The phosphotransfer from ATP to 
substrate is dependent upon ATP binding to Mg; this neutralises negative charges on 
the polyphosphate chain.214, 216 Indeed, ATP affinity for Mg is extremely high and in 
vivo there is usually very little free ATP present in the cell.217 Previous studies have 
shown that physiologically, MgATP is the most important cation-ATP complex utilised 
by the PK enzyme.176 
 
 
 
 
 
Figure 5.3: Kinetics of recombinant PK protein when varying ATP concentration.  Km of ATP: WT = 4.4 
µmol/L; p.A228T = 41.5 µmol/L as calculated from the nonlinear fit of PLP formation. Conditions: 20 mmol/L 
potassium phosphate pH 6.1; 10 µmol/L PL; 300 µmol/L MgCl2; 0 – 500 µmol/L ATP; 37°C; 10 minute incubation. 
Figure 5.3 (a) is a nonlinear fit of PLP formation between 0 – 500 µmol/L ATP; Figure 5.3 (b) is a nonlinear fit of 
PLP formation between 0 – 50 µmol/L ATP. Error bars indicate SEM. (n = 3 at each point). 
(a) (b) 
194 
 
 
Figure 5.4 shows the effect of ATP concentration on pyridoxal kinase activity 
measured by PLP formation in the presence of 50 µmol/L pyridoxal and 3 mmol/L 
MgCl2. Intriguingly, the Vmax of p.A228T PK protein was higher than that of wild-type 
protein (p.A228T = 2.1 µmol/L/h; WT = 1.0 µmol/L/h).  
 
In human176, T. Brucei218 and E. Coli219 PK, different divalent cations (Mg2+, Zn2+ and 
Mn2+) have been shown to affect PK activity in different ways. It is possible that the 
structural alteration of human PK caused by p.A228T could raise the Km of Mg2+, 
hence increasing activity in the conditions used in Figure 5.4. Additional work is 
required to confirm this hypothesis. The Km of p.A228T protein with PL as substrate 
was still higher at 4.8 µmol/L compared to 3.7 µmol for wild-type protein.  
Studies on the enzyme kinetics of pyridoxal kinase have been carried out by varying 
Mg2+ and ATP concentrations independently218 or by varying MgATP concentration.215 
In the work shown in Figures 5.3 and 5.4, Mg2+ concentrations were kept constant at 
either 0.3 or 3 mmol/L, respectively. However, this was added in the form of MgCl2 
and was not adjusted alongside the variation in ATP concentration.  
Figure 5.4: Kinetics of recombinant PK protein when varying ATP concentration in the presence of 
an excess of MgCl2 and PL.  Vmax: WT = 1.16 µmol/L/h; p.A228T = 2.36 µmol/L/h. Km: WT = 3.7 µmol/L; 
p.A228T = 4.8 µmol/L as calculated from the nonlinear fit of PLP formation. Conditions: 20 mmol/L potassium 
phosphate pH 6.1; 50 µmol/L PL; 3 mmol/L MgCl2; 0 – 500 µmol/L ATP; 37°C; 10 minute incubation. Error bars 
indicate SEM. (n = 3 at each point). 
195 
 
 
Next, MgATP was varied from 0 – 500 µmol/L, while keeping other parameters 
identical (Figure 5.5); sigmoidal enzymes kinetics were clearly identified. This was 
unexpected, upon the variation of only one substrate (of the two used, pyridoxal and 
ATP) standard Michaelis-Menten kinetics were predicted. Indeed, studies by other 
groups using MgATP had shown Michaelis-Menten kinetics. However, due to the 
increased sensitivity of this LC-MS/MS-based method, we were able to detect activity 
at far lower MgATP concentrations than the 50 - 800 µmol/L previously used when 
studying MgATP kinetics. It is possible that other groups were unable to detect the 
sigmoidal relationship observed in our data. 
 
In addition, an assumption was made that the concentrations of Mg2+ and ATP in the 
purchased MgATP compound were equimolar. It is possible that, if excess Mg2+ was 
present in the MgATP complex, the variation in Mg2+ and ATP concentration was not 
equal across the range tested. If Mg2+ and ATP were equimolar, Mg2+ should be 4.8% 
of the total weight of the MgATP sourced from Sigma-Aldrich (Product number 
A9187). However, the product specification showed that Mg2+ ions constituted 
anywhere from 2.5 – 13.5% of the total weight of the product (measured by ICP-MS) 
meaning assumptions could not be made according to the exact proportion of Mg2+ 
contained therein. 
Figure 5.5: Sigmoidal kinetics of recombinant PK protein using MgATP as substrate.  Vmax: WT = 2.52 
µmol/L/h; p.A228T = 0.95 µmol/L/h. Khalf: WT = 53.4 µmol/; p.A228T = 174.4 µmol/L as calculated from the 
sigmoidal fit of PLP formation, shown in this graph when plotting velocity (µmol/L/h) against substrate 
concentration (µmol/L). Conditions: 20 mmol/L potassium phosphate pH 6.1; 50 µmol/L PL; 0 - 500 µmol/L 
MgATP; 37°C; 10 minute incubation. Error bars indicate SEM. (n = 3 at each point). Khalf = the concentration of 
substrate that produces half the maximum enzyme velocity. 
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This is also complicated by the fact that, as previously mentioned, two Mg2+ ions are 
shown bound at the active site of PK, one stabilising the β and γ phosphates of ATP 
and another at the 5’-phosphate of PLP.214 It could be hypothesised that Mg2+ is 
important in releasing PLP from the active site after the completion of a catalytic cycle. 
It is certainly critical for the neutralisation of negative charges during phosphotransfer. 
Alterations in the molarity of Mg2+ ions in solution could affect the observed enzyme 
kinetics by altering these processes. 
The Khalf and Vmax for MgATP both indicate reduced activity of the p.A228T enzyme, 
in accordance with previous results in Figures 5.3 and 5.4 (Wild-type: Khalf = 53.4 
µmol/L; Vmax = 2.5 µmol/L/h, p.A228T: Khalf = 174.4 µmol/L; Vmax = 0.9 µmol/L/h. 
However, in vivo, intracellular free ATP concentrations are usually in the low mmol/L 
range220, saturating concentrations for the pyridoxal kinase enzyme. This would make 
the more dramatic reduction in activity seen at low ATP concentrations unimportant 
in vivo. 
In conclusion, PK protein carrying the p.A228T variant, although still capable of the 
enzymatic conversion of PL to PLP, showed alterations in enzyme kinetics consistent 
with reduced catalytic activity.  
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 The effect of p.A228T on the activity of pyridoxal kinase 
in red blood cells 
In order to confirm the potential pathogenicity of the p.A228T variant, PK activity was 
measured in vivo using dried blood spot (DBS) samples taken from control individuals 
and the patients in whom the variant was identified. 
Previous assays have been used to measure PK activity from erythrocytes.38, 178, 221-
222 However, these assays used washed red blood cells separated from plasma in a 
relatively complex procedure and/or radioactive substrates. The simplicity of sample 
collection and volume in DBS is an advantage, as discussed in Section 4.  
It was already shown in Section 4 that pyridoxal kinase activity was measurable from 
a 3 mm dried blood spot (DBS) as the first step of a coupled PN>PNP>PLP enzyme 
assay. When designing this new PK assay, the choice of substrate was considered. 
It was postulated that the best method for the sole measurement of PK activity from 
DBS would be the quantification of pyridoxal 5’-phosphate (PLP) formation on 
incubation with pyridoxal (PL). If either of the other two physiological substrates (PN 
or pyridoxamine (PM)) were used, an added complication would be conversion of 
their phosphorylated products (PNP or pyridoxamine 5’-phosphate (PMP), 
respectively), to PLP by the PNPO enzyme. Quantification of PLP formation was 
carried out using the same LC-MS/MS method described elsewhere (Section 2.4). 
 
  Method development 
The protocol developed for measuring PK activity measurement was an adaptation 
of the previously developed coupled PNPO enzyme assay described in Section 4. 
Alterations were made to the buffer type as well as the substrate, as described below. 
Two 3 mm DBS punches were placed in 60 µL 40 mmol/L potassium phosphate buffer 
pH 6.1 and sonicated for 2 minutes before the addition of 60 µL reaction buffer 
containing 300 µmol/L ATP & MgCl2 or 300 µmol/L MgATP and 10 µmol/L pyridoxal. 
120 µL of a 0.3 N TCA reaction stop mix was then added immediately to the T0 tube 
and to the other reaction tubes after their allotted incubation time. Samples were then 
left on ice for 45 minutes prior to sonication for 5 minutes and then centrifuged at 
14,000 g for 10 minutes. The supernatant was taken for analysis.  
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The buffer used was similar to that optimised for the study of recombinant PK protein, 
and that using the coupled PK/PNPO assay; 300 µmol/L MgCl2 and 300 µmol/L ATP 
(or 300 µmol/L MgATP) had previously been shown to saturate the PK enzyme in 
Section 5.1. 10 µmol/L pyridoxal was chosen as the substrate concentration based 
on the Km of wild-type recombinant PK protein for pyridoxal. This pyridoxal 
concentration had also been used by Kark et al. for the assay of PK activity from 
haemolysates.222 Previous experiments (Section 5.1) utilising recombinant PK 
protein showed that the activities of WT and p.A228T PK enzyme were readily 
distinguishable at this concentration. Saturating PL concentrations would be less 
representative of physiological conditions as PL concentrations are in the nanomolar 
range in vivo.  
In order to optimise the incubation time, a 3 mm DBS punch from an adult control was 
incubated over a 30 minute period. PLP formation was linear (R2 = 0.99) over this 
time period (Figure 5.6). A 10 minute incubation period was therefore used for all 
subsequent experiments. PLP formation was measured by subtracting the PLP from 
the T0 punch from that in the T10 punch and expressed as pmol PLP/DBS/h. 
 
 
 
 
Figure 5.6: Pyridoxal kinase activity in a 3 mm DBS. Conditions: 20 mmol/L potassium 
phosphate pH 6.1; 10 µmol/L PL; 300 µmol/L MgATP; 37°C. R2 = 0.99.  Error bars indicate SEM. 
(n = 3 at each point). 
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 Analysis of patient samples 
An initial experiment was carried out using 3 mm DBS punches from the two p.A228T 
homozygote siblings (Subjects PK1 and PK2) and the p.A228T heterozygote 
daughter (Subject PKHET1) of Subject PK1. Also analysed were DBS from the 78-
year-old spouse of Subject PK1 and three healthy adult controls (Figure 5.7). 
Reduced PK activity was evident in Subjects PK1 and PK2; 1.3 and 2.7 pmol/DBS/h, 
respectively. The PK activity of the spouse of Subject PK1 and 3 healthy controls 
ranged from 12.4 to 20.7 with a mean of 15.4 pmol/DBS/h. The heterozygote daughter 
of Subject PK1 had an intermediate activity of 6.6 pmol/DBS/h. Importantly, a small 
amount of residual activity was detected for the individuals homozygous for p.A228T, 
which correlated with in vitro experimentation showing that p.A228T protein retains 
some ability to catalyse PLP formation from pyridoxal.  
 
 
Figure 5.7: Preliminary pyridoxal kinase assay from DBS indicated reduced PK activity in p.A228T 
individuals. Conditions: 20 mmol/L potassium phosphate pH 6.1; 10 µmol/L PL; 300 µmol/L MgCl2 300 
µmol/L ATP; 37°C. PK activities: Subjects PK1 and PK2 = 1.3 and 2.7 pmol/DBS/h; heterozygous p.A228T = 6.6 
pmol/DBS/h; mean of 4 adult controls = 15.5 pmol/DBS/h. (n = 3 at each point). 
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In order to confirm the low blood PK activity of Subjects PK1 and PK2, DBS were 
collected from 22 adults whose ages ranged from 15 – 92 years (Table 5.1). These 
were individuals attending an outpatient’s clinic of the National Hospital for Neurology 
and Neurosurgery, London, UK. Samples were retrieved from individuals with varying 
ethnicities as published work has shown lower PK activity in blood samples from 
African Americans compared to White Americans.221 
Subject Age Gender Ethnicity 
PK activity in 
DBS 
(pmol/DBS/h) 
PKC1 25 Female African 4.4 
PKC2 50 Female Caucasian 9.1 
PKC3 71 Female Indian 4.2 
PKC4 50 Female Caucasian 4.2 
PKC5 49 Female Caucasian 7.8 
PKC6 48 Male Caucasian 8.7 
PKC7 30 Male Caucasian 6.0 
PKC8 70 Female Caucasian 9.0 
PKC9 35 Female East Asian 5.4 
PKC10 27 Male Caucasian 12.3 
PKC11 52 Female African 2.6 
PKC12 71 Female Caucasian 10.1 
PKC13 92 Male Caucasian 9.8 
PKC14 55 Male South Asian 7.7 
PKC15 15 Male Caucasian 7.7 
PKC16 64 Female Caucasian 7.6 
PKC17 56 Male Caucasian 5.9 
PKC18 38 Female Caucasian 11.7 
PKC19 31 Male Arabic 14.7 
PKC20 34 Male Caucasian 10.1 
PKC21 78 Female Cypriot 9.0 
PK p.Ala228Thr homozygous 
PK1 79 Male Cypriot 1.1 
PK2 74 Female Cypriot 0.9 
PK p.Ala228Thr/WT 
PKHET1 52 Female Cypriot 4.9 
Table 5.1: Summary of control and affected subjects collected for DBS pyridoxal 
kinase activity analysis. PKC21 is the wife of subject PK1. Subjects PK1 and PK2 are siblings. 
Subject PKHET1 is the daughter of subject PK1 and Subject PKC21. 
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PK activity for each of these individuals was measured (Figure 5.8). Controls (n = 22) 
had activities ranging from 2.6 – 14.7 pmol/DBS/h (mean = 8.2 pmol/DBS/h). This 
wide variety in activity has been identified previously.221 The two individuals of African 
descent in our control cohort had relatively low activities of 2.6 and 4.5 pmol/DBS/h.   
 
 
 
Published work measuring PK activity in haemolysates using both pyridoxal222 and 
[3H]pyridoxine38, 40, 221 as substrates has reported activities of 30 - 120 nmol 
PLP/gHb/h. If each DBS is assumed to contain 3.2 µL of whole blood at 14 gHb/dL 
(individual patient haematocrits were unavailable), results in pmol/DBS/h can be 
converted to nmol/gHb/h using a conversion factor of x2.2; resulting in activities of 5.7 
– 31.7 nmol/gHb/h in our control cohort. This is lower than those reported previously. 
Differences in methodology that could account for this discrepancy include the use of 
DBS rather than a haemolysate and the pH of buffers used. 
The PK activities measured for Table 5.1 and Figure 5.8 are lower than those 
determined for Figure 5.7. For example, the mean activity measured from control 
DBS was 47% lower, at 8.2 pmol/DBS/h instead of 15.4 pmol/DBS/h. The later data 
Figure 5.8: Pyridoxal kinase activities in controls and subjects PKHET1, PK1 and 
PK2. A non-parametric Mann-Whitney test was carried out to compare the two p.A228T 
individuals to controls and a significant difference was identified (p = 0.0072). Each point is 
the mean of the analysis of 2 separate DBS. 
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was collected using 300 µmol/L MgATP as substrate, earlier experiments used 300 
µmol/L MgCl2 & 300 µmol/L ATP, providing an explanation for this difference. The 
effect of different types of ATP substrate on PK activity is discussed in Section 5.1.2. 
As before (Figure 5.7), PK activities in Subjects PK1 and PK2 were lower than all 
controls analysed at 1.1 and 0.9 pmol/DBS/h, respectively. The heterozygous subject 
HET1 had activity of 4.9 pmol/DBS/h, within the normal range. A significant difference 
was identified between subjects PK1 and PK2 vs the 22 controls (p = 0.007) using a 
Mann-Whitney test. These results indicated that Subjects PK1 and PK2 were indeed 
PK deficient in the blood. 
 
 
 
Given the age of Subjects PK1 and PK2 (79 and 74 years old, respectively) it was 
important to identify any correlation of blood PK activity with age (Figure 5.9) No 
correlation was observed; the nonparametric Spearman correlation r value was -0.12 
with a two-tailed P value of 0.63. This data indicated that the low PK activities of 
Subjects PK1 and PK2 were not due to their age. It should be noted that DBS from 
children have not been analysed (apart from one 15-year-old adolescent). In the 
human foetus, PK activity increases throughout gestation.223 It is possible that an age-
Figure 5.9: Age does not affect erythrocyte pyridoxal kinase activity.  The line 
displayed is that generated on linear regression of the data sets; there was no relationship 
between PK activity and age (R2 = 0.007). Spearman correlation r value was -0.12 with a two-
tailed P value of 0.63. Each point is the mean of the analysis of 2 separate DBS.  
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related correlation does exist in childhood, particularly the neonatal period, to our 
knowledge this has not been studied. 
 
 
Whilst there was no correlation of PK activity with age, there was a difference 
approaching significance (p = 0.11) between the measured PK activities in males and 
females (Means = 9.2 and 7.1 pmol/DBS/h, respectively; (Figure 5.10). This has not 
been reported previously. On average, females have a lower haematocrit compared 
to males (~12% lower)224, which could account for at least part of the reduction in PK 
activity seen (29%). A lower haematocrit of the blood spotted onto a DBS can lead to 
a reduced blood volume within the 3 mm punch taken for analysis (discussed in detail 
in Section 4.1.2.6). Equally, as PK is a red cell enzyme, a lower red cell count per 
mL would lead to lower measured PK activity. Unfortunately, it was not possible to 
investigate this further in our cohort as the haematocrits or haemoglobin levels of the 
samples analysed had not been measured. In the future, it would be valuable to obtain 
a larger cohort of samples in order to confirm this finding. 
 
Figure 5.10: Effect of gender on pyridoxal kinase activity.  Unpaired T test P value = 
0.11; each point is the mean of the analysis of 2 separate DBS.  
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 Effect of the c.(-306_-305insGCGCGGCG) insertion in the 
PK promoter region on enzymatic activity of pyridoxal 
kinase in red blood cells. 
Reports suggest that there is a wide range of erythrocytic PNPO89, 170 and PK221 
activities within the human population. With regards to PK, it has been speculated 
that this variation is due to the presence or absence of the c.(-306_-
305insGCGCGGCG) variant, thought to introduce an erythroid-specific core promoter 
binding protein (CPBP) binding site in the 5’ region of the PDXK gene. The absence 
of this variant has been suggested to be the cause of reduced PK activity in the 
erythrocytes of Black Americans.40 It is possible that the reduced dried blood spot PK 
activity identified in the two p.A228T homozygous individuals and/or the lowest values 
amongst the control samples was caused by the absence of this insertion. The PDXK 
promoter region was therefore sequenced for each of the samples. 
 
 Optimisation of the amplification of the PDXK promoter region. 
Primers used for the amplification of genomic DNA by PCR must be designed with 
several parameters in mind.225 A summary of ideal primer design parameters for the 
amplification and sequencing of genomic DNA, as well as the set of primers designed 
for amplification of the PDXK promoter region, is shown in Table 5.2. Standard PCR 
conditions used can be found in Section 2.12.3.1; Table 2.10. These conditions 
formed a basis from which the parameters were altered to facilitate amplification of 
the PDXK promoter region. The 5’ promoter regions of genes are often difficult to 
amplify given their high %GC content, causing higher Tm’s and the formation of 
secondary structures such as hairpins; the 5’ region of PDXK is GC-rich with a GC 
content of approximately 75%.  Techniques and protocols have been developed to 
facilitate the amplification of these regions; some are discussed below. 
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Table 5.2: Optimal parameters for PCR primer design and primer sequences for amplification of the 
PDXK 5’ promoter region.  Parameters adapted from Baumforth et al.225 Tm = melting temperature; GC% = 
percentage of bases that are either C or G in the sequence chosen. 
Parameter Range 
Primer length 18-24 bases 
Tm 55 – 65°C; Tm of primers should not differ by more 
than 2°C 
Primer GC content 40 - 60% 
Amplicon size 
100 – 1000 bp typical but variable according to 
application 
Annealing temperature Typically 2°C below the primer Tm 
3' End stability Less than 3 Gs or Cs in the last 5 bases 
Primer dimers Self-complementarity should be avoided 
Runs of bases No more than 3-4 of the same base in a run 
Secondary structures 
Primers predicted to form secondary structures 
such as hairpin loops should be avoided. 
Specificity Each primer should differ by more than 3 bases 
from other genomic DNA regions 
Primers selected for amplification of the 5’ promoter region of PDXK 
Primer name Sequence Tm (°C) GC% 
Predicted 
Amplicon size 
Primer Prom_F 5’-GCGGTTCCCTTGGGTATC-3’ 57.5 61.1 
470 bp 
Primer Prom_R 5’-ACGCCTCCTTCTGACCTC-3’ 58.3 61.1 
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Two primers (Primers Prom_F & R) were designed for the amplification of the PK 5’ 
promoter region using the parameters shown in Table 5.2. Amplification of 50 ng 
control DNA was attempted under standard conditions (See Section 2.12.3.1) using 
annealing temperatures ranging from 54 – 64 °C. Some nonspecific signal was 
identified at lower temperatures but none of the products corresponded to an 
amplicon of the predicted length (470 bp) (Figure 5.11). 
 
Subsequent experiments involved reducing the MgCl2 concentration from 1.5 mmol/L 
to 1 mmol/L in order to discourage non-specific amplification and increasing the 
number of amplification cycles from 35 to 38, to increase the quantity of PCR product 
amplified.  Unfortunately, under these conditions no bands were detected irrespective 
of the annealing temperature used (54 – 64°C) (data not shown). One technique 
often used to enhance PCR amplification of GC-rich areas of the genome, such as 
the PK 5’ promoter region, is the addition of organic compounds such as betaine and 
dimethyl sulphoxide (DMSO) to the reaction mixture.226-227 These compounds 
promote amplification by destabilising secondary and tertiary DNA structures such as 
the DNA double helix.228 This facilitates the melting of DNA and coupling of primers 
to their target sequences, hence facilitating DNA amplification by Taq polymerase. 
Figure 5.11: Annealing temperature optimisation of primers Prom F &  Prom R. Invitrogen 1 Kb Plus 
DNA ladder used for DNA sizing. No bands specific for the desired amplicon of 470 bp were identified at any 
annealing temperature. Non-specific bands can be visualised at 50 – 54°C. Blank = 1 µL H2O in place of 1 µL 50 
ng/L control genomic DNA. PCR conditions as specified in Section 2.12.3.1; Table 2.10 unless stated. 
470 bp 
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Several concentrations of DMSO (3, 6 and 9%) were trialled with annealing 
temperatures of between 54 – 64°C (Figure 5.12). Under some conditions, gel 
electrophoretic analysis showed a strong and specific signal at the expected 
molecular weight of the target amplicon (470 bp). Non-specific products were evident 
at lower temperatures and in the presence of 3% DMSO. The strongest and most 
specific signal was seen when the reaction was carried out using an annealing 
temperature of 58°C and 6% DMSO. All subsequent experimentation was therefore 
carried out using these conditions. 
DNA was extracted from the same dried blood spots that had been used to determine 
PK enzyme activity using a QIAamp DNA micro kit (QIAGEN, Venlo, Netherlands). 
The concentration of genomic dsDNA in the final elution solution was low for each of 
these DBS extracts, close to or below the 2 ng/µL LLOQ of the DNA quantification 
technique used (NanoDrop ND-1000 UV-VIS Spectrophotometer).  
No PCR product was evident for many of the samples when 1 µL (50 ng) of DNA and 
35 PCR cycles were used for amplification (Figure 5.13 (a)). However, when the DNA 
quantity was doubled to 2 µL (100 ng) and the number of PCR cycles was increased 
to 38 it led to successful amplification of the target DNA sequence (Figure 5.13 (b)). 
Although the signal from some individuals was low or showed some non-specific 
bands, resulting products were sequenced successfully. 
Figure 5.12: Effect of DMSO on the amplification of the PDXK 5’-promoter region. Invitrogen 1 Kb Plus 
DNA ladder utilised for DNA sizing. PCR conditions as specified in Section 2.12.3.1; Table 2.10 unless specified. 
470 bp 
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Examples of electropherograms from individuals homozygous for the c.(-306_-
305InsGCGCGGCG) and wild-type alleles, as well as a heterozygous individual, are 
shown in Figure 5.14. Four controls were homozygous for the wild-type allele, two 
were heterozygous and fifteen were homozygous for the c.(-306_-
305InsGCGCGGCG) insertion. Subjects PK1 and PK2 were both homozygous for the 
wild-type allele (Table 5.3). 
Figure 5.13: Amplification of the PDXK 5’-promoter region using genomic DNA extracted from DBS taken from 
PK-deficient individuals and controls. Invitrogen 1 Kb Plus DNA ladder used for DNA sizing. PCR conditions as specified in 
Section 2.12.3.1; Table 2.10 unless adjusted as described in the main text. PC = positive control (genomic DNA extracted from 
whole blood of a control) NC = negative control (H2O in place of genomic DNA). 
Figure 5.14: Representative electropherograms of the wild-type, heterozygous and homozygous 
c.(-306_-305InsGCGCGGCG) alleles from DBS extracts. 
470 bp 470 bp 
470 bp 
(a) 
(b) 
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Table 5.3: Presence of the PDXK variant c.(-306_-305InsGCGCGGCG) in subjects collected for DBS 
pyridoxal kinase activity analysis. For the genotype of promoter region: Ins/WT indicates the presence or 
absence of c.(-306_-305InsGCGCGGCG), respectively.  
Subject Age Gender Ethnicity 
Genotype of promoter 
region 
(Ins = insertion present; 
WT = insertion absent) 
PK activity in 
DBS 
(pmol/DBS/h) 
PKC1 25 Female African Ins ; Ins 4.4 
PKC2 50 Female Caucasian Ins ; Ins 9.1 
PKC3 71 Female Indian Ins ; WT 4.2 
PKC4 50 Female Caucasian Ins ; Ins 4.2 
PKC5 49 Female Caucasian Ins ; Ins 7.8 
PKC6 48 Male Caucasian Ins ; Ins 8.7 
PKC7 30 Male Caucasian WT ; WT 6.0 
PKC8 70 Female Caucasian Ins ; Ins 9.0 
PKC9 35 Female East Asian Ins ; Ins 5.4 
PKC10 27 Male Caucasian Ins ; Ins 12.3 
PKC11 52 Female African Ins ; WT 2.6 
PKC12 71 Female Caucasian WT ; WT 10.1 
PKC13 92 Male Caucasian Ins ; Ins 9.8 
PKC14 55 Male South Asian Ins ; Ins 7.7 
PKC15 15 Male Caucasian Ins ; Ins 7.7 
PKC16 64 Female Caucasian WT ; WT 7.6 
PKC17 56 Male Caucasian WT ; WT 5.9 
PKC18 38 Female Caucasian Ins ; Ins 11.7 
PKC19 31 Male Arabic Ins ; Ins 14.7 
PKC20 34 Male Caucasian Ins ; Ins 10.1 
PKC21 78 Female Cypriot Ins ; Ins 9.0 
PK p.Ala228Thr homozygous 
PK1 79 Male Cypriot WT ; WT 1.1 
PK2 74 Female Cypriot WT ; WT 0.8 
PK p.Ala228Thr/WT 
PKHET1 52 Female Cypriot Ins ; WT 4.9 
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 Dried blood spot pyridoxal kinase activity does not correlate 
with the presence of the c.(-306_-305InsGCGCGGCG) insertion 
in the promoter region of PDXK 
A comparison of the DBS PK activity from individuals homozygous for the c.(-306_-
305InsGCGCGGCG) insertion and wild-type alleles showed that the presence of this 
insertion did not significantly alter PK kinase activity (Figure 5.15). The mean PK 
activity in controls homozygous for the ‘wild-type’ allele was 7.4 pmol/DBS/h (range 
5.9 – 10.1 pmol/DBS/h; n = 4).  In DBS from controls homozygous for the insertion, 
mean activity was 8.8 pmol/DBS/h (range 4.2 – 14.7 pmol/DBS/h; n=15). Hence, the 
reduction in activity seen in the patients is not due to the presence or absence of this 
insertion. Intriguingly, the two control individuals heterozygous for the insertion had 
among the lowest activities (2.6 and 4.2 pmol/DBS/h). However, the numbers in this 
study were too small to determine whether this was a real biochemical effect or simply 
an anomaly based on insufficient data. 
 Figure 5.15: Comparison of pyridoxal kinase activity with genotype data for c.(-
306_-305InsGCGCGGCG). ns = not significant. WT = Wild-type; Ins = c.(-306_-
305InsGCGCGGCG) insertion present. 
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It is worth noting that although this variant was initially described as an ‘insertion’ 
event, more recent data has shown that the prevalence of the insertion allele is >50% 
in the general population. The overall allele frequency from the Genome Aggregation 
Database (gnomAD) is 0.56 from 28,218 alleles. The only ethnicity for which the allele 
frequency is less than 0.5 is African (0.44). In our cohort (including patients with the 
p.A228T variant) the allele frequency of c.(-306_-305InsGCGCGGCG) was 0.69. 
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 Discussion & future work 
 Implications of the association between vitamin B6 metabolism 
and peripheral neuropathy 
Subsequent to the genetic and biochemical diagnosis of pyridoxal kinase deficiency 
for Subjects PK1 and PK2, a treatment regime was initiated that consisted of 
moderate (50 mg/day) PLP supplementation. PLP was chosen as high doses of 
pyridoxine have been shown to cause peripheral neuropathy.110 The aetiology of 
pyridoxine-induced neuropathy is unclear but it was important to avoid exacerbating 
the disorder in these patients.  
As discussed elsewhere (Section 1.1.1), on ingestion, the phosphorylated B6 
vitamers are hydrolysed by intestinal phosphatases and absorbed as the non-
phosphorylated forms. Despite Subjects PK1 and PK2 having plasma PLP 
concentrations (7.5 & 9 nmol/L, respectively) below the normal range (15 – 73 nmol/L) 
before supplementation, within four weeks plasma PLP concentrations had increased 
to 492 and 407 nmol/L, above the normal range of individuals not receiving B6 
supplementation. This suggested that the patients had some residual PK activity, 
supporting our biochemical findings. PLP levels have remained higher than the 
reference range after 12 months of continuous supplementation at 50 mg/day. 
In addition, Subjects PK1 and PK2 improved clinically. Prior to supplementation, 
both individuals had impaired mobility; Subject PK1 was confined to a wheelchair. 
On follow-up after 12 months, both patients were able to walk unaided. In addition, 
neuropathy had been causing considerable chronic pain which, on treatment, 
subsided completely; withdrawal of pain medication was enabled. 
It has been reported that a mouse model lacking the circadian PAR bZip transcription 
factors DBP, HLF and TEF develops seizures attributed to lowered expression of the 
pdxk gene encoding pyridoxal kinase; brain levels of dopamine and serotonin were 
reduced.41 A model of Drosophila melanogaster with suppressed expression of its 
PDXK homologue developed what was thought to be a Parkinsonian phenotype.229 A 
link between pyridoxal kinase and Parkinson’s disease has also been established in 
a human dopaminergic cell line.230 These findings suggest that PK deficiency in the 
brain would lead to PLP deficiency causing either seizures or a Parkinson’s disease-
like movement disorder. However, this was not seen in our patients. On the other 
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hand, as mentioned in the introduction to this section, peripheral PLP deficiency is 
known to lead to neuropathy. This is apparent in the case of drugs that form a complex 
with PLP (e.g. isoniazid) and those that inhibit pyridoxal kinase (e.g. theophylline108 
and gingkotoxin211). These compounds also lead to seizures at higher doses.  
It has been shown that the regulation of PK activity is tissue-specific in PLP-deficient 
rats. Activity is preserved in the brain but reduced in the peripheries.231 Interestingly, 
the same preservation of brain activity is not seen for other B6 metabolic enzymes. It 
is possible that the neurological system is protected through the modulation of PK 
transcription in conditions of B6 deficiency. The mechanism by which this adaptation 
is carried out is currently unknown although PK expression is known to vary according 
to the action of transcription factors linked to the circadian rhythm in mice41 and MocR-
like transcription factors in Salmonella.42 
One hypothesis for the attenuated PLP deficiency in these patients is that the residual 
enzymatic activity of p.A228T PK protein is able to provide adequate PLP within the 
central nervous system (as well as in other organs such as the liver) but not in the 
peripheral nerves. Given that the effect of p.A228T on enzyme activity is more 
pronounced at low substrate concentrations, the diseased state caused by PLP 
deficiency could be present only in tissues where these substrates are in limited 
supply. The axonal transport or import mechanism into the axons of peripheral 
neurones could be insufficient to provide the substrate concentrations required to 
compensate for the deleterious effect of the p.A228T variant in PK.  
Individuals with other B6 metabolic disorders such as PDE and PNPO deficiency have 
not reported peripheral neuropathy as part of their disorder, only that linked to high 
doses of pyridoxine. However, it is possible that individuals with other B6 metabolic 
disorders who present with seizures receive treatment in the form of B6 
supplementation before peripheral neuropathy becomes a feature of their disorder. 
These patients start treatment with B6 supplements on (or before) diagnosis. In 
addition, very few patients have been reported to present with these disorders past 
infancy. Typically, the oldest cases present in early childhood (4-5 years of age; one 
case of ALDH7A1 deficiency has presented at age 19).232 Subject PK1 reported first 
experiencing his symptoms at age 8.  
More broadly, it could be hypothesised that a (perhaps small) proportion of genetic 
peripheral neuropathies are caused by deficiency of the PK enzyme. Screening 
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patients using the newly developed DBS enzyme assay described would be a useful 
process. Potentially, if some genetic neuropathies could be treated with PLP, an 
inexpensive and relatively safe drug, this would be of huge benefit for management 
of these disorders. For clinicians, the measurement of plasma PLP in individuals with 
peripheral neuropathy could be a simple and useful test that could indicate whether 
PLP supplementation may be a beneficial treatment. 
The identification of this novel disorder of B6 metabolism further underlines the 
intricate link between vitamin B6 and the function of both the central and peripheral 
nervous systems. As discussed previously (Section 1.2), seizures caused by PLP 
deficiency are thought to be caused by deranged neurotransmitter metabolism in the 
brain.209 However, this has never been conclusively proven to be the sole cause of 
these seizures and is probably a simplistic explanation. The optic atrophy and axonal 
peripheral neuropathy in the PK deficient patients described are similar to features of 
inherited disorders leading to mitochondrial dysfunction. Indeed, the patients 
described were initially suspected to have a mitochondrial disorder and were 
investigated as such prior to NGS technologies becoming available. 
Transcriptomic co-expression analysis of the human tibial nerve performed by 
collaborators (including populations of neurones and Schwann cells) showed that 
PDXK was expressed alongside genes involved in the oxidation-reduction process. 
Equally, PDXK was expressed strongly in nervous tissues when compared to other 
cell types. This correlates with the importance of B6 metabolism in central and 
peripheral nerves but also indicates a link to mitochondrial function.  
Recently a mitochondrial B6 transporter has been identified in yeast (Mtm1p)30 and its 
homologue in Drosophila has been linked to neuronal survival.31 To date a human 
mitochondrial B6 transporter has not been characterised but two orthologues of the 
Mtm1p gene exist in the human genome (SLC25A39/40); SLC25A39 lies at a 
susceptibility locus for epilepsy.233 The mitochondrial metabolism of Schwann cells is 
linked to long-term peripheral nerve survival.234 Multiple PLP-dependent enzymes are 
mitochondrial or have mitochondrial isoforms including those involved in haem 
synthesis (δ-Aminolevulinate synthase), the one-carbon pathway (serine 
hydroxymethyltransferase), the glycine decarboxylase complex and branched-chain 
amino acid aminotransferase.  
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Overall, our knowledge of human metabolism and the important role than PLP plays 
as a cofactor is insufficient to come to a firm conclusion as to the biochemical 
mechanisms behind the neuronal dysfunction present in both the central and 
peripheral nervous systems during the PLP-deficient state. It is likely that the answer 
is a complex multifactorial one including multiple metabolic pathways with multiple 
simultaneous pathological mechanisms.  
 
 Further biochemical characterisation of pyridoxal kinase and 
activity variation in the general population 
In order to fully characterise the p.A228T PK protein, additional studies exploring 
factors such as the thermal stability, pH dependency and substrate specificity (e.g. 
towards PN and PM) of this mutant PK protein will need to be performed in the future. 
The method presented for the assessment of PK enzyme kinetics is more sensitive 
and accurate than those reported previously, this is of value to the field of B6 
metabolism. In particular, it would be important to confirm sigmoidal kinetics of 
MgATP saturation as this had not previously been identified. A full characterisation of 
PK kinetics is important as it could have implications for the treatment of patients 
receiving high doses of B6 vitamers, for example, if high concentrations were liable to 
inhibit the enzyme.  
The conclusion that p.A228T diminished PK activity but resulted in an intact and 
catalytically active protein was supported by collaborator’s work showing that 
expression of p.A228T PK in fibroblasts was normal as measured using a western 
blot. This indicated a stable protein conformation. However, structural changes were 
apparent by far and near-UV circular dichroism. In particular, the α-helix and β-sheet 
proportion was altered and conformational changes were identified in aromatic side 
chains at the catalytic site. In addition, collaborators showed through isothermal 
titration calorimetry that ATP binding was impaired in p.A228T PK. This supported 
modelling data showing that p.A228 is close to the ATP binding site, and our data 
indicating that the kinetics alterations caused by p.A228T are particularly ATP-
dependent. 
The development of an assay which uses dried blood spots for the measurement of 
PK activity could be useful for the assessment of PK function in larger cohorts and 
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thereby identifying potential population differences. This could have two major 
implications. Firstly, if low PK activity is detected in certain individuals, they could be 
more susceptible to peripheral neuropathy (or seizures, though this could be unlikely 
given the phenotypes of patients in our study) and, if so, receptive to PLP 
supplementation. Secondly, it has long been postulated that low activity of the B6 
metabolic enzymes could be a protective mechanism against malaria due to the 
inability of Plasmodium falciparum to produce its own PLP.182, 235 Although Flanagan 
and Beutler suggested they had identified the mechanism behind low erythrocyte PK 
activity in black Americans (the c.-306_-305InsGCGCGGCG variant)40, our data 
conflicted with theirs. A study looking at PK (and PNPO) activities in dried blood spots 
taken from large cohorts could lead to an improved understanding of the possible role 
of PK in malaria and provide new avenues for treatment.  
 
 
Since the report of Flanagan and Beutler in 2006, considerable additional data has 
been collected on natural variation of the PDXK gene. For example, in-silico analysis 
using the UCSC Human Genome Browser236 shows that just four variants with a minor 
allele frequency of greater than 0.1 are found in the PDXK 5’-promoter region. These 
could potentially alter PK protein expression and/or provide a tissue-specific 
expression profile (Figure 5.16).  
The area of the PDXK 5’-promoter region sequenced to provide the data in Figure 
5.15 also included the variant (b): c.-466_-460delGCGGGGC. This allowed analysis 
of the inheritance of this variant as well as correlation with PK activity. Overall 3/24 
Figure 5.16: The PDXK 5’-promoter region showing common variants with a minor allele frequency 
(MAF) greater than 0.1 in GnomAD. Variants: (a) rs9981249; c.-756C>G; MAF = 0.57 (b) rs72004735; c.-466_-
460delGCGGGGC; MAF = 0.70 (c) rs146826482; c.-306_-305InsGCGCGGCG; MAF = 0.57 (d) rs62229179; c.-246G>T; 
MAF = 0.57. H3K27ac is the acetylation of the 27th lysine of the H3 histone protein. This indicates a transcription 
activation site at this location; variants at this site are more likely to affect expression of the gene. The ‘RefSeq 
Curated’ track shows exon 1 and the 5’ UTR region as well as part of intron 1-2 of the PDXK gene. Data collected 
using the UCSC Human Genome Browser (http://genome.ucsc.edu/) and utilising the GRCh37/hg19 genome 
assembly. 
(a) 
(b) 
(c) 
(d) 
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individuals were homozygous for the ‘wild-type’ allele, with 21/24 homozygous for the 
c.-466_-460delGCGGGGC allele. The allele frequency of this ‘minor’ allele in our 
cohort (0.875) was higher than that of the c.-306_-305InsGCGCGGCG ‘minor’ allele 
(0.69). Inheritance of these variants was also not concurrent in specific individuals. 
This suggests that these variants are not inherited together, at least in our cohort. 
Again, the presence of variant (b) did not significantly affect PK activity measured 
from DBS (data not shown). 
As mentioned above in Section 5.4.1, work has been carried out in bacteria to study 
the mechanisms regulating expression of the B6 salvage pathway enzymes. MocR-
like transcription factors have been shown to bind pyridoxal 5’-phosphate237-238 and 
regulate the expression of a PK orthologue in Salmonella typhimurium.42 This system 
has yet to be extended to higher organisms, however. One potential modulator of 
pyridoxal kinase expression in mammals is the circadian rhythm. In the brain circadian 
oscillations of clock genes are known to alter expression of the PAR bZip transcription 
factors TEF, DBP and HLF which in turn control the transcription of many genes 
including PK. Indeed, in a mouse model, the genetic deletion of these transcription 
factors leads to epilepsy. This is hypothesised by Gachon et al. to be due to PLP 
deficiency caused by insufficient PK activity.41 Important additional work would be to 
use RNA sequencing technology to identify tissue-specific, circadian and feedback 
modulation of PK expression (as well as other B6 metabolic enzymes) and assess the 
implications of this regulatory pathway on B6 metabolism, particularly with regards to 
neurological health. 
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PHOSPHATE FOR THE TREATMENT OF VITAMIN 
B6-RESPONSIVE DISORDERS 
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The United States National Institutes of Health (NIH) recommended daily allowance 
(RDA) of pyridoxine intake for adults is 1.3 mg/d and the recommended upper limit is 
100 mg/d.239  Assuming a weight of 80 kg, these translate to 0.016 mg/kg/d and 0.8 
mg/kg/d, respectively. No RDA specific to PLP has been established. Patients with 
seizure disorders responsive to vitamin B6 typically require oral doses of pyridoxine 
or PLP from 10 – 50 mg/kg/d in order to control their seizures. Doses as high as 100 
mg/kg/d have been used and doses lower than 10 mg/kg/d have also been reported 
as being effective.27, 65, 103, 240-241 These supraphysiological doses are reflected in the 
blood of a supplemented patient, with concentrations of the B6 vitamers orders of 
magnitude higher than those of controls (Section 3).  
High doses of pyridoxine are known to cause peripheral neuropathy thought to be 
due to inhibition of PLP-dependent enzymes, as discussed in Section 5.1 and 
Section 5.4. Peripheral neuropathy has been described in adults after long term (> 1 
year) pyridoxine supplementation, even with doses lower than the recommended 
upper limit (50 mg/d).107 It can also be a side-effect in ALDH7A1-deficient individuals 
receiving pyridoxine for treatment of their seizures232 and has been reported in at least 
one PNPO-deficient child (Patient 10; Mills et al. 201487) 
There are reports of raised liver function tests (LFTs) and hepatic cirrhosis in patients 
with PNPO deficiency receiving high-dose (> 30 mg/kg/d) PLP supplementation.99, 103 
As of early 2019, in the most severe case, this has necessitated a liver transplant in 
one PNPO deficient child.(unpublished data) There is one report of a patient with 
homocystinuria suffering from ‘hepatitis’ (probably PLP-induced liver damage) on 
1,000 mg/d PLP242 and another describing 14/28 patients presenting with transiently 
raised liver function tests upon treatment with high-dose PLP (30 – 50 mg/kg/d) for 
the control of infantile spasms.243  
PLP is a photolabile compound; this was investigated initially more than 50 years 
ago244 and has been studied by others in subsequent decades.105-106 4-Pyridoxic Acid 
5’-Phosphate (PAP) and PLP dimers were identified as photodegradants but, apart 
from a brief study of the degradation rates of different B6 vitamers in CSF21 and one 
looking at the stability of plasma PLP245, little work has been performed on the subject 
over the last 30 years. 
It is currently unknown whether the hepatic dysfunction seen in patients receiving high 
doses of PLP is due to a secondary effect of PNPO deficiency itself, the presence of 
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extremely high B6 vitamer concentrations in the liver, or the ingestion of potentially 
hepatotoxic photodegradants of PLP. To date, however, no PNPO patients receiving 
PN (rather than PLP) for the treatment of their seizures have been reported to develop 
hepatic dysfunction. Indeed, no reports describe PN supplementation as causing 
deranged liver function tests or liver damage in any disorder. This suggests that 
PNPO deficiency is not causing the pathology, rather it is a side-effect of 
supraphysiological PLP doses. However, this could be countered with the hypothesis 
that pyridoxine-responsive PNPO deficient individuals have a milder form of the 
disorder with some residual PNPO activity.87, 98 This could also be protecting their 
liver. 
Coman et al. have hypothesised that the mechanism behind this hepatic dysfunction 
could be linked to high concentrations of B6 vitamers modulating purinergic P2 
receptors on hepatic stellate cells.246 These cells are known to initiate fibrosis through 
increased production of collagen upon P2 receptor activation. PLP and its derivatives 
are known to act upon P2 receptors.247 It is also possible that degradation products 
of PLP could be acting upon P2 receptors and causing hepatic fibrosis in patients on 
high-dose PLP supplementation. PLP is photolabile and if prepared in aqueous 
solution, photodegradation could occur prior to patient administration, leading to the 
ingestion of any PLP photolysis products.104  
In recent years, advice on the preparation of PLP supplements has been increasingly 
stringent; advising the protection of aqueous PLP from light and its immediate 
administration after dissolution. It is generally advised to supplement with the lowest 
dose that allows seizure control.  
In order to investigate the photodegradative products of PLP and identify whether 
they could be responsible for the hepatic dysfunction in individuals receiving high-
dose PLP supplementation, LC-MS/MS was used for the analysis of photodegraded 
PLP.  
Using this technique, the qualitative confirmation of two photoproducts (PAP and a 
diketone PLP dimer) was performed. PAP formation from PLP was also quantified 
using LC-MS/MS over a time course under controlled light irradiation. The preliminary 
identification of other potential photodegradation products was carried out. The 
potential hepatotoxicity of these products and implications for the treatment of 
patients is discussed.  
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Finally, the PLP content and photodegradation rates of several commercially 
available PLP formulations were assessed in an environment that closely replicated 
the preparation of these solutions for administration to patients. Currently, patients 
are treated using over-the-counter nutraceuticals; defined as ‘Nutritional products that 
provide health and medical benefits, including the prevention and treatment of 
disease’.248 These are not subject to the same regulations that apply to 
pharmaceutical products. Currently, no pharmaceutically licensed form of pyridoxal 
5’-phosphate is available in Europe and the United States. This part of the project 
was carried out in collaboration with the UCL School of Pharmacy in order to assess 
the need for a pharmaceutical-grade PLP formulation. 
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 Characterisation of the pyridoxal 5’-phosphate 
photodegradation profile 
 Investigation and identification of pyridoxal 5’-phosphate 
photodegradants 
PLP is known to be unstable in aqueous solution at a neutral pH under light irradiation, 
undergoing rapid photolysis.106, 244 PLP photodegradation products were prepared by, 
after mixing, leaving an aqueous 1 mmol/L PLP solution in a sealed glass vial on a 
sunlit shelf for 144 hours (6 days). Samples were taken from this solution after 0, 1, 
5, 72 and 144 hours, frozen and kept in the dark at -20°C until analysis, in order to 
halt photodegradation. Previous work has shown that the photodegradation products 
of PLP differ according to the presence or absence of oxygen.244 In this study all 
solutions were oxygenated by mixing prior to incubation. All samples underwent an 
identical number of freeze-thaw cycles. After defrosting, solutions were analysed by 
Flow Injection Analysis-Mass Spectrometry. This consists of the direct infusion of the 
photodegraded PLP solutions, with no liquid chromatography separation step. This 
was carried out in order to identify potential photodegradants according to their m/z 
ratios. 
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Figure 6.1: MS1 Scan acquisitions after (a) 0 and (b) 72 h light irradiation of a 1 mmol/L PLP solution. 1 minute acquisition time. PLP = m/z 
248.0. Spectra collected using flow injection analysis-mass spectrometry (combined flow with 97.5% H2O w/ 3.7% Acetic acid + 0.01% HFBA, 2.5% Methanol) 
in positive ion mode using a cone voltage of 27 V. 
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Initial analyses were performed using a full scan with the MS1 quadrupole. At T = 0 
h, the most intense peak was detected at m/z 248.0, corresponding to the [M+H]+ ion 
of PLP (Figure 6.1a). However, at later time points mass spectra were difficult to 
interpret given the appearance of many potential PLP photodegradants over a wide 
range of m/z ratios (Figure 6.1b). All spectra also contained many unidentified peaks, 
likely related to contaminants or from the mobile phase used. For example, in Figure 
6.1a there is a peak known to correspond to an acetic acid-Fe-O complex 
([C2H4O2)6-6H+3Fe+O]) at m/z 537.8. 
Further investigation was therefore carried out using neutral loss scans pertaining to 
a loss of H3PO4 upon fragmentation (-98) (Figure 6.2). This allowed the identification 
of all compounds containing a phosphate moiety and resulted in a more easily 
interpretable mass spectrum, with the caveat that non-phosphorylated PLP 
photodegradants would not be detected. 
 
 
Figure 6.2: Neutral loss (- 98) acquisitions after (a) 0 and (b) 72 h light irradiation of a 1 mmol/L PLP 
solution. 1 minute acquisition time. Parent ions of m/z ratios -98 are shown. PLP = m/z 248.0. Spectra collected 
using flow injection analysis-mass spectrometry (combined flow with 97.5% H2O w/ 3.7% Acetic acid + 0.01% HFBA, 
2.5% Methanol) in positive ion mode and a cone voltage of 27 V. The collision energy was 16 V. 
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Several potential photodegradants were identified with an m/z of 264, 381, 397 and 
493 (Figure 6.2). The compounds at m/z 264 and 493 were postulated to correspond 
to 4-pyridoxic acid 5’-phosphate and a PLP dimer105 (Figure 6.3).  
 
 
 
 
 
 
 
 
 
Figure 6.3: Postulated PLP photodegradation products 
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Proposed analyte 
Retention 
time 
(min) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Cone 
voltage 
(V) 
Collision 
energy 
(V) 
Loss upon 
Fragmentatio
n 
?PLP Dimer 0.49 493.10 395.00 27 16 H3PO4 
4-Pyridoxic acid  
5’-phosphate 
0.82 264.07 166.07 27 16 H3PO4 
d3-pyridoxal  
5’-phosphate 
0.96 251.16 152.18 30 18 H3PO4 
Pyridoxal  
5’- phosphate 
0.96 248.00 150.01 30 18 H3PO4 
Pyridoxic Acid 1.02 184.06 147.99 18 18 2H2O 
Pyridoxal 1.08 168.10 150.05 21 12 H2O 
Compound m/z 
381 peak 1 
2.12 381.04 283.04 27 16 H3PO4 
Compound m/z 
397 
2.20 397.00 299.00 27 16 H3PO4 
Compound m/z 
381 peak 2 
2.39 381.04 283.04 27 16 H3PO4 
 
In order to confirm that several potential photodegradation products of PLP were 
formed upon exposure to light these products were quantified over the 144 h time 
period. MRM transitions were created using the precursor and product ions of the 
compounds identified, these are shown in Table 6.1. All photodegraded solutions 
were diluted to a nominal value of 100 nmol/L PLP (assuming no degradation) and 
analysed using the same LC-MS/MS method used for B6 vitamer analysis (Section 
2.4 and Section 3). Peaks derived from MRM transitions corresponding to the 
identified products were quantified by calculating the AUC for each compound at 
Table 6.1: Parameters used for the MRM-based identification of PLP, PL, PA and photodegradants of PLP. 
Transitions arranged according to retention time on LC-MS/MS analysis. d3-pyridoxal 5’-phosphate was used as an internal 
standard during later experimentation for quantification of pyridoxal 5’-phosphate and 4-pyridoxic acid 5’-phosphate. 
Compounds other than PLP, PL, PA and d3-PLP were identified using neutral loss scans of -98 as shown in Figure 6.2. 
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respective time points (Figure 6.4). Two peaks were identified for the compound with 
a parent m/z of 381; these were quantified separately. 
 
 
 
Depletion of PLP was seen over the 144 h incubation period, this is consistent with 
work of others.21, 106 A corresponding increase in several other compounds was seen; 
the two compounds with the largest signals were those with parent ions with m/z ratios 
of 264 and 493. These correspond to the predicted masses of PAP and the diketone 
dimer of PLP, respectively. The signal from the transition thought to correspond to 
Figure 6.4: Formation of PLP photodegradation products. At each data point n=1. AUC = 
area under curve. a) = known compounds; b) = postulated photodegradation products. Points 
below Y-axis graph limit were undetectable at this time point. 
a) 
b) 
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PAP increased rapidly from 0 - 1 h to an AUC of approximately 1,582,000 before 
slowing to an eventual 2,197,000 after 144 h. The signal from the compound with m/z 
of 493 increased more slowly to 139,000 after 5 h, before declining again to 86,000 
after 144 h (Figure 6.4). This could be indicative of either reversible formation of the 
diketone dimer or formation by a first step followed by subsequent degradation via a 
second step. 
A small signal derived from PL, PA, PAP and the dimer can be seen at T=0. Although 
samples were chilled and protected from light before deliberate light irradiation, the 
presence of these compounds was thought to be due to some degradation occurring 
during sample preparation.  In the case of PL, this could also be due to a small amount 
of PL as an impurity in the PLP standard (Applichem; > 98% purity by HPLC). 
The levels of pyridoxal (PL) and 4-pyridoxic acid (PA) also increased across the time 
course. It is possible that this is due to hydrolysis of PLP to PL and PAP to PA. It has 
been reported that PLP hydrolysis to PL is the most prevalent degradative mechanism 
in the absence of light irradiation at a low PLP concentration (1 µmol/L), particularly 
at a low pH.106 However, initial PLP concentrations of 1 mmol/L were used in the 
experiment shown in Figure 6.4, 1000 times higher than the concentration in the 
previously published work. PL formation in our experiment was insignificant 
compared to that of PAP and the PLP dimer, with concentrations below the limit of 
quantification (<0.5% of initial PLP at T=0).  
In order to provide additional evidence that the compound identified at m/z 264 
pertained to PAP, a flow injection analysis-mass spectrometry daughter scan of the 
1 mmol/L T=72 h photodegraded PLP solution was performed for m/z 264 and 
significant fragment ions at 246 and 166 were identified. These are hypothesised to 
correspond to [M+H-H2O]+ and [M+H-H2O-H3PO4]+, respectively (Figure 6.5).  This 
fragmentation pattern would be expected from a pyridine derivative containing a 
carboxyl group, such as PAP.249-250 
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In order to confirm the identity of this compound, a custom synthesised PAP standard 
was purchased. Fragmentation of this was compared to of the compound of m/z 264; 
the patterns were found to be identical. Furthermore, the PAP standard eluted at the 
same retention time (0.82 min) as the previously identified compound of m/z 264 on 
LC-MS/MS analysis.  
 
 
 
 
Figure 6.5: Postulated structures of MS fragments derived from m/z 264, identified as pyridoxic acid 
5’-phosphate. At each data point n=1. AUC = area under curve. a) = known compounds; b) = postulated 
photodegradation products. Points below Y-axis graph limit were undetectable at this time point. 
m/z 264 (precursor ion; PAP) 
m/z 246 m/z 166 
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 The effect of light irradiation on the rate of pyridoxal 5’-
phosphate degradation and 4-pyridoxic acid 5’-phosphate 
formation 
In order to accurately quantify the PAP formation from 1 mmol/L PLP over time, under 
conditions of light irradiation, samples were sealed and placed in a light box over a 
24 hour period. PAP and PLP were quantified using d3-PLP as an internal standard; 
similar to the methodology used in Section 3 for the quantification of B6 vitamers and 
pyridoxic acid. The 1 mmol/L PLP solutions, after light irradiation for 0, 1, 4 and 24 h 
were frozen at -20°C until LC-MS/MS analysis at which time they were diluted to a 
nominal concentration of 100 nmol/L. 
 
Quantification of PLP lost and PAP formed after 0, 1, 4 and 24 h of light irradiation is 
shown in (Figure 6.6). Percentage loss or formation was calculated as a proportion 
of the original 100 nmol/L PLP concentration with 94.7% of the total PLP lost after 24 
h of light irradiation. PAP formed over 24 h constituted only 22.7% (± 4.6), 20.2% (± 
1.8) and 27.5% (± 4.6) of the ‘missing fraction’ of PLP after 1, 4 and 24 hours, 
respectively. This confirms work by Reiber (1972) showing that photolysis of PLP 
produces mostly compounds other than PAP, such as the diketone dimer with m/z 
493. 
Figure 6.6: Percentage PLP and PAP levels after light irradiation. Error bars correspond to SEM. (n=3) 
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 Confirmation of a diketone pyridoxal 5’-phosphate dimer 
as a pyridoxal 5’-phosphate photodegradation product  
As discussed in the introduction to this chapter, this project was part of a collaboration 
with the UCL School of Pharmacy. During their investigation of photodegraded PLP 
using HPLC-UV/VIS, these collaborators identified a major degradation product 
eluting before PLP. This compound had a different retention time to that of the pure 
PAP standard. The major PLP photodegradants identified by Reiber were described 
as the ‘288 nm absorbing species’ due to their peak absorbance at this wavelength; 
the wavelength monitored during HPLC-UV/VIS analysis was 285 nm so an intense 
signal would be expected from these compounds. Collection of the HPLC eluent and 
spectrophotometric measurement between 200 – 500 nm showed that there was a 
compound that absorbed maximally at 296 nm (Figure 6.7), close to Reiber’s ‘288 
nm absorbing species’. PLP has an absorbance maximum of 388 nm and PAP 313 
nm, hence the peak is unlikely to correspond to either of these compounds.105 
 
 
Figure 6.7: Absorbance spectrum of the HPLC eluent thought to be a PLP diketone dimer. 
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It was hypothesised that this peak with a maximal absorption of 296 nm corresponded 
to the postulated PLP dimer that had an m/z of 493 and eluted at 0.49 mins using the 
LC-MS/MS method shown in Section 6.1. A fraction derived from the HPLC-UV/VIS 
peak was analysed using an MS1 scan and flow injection analysis-mass 
spectrometry. As predicted, the most abundant ion identified had an m/z ratio of 493, 
with additional peaks at m/z of 395, 297, 515 and 247 (Figure 6.8). These were 
predicted to correspond to [M+H-H3PO4]+, [M+H-2(H3PO4)]+, [M+Na]+ and [M+2H]2+ 
of the diketone dimer shown in Figure 6.3.  
This evidence provides yet further evidence that the peak at m/z 493 does indeed 
correspond to a PLP diketone dimer. However, the compound could not be accurately 
quantified as its predicted instability did not facilitate custom synthesis as for PAP. It 
is therefore unknown how much of the uncharacterised proportion of PLP photolysis 
products this dimer constitutes. This would be important future work. 
 
 
  
Figure 6.8: Mass spectrum of the eluent fraction thought to correspond to a PLP diketone dimer. 
Data collected using a MS1 scan 0 – 1000 Da; Cone voltage ramped between 0 – 27 V; Capillary Voltage = 2.5 
kV; Source temp. = 150°C; Desolvation temp. = 150°C. m/z ratios of interest highlighted as appropriate. 
[M+2H]2+ 
[M+Na]+ 
[M+H-2(H3PO4)]+ 
[M+H-H3PO4]+ 
[M+H]+ 
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 Assessment of commercially available pyridoxal 5’-
phosphate dietary supplements 
Patients treated with PLP for seizure control in Europe and the United States currently 
have to rely on over-the-counter nutraceutical products. These are subject to less 
stringent regulation than pharmaceutically licensed compounds and are not 
recommended for clinical use. Indeed companies selling these products typically 
include disclaimers on their products such as ‘This product is not intended to 
diagnose, treat, cure, or prevent any disease’ (Thorne, New York, US). The dose that 
patients receive is titrated to that which allows seizure control and is often far higher 
than the dose that would be taken as a vitamin supplement by a healthy individual. 
Variation of PLP content between products could lead to inaccurate dosage and poor 
seizure control upon change of formulation.  
We assessed the PLP content and photodegradation rate of several widely available 
nutraceutical PLP capsules/tablets from: Country Life, New York, US; Solgar, 
Aldbury, UK; Thorne, New York, US and Vitacost, Florida, US. Each brand of PLP 
was sold in capsules or tablets of 50 mg. A > 98% pure PLP standard (Applichem, 
Darmstadt, Germany) was also analysed. 
Experimentation mimicked, as closely as possible, the procedure used to prepare 
PLP supplementation of patients with PLP-dependent epilepsy. When in tablet form, 
they were ground using a mortar and pestle before dissolution in Milli-Q H2O at a 
concentration of 5 mg/mL (20.24 mmol/L PLP) and agitation for one hour in the dark 
to ensure all PLP was dissolved. Capsules were prepared by emptying the contents 
into MQH2O, before preparation as above. After dilution to a nominal 100 nmol/L, PLP 
content was assessed using the LC-MS/MS-based method for B6 vitamer 
quantification detailed elsewhere (Section 2.4).  
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Formulation Form 
PLP (mg) measured from a 50 
mg (nominal) capsule  
Pure PLP (Applichem) Powder 50.9 ±1.5 
Countrylife Tablet 3.0 ±2.0 
Solgar Tablet 43.0 ±15.7 
Thorne Capsule 60.0 ±10.0 
Vitacost Tablet 44.7 ±12.7 
 
The recovery of pure PLP was accurate, with 50.9 ±1.5 mg measured from a nominal 
50 mg (Table 6.2). However, other formulations had variable PLP content. The 
Countrylife formulation contained only 3.0 ±2.0 mg within a tablet purported to contain 
50 mg. Tablets/capsules from Solgar, Thorne and Vitacost had PLP contents of  
43.0 ±15.7, 60.0 ±10.0 and 44.7 ±12.7 mg, respectively. However, the variability of 
PLP measurement was large for these products and 50 mg was within the error of 
measurement for each of them (< 1 SD). This variability was not due to poor precision 
of the LC-MS/MS assay for PLP measurement: The coefficient of variation for PLP 
quantitation using this method was determined previously as < 5% at all 
concentrations tested (Section 4.1.2.4). It is unlikely that PLP was still bound to 
excipients in the formulations as TCA was used in the method, this cleaves PLP 
bound to proteins or other molecules, bringing PLP into solution. 
Preparations were also analysed for the presence of other B6 vitamers to ensure that 
PLP was indeed the main B6 vitamer within them. No other B6 vitamers were detected 
above the lower limit of quantification (< 0.25 mg per tablet/capsule). 
It was shown in Figure 6.5 that 94.7% of a 1 mmol/L solution of PLP was 
photodegraded after 24 hours of light irradiation. This experiment was repeated with 
a higher concentration of 5 mg/mL (20.24 mmol/L) to mimic clinical preparation, 
alongside the same nutraceutical products investigated previously (Table 6.3). Light 
irradiation was carried out at room temperature after mixing for 60 minutes in the dark 
to solubilise PLP. It was hypothesised that if PLP was bound to excipients found in 
the tablets/capsules sold as nutraceuticals, this could convey some protection from 
photodegradation. This would be analogous to the binding of PLP to albumin in the 
blood. 
Table 6.2: Quantification of PLP contained in 50 mg nutraceutical formulations.  
Error = SD; n = 3 tablets/capsules analysed. 
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Formulation Form PLP lost (% of initial PLP) 
PAP Formed (% of PLP 
lost) 
Pure PLP 
(Applichem) 
Powder 83.5 ±2.7 27.5 ±0.7 
Countrylife Tablet > 91.7*  22.9 ±10.2 
Solgar Tablet 81.2 ±3.7 23.1 ±5.3 
Thorne Capsule 78.4 ±9.3 26.6 ±11.5 
Vitacost Tablet 84.0 ±11.1 18.7 ±10.6 
 
No significant difference (p < 0.05) was identified when comparing the rate of PLP 
photodegradation or PAP formation between any of the formulations studied. A pure 
PLP solution at 20.24 mmol/L revealed a slightly lower photodegradation rate at 
83.5% after 24 hours compared to 94.7% from a 1 mmol/L solution. This correlates 
with previous reports that PLP photolysis occurs at a slower rate at higher 
concentrations.244 The proportion of PAP formed as a percentage of PLP lost was 
identical in the 20.24 and 1 mmol/L solutions, at 27.5%. 
One limitation of the work detailed in this section is the wide variability between 
repeated analyses of each product. Vials were divided into separate 2.5 ml vials for 
light irradiation. Insoluble excipients were present in all of the formulations, these 
were homogenised before division. It is possible, if PLP was bound to excipients in 
the formulations, that an uneven amount of PLP was divided between these vials due 
to incomplete homogenisation, accounting for the variability identified. This is 
supported by accurate recovery of the pure PLP solutions; these were fully dissolved 
and contained no excipients.  
Further investigation into the composition of commercially available PLP nutraceutical 
products was carried out by the aforementioned collaborators at the UCL School of 
Pharmacy and is detailed in our recently published manuscript.104 
Table 6.3: Proportion of PLP lost and PAP formed on light irradiation of 5 mg/mL PLP formulations. 
Error = SD; N = 3. *For the Countrylife tablet, PLP lost was expressed as > 91.7% as remaining PLP after 24 hours 
light irradiation was below 0.25 mg, meaning more than 91.7% of the original 3.0 mg had been 
photodegradation. Light irradiation was for 24 hours. 
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 Discussion & future work 
The confirmation of PAP and a diketone PLP dimer as photodegradants of PLP was 
a useful step towards determining the pathogenic mechanism behind liver damage in 
PNPO deficient individuals receiving PLP for seizure treatment. It appeared that a 
large proportion of degraded PLP was unaccounted for by PAP formation and that 
other uncharacterised and potentially hepatotoxic photodegradants are produced.  
Morrison and Long244 observed the formation of a dihydroxy PLP dimer in place of a 
diketone dimer upon the light irradiation of PLP in the absence of oxygen. No 
evidence of this dihydroxy dimer was identified in our work. Indeed, prior to the 
incubation of PLP, each mixture was stirred for 30 – 60 minutes to ensure that all PLP 
was in solution. This likely oxygenated the solution and made dihydroxy dimer 
formation undetectable. Morrison and Long created an oxygen-free solution by 
purging with nitrogen gas. 
PAP is known to inhibit transaminases and could potentially be hepatotoxic.33, 251-252 
However, it is unlikely to cross the gut barrier before hydrolysis to PA, the natural 
excretory product of vitamin B6 in humans. PAP is therefore unlikely to cause the 
hepatic cirrhosis seen in patients on high doses of PLP. As PAP accounts for only 20-
30% of the PLP photodegradatants, it does not rule out the implication of another 
compound.  
A study at the Department of Pharmaceutical and Pharmacological Sciences in 
Leuven, Belgium, has recently been published regarding the identity of the additional 
degradation products.253 That study closely mirrored our work and further confirmed 
the formation of PAP and a diketone dimer upon the photodegradation of PLP. They 
also identified 4-pyridoxolactone (m/z 166) as a degradation product and proposed 
several others, including one that may explain the identity of the ion of m/z 381 in our 
study. However, they did not quantify these compounds or determine their potential 
hepatotoxicity.  
In the future, determining whether the PLP photodegradants identified are present in 
the blood of patients receiving high-dose PLP supplementation would be a priority. 
This would help determine whether they could be hepatotoxic and indeed whether 
they are even absorbed after oral ingestion.  
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The most severe example of hepatotoxicity in a PNPO deficient patient is that of a 
13-year-old who, after chronic liver dysfunction, developed hepatocellular carcinoma 
on PLP supplementation of > 50 mg/kg/d (unpublished communication). Otherwise this 
individual was healthy and developmentally normal. The patient received a liver 
transplant; it was hoped a healthy liver with intact PNPO activity would reduce PLP 
dependency and facilitate a move towards PN supplementation. However, the patient 
remained PLP dependent at a similar dose (both intravenous and oral; withdrawal or 
weaning produced seizures) and did not respond to PN supplementation. This 
indicates the importance of organ-specific rather than systemic B6 metabolism in 
providing adequate PLP to the brain. 
The fate of the donor liver given to this individual will be interesting. If damaged over 
time, high B6 vitamer concentrations or PLP photodegradants would be implicated in 
the liver pathology. If not, it would indicate that the PNPO deficiency itself is causative. 
A combination of these factors is perhaps likely. For example, it is known that high 
PNP and PMP levels are present in the blood of PNPO deficient patients. If these 
were causing liver damage, in a liver with intact PNPO activity these could be 
metabolised to PLP and eventually excreted as PA, sparing the liver. It is known that 
high concentrations of PN can inhibit PLP-dependent enzymes, this is thought to be 
the mechanism behind pyridoxine-induced peripheral neuropathy.110 It remains to be 
seen whether any PNPO-deficient patients receiving PN for seizure treatment 
develop liver dysfunction, to our knowledge however this has not yet been seen. 
Part of the difficulty identifying the pathology behind hepatic dysfunction in these 
PNPO deficient patients is that most known individuals are still in childhood due to 
the relatively recent discovery of PNPO deficiency as an inborn error of metabolism. 
Indeed, this work is given greater urgency by the worry that, as these patients age, 
hepatic dysfunction could become a more common presentation. In addition, it 
appears that at least some PNPO deficient patients can have a good quality of life 
with no developmental delay if treated appropriately.65, 87 Making this treatment safe 
would be a major step towards the long-term wellbeing of these individuals.  
A priority would be the development of a reliable pharmaceutically licensed formation 
of PLP, to ensure accurate dosage. For example, the low amounts of PLP solubilised 
in the product sold by Countrylife is particularly dangerous, given that non‐response 
to these supplements can be taken to be diagnostically indicative of a seizure disorder 
that does not respond to PLP.  
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 THE IDENTIFICATION OF NOVEL GENETIC 
CAUSES OF VITAMIN B6-RESPONSIVE EPILEPSY 
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Since the identification of vitamin B6-dependent epilepsy by Hunt et al. over 60 years 
ago240, considerable effort has been spent identifying the underlying genetic causes 
of these inherited disorders. In the last 15 years, mutations in the ALDH7A1, PNPO 
and PLPBP genes have been identified as being causative of B6-dependent 
epilepsies. However, it has become clear that variants in these genes cannot explain 
all the seizure disorders that are treatable by vitamin B6 supplementation. Wang et al. 
showed that 11/94 patients with idiopathic intractable epilepsy showed a dramatic 
and sustained response to PLP supplementation.113 Ohtahara et al. reported that a 
similar proportion of individuals with West Syndrome responded to vitamin B6 
supplementation (13.9% of 216 individuals) and that treatment was effective in 
patients both with and without identifiable brain pathologies.114 In Japan vitamin B6 
supplementation is used more widely than in Europe or the US with 67.4% of 
institutions using vitamin B6 as the first choice drug for the treatment of West 
Syndrome.254 
It is currently uncertain whether the anti-epileptic effect of pharmaceutical doses of 
vitamin B6 is because higher PLP levels allow the brain to better control 
concentrations of excitatory and inhibitory neurotransmitters at the synapse (see 
Section 1.1), or whether other mechanisms are responsible. For example, it is 
possible that the neuroinflammation caused by ATP-mediated activation of P2X7 
receptors is antagonised by high PLP concentrations thus halting the feedback loop 
of neuronal inflammation caused by ATP release that can lead to the kindling of 
further seizures.48-50  
Understanding the mechanism behind the anticonvulsant effect of vitamin B6 could 
help us to understand which genetic epilepsies are likely to benefit from vitamin B6 
supplementation as their mechanisms can vary wildly. For example, if B6 was effective 
as a sodium channel agonist/antagonist this treatment could be useful in 
channelopathies such as SCN1A-related epilepsy (MIM: [182389]) but less so in 
mTORopathies causing structural changes (e.g. focal cortical dysplasia) such as focal 
epilepsy due to DEPDC5 mutations (MIM: [614191]). 
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 Investigation of individuals with B6-responsive epilepsy 
using next generation sequencing technology 
Genetic causes are thought to be responsible for 70 – 80% of epilepsy cases.255 
Currently, the first stage of genetic testing is often targeted sequencing of specific 
candidate genes or a gene panel containing a number of potential candidate genes.256 
If this is unsuccessful in achieving a diagnosis, it is possible to use either whole exome 
or whole genome sequencing (WES or WGS) to identify a genetic basis for the 
patient’s seizures. This is important for the identification of novel genetic disorders  
and valuable in providing a diagnosis for the patients and their families.257 In addition, 
NGS technologies can identify mutations that are not found using more targeted 
techniques (e.g. intronic variants).258 For these reasons, as well as continually 
diminishing prices as the technology matures, the use of WES and WGS as a first-
line diagnostic tool for epilepsy is increasing.259  
This chapter describes the investigation of five individuals with vitamin B6-responsive 
epilepsy using whole exome/genome sequencing. These patients had thus far 
escaped diagnosis by more targeted approaches. It was hoped that novel disorders 
conveying B6-responsive epilepsy would be identified through the investigation of 
potentially pathogenic variants in these individuals; thereby providing a diagnosis for 
these patients. 
After filtering according to parameters detailed in Section 7.1.1, the variants predicted 
as potentially pathogenic in these individuals were manually assessed. Specific 
attention was paid to variants in genes encoding proteins associated with vitamin B6 
metabolism, known/predicted epileptic loci and PLP-dependent enzymes.  
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 Assessment of variants identified using NGS technology that 
could lead to B6-dependent epilepsy 
DNA was extracted from whole blood. In four cases (Subjects NGS1, NGS2, NGS4 
and NGS5), the DNA was sequenced by the Universitair Medisch Centrum Groningen 
(UMCG). In one case (Subject NGS3), data was sent to BGI Genomics (Hong Kong) 
for sequencing, in collaboration with GOSgene (UCL GOS Institute of Child Health). 
In all cases, the raw data was processed and aligned by GOSgene (UCL GOS 
Institute of Child Health). All patients included in this study presented with a previously 
intractable seizure disorder that responded to vitamin B6 supplementation. In all 
cases, known causes of B6-dependent epilepsy were already excluded either 
genetically or biochemically (e.g. ALDH7A1, PLPHP, PNPO deficiencies, 
hypophosphatasia). 
The QIAgen Ingenuity Variant Analysis (IVA) pipeline was used in order to assess the 
pathogenicity of each variant identified. This utilises a cascade of filters in order to 
exclude variants that are unlikely to be pathogenic, leading to the identification of a 
relatively small number of variants that can then be manually assessed. Typically, for 
WGS, this results in the reduction of variants identified from >5,000,000 to <10, 
depending on the exact parameters used for filtering. Figure 7.1 gives a summary of 
these filters and the default parameters used for analysis can be found in Section 
2.11.   
Whereas the first three layers in the filtering cascade (i.e. ‘call confidence’, ‘common 
variants’ and ‘predicted deleterious’) were kept consistent, the filters for inheritance 
and for biological context were adjusted for each patient. Where available, parental 
DNA was compared to that of the patients in order to identify the mode of inheritance. 
The genes interrogated with regard to biological context included, unless specified: i) 
a list of 112 genes known to use vitamin B6 as a cofactor or implicated in vitamin B6 
metabolism ii) 73 genes on the early infantile epileptic encephalopathy (EIEE) panel 
used by GOSH iii) 237 genes known to code for ion channels in the human genome. 
A complete list of these genes can be found in the appendix (Section 9.2). 
Visualisation of identified variants was carried out using the Intregrated Genomics 
Viewer (IGV) software package in order to exclude sequencing artefacts that were 
not automatically excluded by IVA. 
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The following Sections 7.1.1.1 – 7.1.1.4 describe the five patients with B6-responsive 
epilepsy investigated using NGS technologies. A brief case report of each individual 
is included before a summary of the potentially pathogenic variants identified and a 
discussion of these variants within the context of their disorders.  
 
 
 
 
Figure 7.1: Summary of the filter cascade used for variant analysis. Blue boxes = level of the filter 
cascade; filtering is carried out sequentially from top to bottom. Green boxes = description of the parameters 
used at each level of filtering. More detailed parameters for each filter can be found in Section 2.11. Analysis 
performed using the QIAgen Ingenuity Variant Analysis software tool. AFC = Allele Frequency Community; ExAC 
= Exome Aggregation Consortium; GnomAD = Genome Aggregation Database; CADD = Combined Annotation 
Dependent Depletion; SIFT = Sorting Intolerant from Tolerant; AMCG = American College of Medical Genetics. 
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7.1.1.1 Subject NGS1 
The following clinical and biochemical data was provided by the treating clinician at 
the Universitair Medisch Centrum Groningen (UMCG), The Netherlands. WGS data 
was provided to us by the UMCG in order to assist in the diagnosis of this patient. No 
parental WGS data was supplied so filtering according to inheritance was not 
possible. However, parental DNA was available so where appropriate segregation 
could be checked using Sanger sequencing. 
Subject NGS1 was a male born at 35 weeks whose seizures began hours after birth. 
Brain MRI was normal. Seizures did not resolve with midazolam. At day 4 IV 
pyridoxine was introduced (dose unknown). At day 6 EEG showed less intensive 
multifocal epileptic features than an earlier EEG. At day 8 he was switched from 
pyridoxine to oral pyridoxal 5’-phosphate (30 mg/kg/day). Over the next several days 
he improved clinically with fewer seizures. At day 10 levetiracetam was introduced. 
Thereafter, seizures have been well controlled with breakthrough seizures treated by 
increases of levetiracetam dosage. 
Biochemical studies in the neonatal period at the UMCG showed normal plasma 
alkaline phosphatase and urinary α-AASA (0.3 μmol/mmol creatinine), excluding 
hypophosphatasia and pyridoxine-dependent epilepsy due to mutations in ALDH7A1, 
respectively. PNPO and PLPHP deficiencies were also excluded by sequencing the 
PNPO and PLPBP genes. At day 6, when the patient was receiving pyridoxine 
supplementation, CSF analysis showed low tyrosine (1 μmol/L; ref 11-53 μmol/L) and 
slightly low homovanillic acid (HVA) (419 nmol/L; ref 543 – 1102 nmol/L). 5-
hydroxyindoleacetic acid (5-HIAA) was normal. Concentrations of other 
neurotransmitters and amino acids were normal. Low HVA could indicate PLP 
deficiency through a secondary AADC deficiency but low tyrosine and normal 5-HIAA 
dispute this conclusion. 
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B6 vitamer 
Concentration nmol/L 
(ref. range) 
Pyridoxal 5’-phosphate 16.5 (7-23) 
Pyridoxamine 5’-phosphate ND (0-0) 
Pyridoxal 6110 (12-48) 
Pyridoxine 2700 (0-0) 
Pyridoxamine 84 (0-0.1) 
Pyridoxic acid 629 (0.4-15.5) 
 
CSF B6 vitamers were also measured at this stage at the UMCG (Table 7.1). As the 
patient was receiving pyridoxine supplementation of an unknown dose, it was difficult 
to draw definitive conclusions from B6 vitamer concentrations. However, it was 
intriguing that the concentrations of pyridoxal, pyridoxine, pyridoxamine and pyridoxic 
acid were raised well above reference ranges but PLP was within the normal range. 
Although not as high as other vitamers, CSF PLP is usually raised in patients 
receiving pyridoxine supplementation.260 A very high pyridoxal/pyridoxal 5’-phosphate 
ratio could indicate pyridoxal kinase deficiency; this was investigated during NGS 
analysis but no abnormalities were found in the PDXK gene or in the PAR bZip 
transcription factors (DBP, HLF and TEF), known to modulate the expression of 
PDXK. 
Data was analysed using the IVA pipeline (Section 2.11) and nine variants 
considered most likely to cause this patient’s B6-responsive seizures were identified 
(Table 7.2).  
One variant identified was the heterozygous change c.6471C>A in CACNA1A. The 
CACNA1A gene encodes a protein subunit of the P/Q-type calcium channel. 
Autosomal dominant mutations in CACNA1A are known to cause several disorders 
including familial migraines [MIM: 141500], episodic ataxia [MIM: 108500] and early 
Table 7.1: CSF B6 Vitamers and pyridoxic acid concentrations 
in Subject 1. ND = not detected. Subject 1 was receiving pyridoxine 
supplementation. 
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infantile epileptic encephalopathy [MIM: 617106]. Furthermore, there is one report of 
a patient with a de novo variant in CACNA1A with absence seizures treatable by 
pyridoxine supplementation.261 This evidence alongside the fact that this variant had 
not previously been seen in GnomAD led to the further investigation of the possible 
pathogenicity of this variant. However, the missense change caused by c.6471C>A 
is relatively mild (aspartic acid > glutamate), introducing just one additional CH2 in the 
amino acid side-chain. Accordingly, this variant was predicted tolerated/benign by the 
SIFT/Polyphen variant pathogenicity analysis tools, respectively. Sanger sequencing 
of parental DNA revealed that the heterozygous c.6471C>A variant was inherited 
maternally and was not a de novo variant. The optimised primers and conditions used 
for this analysis can be found in the appendix (Section 9.1). Episodic ataxia caused 
by mutations in CACNA1A is known to have incomplete penetrance.262 However, in 
this case with the relatively severe clinical presentation, it was considered unlikely 
that this CACNA1A variant was causing the severe neonatal epileptic phenotype of 
Subject NGS1. 
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Gene 
Mutation; 
Amino 
acid 
change 
Zygosity 
Prevalence; gnomAD 
(no. of 
homozygotes) 
Protein function  
[UniProtKB – ref] 
SIFT/Polyphen 
prediction 
Most relevant disease association 
& observations 
CACNA1A 
c.6471C>A; 
p.D2157E 
Heterozygous Novel 
Voltage-dependent P/Q-type calcium 
channel subunit 
[UniProtKB - O00555] 
SIFT: Tolerated 
Polyphen: Benign 
Autosomal dominant epileptic 
encephalopathy. Also linked to migraines 
and episodic ataxia (MIM: [601011]). 
SLC15A5 
c.1403T>C; 
p.M468T 
Homozygous 
 
0.002% 
(0 homozygotes) 
Protein oligopeptide cotransporter 
(proton symporter) 
[UniProtKB - A6NIM6] 
SIFT: Damaging 
Polyphen: Probably 
damaging  
Unknown - mostly uncharacterised protein. 
50% homology to other SLC15 proteins. 
Poor expression in almost all tissues 
studied.263 Gene only present in 
vertebrates. Met468 not conserved in 
zebrafish. 
ZIC1 
c.761C>T; 
p.T254M 
Heterozygous Novel 
Acts as a transcriptional activator. 
Involved in neurogenesis. 
[UniProtKB – Q15915] 
SIFT: Damaging 
Polyphen: Probably 
damaging 
Autosomal dominant craniosynostosis and 
intellectual disability – but not linked to 
seizures (MIM: [616602]). 
GRIK3 
c.2599C>T; 
p.R867C 
Heterozygous 0.002% (0 homozygotes) 
Glutamate receptor ionotropic, 
kainate 3 
[UniProtKB – Q13003] 
SIFT: Tolerated 
Polyphen: Possibly 
damaging 
Autosomal recessive GRIK2 mutations cause 
developmental delay. In addition, het 
deletion of GRIK3 is linked to 
developmental delay.264  
Table 7.2: Candidate variants that may be causative for the B6-responsive seizures of Subject NGS1. Variants identified using whole genome sequencing. Data filtered according 
to the parameters defined in Sections 2.11 & 9.1. Ppi = inorganic pyrophosphate; ECM = extracellular matrix; PIP = phosphatidylinositol phosphate  
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PI4KB 
c.110T>G; 
p.V37G 
Heterozygous Novel 
Phosphatidylinositol 4-kinase beta – 
first committed step in PIP synthesis 
[UniProtKB – Q9UBF8]  
SIFT: Damaging 
Polyphen: Benign – 
often V>L or A 
Not linked to disease but a well-conserved 
gene – Loss of function and missense 
variants are rare. 
RUBCN 
c.3050T>G; 
p.L1017R 
Heterozygous 0.033% (0 homozygotes) 
Negatively regulates PI3K complex II 
(PI3KC3-C2) function in autophagy – 
late endosome maturation 
[UniProtKB – Q92622]  
SIFT: Damaging 
Polyphen: Probably 
damaging 
Spinocerebellar ataxia, autosomal recessive. 
(MIM: [613516]). Also causes 
developmental delay and epilepsy but 
heterozygotes unaffected. 
TRIM9 
c.265A>C; 
p.T89P 
Heterozygous Novel 
E3 ubiquitin-protein ligase; may play 
a role in regulation of neuronal 
functions 
[UniProtKB – Q9C026]  
SIFT: Tolerated 
Polyphen: Benign 
 
Not linked to disease but a well-conserved 
gene – loss of function and missense 
variants are rare. 
ANKH 
c.959C>T; 
p.T320M 
Heterozygous 0.001% (0 homozygotes) 
Regulates intra- and extracellular 
levels of inorganic pyrophosphate 
(PPi), probably functioning as PPi 
transporter. 
[UniProtKB – Q9HCJ1]  
SIFT: Damaging 
Polyphen: Possibly 
damaging 
 
Extrudes intracellular PPi to the ECM. 
Mutations cause craniometaphyseal 
dysplasia and chondrocalcinosis (autosomal 
dominant). (MIM: [605145])   
NOTCH1 
c.508A>G; 
p.K170E 
Heterozygous Novel 
Signalling and cell fate during 
development. 
[UniProtKB – P46531]  
SIFT: Damaging 
Polyphen: Possibly 
damaging 
Autosomal dominant Adams-Oliver 
syndrome (aplasia cutis congenita + 
terminal limb defects) (MIM: [190198]) - 
specific phenotype with no epilepsy. 
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The segregation of c.1403T>C (p.M468T) in SLC15A5 was analysed using Sanger 
sequencing. Primers were designed and optimised for analysis; conditions can be 
found in the appendix (Section 9.1). Both parents were heterozygous for this variant 
and Subject NGS1 was confirmed homozygous, fitting a classical autosomal 
recessive inheritance pattern. No homozygotes have been reported in GnomAD 
(0.002% allele frequency) and the variant is predicted to be damaging by both SIFT 
and Polyphen. To our knowledge, no pathogenic variants in SLC15A5 have been 
previously identified that lead to B6-responsive seizures or indeed any other disorder.  
The protein encoded by SLC15A5 has been assigned, by sequence similarity, to a 
family of 5 promiscuous di/tripeptide transporters and likely has a similar function, 
though this has not been characterised. Orthologues of the gene are present in all 
vertebrates but SLC15A5 is poorly expressed in all human tissues studied.263   
Functional studies are therefore needed to elucidate the function of the SLC15A5 
transporter and whether it has a role in the metabolism of vitamin B6. However, the 
closely related SLC15A3 & 4 transporters are known to transport histidine as well as 
di/tripeptides.265 SLC15A4 transports carnosine, a histidyl dipeptide and effective 
carbonyl scavenger.266 Carbonyl scavengers are depleted in PLPHP deficiency, 
presumable due to their reaction with ‘unprotected’ PLP. If SLC15A5 also transports 
histidyl dipeptides such as carnosine these could be accumulating and producing a 
localised PLP deficiency by reacting with free PLP. 
In addition, PLP is the cofactor for histidine decarboxylase (HDC), the enzyme 
responsible for histidine conversion to histamine (Table 1.1). Autosomal dominant 
mutations in HDC are linked to Tourette syndrome.267  It is feasible that a tissue-
specific histidine or histamine deficiency caused by impaired histidine transport (due 
to impaired SLC15A5 function) could manifest as a neurological disorder treatable by 
vitamin B6 supplementation, though this remains purely speculative.  
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7.1.1.2 Subject NGS2 
Less clinical and biochemical information is available for this patient. They presented 
with intractable seizures within hours of birth up to the age of 1.5 years, culminating 
in up to 30 seizures per day. The patient was severely developmentally delayed, with 
no psychomotor development. The only treatment thought to have any effect on 
seizure frequency was PLP supplementation. This was eventually stopped due to 
excessive vomiting, a documented side-effect of oral PLP administration.104 
Parental DNA was not available for analysis via the WGS pipeline. It was therefore 
not possible to filter variants according to inheritance for this individual. Otherwise, 
standard filters were used for analysis through the IVA pipeline. The seven best 
candidate variants are detailed in Table 7.3. 
The variant considered most likely to be pathogenic in this patient was identified in 
the GABRD gene. This was a heterozygous missense change, c.1156A>T (p.N386Y). 
This variant has been reported only once previously, in heterozygote form, in gnomAD 
(238,052 alleles). It is predicted to be damaging by SIFT but benign by Polyphen. 
Heterozygous GABRD variants have previously been linked to epilepsy susceptibility; 
GABRD encodes the δ-subunit of the GABAA receptor.268 Given the important 
function PLP has as a cofactor for the biosynthesis and degradation of GABA, it is 
feasible that epilepsy caused by GABA receptor dysfunction would respond to vitamin 
B6 supplementation. Parental DNA was not available to confirm whether the variant 
was de novo and hence more likely to be considered pathogenic; this has been 
previously suggested as the mode of inheritance for GABRD-related epilepsy. This 
analysis emphasises the importance of parental DNA for the diagnosis of genetic 
epilepsies, particularly as many of these disorders are caused by de novo 
heterozygous mutations.
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Table 7.3: Candidate variants for the B6-responsive seizures of Subject NGS2. Variants identified using whole genome sequencing. Data filtered according to the parameters defined 
in Sections 2.11 & 9.1. GEFS+ = Generalized epilepsy with febrile seizures plus; kb = 1,000 base pairs. CoA = Coenzyme A; ADP = adenosine diphosphate; A3,5BP = adenosine 3’,5’-bisphosphate. 
Gene 
Mutation; 
Amino 
acid 
change 
Zygosity 
Prevalence; 
gnomAD (no. of 
homozygotes) 
Protein function 
[UniProtKB – ref] 
SIFT/Polyphen 
prediction 
Most relevant disease association & 
observations 
GABRD 
c.1156A>T; 
p.N386Y 
Heterozygous 
0.001% 
(0 homozygotes) 
GABA(A) receptor subunit 
delta 
[UniProtKB – O14764] 
 
SIFT = Damaging 
PolyPhen = Benign 
Dibbens et al.268 found heterozygous 
mutations in GABRD (E177A + R220H) in two 
families with GEFS+ and identified them as 
susceptibility factors for generalised epilepsy 
(MIM: [137163]).  
CPZ 
c.817C>T; 
p.R273C,  
Homozygous 
0.092% 
(1 homozygote) 
Cleaves substrates with C-
terminal arginine residues 
[UniProtKB – Q66K79] 
SIFT = Probably damaging 
PolyPhen = Possibly 
damaging  
Low CPZ activity interrupts the effect of 
thyroid hormone on alkaline phosphatase 
and Col10a1 expression.269 
TRIM17 
c.525+2T>G; 
predicted to 
affect 
splicing + 
c.525+6T>G; 
predicted to 
affect 
splicing 
Compound 
heterozygous 
0.081%; 0.008% 
(0 homozygotes;            
0 homozygotes) 
E3 ubiquitin-protein ligase 
[UniProtKB – Q9Y577] 
+2, +6 splice site mutations 
so not analysed using 
SIFT/Polyphen 
 +2 predicted damaging, +6 
not damaging when using the 
human splicing finder tool.194 
Thought to control neuronal apoptosis + 
autophagy. 
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TRIM21 
c.1055A>G; 
p.E352G 
Heterozygous 
0.013% 
(0 homozygotes) 
E3 ubiquitin-protein ligase 
[UniProtKB – P19474]  
SIFT = Damaging 
PolyPhen = Possibly 
Damaging 
TRIM21 is thought to ubiquitinate proteins, 
leading to protein degradation.270 
SLC25A42 
c.499T>G; 
p.Y167D 
Heterozygous 
0.021% 
(0 homozygotes) 
Mitochondrial CoA/ADP or 
A3,5BP cotransporter (CoA 
import) 
[UniProtKB – Q86VD7]  
SIFT = Damaging 
PolyPhen = Possibly 
Damaging 
Deficiency causes a newly identified 
mitochondrial myopathy271 (MIM: [610823]) 
ANK2 
c.6884C>T; 
p.T2295I 
Heterozygous Novel 
Required for proper 
localisation of several ion 
channels in the heart and in 
rod photoreceptors 
[UniProtKB – Q01484] 
SIFT = Tolerated 
PolyPhen = Benign 
Linked to cardiac dysfunction + long QT 
syndrome but no direct epilepsy link (MIM: 
[106410]). 
SLC6A3 
(DAT1) 
c.1676>T; 
p.A559V 
Heterozygous 
0.042% 
(0 homozygotes) 
Dopamine transporter. 
Terminates the action of 
dopamine by its high affinity 
sodium-dependent reuptake 
into presynaptic terminals 
[UniProtKB – Q01959] 
SIFT = Tolerated 
PolyPhen = Benign 
Homozygous mutations lead to neonatal 
dystonia/hypotonia, in one case 
misdiagnosed as EE.272 Leads to high HVA and 
high HVA/5-HIAA ratio. Inheritance is 
autosomal recessive although in one patient 
was as a result of an 8.1kb deletion (MIM: 
[126455]). 
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7.1.1.3 Subject NGS3 
Subject NGS3 was a patient treated at Great Ormond Street Hospital (GOSH). She 
was hypotonic from birth with stereotypic movements, microcephaly and infantile 
spasms with a spike-wave pattern rather than the more common hypsarrhythmia on 
EEG analysis. The patient was also developmentally delayed. Seizures were 
resistant to standard antiepileptic drugs but well controlled by PLP supplementation. 
The use of PLP appeared to improve developmental progress but delay was still 
apparent. Known genetic causes of vitamin B6-dependent epilepsy (mutations in 
PNPO, ALDH7A1, PLPBP) were excluded through genetic testing and the GOSH 
early infantile epileptic encephalopathy (EIEE) gene panel did not reveal any 
causative mutations.  
WGS analysis was performed as described previously. Maternal DNA was also 
analysed and filtering was therefore adjusted according to predicted inheritance 
patterns. Paternal DNA was unavailable for both initial WGS and Sanger sequencing 
to study the segregation of identified variants. The seven candidate variants identified 
are summarised in Table 7.4. The variants thought most likely to lead to the 
phenotype are discussed in more detail below. None of these variants are in genes 
known to be directly linked to vitamin B6 metabolism. 
Two potentially deleterious heterozygous variants were identified in the SLC4A3 
gene. This encodes a widely expressed Cl-/HCO3- anion exchange protein, known to 
be particularly important for regulating the intracellular pH of neurones. A known 
variant in SLC4A3 is linked to epilepsy in humans273 and in mice disruption of this 
gene leads to a reduced seizure threshold.274 Although poorly understood, 
dysregulation of intracellular pH is thought to lead to the promotion of neuronal 
hyperexcitability.275 The SLC4A3 variants identified were c.815A>G (p.H272R) and 
c.-318_-306delCCGCGCGTGGGGG, both variants were heterozygous. c.815A>G is 
a novel missense variant, not reported in GnomAD and predicted to be damaging by 
both Polyphen and SIFT. c.-318_-306delCCGCGCGTGGGGG is also not reported in 
GnomAD and lies in a gene regulatory area, according to the USCS genome browser.  
It is possible that these variants together could be pathogenic as the result of a 
compound heterozygous inheritance pattern (one variant from each parent). 
However, maternal DNA showed that neither of these variants were present in 
heterozygous form, excluding this mode of inheritance. It remains possible that one 
253 
 
 
of these variants was inherited from the father of Subject NGS3 while the other was 
de novo. However, paternal DNA was not available to confirm or exclude this 
possibility. 
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Table 7.4: Candidate variants for the B6-responsive seizures of Subject NGS3. Variants identified using whole genome sequencing data filtered according to the parameters defined 
in Sections 2.11 & 9.1. TFAP2A = Transcription factor AP-2 alpha. 
Gene 
Mutation; 
Amino 
acid 
change 
Zygosity 
Prevalence; 
gnomAD (no. of 
homozygotes) 
Protein function 
[UniProtKB – ref] 
SIFT/Polyphen 
prediction 
Most relevant disease association & 
observations 
SLC4A3 
(AE3) 
c.815A>G;p.
H272R + c.-
318_-
306delCCGC
GCGTGGGG
G 
Compound 
heterozygous 
c.815A>G;p.H272R  = 
novel 
 
c.-318_-
306delCCGCGCGTGG
GGG =  0.014% 
(0 homozygotes) 
Mediates neuronal pH via 
CL-/HCO3- exchange. 
 
[UniProtKB – P48751] 
(c.815A>G;p.H272R) : 
 SIFT = Damaging;  
PolyPhen = Probably damaging. 
(c.-318_-
306delCCGCGCGTGGGGG) lies 
at a TFAP2A binding site. 
Linked to epilepsy through the regulation of 
intracellular pH of neurones but no patients 
identified with pathogenic SLC4A3 variants.273-
275 
ALG13 
c.2338T>G; 
p.L780V 
Homozygous 
0.012% 
(0 homozygotes; 20 
hemizygotes) 
Glycosylation and possibly 
deubiquitination. 
 
[UniProtKB – Q9NP73] 
SIFT = Tolerated 
PolyPhen = Likely Benign 
Congenital disorder of glycosylation (MIM: 
[300776]) – X-linked dominant mutations can 
lead to early infantile epileptic encephalopathy.  
GRK2 
c.859G>A, 
p.G287R 
Heterozygous 
(not found in 
mother - ?de 
novo if not 
inherited from 
father) 
Novel 
Responsible for short-
term desensitization of 
the potassium channels 
GIRK1 (KCNJ3; MIM: 
[601534]) and GIRK4 
(KCNJ5; MIM: [600734]). 
 
[UniProtKB – P25098] 
SIFT = Damaging 
Polyphen = Probably Damaging 
Low levels induce glutamate-mediated 
neuronal death in a cell model.276 However, in 
mouse models only linked to cardiac 
dysfunction.277 
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RAB5A 
c.313C>T; 
p.Q105* 
Heterozygous Novel 
Required for the fusion of 
plasma membranes and 
early endosomes. GTP 
regulated. RAB5B very 
similar. 
 
[UniProtKB – P20339] 
Stop gain 
Not currently implicated in any disorder. 
Important in endosome 
formation/phagocytosis (MIM: [179512]). 
COL14A1 
c.2444G>A; 
p.G815D 
Homozygous 
(mother 
heterozygous) 
0.002%  
(0 homozygotes) 
Large structural 
glycoprotein (1,000kD) of 
the interstitial ECM. 
 
[UniProtKB – Q05707] 
SIFT = Damaging 
Polyphen = Probably Damaging 
None known (MIM: [120324]). 
SMYD2 
c.875G>A; 
p.R292Q 
Homozygous 
(mother 
heterozygous) 
 
0.021%  
(0 homozygotes) 
Protein-N-Lysine 
methyltransferase that 
methylates both histone 
and non-histone proteins. 
 
[UniProtKB – Q9NRG4] 
SIFT = Tolerated 
Polyphen = Benign 
None – possible oncogene (MIM: [610663]). 
CHRNE 
c.313G>A; 
p.V105M 
Heterozygous 
(?de novo) 
Mother = wild-
type allele 
0.002%  
(0 homozygotes) 
Subunit of acetylcholine 
receptor. 
 
[UniProtKB – Q04844] 
SIFT = Damaging 
Polyphen = Possibly Damaging 
Mutations can cause myasthenia. Usually 
autosomal recessive but can be autosomal 
dominant. No epilepsy link (MIM: [100725]). 
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Another candidate variant identified was a homozygous c.2338T>G (p.L780V) 
change in the ALG13 gene. This gene is on the X chromosome. The protein encoded 
by ALG13 is involved in glycosylation and X-linked dominant variants are known to 
lead to early infantile epileptic encephalopathy (MIM: 300884). The mother of this 
individual however was heterozygous for the variant suggesting that it is unlikely to 
be cause of Subject NGS3’s disorder as inheritance of two alleles would require the 
father to be hemizygous. However, upon further investigation by our collaborators 
from GOSgene, a large run of homozygosity (ROH) of approximately 50 Mb was 
identified in the same area as ALG13. This ROH spanned from bases 79,675,080-
129,174,142 on chromosome X in the Homo sapiens (human) genome assembly 
GRCh37 (hg19).  
Usually, a ROH of this size would indicate a large deletion, leading to hemizygosity 
of this region of the chromosome. However, analysis by GOSgene showed that there 
was no drop in the read depth of this region in the patient compared to the mother. 
This indicated segmental isodisomic uniparental disomy (UPD) of the region rather 
than a large deletion. Segmental isodisomic UPD is a phenomenon whereby a section 
of a chromosome is inherited from a single chromosome derived from one parent; 
both alleles can be inherited from that single parent. This conveys an increased 
chance of inheriting autosomal recessive genetic diseases (or, in this case, perhaps 
an  X-linked dominant disease in a female).278 However, a more common pathogenic 
mechanism of UPD is that imprinted genes are inherited uniparentally. Imprinted 
genes are those that can be silenced, meaning expression of a gene on one 
chromosome is halted, with only the second copy expressed.279 The inheritance of 
two identical gene copies from a single parent can lead to the silencing of both copies 
of a gene (or neither). Disorders that can be caused by this include Prader-Willi (MIM: 
[176270]) and Silver-Russell (MIM: [180860]) syndromes. 
Complicating matters, in this case, is the presence of the UPD region on the X 
chromosome. In human females, one copy of the X chromosome is silenced in each 
cell (X-inactivation); this means that all genes on the X chromosome are, in effect, 
subject to imprinting. The exact mechanism by which X-inactivation occurs is not fully 
understood, but the X-inactivation centre (XIC) is known to be important.280 This is 
present approximately 6 mb from the beginning of the 50 mb homozygous region in 
this patient and is therefore unlikely to be affected. However, not all genes on the 
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inactivated X chromosome are silenced, with some (including ALG13) partially 
escaping this process.281-282 
Due to the presence of the UPD region on the X chromosome, it was hypothesised 
that genes in this region could be affected by aberrant silencing (linked to X-
inactivation) leading to altered expression of the gene products. A list of all genes 
within the homozygous region was retrieved using the UCSC genome browser. This 
consisted of 380 known genes. 
These 380 genes were then searched for predicted pathogenic homozygous variants 
using the IVA tool, none were identified. In addition, no genes encoding PLP-
dependent enzymes or linked to vitamin B6 metabolism were found. However, several 
genes implicated in genetic epilepsy and/or developmental delay were identified. 
These are listed in Table 7.5. 
Gene Protein function Implicated disorder 
ALG13 
Constitutes the UDP-GlcNAc 
transferase 
EIEE36; MIM: [300884] 
UBE2A 
A ubiquitin-conjugating enzyme 
important for protein 
degradation 
Developmental delay, 
Nascimento-type; MIM: [300860] 
PCDH19 A cell-cell adhesion protein EIEE9; MIM: [300088] 
PLP1 
Component of central nervous 
system myelin 
Pelizaeus-Merzbacher disease; 
MIM: [312080] 
 
The PCDH19 gene is found in this isodisomic area. The EIEE caused by PCDH19 
dysfunction is usually female-restricted dominant by inheritance. It is thought that a 
homogenous cell population of either mutant or wild-type cells does not lead to 
disease. Instead, a mixed population leads to aberrant cell-cell communication in the 
brain and hence the phenotype observed. Males with only one allele (either wild-type 
or mutant) do not present with EIEE. However, affected females are mosaics due to 
Table 7.5: Genes linked to early infantile epileptic encephalopathy and developmental 
delay in the isodisomic region of chromosome X in Subject 3. Variants identified using whole 
genome sequencing. Data filtered according to the parameters defined in the appendix (Section 9.1). 
Information obtained from https://www.omim.org. EIEE = early infantile epileptic encephalopathy 
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X-inactivation occurring on different alleles, they therefore develop a mixed 
population of cells.283-284 In this patient, it is possible that PCDH19 is being silenced 
on neither or both X chromosome/s, due to the isodisomic nature of the region. This 
would lead to a mixed population of cells (with regards to PCDH19 expression) and 
hence the phenotype of neurological disease observed. 
It is possible that aberrant silencing or overexpression of any one or more of the genes 
listed in Table 7.4 is leading to the phenotype of Subject NGS3. Further work would 
be needed to define the precise mechanism involved, this could include 
transcriptomic analysis in order to characterise the expression of genes within the 
UPD region. 
 
 Subjects NGS4 & NGS5  
Subject NGS4 presented with a refractory epilepsy at three days of age. The 
concentration of PLP in the CSF was low prior to treatment. PLP was found to control 
seizures where pyridoxine was ineffective. At five years of age seizures worsened 
and PLP was no longer fully effective. At this time nocturnal epilepsy also became a 
feature of the disorder. Development was normal. IVA was used to search for 
pathogenic variants related to vitamin B6 metabolism or other epilepsy disorders. 
However, no plausible candidates were identified. Subsequently it was found (using 
a SNP array by collaborators in UMCG) that a 107 kb deletion was present on the 
long arm of chromosome 20; an area that included the KCNQ2 gene at 20q13.33. 
This was considered likely to be pathogenic; duplications and deletions of the KCNQ2 
gene have previously been linked to epilepsy disorders.285 
Subject NGS5 presented with drug-resistant epilepsy at three months of age. They 
became seizure free on the introduction of PLP to their treatment regime (dose 
unknown). PLP was later withdrawn at seven months of age before seizure 
recurrence one month later. Since then seizures have been well controlled with 
pyridoxine supplementation. The patient is now six years old. Sequencing of the 
PNPO, ALDH7A1 and PLPBP genes did not reveal any pathogenic variants. A 
heterozygous splice site variant was identified in the KCNQ2 gene (c.297-1G>C). 
Sanger sequencing was performed on the parents of Subject NGS5 and c.297-1G>C 
was absent in both, confirming it as a de novo variant. This, in addition to its location 
on an exon boundary, meant that the variant was considered pathogenic.  
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 Investigation of the effect of B6 vitamers on the  
M-current facilitated by KCNQ2 channels 
To our knowledge, at least six patients (including Subjects NGS4 and NGS5 above) 
with de novo mutations or copy number variations in KCNQ2 have recently been 
shown to respond to treatment with B6.116-117, 286 (& unpublished observations) Better 
understanding of the mechanism by which seizures are controlled by B6 in patients 
with mutations in KCNQ2 would help us to understand which genetic epilepsies could 
benefit from treatment with pharmacological doses of vitamin B6.  
Two of these patients had low CSF PLP prior to treatment which could be significant 
with regards to the B6 response seen specifically with mutations in KCNQ2. In other 
patients CSF PLP was either normal or had not been measured. Low CSF PLP has 
also (inconsistently) been found in larger childhood epilepsy cohorts. Overall, these 
patients with KCNQ2 mutations also seemed to show a better response to PLP than 
PN, a finding reported in a wider cohort of children with genetic epilepsy by  
Wang et al.113 
Potassium voltage-gated channel subfamily Q member 2 (KCNQ2)-related epilepsy 
is an autosomal dominant disorder that can lead to a phenotype ranging from 
relatively mild benign familial neonatal seizures (BFNE) to severe neonatal epileptic 
encephalopathy (NEE).285 The KCNQ2 protein is an integral part of the KCNQ or ‘M’-
channels, responsible for carrying the M-current, important for modulating the resting 
potential of neurones and hence regulating neuronal excitability.118 Retigabine is a 
recently developed anti-epileptic drug that functions by opening KCNQ channels.119 
Valproate is also thought to maintain the M-current as part of its anti-epileptic 
action.120 
Why seizures caused by mutations in KCNQ2 would respond to vitamin B6 
supplementation has not been investigated previously. There are several potential 
hypotheses that may explain the mechanism behind this response: 
i. Vitamin B6 attenuates the potentially neurotoxic effects of reactive oxygen 
species (ROS) production which can occur due to unregulated neuronal firing; 
the B6 vitamers have known antioxidant properties.51 
ii. PLP is a ligand of KCNQ2 channels and directly modulates the M-current. 
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iii. The M-current is modulated by P2X7 receptors, at which PLP is a known 
antagonist. 
iv. PLP, through its activity as a cofactor, restores the balance of 
neurotransmitters, particularly glutamate/GABA, thereby countering 
excessive neuronal excitability. 
This section details experiments carried out in order to elucidate the mechanism 
behind the B6 response of the epilepsy in patients with mutations in KCNQ2 by using 
the electrophysiological technique patch clamping to measure the M-current 
amplitude from single cells.118 
 
 
 The effect of PL and PLP on the M-current in CHO cells 
overexpressing KCNQ2/3 
M channels are formed by a tetramer comprised of two KCNQ2 and two KCNQ3 
protein subunits.118 Chinese hamster ovary (CHO) cells transfected with the genes 
encoding these proteins have previously been shown to express a measurable  
M-current susceptible to pharmacological manipulation.287 This cell model was 
prepared by collaborators at the UCL department of Neuroscience, Physiology & 
Pharmacology. We were able to use this model to study the M-current of single cells 
and their response to PLP and PL.  
Initial experiments were performed in order to confirm the expression of KCNQ2/3 
channels in CHO cells. This was carried out by detecting the M-current through 
perforated patching (Figure 7.2a). A perforated patch is achieved by manoeuvring a 
borosilicate glass pipette with an aperture of approximately 1 µm into contact with the 
membrane of a suitable cell and applying negative pressure to the pipette. This forms 
a ‘gigaseal’ on the cell membrane (a seal with an electrical resistance > 1 GΩ). The 
patch is then permeabilised using amphotericin. Amphotericin treatment makes the 
cell permeable to monovalent ions such as K+, Na+ and Cl- while remaining 
impermeable to larger molecules and proteins. It is then possible to measure the M-
current by monitoring the current, in nanoamperes (nA), which occurs when the 
potential difference across the cell membrane is changed from -60 mV (inside 
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negative) to 0 mV using electrodes; one within the patching pipette and another in the 
bath solution.  
A choice was made to use perforated patching in place of whole-cell patching 
because this method is less disruptive to the integrity of the cell membrane and 
therefore allows measurement of electrophysiological characteristics for a longer 
period before cell death.  
 
In CHO cells transfected with KCNQ2/3 channels the amplitude of the M-current 
measured is proportional to the number of M-channels open. The protocol used 
involved holding the membrane potential at -60 mV, before applying pulses at -60 to 
+20 mV, in ascending 10 mV steps for 500 ms. After each step the potential would 
be returned to the -60 mV resting potential for 5 seconds before proceeding to the 
next step of the protocol (Figure 7.2b). The peak current measured at 0 mV was used 
to quantify the M-current in each cell. An amplitude of approximately 0.5 – 1.5 nA 
would be expected at this voltage.287 
The effect of compounds on the M-current can be tested by applying them to the bath 
solution in which the cells are contained. This solution is continuously replenished 
and can be exchanged rapidly. In order to test whether this bath solution exchange 
was effective, the step protocol shown in Figure 7.2b was carried out at one-minute 
Figure 7.2: M-Current measured in CHO cells overexpressing KCNQ2/3 channels. Recording (a) shows 
the M-current measured with a perforated patch electrode using the step protocol shown in (b). The step 
protocol depolarised the cell in 10 mV steps from -60 mV to +20 mV. 
a) 
b) 
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intervals before and after exchange of a standard bath solution (composition in 
Section 2.14.1) with one containing 10 µmol/L linopirdine (PubChem CID: 3932). This 
compound blocks the M-current with an IC50 of 2.4 µmol/L.288 A reduction of the M-
current amplitude of 31.8% (mean reduction of 3 cells) was observed after application 
of linopirdine to the bath solution, compared to the amplitude measured from the 
same cell prior to its addition. 
Using the same protocol, the effect of 10 µmol/L PLP on the measured M-current was 
tested by its addition to the bath solution. A concentration of 10 µmol/L was chosen 
as this is expected to be at least ten times higher than free concentrations in vivo, but 
within the range potentially expected in patients receiving supplementation, based on 
circulating blood concentrations (Section 3). No difference in the measured M-current 
of each individual cell could be identified after exchanging the standard bath solution 
for that containing 10 µmol/L PLP. The mean amplitude of both conditions was almost 
identical and any difference was not statistically significant (Control bath solution = 
0.346 ±0.144 nA; PLP bath solution = 0.353 ±0.133 nA (n = 12 cells) (Figure 7.3a).  
 
 
The effect of PLP on the M-current can also be quantified as the change in amplitude 
before and after the exchange of the standard bath solution for that containing PLP. 
This was found not to deviate significantly from zero (Mean change = 0.006 nA ±0.07; 
Figure 7.3: The effect of 10 µmol/L PLP on the M-current in CHO cells over-expressing KCNQ2/3 
channels. a) The M-current amplitude measured at 0 mV before and after the addition of 10 µmol/L PLP to the 
bath solution (n=12). b) The change in M-current amplitude from each individual cell measured before and after 
10 µmol/L PLP (n=12). Error bar = SD; central line = mean. 
a) b) 
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n = 12 cells), providing further evidence that a bath solution containing PLP had no 
effect on the M-current (Figure 7.3b). 
It is not fully understood how the B6 vitamers cross the cell membrane but it is thought 
that the non-phosphorylated vitamers are able to move across more easily than the 
phosphorylated forms.16 It was hypothesised that, although 10 µmol/L PLP had not 
altered the M-current, the same concentration of PL may do so. If the effect of vitamin 
B6 upon KCNQ2/3 channels was dependent upon intracellular concentrations, it is 
possible that PL would affect the M-current by entering the cell, whereas PLP would 
remain in the extracellular bath solution. However, this was found not to be the case, 
with 10 µmol/L PL not significantly diminishing or enhancing the measured M-current 
(Control bath solution = 0.563 nA ±0.272; PL bath solution = 0.535 nA ±0.267; n = 3 
cells). 
 
 The effect of growth in B6-depleted medium upon the M-current 
in CHO cells overexpressing KCNQ2/3 
The experiments described above (Section 7.2.1) were performed with CHO cells 
that had been established and maintained in replete media that contains pyridoxine. 
Cells therefore contained what could be considered normal vitamin B6 concentrations 
prior to the acute application of PLP/PL. Further experiments were performed to 
investigate whether chronic vitamin B6 depletion could affect the M-current strength. 
This effect on the M-current could occur, for example, if B6 vitamer concentrations 
affected the localisation of the KCNQ2/3 tetramers to the cell membrane. This occurs 
through a PIP2 regulated pathway and is inhibited by Gq receptor innervation.289 CHO 
cells have previously been used as a model to characterise the link between this 
pathway and KCNQ2/3 channels.290 
CHO cells were cultured in both the cell culture medium previously used (Ham’s F-12 
with normal fetal bovine serum (FBS)) and in a B6-depleted Ham’s F-12 medium. The 
standard Ham’s F-12 medium contains 62 µg/L (367 nmol/L) pyridoxine. The B6-
depleted medium was identical in all aspects except for the removal of pyridoxine. 
The B6-depleted cell culture media was supplemented with FBS that had been 
dialysed to ensure that this was not a source of B6 vitamers. Oppici et al. have used 
a similar protocol of B6 depletion.291 Cells were transitioned over a 6 week period from 
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normal medium into the B6-depleted medium. B6-depleted cell lines were viable 
although they grew slower than those in replete media. 
The concentrations of B6 vitamers in: i) B6-depleted Ham’s F-12 medium; ii) normal 
Ham’s F-12 medium; iii) dialysed FBS; iv) normal FBS were measured and are shown 
in Figure 7.4. In addition, B6 vitamers were measured from the cell culture mixtures 
of: v) 10% dialysed FBS in B6-depleted Ham’s F-12 medium 1; vi) 0% normal FBS in 
Normal Ham’s F-12 medium. This was carried out using the LC-MS/MS-based 
method detailed in Section 2.4.1. 
 
Only PLP, PL and PN were measurable in the media mixtures, with other vitamers 
below the limit of detection (6 nmol/L for this experiment; see Section 2.4.3.2). 
Normal Ham’s F-12, as expected, contained mostly PN, at a concentration of 247 
nmol/L. Also present was a small amount of PL (7 nmol/L). Normal serum contained 
a high concentration of PL (295 nmol/L) and lower concentrations of PLP (12 nmol/L) 
and PN (9 nmol/L). This high PL/PLP ratio could be due to either phosphatases still 
active during the preparation of FBS or differences in foetal B6 metabolism. For 
example, preterm infants are reported to have a higher PL/PLP ratio than term infants 
in both serum and CSF.292 Dialysed FBS contained lower concentrations of PL (33 
nmol/L) and PLP (11 nmol/L) but no PN. The B6-depleted Ham’s F-12 and the mixture 
of this with 10% dialysed FBS contained no measurable B6 vitamers. Dialysed FBS 
contains low amounts of PLP and PL, therefore it can be assumed that the B6-
depleted cell culture medium supplemented with dialysed serum also contains 
Figure 7.4: The B6 vitamer concentrations in media used for the culture of normal and B6-depleted 
CHO cells. n=3; Error bars = SD. 
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vitamers but at a concentration below 6 nmol/L (i.e. the LLOQ). Residual low B6 
concentrations are likely required for cell viability. 
B6 vitamer concentrations were measured in cell lysates from the B6-depleted cell line 
and compared to the normal cell line. Lysates were prepared by freeze thawing the 
cells, as described by Oppici et al.291 (Section 2.13.1). Results were normalised to 
the protein concentration of the lysate, measured using the bicinchoninic acid (BCA) 
assay (Section 2.13.2) and expressed as pmol/mg protein (Figure 7.5).  
PLP (Normal medium: 3.27 pmol/mg protein; B6-depleted medium: 1.02 pmol/mg 
protein) and PMP (Normal medium: 2.82 pmol/mg protein; B6-depleted medium: 0.93 
pmol/mg protein) were detectable in both the depleted and replete cell lines. Levels 
of both vitamers were lower in the B6-depleted lysates, with an approximately 3-fold 
drop in both, confirming B6 depletion. A concentration of pyridoxine similar to those of 
PLP and PMP was detected in the B6 depleted cell line. This was unexpected as no 
PN was present in the media of these cells, as shown in Figure 7.4. No other B6 
vitamers were detectable in lysates from either cell line. 
 Figure 7.5: The concentration of the B6 vitamers in normal and  
B6-depleted CHO cells. n=3; Error bars = SD; ** = p <0.01; **** p < 0.0001. 
Normal = CHO cells cultured in standard Ham’s F-12 medium with the addition 
of standard serum; B6 depleted = CHO cells cultured in B6-depleted  
Ham’s F-12 with the addition of dialysed serum. 
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Subsequent to B6 depletion the M-current was measured in both populations (i.e. B6 
depleted and replete CHO cells) as described in Section 7.2.1. The mean M-current 
measured was found to be slightly higher in the B6-depleted cell line (Normal = 0.569 
±0.307 nA (n = 15) B6-depleted = 0.721 ±0.258 nA (n = 14) (Figure 7.6). However, 
this difference was not significant (p = 0.161). 
 
 
In summary, no effect on the M-current could be measured during the acute 
application of PLP or PL to the bath solution. In addition, there was no significant 
effect of culturing the CHO cells in a custom B6-depleted medium. This B6 depletion 
was confirmed by measuring the B6 status of the CHO cells used for M-current 
measurement. Additional work could be performed in order to further investigate the 
mechanism by which patients with KCNQ2 variants respond to vitamin B6 
supplementation. This is discussed below. 
 
 
 
  
Figure 7.6: The M-current amplitude of normal and B6-depleted CHO cells. 
Normal cells n=14; B6-depleted cells n=15. Error bar = SD; central line = mean. 
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 Discussion & future work 
 Investigation of patients with vitamin B6-dependent epilepsy 
using NGS data 
In the cohort of five individuals investigated, two conclusive diagnoses were achieved 
in Subjects NGS4 and NGS5. Both were found to have mutations in the KCNQ2 
gene. This provides additional evidence for a link between KCNQ2-related epilepsy 
and vitamin B6.  
In Subjects NGS1, NGS2 and NGS3, no mutations were found in genes known to 
cause vitamin B6 dependent epilepsy or linked to the metabolism of vitamin B6. In all 
three of the patients however either novel candidates or variants of unknown 
significance were discovered but their pathogenicity was not confirmed. Although in 
silico tools such as SIFT and PolyPhen were used to determine the evolutionary 
conservation and structural effect of variants identified, these results are often 
inconclusive, particularly where novel gene loci or large abnormalities such as 
Subject 3’s area of UPD are implicated. Hence, it is also important to assess the 
predicted biochemical effect of a variant functionally; this can often be challenging as 
many pathways are still poorly characterised.   
The processing of data and assessment of millions of potentially benign or pathogenic 
variants is a problem in an ever-growing genetic landscape. This will become easier 
as our understanding of human genomics and biochemistry expands but is also a 
perfect arena for machine learning and artificial intelligence due to the required 
integration, understanding and analysis of huge datasets and pathways. 
Considerable work is currently being performed towards this end293, the culmination 
of which would be the integration of several ‘omics’ technologies (such as genomics, 
epigenomics, proteomics, metabolomics and transcriptomics) to provide a complete 
biological snapshot of each individual patient (or cell type within that patient), leading 
to a rapid and accurate diagnosis.294 Hopefully this will also lead to a new era of the 
personalised treatment for individual patients. 
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 The mechanism of response to vitamin B6 supplementation in 
patients with mutations in KCNQ2 
Under the conditions tested, there was no direct effect of PLP or PL on the M-current 
facilitated by KCNQ2/3 channels expressed in CHO cells. There is wide scope for 
further investigation of the response of patients with mutations in KCNQ2 to vitamin 
B6. This includes testing whether higher concentrations of PL/PLP than the 10 µmol/L 
used would modulate the M-current. There was a concern that these extremely high 
concentrations of PL or PLP could damage cells through aldehyde stress. However, 
recent work has shown that PN is in fact more toxic to cells in culture than PL and 
PLP, with the latter two vitamers proving non-toxic even at concentrations of  
100 µmol/L.111 It is possible that PL and PLP are present at these concentrations 
physiologically, as shown by the data from DBS in Section 4. 
It is known that a relatively minor reduction in M-current of 20 – 30% can increase 
neuronal excitability.295 It is possible that a minor change like this would be important 
in vivo but undetectable by the patch-clamping technique used, at least without 
increasing the number of replicates by an order of magnitude, something that was 
beyond the scope of this study.  
Concerning the M-current in B6-depleted cell lines, whilst no significant difference was 
seen, it is possible that the depletion of cells was inadequate. Although lower B6 
vitamer concentrations were detected and cell growth was notably slower, further B6 
depletion may have been required to see an effect of the B6 vitamers on the 
measurable M-current. 
During the acute application of B6 vitamers to CHO cells, it is possible that both PLP 
and PL were unable to cross the cell membrane and were retained in the bath 
solution. The transporters that carry B6 vitamers across the cell membrane are, as 
yet, uncharacterised (see Section 1.1.1). If intracellular concentrations are more 
important than those extracellularly in modulating the M-current, an effect would not 
have been seen using the approach used. In future studies, the B6 vitamer of interest 
could be included inside the pipette used for patching. This could allow diffusion into 
the cytosol but would be ineffective with perforated clamping, as used in this study, 
as amphotericin permeabilisation does not permit the movement of PL or PLP across 
the cell membrane, only ions such as K+ and Cl-. It could be used with whole-cell 
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patch clamping; however, this would result in inferior data as recording would only be 
permitted for short amounts of time.118, 296 
A P2X7 receptor analogue is expressed in CHO cells297, useful future work would be 
the investigation of the effect of P2X7R activation by ATP on the M-current. As 
mentioned previously, PLP is a known P2X7R antagonist. If an effect of ATP upon 
the M-current was identified, it would be important to identify whether this could be 
antagonised by PLP within a CHO cell model. 
Finally, a caveat of these experiments is that they were carried out in CHO cells. This 
is a good model for the direct pharmacological manipulation of KCNQ2/3 channels. 
However, if in vivo the effects of B6 depletion on the M-current are facilitated by 
neuron-specific mechanisms or by effects upon gene expression these would not be 
identified in a CHO cell model. It would be valuable to repeat this experimentation in 
a neuronal cell line that innately expresses KCNQ2/3 channels. 
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Over the past 20 years it has become increasingly apparent that vitamin B6 
supplementation can be useful in the treatment of a number of genetic seizure 
disorders. Several of these disorders have been defined as those directly affecting B6 
metabolism. These include PNPO63, PLPHP27 and ALDH7A164 deficiencies. 
However, supplementation is also useful in other genetic epilepsies and vitamin B6 
appears to have a general anticonvulsant effect.114 This thesis describes the 
development of novel techniques for the diagnosis of B6-dependent disorders as well 
as molecular investigation of the proteins involved in these disorders and the 
metabolism of vitamin B6. A particular focus was the use of mass spectrometry 
techniques for analysis and dried blood spots (DBS) as a sample medium.  
Chapter 3 details the assessment of DBS as a sample source for the measurement 
of B6 vitamers. DBS were found to be a suitable storage medium and the method was 
used in order to profile the B6 vitamers in patients with PNPO deficiency and other 
B6-dependent epilepsies receiving B6 supplementation. A raised pyridoxine 5’-
phosphate/pyridoxal 5’-phosphate (PNP/PLP) ratio was found to be diagnostically 
indicative of PNPO deficiency, though it did not allow complete delineation of PNPO 
deficient patients from others receiving B6 supplementation. Unfortunately, only a 
limited cohort was collected for the other B6-dependent disorders. In the future it 
would be important to profile the DBS B6 vitamers in larger numbers of individuals 
with other B6-dependent epilepsy disorders (e.g. PLPHP and ALDH7A1 deficiencies) 
to identify whether B6 vitamer profiles could be useful for diagnosis.  
An important finding from this work was additional evidence that the phosphorylated 
B6 vitamers are compartmentalised within red blood cells. In particular, high 
concentrations of PNP in the case of PNPO deficient patients were found due to 
substrate accumulation. More work should be carried out on the effect of high 
concentrations of other vitamers on B6-dependent enzymes. It is thought, for 
example, that high PN concentrations can cause peripheral neuropathy by inhibiting 
these enzymes.111 It is quite possible that this also occurs for PNP. If so, there could 
be implications for the prognosis of PNPO deficient individuals.  
Chapter 4.1 describes the development of a novel diagnostic enzyme assay for the 
diagnosis of pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency from DBS using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method was 
fully validated for the clinical diagnostic arena and can be performed rapidly with a 
turnaround time of less than 24 hours. This is of great clinical utility as a good 
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developmental outcome can be obtained when appropriate treatment of this disorder 
is initiated promptly.65, 87 Assay of the PNPO enzyme from DBS was found to provide 
a more conclusive diagnosis of PNPO deficiency than DBS B6 vitamer profiles. 
However, profiling of the B6 vitamers from DBS could be used in conjunction with DBS 
PNPO activity to provide a stronger diagnosis in cases, for example, of borderline 
enzyme activity.  
In Chapter 5, biochemical characterisation of the homozygous p.A228T variant in 
PDXK, encoding pyridoxal kinase (PK), is detailed. This variant was identified by 
collaborators in a Cypriot family presenting with peripheral neuropathy. Pathogenicity 
of p.A228T was confirmed using LC-MS/MS to assay for the PK enzyme in DBS and 
in recombinant PK protein. Treatment with 50 mg/d PLP was commenced in two 
elderly siblings of the family described; this was found to improve their presentation. 
The identification of this treatable disorder has implications for genetic peripheral 
neuropathies; the development of a rapid assay from DBS could enable the screening 
of larger populations for this disorder.  
Section 4.2 describes the biochemical characterisation of the PNPO p.R116Q 
variant. In DBS from p.R116Q homozygotes, enzyme activity was undetectable but 
studies with the recombinant enzyme activity showed that this variant had comparable 
activity to that of the wild-type enzyme, except for when its cofactor, flavin 
mononucleotide (FMN) was limited. Some individuals homozygous for p.R116Q 
present with seizures characteristic of PNPO deficiency but others are asymptomatic. 
A recent publication has reported that thermal stability of the p.R116Q PNPO protein 
is reduced.74 It is possible that low blood PNPO activity in the DBS patients is due to 
this reduced stability but perhaps activity was retained in others tissues such as the 
brain, protecting from seizures, future work would study this hypothesis.  
That the activity of B6 metabolic enzymes could be tissue-specific in at least some 
cases is interesting. This is also implicated in the pathogenesis of the PDXK p.A228T 
variant in the patients described in Section 5 as they were not reported to have 
developed seizures at any point in their lives. It is possible that mechanisms exist to 
protect the brain from PLP deficiency but these have not been characterised in 
humans. A study into the tissue-specific regulation of B6 vitamer metabolism should 
be an important part of any future work. 
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Overall, Chapters 3, 4 and 5 exemplify how modern advances in LC-MS/MS 
technology have enabled the use of lower sample volumes found in DBS as a source 
for analytes monitored for the diagnosis of inborn errors of metabolism (IEMs). This 
has implications outside the field of B6-dependent disorders and it is likely that DBS 
will be increasingly useful, particularly for the measurement of enzyme activity in 
IEMs. In addition, the assays developed to assess the in vitro effect of PK and PNPO 
variants were performed in 96-well plates using an extremely small amount of 
recombinant enzyme (100 ng/well). This technique can be adapted for other enzymes 
and could be important for the characterisation of newly identified variants of unknown 
significance. 
In cohorts of genetic epilepsy patients, PLP appears more effective than pyridoxine 
for seizure treatment.113 Many PNPO patients require PLP supplementation for 
control of their seizures as pyridoxine is not effective. Some PNPO deficient patients 
receiving long-term PLP supplementation seem to develop hepatic cirrhosis and in 
one case, hepatocellular carcinoma.103, 246 Chapter 6 describes an assessment of the 
rate and profile of PLP degradation in solutions prepared similarly to those used in a 
clinical environment. 4-Pyridoxic acid 5’-phosphate (PAP) and a diketone PLP dimer 
were identified as PLP degradation products. This work will help to inform the 
treatment of patients. Identification of the mechanism by which high-dose PLP 
supplementation causes liver damage is important for the long-term outcome of these 
patients. Future work should include this as a priority. 
Chapter 7.1 describes the investigation of several patients with B6 responsive 
epilepsy using next generation sequencing technology. Sequencing data was studied 
from these patients in order to achieve a diagnosis for these patients or to identify a 
novel gene implicated in B6-responsive epilepsy. In three of these individuals, 
pathogenic variants were not discovered but candidates in a number of genes are 
detailed. In the remaining two individuals, pathogenic abnormalities in the KCNQ2 
gene were identified. This added to the mounting evidence that KCNQ2-related 
epilepsy is amenable to treatment with vitamin B6 supplementation.116-117, 286 
Finally, Chapter 7.2 describes the use of electrophysiological techniques to establish 
the effect of PLP and PL on the KCNQ2-facilitated M-current expressed in a cell 
model. No effect of the acute application of these B6 vitamers was detected. In 
addition, culture of these cells in B6 depleted medium did not affect the M-current 
amplitude. More advanced models such as a neuronal cell line or KCNQ2 
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haploinsufficient mice would be useful as further work in order to elucidate the 
mechanism behind a B6 response in KCNQ2-related epilepsy. This would also have 
implications with regards to the mechanism behind a response to PLP in wider 
epilepsy cohorts and could lead to the development of novel treatment protocols. 
Indeed, this leads us to the overarching question of what is causing a response to B6 
supplements in patients with variants not thought to directly impact B6 metabolism 
itself. There are currently three main hypothesis as to the cause of this effect, only 
one of which is related to the activity of PLP as a cofactor: i) supplementation is able 
to restore imbalances of neurotransmitters such as GABA and glutamate. ii) PLP is 
able to quench reactive oxygen species that are produced as a result of uncontrolled 
neuronal firing in cases of epilepsy. iii) PLP can inhibit the activation of P2X7 
receptors, this could reduce neuroinflammation from excitotoxicity following seizures. 
In the future, models should be developed in order to identify the specific mechanisms 
involved. 
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 Conditions used for PCR amplification of candidate 
variants identified by next generation sequencing 
 
Primer Variant of interest Sequence 5’ → 3’ 
Tm 
(°C) 
MgCl2 
(mmol/L) 
Predicted 
product 
size (bp) 
CACNA1A_F 
c.6471C>A 
AGACCATCTCAGACACCAGC 
64 1.5 398 
CACNA1A_R GCCCTAGAGATCCCCTGAAC 
SLC15A5_F 
c.1403T>C 
TCATTGTAGCTGGGTCAAGGT 
56 1.5 455 
SLC15A5_R AAGACTGCACTGACAAAGCC 
KCNQ2_F 
c.297A>G 
GTAACAGGAAGCGGAAGACAGACG 
64 1.5 510 
KCNQ2_R GACGTTGCCAAAGGATGAGGCTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 9.1: Primers and conditions used to amplify the regions containing pathogenic variants of unknown 
significance identified using NGS analysis. F = primer complementary to the forward strand; R = primer 
complementary to the reverse strand; bp = base pairs; Tm = annealing temperature used during PCR amplification. Other 
conditions are as stated in Section 2.12.3.1; Tables 2.10 & 2.11. Sanger sequencing was performed as described in Section 
2.12.4.2 
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 Gene lists used as biological context filters during 
analysis of next generation sequencing data using 
Ingenuity Variant Analysis 
 
 
 
 
 
 
 
 
Table 9.2: Genes encoding PLP-dependent proteins or proteins implicated in the metabolism of vitamin B6. 
AADAT CIN KBL PNPO 
AADC CSAD KIAA0251 PRED79 
AAT1 CSD KIAA0526 PROSC 
AAT2 CTH KIAA1252 PSA 
ABAT DDC KIAA1945 ODCP PSAT1 
ADC ECA39 KYNU PYGB 
AGT2 ECA40 LCB1 PYGL 
AGXT FAS LCB2 PYGM 
AGXT2 FASN MARC1 SCL 
ALAS1 FTCD MARC2 SCLY 
ALAS2 GABAT MOCOS SDH 
ALAS3 GAD MOSC1 SDS 
ALASE GAD1 MOSC2 SDSL 
ALASH GAD2 MTHFR SEPSECS 
ALT2 GAD65 NFS1 SEPSECS 
ASB GAD67 NIFS SGPL1 
BCAT1 GCAT OAT SHMT1 
BCAT2 GOT1 ODC1 SHMT2 
BCATM GOT2 OK/SW-cl.121 SLA/LP 
BCT1 GPT pcap SPTLC1 
BCT2 GPT1 PDXDC1 SPTLC2 
C20orf38 GPT2 PDXK SPTLC2L 
C21orf124 hCG_18250 PDXP SPTLC3 
C21orf97 hCG_30593 PHOSPHO2 SRR 
CBS HDC PKH TAT 
CCBL1 HUSSY-08 PLP THNSL1 
CCBL1 KAT2 PLPP THNSL2 
CCBL2 KAT3 PNK TRNP48 
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ADSL GABRA1 PCDH19 SPTAN1 
ALG13 GABRB3 PIGA STX1B 
ARHGEF9 GATAD2B PIGQ STXBP1 
ARX GRIN1 PLCB1 SYNGAP1 
ATP1A3 GRIN2A PNKP TBC1D24 
ATRX GRIN2B POLG TCF4 
CBL HCN1 PRRT2 UBE2A 
CDKL5 IQSEC2 QARS UBE3A 
CHD2 KCNA2 RYR3 WDR45 
CHRNA2 KCNB1 SCN1A ZEB2 
CHRNA4 KCNC1 SCN2A SPTAN1 
CHRNB2 KCNQ2 SCN8A STX1B 
CNTNAP2 KCNT1 SIK1 STXBP1 
CSNK1G1 KIF1BP SLC12A5 SYNGAP1 
DNM1 KIAA1279 SLC13A5 TBC1D24 
DOCK7 LGI1 SLC16A2 TCF4 
DYRK1A MAGI2 SLC25A22 UBE2A 
EHMT1 MBD5 SLC2A1 UBE3A 
FASN MECP2 SLC35A2 WDR45 
FOXG1 MEF2C SLC6A1 ZEB2 
GABBR2 NRXN1 SLC9A6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.3: Genes on the early infantile epileptic encephalopathy gene panel at Great Ormond Street Hospital. 
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Voltage-gated Calcium Channel Genes 
CACNA1A CACNA1H CACNB1 CACNG4 
CACNA1B CACNA1I CACNB2 CACNG5 
CACNA1C CACNA1S CACNB3 CACNG6 
CACNA1D CACNA2D1 CACNB4 CACNG7 
CACNA1E CACNA2D2 CACNG1 CACNG8 
CACNA1F CACNA2D3 CACNG2  
CACNA1G CACNA2D4 CACNG3  
Cholinergic Receptor Genes 
CHRNA1 CHRNA4 CHRNA9 CHRNB4 
CHRNA10 CHRNA5 CHRNB1 CHRND 
CHRNA2 CHRNA6 CHRNB2 CHRNE 
CHRNA3 CHRNA7 CHRNB3 CHRNG 
Chloride Channel Genes 
CLCN1 CLCN4 CLCN6 CLCNKA 
CLCN2 CLCN5 CLCN7 CLCNKB 
CLCN3    
Dopamine Receptor Genes 
DRD1 DRD3 DRD4 DRD5 
DRD2    
GABA Receptor Genes 
GABBR1 GABRA4 GABRB3 GABRG3 
GABBR2 GABRA5 GABRD GABRP 
GABRA1 GABRA6 GABRE GABRQ 
GABRA2 GABRB1 GABRG1 GABRR1 
GABRA3 GABRB2 GABRG2 GABRR2 
Glycine Receptor Genes 
Gcom1 GLRA3 GRIA1 GRIA3 
GLRA1 GLRB GRIA2 GRIA4 
GLRA2    
Ionotropic Glutamate Receptor Genes 
GRID1 GRIK3 GRIN2A GRIN3A 
GRID2 GRIK4 GRIN2B GRINA 
GRIK1 GRIK5 GRIN2C  
GRIK2 GRIN1 GRIN2D  
Metabotropic Glutamate Receptor Genes 
GRM1 GRM3 GRM5 GRM7 
GRM2 GRM4 GRM6 GRM8 
Cyclic Nucleotide-gated Channel Genes 
HCN1 HCN2 HCN3 HCN4 
Serotonin Receptor Genes 
HTR1A HTR1F HTR3B HTR4 
HTR1B HTR2A HTR3C HTR5A 
HTR1D HTR2C HTR3D HTR6 
HTR1E HTR3A HTR3E HTR7 
Voltage-gated Potassium Channel Genes 
KCNA1 KCNC1 KCNG1 KCNQ2 
Table 9.4: Genes in the human genome known to encode ion channels. 
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KCNA10 KCNC2 KCNG2 KCNQ3 
KCNA2 KCNC3 KCNG3 KCNQ4 
KCNA3 KCNC4 KCNG4 KCNQ5 
KCNA4 KCND1 KCNH1 KCNRG 
KCNA5 KCND2 KCNH2 KCNS1 
KCNA6 KCND3 KCNH3 KCNS2 
KCNA7 KCNE1 KCNH4 KCNS3 
KCNAB1 KCNE1L KCNH5 KCNT1 
KCNAB2 KCNE2 KCNH6 KCNV1 
KCNAB3 KCNE3 KCNH7 KCNV2 
KCNB1 KCNE4 KCNH8  
KCNB2 KCNF1 KCNQ1  
Potassium Inwardly Rectifying Channel Genes 
KCNJ1 KCNJ14 KCNJ3 KCNJ8 
KCNJ10 KCNJ15 KCNJ4 KCNJ9 
KCNJ11 KCNJ16 KCNJ5  
KCNJ12 KCNJ2 KCNJ6  
Twin Pore Potassium Channel Genes 
KCNK1 KCNK15 KCNK3 KCNK7 
KCNK10 KCNK16 KCNK4 KCNK9 
KCNK12 KCNK17 KCNK5  
KCNK13 KCNK2 KCNK6  
Calcium Activated Potassium Channel Genes 
KCNMA1 KCNMB3 KCNN1 KCNN3 
KCNMB2 KCNMB4 KCNN2 KCNN4 
Ryanodine Receptor Genes 
RYR1 RYR2 RYR3  
Voltage-gated Sodium Channel Genes 
SCN10A SCN2A2 SCN4A SCN8A 
SCN11A SCN2B SCN4B SCN9A 
SCN1A SCN3A SCN5A  
SCN1B SCN3B SCN7A  
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